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Abstract 
Numerous studies have demonstrated the substantial improvement in the photodynamic 
therapy (PDT) of cancer using multifunctional nanoparticles. The tumour-selectivity of 
nanoparticles carrying PDT agents can be achieved through conjugation to cancer-specific 
biomolecules that provide the particles with an improved tumour localisation and a 
marked enhancement in the therapeutic outcome. 
The primary aim of this thesis was to establish the therapeutic potential of lectin, a 
carbohydrate binding protein, targeted PDT treatment of cancer cells using zinc 
phthalocyanine (C11Pc)-PEG gold nanoparticles (ca. 4 nm). Using a number of 
colorimetric techniques the interactions of Concanavalin A and succinyl-Concanavalin A 
with MCF-7 and SK-BR-3 human breast cancer cells expressing α-mannose was explored. 
The targeted PDT treatment of the breast cancer cells was attempted using C11Pc-PEG 
gold nanoparticles conjugated to Concanavalin A. However, Concanavalin A conjugation 
provided no enhancement in photodynamic breast cancer cell kill, as compared to the non-
conjugated C11Pc-PEG gold nanoparticles.  
The lectin jacalin was also conjugated to C11Pc-PEG gold nanoparticles to target HT-29 
human colon cancer cells expressing the oncofoetal Thomsen-Friedenreich (T) antigen. 
Using laser scanning confocal microscopy a substantial improvement in the cellular 
internalisation was observed with the jacalin nanoparticle conjugates, as compared to the 
non-conjugated particles. Similarly, the phototoxicity of the HT-29 cells incubated with the 
jacalin conjugates was dramatically improved following irradiation at 633 nm, as 
compared to treatment using the non-conjugated particles. The PDT efficacy of the lectin-
photosensitising nanoparticle conjugates was competitively inhibited by methyl-α-
galactopyranoside and the T antigen-expressing glycoprotein, asialofetuin. The ApoTox-
GloTM triplex assay confirmed that the jacalin targeted phototoxicity of the HT-29 cells was 
through necrosis, with no evidence of apoptotic induction. Overall, it was found that 
jacalin conjugated nanoparticles achieved a ca. 95-98% photodynamic cancer cell kill, 
whereas the non-conjugated particles were minimally phototoxic.  
The targeting efficiency of jacalin was compared to that of a monoclonal anti-HER-2 
antibody. C11Pc-PEG gold nanoparticles functionalised with either the lectin or the 
antibody were used to target SK-BR-3 breast cancer cells and HT-29 colon cancer cells. 
Both nanoparticle conjugates exerted a similar level of targeted phototoxicity in both the 
breast cancer and colon cancer cell lines. The predominant mechanism of lectin or 
antibody targeted phototoxicity was found to be necrosis in both the SK-BR-3 cells and the 
HT-29 cells. Using confocal microscopy, both conjugates were shown to partially localise 
in the acidic organelles, suggesting that the conjugates were uptaken by the SK-BR-3 cells 
and the HT-29 cells through receptor mediated endocytosis.  
Finally, in an exploratory study, titanium dioxide nanoparticles coated in polyacrylic acid 
were investigated as potential agents for sonodynamic cancer therapy. The findings 
suggested that exposure of the particles to ultrasound (1 MHz, 0.5 W.cm-2) lead to a 
sonocatalytic enhancement in singlet oxygen production. Preliminary in vitro studies using 
HT-29 colon cancer cells show that preincubation with the nanoparticles had no effect on 
sonodynamic cell death. However, extracellular sonodynamic activation of the 
nanoparticles may prove more effective than intracellular activation at delivering the 
ultrasound-induced reactive oxygen species to the cancer cells.   
vi 
 
Contents 
 
Chapter 1 Introduction        1 
   1.1 Photodynamic cancer therapy      1 
1.1.1 Photosensitisation      1 
1.1.2 Photosensitisers in clinical PDT for cancer   4 
   1.2 Nanoparticles for enhanced PDT      10 
 1.2.1 Gold nanoparticles      11 
  1.2.2 ORMOSIL nanoparticles      14 
 1.2.3 Polymeric nanocarriers      18 
 1.2.4 Multimodal magnetic nanosystems    22 
 1.2.5 Metal oxide semiconductors     26 
 1.2.6 Quantum dots       29 
 1.2.7 Scintillation nanocrystals     33 
 1.2.8 Upconverters       35 
 1.2.9 Future prospects for nanoparticles in  
   photodynamic cancer therapy     39 
   1.3 Targeted PDT using lectins      39 
 1.3.1  Aberrant glycosylation pathways in cancer  
   Development and progression     39 
 1.3.2 Lectins - from discovery to biomedicine   44 
 1.3.3 Targeting tumour cells with lectins    45 
   1.4 Thesis outline        51 
   1.5 References         53 
 
  
vii 
 
Chapter 2 Materials and Methods      66 
   2.1 Concanavalin A conjugated phthalocyanine-PEG gold  
 nanoparticles for targeted PDT of MCF-7 and SK-BR-3  
 human breast adenocarcinoma cells     66 
 2.1.1 Synthesis of citrate capped gold nanoparticles  66 
 2.1.2  Conjugation of Concanavalin A and  
   succinyl-Concanavalin A to gold nanoparticles 
    through SPDP       66 
 2.1.3 Approximation of lectin coverage on gold  
   nanoparticles – electrolyte induced aggregation assay 67 
 2.1.4 Colorimetric labelling of breast cancer cells  
   with lectin conjugated gold nanoparticles   69 
 2.1.5 Concentration and time dependence of lectin  
   conjugated gold nanoparticle aggregation   70 
 2.1.6 Synthesis and characterisation of PEG modified gold  
   nanoparticles functionalised with Con A, ECL and SSA 70 
 2.1.7 Physiological stability assessment of lectin conjugated 
   PEG modified gold nanoparticles    72 
 2.1.8 Colorimetric formazan-based lectin cytoadhesion assay 72 
 2.1.9 Synthesis of zinc phthalocyanine-polyethylene glycol 
   gold nanoparticles      73 
 2.1.10 Con A conjugation to C11Pc-PEG gold nanoparticles  74 
 2.1.11 TEM characterisation and singlet oxygen measurement 
   of the non-conjugated and Con A conjugated C11Pc-PEG 
   gold nanoparticles      75 
 2.1.12 MTT viability assay of MCF-7 breast cancer cells  
   following Con A targeted PDT treatment   75 
 2.1.13 CellTiter-BlueTM viability assay of SK-BR-3 breast 
   cancer cells following Con A targeted PDT treatment 77 
    
  
viii 
 
   2.2 Targeting the oncofoetal T antigen disaccharide with jacalin  
 functionalised phthalocyanine-PEG gold nanoparticles for 
 selective PDT of HT-29 colon adenocarcinoma cells   78 
 2.2.1 Jacalin conjugation to C11Pc-PEG gold nanoparticles 78 
 2.2.2 Singlet oxygen production by the irradiation of  
   non-conjugated and jacalin conjugated C11Pc-PEG 
   gold nanoparticles      78 
 2.2.3 In vitro PDT of HT-29 cells using jacalin conjugated 
    nanoparticles       79 
 2.2.4 Synthesis of high yield C11Pc-PEG gold nanoparticles 
   in DMF        79 
 2.2.5 ICP-OES elemental analysis of the C11Pc-PEG gold  
   nanoparticles       82 
 2.2.6 Conjugation of jacalin to C11Pc-PEG gold nanoparticles 
   synthesised in DMF      82 
 2.2.7 Characterisation and singlet oxygen measurement of 
   the jacalin conjugated C11Pc-PEG gold nanoparticles  
   synthesised in DMF      82 
 2.2.8 Optical microscopy of HT-29 cells following jacalin  
   targeted PDT       83 
 2.2.9 Laser scanning confocal microscopy of HT-29 cells  
   incubated with jacalin conjugated and non-conjugated 
   C11Pc-PEG gold nanoparticles     83 
 2.2.10 In vitro PDT treatment of HT-29 cells using jacalin  
   conjugated C11Pc-PEG gold nanoparticles synthesised 
   in DMF – MTT viability assay     84 
 2.2.11 Competitive inhibition of jacalin targeted phototoxicity 
   using methyl-α-galactopyranoside and asialofetuin  85 
 2.2.12  ApoTox-GloTM triplex assay following jacalin targeted 
   PDT treatment of HT-29 cells     85 
  
ix 
 
   2.3 A comparative study of targeted phototoxicity of HT-29 colon 
 and SK-BR-3 breast adenocarcinoma cells using jacalin or 
 anti-HER-2 antibodies       87 
 2.3.1  Synthesis of jacalin and anti-HER-2 antibody conjugated 
    C11Pc-PEG gold nanoparticles     87 
 2.3.2 Singlet oxygen measurements of the conjugated and  
   non-conjugated C11Pc-PEG gold nanoparticles  87 
 2.3.3 Comparative targeted PDT of HT-29 cells  
   – MTT Assay       88 
 2.3.4 Comparative targeted PDT of SK-BR-3 cells  
   – CellTiter-BlueTM Assay     88 
 2.3.5 ApoTox-GloTM triplex assay following targeted PDT 
   treatment       88 
 2.3.6 Lysosomal colocalisation of targeted nanoparticle  
   conjugates       89 
   2.4 Sonodynamic therapy (SDT) of HT-29 colon adenocarcinoma 
 cells using titanium dioxide nanoparticles    89 
 2.4.1 Synthesis of tetramethylammonium hydroxide capped 
   titanium dioxide nanoparticles     89 
 2.4.2 Thermal annealing of polyacrylic acid onto the 
   TiO2NP.TMAOH particles     90 
 2.4.3 Imaging of TiO2NP.TMAOH and TiO2NP.PAA particles 91 
 2.4.4 Photocatalytic •OH production using TiO2NP.TMAOH  
   particles - coumarin-3-carboxylic acid    91 
 2.4.5 Photocatalytic •OH production using TiO2NP.TMAOH  
   particles - methylene blue     92 
 2.4.6 Sonocatalytic •OH production using TiO2NP.TMAOH 
   particles - methylene blue     92 
 2.4.7 In situ sol-gel synthesis of TiO2NP.PAA particles  92 
 2.4.8 Characterisation of TiO2NP.TMAOH and TiO2NP.PAA 
   particles        93 
  
x 
 
 2.4.9 Sonocatalytic singlet oxygen production using 
    TiO2NP.PAA particles – ADPA     93 
 2.4.10 Methanol as a scavenger for •OH but not for singlet  
   oxygen        93 
 2.4.11  In situ sol-gel synthesis of dispersed TiO2NP.PAA 
   nanoparticles       94 
 2.4.12 Purification of the TiO2NP.PAA (x/30) nanoparticles  95 
 2.4.13 Sonocatalytic efficiency of purified  
   TiO2NP.PAA (x/30) nanoparticles    96 
 2.4.14  TEM and SEM imaging, and elemental analysis of 
   purified TiO2NP.PAA (x/30) nanoparticles   96 
 2.4.15 HT-29 cell tolerance to ultrasound    97 
 2.4.16 Attenuation of ultrasound through 6 and 48 well 
   multidishes       97 
 2.4.17 MTT viability assay of HT-29 cells following SDT 
   using TiO2NP.PAA (x/30) nanoparticles   97 
   2.5 References         99 
  
xi 
 
Chapter 3 Concanavalin A conjugated phthalocyanine-PEG gold  
  nanoparticles for targeted PDT of MCF-7 and SK-BR-3 
  human breast adenocarcinoma cells    100 
   3.1 Introduction        100 
 3.1.1 Reactivity of Concanavalin A towards breast cancer cells 100 
 3.1.2 The dimeric succinylated derivative of Con A   102 
   3.2 Results and Discussion       104 
 3.2.1 Colorimetric labelling of breast cancer cells using 
   lectin-gold nanoparticle conjugates    104 
 3.2.2 Lectin cytoadhesion assay     114 
 3.2.3 Synthesis and characterisation of Con A conjugated  
   C11Pc-PEG gold nanoparticles     118 
 3.2.4 Con A targeted PDT treatment of MCF-7 cells using  
   C11Pc-PEG gold nanoparticles – MTT viability assay  125 
 3.2.5 Con A targeted PDT treatment of SK-BR-3 cells using  
   C11Pc-PEG gold nanoparticles – CellTiter-BlueTM  
   viability assay       128 
   3.3 Conclusions         130 
   3.4 References         133 
  
xii 
 
Chapter 4 Targeting the oncofoetal T antigen disaccharide with 
  jacalin functionalised phthalocyanine-PEG gold  
  nanoparticles  for selective PDT of HT-29 colon  
  adenocarcinoma cells      136 
   4.1 Introduction        136 
 4.1.1 The origin of the Thomsen-Friedenreich antigen  136 
 4.1.2 Jacalin as a T antigen specific lectin    139 
   4.2 Results and Discussion       141 
 4.2.1 Synthesis of jacalin conjugated C11Pc-PEG gold  
   nanoparticles       141 
 4.2.2 Singlet oxygen production by the C11Pc-PEG gold  
   nanoparticles       142 
 4.2.3 PDT of HT-29 cells using the jacalin conjugated  
   C11Pc-PEG gold nanoparticles synthesised in THF  144 
 4.2.4 Synthesis and characterisation of high yield  
   C11Pc-PEG gold nanoparticles in DMF    146 
 4.2.5 Jacalin conjugation and characterisation of C11Pc-PEG 
   gold nanoparticle conjugates     156 
 4.2.6 Imaging of HT-29 cells subject to jacalin targeted PDT 158 
 4.2.7 Viability assessment of jacalin targeted PDT of  
   HT-29 cells       163 
 4.2.8 Determining the mechanism of jacalin targeted  
   PDT cytotoxicity       168 
   4.3 Conclusions         173 
   4.4 References         176 
  
xiii 
 
Chapter 5 A comparative study of targeted phototoxicity of HT-29  
  colon and SK-BR-3 breast adenocarcinoma cells using  
  jacalin or anti-HER-2 antibodies     178 
   5.1 Introduction        178 
 5.1.1 Cancer targeting ligands     178 
 5.1.2 Antibodies       180 
 5.1.3 The EGFR family of receptors     183 
   5.2 Results and Discussion       185 
 5.2.1  Jacalin and anti-HER-2 antibody C11Pc-PEG gold  
 nanoparticle conjugates      185 
 5.2.2 Targeted PDT of HT-29 cells – MTT viability assay  188 
 5.2.3 Targeted PDT of SK-BR-3 cells – CellTiter-BlueTM  
   viability assay       190 
 5.2.4 Comparative study of targeted PDT – ApoTox-GloTM  
   triplex assay       192 
 5.2.5 Lysosomal colocalisation of targeted nanoparticle 
   conjugates       198 
   5.3 Conclusions         204 
   5.4 References         208 
 
  
xiv 
 
Chapter 6 Sonodynamic therapy of HT-29 colon adenocarcinoma  
  cells using titanium dioxide nanoparticles   211 
   6.1 Introduction        211 
 6.1.1 Sonochemistry       211 
 6.1.2  Sonosensitisers and ultrasound enhanced 
   chemotherapeutics      214 
 6.1.3 In vitro and in vivo sonodynamic therapy   215 
 6.1.4  Titanium dioxide as a sonosensitiser    216 
   6.2 Results and Discussion       219 
 6.2.1 Synthesis and characterisation of cation stabilised 
   TiO2 nanoparticles      219 
 6.2.2  Photocatalytic and sonocatalytic •OH generation 
   by TiO2NP.TMAOH particles     224 
 6.2.3 In situ synthesis of PAA capped TiO2 particles  227 
 6.2.4 Sonocatalytic singlet oxygen and •OH generation by 
   TiO2NP.PAA particles      229 
 6.2.5 In situ synthesis of monodisperse PAA capped 
   TiO2 nanoparticles      233 
 6.2.6 In vitro SDT of HT-29 cells using TiO2 nanoparticles  243 
   6.3 Conclusions         247 
   6.4 References         250 
 
Chapter 7 Conclusions and Future Work     252 
   7.1 Con A targeted PDT – proof-of-concept     252 
   7.2 Targeting the T antigen for selective PDT treatment   254 
   7.3 Comparative study of lectin versus antibody targeting   256 
   7.4 Sonodynamic therapy       258 
   7.5 Future Work        261 
   7.6 References         262 
 
Publications and Presentations       263  
1 
 
Chapter 1 
Introduction 
Photodynamic therapy is a therapeutic modality that exploits the interaction of light with 
photosensitising molecules to treat a number of conditions including cancer. Some 
photosensitisers suffer from poor aqueous solubility and limited biodistribution. Pre-
clinical studies using nanoparticle technologies have been shown to dramatically improve 
the in vitro and in vivo efficacy of photosensitisers. Further selectivity of photosensitising 
nanoparticle constructs can be achieved through biofunctionalisation with cancer-
targeting ligands. Studies exploring the targeted photodynamic therapy of cancer using a 
variety of nanoparticle formulations have demonstrated a remarkable improvement in the 
specificity and efficacy of the treatment. A number of tumour-associated molecules can act 
as potential targets for selective cancer treatment using multifunctional nanoparticle 
technologies. 
This chapter introduces the photophysical processes within photodynamic therapy and an 
overview of photosensitisers with clinical applications. A number of nanoparticles shown 
to improve photodynamic therapy are described and attempts at targeted treatment using 
nanoparticles are highlighted. Finally, the potential for using lectins as carbohydrate-
specific cancer targeting agents is discussed. Lectins with current and prospective 
therapeutic applications are also outlined in this chapter. 
 
1.1 Photodynamic cancer therapy  
1.1.1 Photosensitisation  
Photodynamic therapy (PDT) is a rapidly expanding therapeutic modality for various 
clinical conditions that has great potential for effective cancer treatment.1 The 
photodynamic process involves the synergistic interaction of light, a photoactive molecule 
known as a photosensitiser, and molecular oxygen to produce cytotoxic reactive oxygen 
species (ROS).2 There are two mechanisms by which photosensitisers can generate ROS: 
type I and type II reactions.3 The photosensitisation reaction type is governed by the 
oxygen partial pressure, the nature and concentration of photosensitiser used, and the 
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concentration of the oxidation substrates.2 Some overlap between the two mechanisms 
may occur.2,3  
The initial stage of photosensitiser excitation is observed in both mechanisms of 
photosensitisation. Upon irradiation with light of a wavelength that is absorbed by the 
photosensitiser, the molecule is excited to its singlet excited state. The photosensitiser 
may then undergo intersystem crossing and be converted to its triplet excited state. 
During type I reactions, the sensitiser in the triplet excited state undergoes electron or 
hydrogen atom transfer to molecular oxygen or directly to cellular substrates to initiate 
free radical chain reactions involving a variety of radical intermediates.3 Radical 
intermediates generated through this mechanism include sensitiser radicals, sensitiser 
radical ions, substrate radicals, substrate radical ions and reactive oxygen intermediates.2,3 
Ultimately the radical chain reactions lead to significant oxidation of the cellular 
substrates inducing cell death.2 The reactive oxygen species formed during type I reactions 
include hydroxyl radicals (•OH), superoxide anions (•O2
-) and hydrogen peroxide (H2O2).3 
Type II photosensitisation is typically the predominant mechanism during PDT, which 
leads to the production of singlet oxygen (1O2), the main cytotoxic species responsible for 
cellular oxidative damage.1 The stages involved in the photosensitised generation of 
singlet oxygen are summarised in equations 1.1-1.4.2  
 
1PS + hν → 1PS*      (1.1) 
1PS*  → 3PS*       (1.2) 
3PS* + 3O2 → 1PS + 1O2    (1.3) 
1O2 + Cellular Substrates → Oxidative Stress  (1.4) 
 
Photoirradiation (hν) of the photosensitiser in its singlet ground state (1PS) excites the 
photosensitiser to its singlet excited state (1PS*) (1.1). Intersystem crossing allows the 
photosensitiser to exist in its triplet excited state (3PS*) (1.2). The long-lived triplet 
excited state of the sensitiser increases the likelihood of it being quenched by triplet 
ground state molecular oxygen (3O2) through a spin-forbidden Dexter energy transfer 
process.4 Molecular oxygen is then converted to singlet oxygen (1O2) (1.3), which induces 
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cell death through oxidative stress (1.4).1,2 These energy transfer processes are also 
summarised in the simplified Jablonski diagram shown in Figure 1.1. 
 
 
Figure 1.1 A Jablonski diagram representing the electronic transitions that occur 
during type II photosensitisation that ultimately lead to singlet oxygen 
production and oxidative stress. 
 
PDT can induce direct cell death through apoptosis, necrosis or autophagy.5,6 Cell death 
following PDT can be multifactorial and some overlap between the three main pathways 
involved can occur. The mechanisms of cell death induced by PDT are dependent on cell 
type, photosensitiser localisation, photosensitiser concentration and light dosage.6 
Typically, apoptosis occurs following PDT damage to the mitochondria leading to 
cytochrome c release, and damage to the anti-apoptotic B-cell lymphoma 2 (Bcl-2) 
proteins. 5-7 Cytoplasmic delivery of singlet oxygen can lead to damage of nuclear factor κ-
light-chain-enhancer of activated B cells (NF-κB), an anti-apoptotic family of dimeric 
transcription factors.6 Autophagy has also been observed following PDT treatment, which 
can be attributed to singlet oxygen generation within the endoplasmic reticulum. Bcl-2 
damage in the endoplasmic reticulum results in a rise in free Beclin-1, a pro-autophagic 
protein. PDT within the endoplasmic reticulum leads to the activation of the mammalian 
target of rapamycin (mTOR), a cell growth regulator involved in the autophagic signalling 
pathway.6 Cell membrane damage by PDT treatment typically induces necrosis. Cells 
undergoing apoptosis can also revert to necrosis if the PDT induced damage becomes 
3O2
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overwhelming.6 Necrosis is typically regarded as a non-regulated, randomised mechanism 
of cell death. However, it has recently been suggested that PDT treatment of glioblastoma 
cells using 5-aminolevulinic acid (ALA) induces necrosis, which can also be programmed 
and regulated through the formation of necrosome complexes leading to ‘necroptosis’.8 
In addition to direct cytotoxicity of the cancer cells, PDT destroys the tumour 
microvasculature causing it to shut down, thus restricting the tumour’s blood supply.9 This 
depletes nutrients and oxygen at the site of the tumour, which can enhance the outcome of 
the treatment. PDT treatment also promotes localised inflammation within the vicinity of 
the irradiated tumour due to the release of cytokines, stress signals and arachidonic acid.10 
These signals result in leukocyte recruitment and tumour infiltration, followed by 
systemic immunity against tumour cell antigens.5,10 
 
1.1.2 Photosensitisers in clinical PDT for cancer 
The clinical outlook of PDT as an effective treatment for cancer is advancing, as many 
photosensitisers are clinically used for several cancers such as those of the skin, bladder, 
and head and neck.5 Clinically available photosensitisers include porphyrins (e.g. 
Photofrin® and Photogem®), porphyrin precursors (e.g. Levulan®, Metvix® and Hexvix®), 
texaphyrins (e.g. Antrin®), chlorins (e.g. Foscan®, Photolon® and Photochlor) and 
phthalocyanines (e.g. Photosens® and Pc4).5,11-14 
Porphyrin sensitisers are photoactive heterocyclic tetrapyrroles, whose photophysical 
properties differ with varying peripheral chemical substituents.13 Photofrin® (Figure 1.2), 
also known as porfimer sodium, is a widely used photosensitiser for the treatment of 
Barrett’s oesophagus,15 oesophageal cancer,16 endobronchial cancer17 and lung cancer,18 
amongst other malignancies. Irradiation at 630 nm is approved for Photofrin® PDT.18 
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Figure 1.2 The chemical structure of Photofrin® (porfimer sodium), adapted from 
Allison et al.14  
 
Prodrugs, such as Levulan® (5-aminolevulinic acid, ALA), exploit cellular biosynthetic 
pathways to synthesise porphyrin photosensitisers. ALA (Figure 1.3 (A)) is the natural 
precursor of the intrinsic photosensitiser protoporphyrin IX (PpIX, Figure 1.3 (B)), which 
is produced in the haem biosynthesis pathway.19,20 Incubation with an excess of the 
prodrug ALA results in an intracellular accumulation of the photosensitising PpIX, and it 
has been shown that malignant cells exhibit higher levels of PpIX accumulation than 
normal cells as a result of altered enzymatic biosynthesis regulation.21-23 ALA is commonly 
used for the treatment of surface malignancies,19 precancerous (e.g. actinic keratosis24) 
and non-cancerous abnormalities (e.g. acne vulgaris20,25). Additionally, ALA has seen 
widespread use for photodynamic diagnosis, where preferential accumulation of ALA and 
protoporphyrin IX biosynthesis is exploited for real-time fluorescence monitoring of 
tumours for diagnostic and surgical applications.20 Blue light (ca. 400 nm) is typically used 
to excite PpIX due to the spectral dominance of the Soret band.26 However, excitation with 
blue wavelengths of light only allows specific imaging of thin tissue (e.g. lung tissue).26 
Derivatives of ALA with more hydrophobic, and cell membrane permeating, 
characteristics are also in use. Examples include the methyl ester (Metvix®), butyl ester, 
hexyl ester (Hexvix®) and octyl ester of ALA.27 The biggest use of ALA in the PDT 
treatment of cancer is for dermatological malignancies. These include Bowen’s disease, 
superficial basal cell carcinoma, superficial squamous cell carcinoma, cutaneous T-cell 
lymphoma, malignant melanoma and Kaposi’s sarcoma.26  
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Figure 1.3 Structures of A) 5-aminolevulinic acid (ALA, Levulan®) and B) its metabolic 
product protoporphyrin IX (PpIX) adapted from Bonnett.28  
 
Texaphyrins are a class of expanded lanthanide metal complexed porphyrin derivatives 
with relatively new applications as photosensitisers for PDT treatment and as 
radiosensitisers for enhanced radiotherapy.11 The archetypal structure of a texaphyrin, a 
macrocyclic porphyrin derivative ring complexed to a central lanthanide ion, is shown in 
Figure 1.4. Antrin® is a water soluble lutetium (III) texaphyrin photosensitiser that has 
been heavily investigated for the treatment of prostate cancer29,30 and other indications, 
such as breast cancer.31,32 The sensitiser exhibits maximal absorption at 732 nm and has a 
unique tumour selectivity (tumour: muscle ratio of 10.55).31 Xcytrin® is a gadolinium (III) 
texaphyrin with potential applications as a radiosensitiser for brain metastases, with the 
added advantage of also being MRI detectable allowing for in vivo monitoring.11,33  
A B
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Figure 1.4 Structure of a typical texaphyrin radio/photosensitiser adapted from Sessler 
and Miller.11 The lanthanide metal ion (Ln) complexed is usually 
gadolinium(III) or lutetium(III). 
 
Like porphyrins, chlorins are aromatic macrocycles consisting of four pyrrole rings, 
however, one of the pyrrole rings is reduced resulting in increased absorption in the red 
region of the spectrum.34 5,10,15,20-tetra(m-hydroxyphenyl)chlorin, also known as 
temoporfin or Foscan®, is a chlorin photosensitiser with four hydroxyphenyl substituents 
(Figure 1.5), which is not FDA approved but has received clinical approval in the EU.35 
Indications for Foscan® use include the treatment of anal cancers, malignant brain 
tumours, breast cancers, malignant mesotheliomas, oesophageal cancers, skin cancers, 
gynaecological cancers and oral cancers.35 The solubility and tumour localisation of 
Foscan® has proven to be challenging and therefore liposomal and PEG-modified 
formulations, namely Foslip® and Fospeg®, respectively, have been extensively 
studied.35,36  
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Figure 1.5 The chemical structure of Foscan® adapted from Bonnet et al.34 
 
Phthalocyanines are azaporphyrin derivatives containing a central ion that exhibit red-
shifted Q-bands, as compared to porphyrins.28,37 The optical characteristics of 
phthalocyanines can be further enhanced by modifying the peripheral substituents of the 
macrocycle, or by introducing axial ligands to the central ion.37,38 By using a closed d shell 
or diamagnetic central ion, such as Zn2+, Al3+ and Ga3+, the sensitisers exhibit longer triplet 
lifetimes and higher singlet oxygen quantum yields of 0.3-0.5.28,37,39 Phthalocyanines 
containing central open d shell or paramagnetic ions, such as Fe2+, exhibit shortened 
triplet lifetimes and minimal singlet oxygen production.28,37 However, phthalocyanines are 
strongly hydrophobic and systemic administration is achieved through preparations of 
liposomes or emulsions.28,37 Increased hydrophilicity of phthalocynanines has been 
commonly achieved through varying degrees of peripheral sulfonation.40 However, studies 
have shown that the PDT efficacy of such sensitisers can be highly variable, as stability, 
biodistribution and pathways of intracellular uptake are dependent on charge, 
hydrophobicity and isomer purity.40-42 
Zinc phthalocyanines have seen extensive use for in vitro and in vivo PDT studies for 
cancer. The delivery of these hydrophobic sensitisers to tumours following liposomal 
administration is known to be through association with lipoproteins.43 Zinc 
phthalocyanines have been shown to be effective PDT agents for the treatment of lewis 
lung carcinomas,44 fibrosarcomas,45 mammary carcinomas,46 and transformed 
fibroblasts,47 amongst other cancers. Photosens® is a sulfonated aluminium 
phthalocyanine that is commercially available in Russia.12,48 Photosens® has been used for 
the treatment of cancers of the oesophagus, lungs, breasts, bladder, cervix, lip, tongue, 
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pharynx and larynx.12,49-51 Silicon phthalocyanine (Pc4, Figure 1.6) is a sensitiser that has 
drawn considerable attention for PDT applications due to its alkyl axial ligand that 
prevents sensitiser aggregation and allows isomeric purity. Pc4 has been extensively used 
in pre-clinical and clinical studies in patients for the treatment of cancerous, precancerous 
and non-malignant skin conditions. These include actinic keratosis, Bowen’s disease, 
squamous cell carcinoma and basal cell carcinoma, amongst others.52-54 
 
 
Figure 1.6 Structure of the axially-substituted silicon phthalocyanine, Pc4, adapted 
from Baron et al.53 
 
When topically applied to early surface carcinomas, photodynamic treatment has the 
capacity to effectively eradicate the malignancy. Sensitisers with hydrophobic or 
amphiphilic characteristics have been found to penetrate the plasma membrane lipid 
bilayer and enter cancer cells more efficiently than hydrophilic photosensitisers.41 
However, a major drawback to the lipophilic nature of hydrophobic photosensitisers is 
their limited solubility in aqueous environments and their high tendency to aggregate, 
which can render them inactive and clinically ineffective.1,5 A balance between 
photoactivity, physiological stability, effective biodistribution, and tumour localisation of 
photosensitisers must be obtained to maximise the PDT outcome. Nanoparticles 
composed of an array of materials have been shown to be an effective technology for the in 
vivo delivery of a variety of photosensitisers. Additionally, the multifunctionality of 
nanoparticles is proving to be increasingly valuable for the PDT treatment of cancer. 
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1.2 Nanoparticles for enhanced PDT  
Nanoparticles, particles with diameters below 100 nm, have seen a dramatic rise in the 
number of applications that make use of their intriguing physical, chemical and optical 
properties. At the nanoscale, materials can possess characteristics that differ from their 
bulk state, expanding the use of such materials for various biomedical applications. Such 
applications include drug delivery, bioimaging and phototherapy, in addition to various 
other clinical, diagnostic and therapeutic applications.55-57 Tumours develop an increasing 
demand for blood that is met by rapidly forming vascularisation. The newly formed 
vessels are of poor quality and are more ‘leaky’ than healthy vasculature, thus giving rise 
to a phenomenon referred to as the enhanced permeability and retention (EPR) effect.56,58 
Given sufficient systemic circulation time, nanoparticles extravasate into the tumour 
stroma and accumulate within the malignant tissue through the EPR effect, making them 
of particular interest for the delivery of anticancer agents.57,59 In addition to their small 
size, nanoparticles can serve as multifunctional platforms for therapy allowing the 
combination of drug delivery and cancer specificity through the conjugation of biological 
targeting ligands.56,60 
Nanoparticles have drawn particular interest in PDT for their ability to stabilise 
photosensitisers in aqueous environments and to preserve the photoactive monomeric 
form of the sensitisers. Some nanoparticles, also known as ‘active’ nanoparticles, possess 
photophysical characteristics that are directly or indirectly involved in the 
photogeneration of ROS.61 In this chapter the potential uses of a variety of nanoparticles 
for PDT-based cancer therapy will be highlighted, including silica and polymeric 
nanocarriers, gold and magnetic nanoparticles for ‘theranostics’62, luminescent and non-
luminescence semiconductors for diagnostics and therapy, and self-illuminating 
nanoparticles for PDT treatment and imaging of deeply situated tumours. The synthesis, 
biocompatibility, functionalisation and phototoxicity of such nanoparticle systems will be 
outlined and their potential for clinical use for the effective treatment of cancer will also 
be discussed based on in vitro and in vivo experiments.  
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1.2.1 Gold nanoparticles 
Gold nanostructures are of particular interest in therapies such as PDT due to their 
biocompatibility, stability, size control and ease of surface functionality.63 The nature of 
the gold-sulfur bond has been exploited in the self-assembly of thiolated photosensitiser 
molecules onto the surface of gold nanoparticles for PDT.64 Figure 1.7 shows a gold 
nanoparticle with a photosensitiser supported on the surface. Excitation of the 
photosensitiser attached to the gold nanoparticle results in the production of singlet 
oxygen and/or other ROS species. The gold core can be used also for plasmonic imaging or 
hyperthermal treatment. 
 
Figure 1.7 A schematic diagram of a gold nanoparticle modified with a photosensitiser. 
Top: Irradiation of the photosensitiser with light induces production of 
singlet oxygen. Bottom: Irradiation of the gold core with light can be used for 
surface plasmon-based imaging and hyperthermal therapy. 
 
The Russell group were the first to use gold nanoparticles for supporting a zinc 
phthalocyanine (Pc) photosensitiser via a C11 mercaptoalkyl tether.64 Reduction of gold 
chloride by sodium borohydride in the presence of the phase transfer reagent, 
tetraoctylammonium bromide (TOAB), and the thiolated Pc yielded stable nanoparticles 
with a diameter of 2-4 nm. The TOAB not only provided solubility for the hydrophobic 
system in polar solvents, but also enhanced the singlet oxygen quantum yield. The same 
Pc-gold nanoparticle system was shown to enhance the PDT effect on HeLa cervical 
adenocarcinoma cells as compared to an emulsion of the free photosensitiser.65 In vivo 
studies further demonstrated the ability of these Pc gold nanoparticle conjugates to inhibit 
the growth of an implanted amelanotic melanoma following irradiation, and showed that 
irradiation of the nanoparticles was effective against the tumours 3 h following 
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intravenous administration in mice.66 Gold nanoparticles have been synthesised carrying 
the same Pc photosensitiser together with polyethylene glycol (PEG).67 PEG provided the 
nanoparticle system with aqueous solubility and colloidal stability, in addition to 
providing terminal carboxyl moieties that allowed conjugation of biomolecules. By 
conjugating anti-HER-2 antibodies to the gold nanoparticles through PEG, it was shown 
that the nanoparticles could actively target human breast cancer cells overexpressing the 
HER-2 receptor for enhanced cancer specific PDT. In the research reported in Chapter 4, 
the cancer-associated carbohydrate T antigen present at the surface of HT-29 human 
colon adenocarcinoma cells has been targeted using the lectin, jacalin, conjugated to PEG-
Pc gold nanoparticles.68 Jacalin conjugation to the gold nanoparticles induced substantial 
targeted phototoxicity (ca. 95-98%) of the HT-29 colon cancer cells.  
The fate of nanoparticles of various compositions and morphologies has been the focus of 
much research in recent years. The in vivo biodistribution, pharmacokinetics and 
excretion of 5 nm PEG modified gold nanoparticles carrying a hydrophobic silicon 
phthalocyanine photosensitiser (Pc4) have been recently studied in a mouse tumour 
model by the Burda group.69 The photosensitiser was non-covalently associated with the 
nanoparticles by association of the aminoalkyl axial ligand of Pc4 with the gold surface. 
The nanoparticles were found to efficiently deliver Pc4 to the cytoplasm of tumour cells by 
diffusion of the hydrophobic photosensitiser through the lipid membrane. It is known that 
PEG modification prolongs systemic nanoparticle circulation times.59,70-72 Clearance of 
nanoparticles from the blood by the reticuloendothelial system (RES) limits the potential 
for nanoparticles to accumulate at the site of the tumour via the EPR effect, leading to a 
rapid build-up of nanoparticles in the liver and spleen, both major organs involved in the 
RES.70 The PEG modified gold nanoparticles were found to have a circulation half-life of 3 
h, avoiding rapid clearance by the RES system. The nanoparticles caused maximal 
accumulation of the photosensitiser deep within the tumour 4 h following intravenous tail 
vein administration. The gold nanoparticles were found to accumulate in the liver and 
spleen throughout the 7 days following administration. However, the nanoparticles that 
escaped RES clearance were observed in the kidneys at 4 h after administration and 
continuously declined in number over the 7 days studied.69 These findings suggests that 
although the particles were eventually cleared by the RES system, some gold nanoparticles 
were likely to be excreted from the body through renal clearance. 
Two conjugates composed of brucine and a porphyrin have been synthesised and 
conjugated to 3-mercaptopropionic acid decorated gold nanoparticles ca. 15 nm in 
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diameter.73 These nanoparticle vehicles showed no evidence of enhanced in vitro PDT 
efficacy on PE/CA-PJ34 squamous cell carcinoma cells as compared to the free 
photosensitiser, possibly due to nanoparticle aggregation. Conversely, the nanoparticles 
were shown to completely eradicate subcutaneous tumours in vivo for up to 30 days post-
PDT. This was thought to be due to the interaction of the nanoparticle conjugates with 
serum proteins, improving their accumulation at the site of the tumour.  
The PDT efficacy of gold nanoparticles functionalised with the widely used photosensitiser 
haematoporphyrin (HP) has been studied in vitro to compare particles of 15 nm and 45 
nm in diameter.74 The citrate capped nanoparticles (15 nm and 45 nm) were stabilised 
with a layer of polyvinylpyrrolidone (PVP) and HP was then adsorbed within the polymer. 
It was found that upon irradiation, these gold-photosensitiser conjugates produced 
significantly more ROS than free HP, which was likely to be due to the heavy atom effect of 
the gold nanoparticles. The in vitro application of these nanoparticle conjugates on MT4 
and Jurkat leukaemia cells showed that the 45 nm gold nanoparticle conjugates were the 
most effective at photodynamic cell destruction. 
Nanoparticles possessing optimal absorption characteristics have been used in 
combination with photosensitisers for dual photothermal-photodynamic therapies. An 
aluminium phthalocyanine photosensitiser and PEG were conjugated to gold nanorods (ca. 
34x9 nm) for in vitro and in vivo photodynamic, photothermal and combined 
photodynamic-photothermal therapy.75 The fluorescence of the phthalocyanine was used 
to monitor both the intracellular uptake and the biodistribution of the free and bound 
phthalocyanine. The nanorods proved to enhance the cellular uptake of the 
photosensitiser and to improve the physiological delivery of the photosensitiser to the 
tumour. In vivo studies of a subcutaneously implanted SCC7 mouse tumour model 
indicated that dual photodynamic-photothermal therapy was significantly more effective 
at inhibiting tumour growth than either therapy alone. The photosensitiser hypocrellin B 
was also trapped within gold nanocages (ca. 50x50x50 nm) that exhibit a broad 
absorption spectrum in the near-infrared region of the spectrum.76 Viability of HeLa 
cervical adenocarcinoma cells incubated with the nanocage complexes following 
irradiation at 790 nm was significantly reduced through synergistic photothermal-
photodynamic effects.  
The surface plasmon absorption characteristics of gold nanoparticles also have been used 
for surface enhanced Raman scattering (SERS) based detection of cancer cells in 
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conjunction with PDT for theranostic (combined therapy and diagnostics) applications in 
cancer treatment. Silica coated star shaped gold nanoparticles with a surface plasmon 
absorption band centred at ca. 900 nm have been synthesised for use in dual SERS-PDT 
theranostics.77 The silica shell was co-doped with a SERS dye to enhance the Raman 
scattering signal and the photosensitiser methylene blue (MB) for singlet oxygen 
generation. The nanoparticle conjugates were shown to induce significant cell death of 
BT549 human breast carcinoma cells following irradiation.  
Citrate capped gold nanoparticles with diameters from 5-250 nm were also found to 
catalytically enhance the generation of •OH and •O2
- upon UV and X-ray irradiation in 
water, thus potentially enhancing the antitumour effect of radiotherapy.78 
Gold has appealing physical and optical qualities that is both appropriate for chemical 
modification with sensitisers and effective for clinical use. Both in vivo and in vitro studies 
have shown the suitability of gold nanoparticles as stable delivery systems of PDT drugs. 
Further studies into the physiological fate of such gold nanoparticles are needed to assess 
the extent and duration of the nanoparticle accumulation in organs such as the liver and 
spleen. 
 
1.2.2 ORMOSIL nanoparticles 
Silica is a robust material with tuneable chemical properties. Its versatile polymerisation 
has meant that silica is frequently used for the stabilisation of photosensitisers and to 
functionalise various types of nanoparticles for biomedical applications.79 A wide range of 
photosensitisers have been entrapped within silica nanoparticles. This method has proven 
to be effective in preserving the activity of hydrophobic photosensitisers in aqueous 
environments. Organically modified silica (ORMOSIL) based nanoparticles have seen 
widespread use due to their flexible hydrophobic/hydrophilic properties, which can be 
tuned in accordance with the degree of hydrophobicity of the photosensitiser.79 In 
addition to the physical entrapment of photosensitisers within a silica nanoparticle, some 
photosensitising drugs have been incorporated within nanoparticles by covalent coupling 
to monomeric precursors of silica. Following condensation of the silica, the nanoparticles 
formed contain covalently integrated photosensitisers with a regulated sensitiser 
content.79 Figure 1.8 shows a schematic representation of silica nanoparticles doped with 
a photosensitiser.  
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Figure 1.8 A schematic diagram of silica nanoparticles with a photosensitiser 
encapsulated within the core. Irradiation of the photosensitiser with light 
produces singlet oxygen.  
 
The Prasad group were the first to encapsulate a photosensitiser in silica nanoparticles to 
yield stable nanoparticulates dispersed in an aqueous medium.80 The ORMOSIL 
nanoparticles were synthesised by loading the photosensitiser 2-devinyl-2-(1-
hexyloxyethyl)pyropheophorbide (HPPH) into the hydrophobic core of micelles along 
with the silica precursor, triethoxyvinylsilane, and the aminoalkyl silica precursor, 3-
aminopropyltriethoxysilane (APTES). Complete condensation of the silica precursors 
yielded 30 nm nanoparticles with a hydrophobic core entrapping HPPH, and a hydrophilic 
amine functionalised surface provided by APTES condensation. These HPPH encapsulated 
nanoparticles were capable of producing singlet oxygen at levels identical to those 
generated by an aqueous emulsion of free HPPH. Importantly, these ORMOSIL particles 
caused substantial cytotoxicity at a HPPH equivalent concentration of 20 µM in both HeLa 
cervical adenocarcinoma cells and UCI-107 ovarian carcinoma cells. The Prasad group 
went on to synthesise 20 nm ORMOSIL nanoparticles by the coprecipitation of the 
photosensitiser iodobenzylpyropheophorbide (IP) covalently coupled to the silica 
precursors 4-(triethoxysilyl)-aniline and vinyltriethoxysilane.81 Three different types of 
ORMOSIL nanoparticles were synthesised by varying the ratio of the two silica precursors. 
All of the nanoparticles covalently incorporated the IP photosensitiser, and preserved both 
the fluorescence properties of the sensitiser and its capacity to produce singlet oxygen. 
Fluorescence imaging confirmed that all three types of nanoparticles were readily 
internalised by Colon-26 mouse adenocarcinoma cells at an IP equivalent concentration of 
2 µM. Phototoxicity was effectively induced with an IP equivalent concentration of 0.5 µM 
in a light dose dependent manner by irradiation at 665 nm. The same group also 
demonstrated the enhanced in vitro PDT efficacy of 30 nm ORMOSIL nanoparticles 
entrapping HPPH through iodination of the particles.82 By using an iodinated silica 
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precursor, the efficiency of singlet oxygen production by the nanoparticle complex was 
potentiated through the heavy-atom effect.  
ORMOSIL nanoparticles have been synthesised from the silica precursor, APTES, 
covalently bound to the photosensitiser protoporphyrin IX (PpIX).83 Singlet oxygen 
production of the PpIX derivatised, amino functionalised silica nanoparticles (ca. 70 nm) 
was verified by the characteristic phosphorescence of singlet oxygen at 1270 nm and also 
by singlet oxygen induced photobleaching of 1,3-diphenylisobenzofuran (DPBF) upon 
illumination with 532 nm light. These authors observed that the efficiency of singlet 
oxygen delivery of the PpIX-nanoparticle system was higher than that of free PpIX, further 
suggesting that by preserving photosensitisers in their monomeric form, nanoparticles can 
enhance singlet oxygen production.84 The same enhancement in singlet oxygen production 
has been reported with haematoporphyrin entrapped in silica nanoparticles (37 nm and 
57 nm).85 Additionally, the nanoparticles were co-doped with fluorescein isothiocyanate 
for simultaneous bioimaging and PDT, whilst maintaining their superior photosensitising 
capacity. 
The PDT agent meso-tetraphenylporphyrin (TPP) was co-encapsulated in ORMOSIL 
nanoparticles with the pH indicator bromothymol blue (BTB) for selective PDT within the 
acidic tumour interstitium.86 In basic pH conditions, spectral overlap between BTB and the 
photosensitisers resulted in competitive light absorption and insufficient TPP activation. 
However, a spectral shift in the pH indicator upon acidification resulted in effective 
sensitiser activation, thus demonstrating their potential as tumour sensitiser delivery 
systems.  
PpIX was also encapsulated in silica nanoparticles ca. 10, 25 and 60 nm in diameter.87 The 
silica precursor, triethoxyvinylsilane, was condensed in the presence of PpIX and 
dioctadecyl tetramethyl indodicarbocyanine chlorobenzene (DID), a fluorophore used for 
bioimaging experiments. Initial studies with all three nanoparticle sizes incubated with 
HCT 116 human adenocarcinoma cells showed no difference in internalisation rate or 
cytotoxicity following irradiation. Phototoxicity of the PpIX doped nanoparticles (25 nm) 
was investigated in human colon, breast, epidermoid and lymphoblastoid cancer cell lines. 
The nanoparticles were most effective on HCT-116 colon cancer cells with a half maximal 
effective concentration (EC50) of 0.44 ± 0.05 µM. 
Mannose functionalised silica nanoparticles carrying a covalently bound photosensitiser 
have been used to target mannose-binding lectins at the surface of MDA-MB-231 breast 
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cancer cells, and have demonstrated the potency of carbohydrates as selective 
cytoadhesive molecules.88 A further study has looked into the functionalisation of silica 
nanoparticles with mannose residues to enhance bioadhesion and cellular uptake.89 The 
nanoparticles contained a covalently bound porphyrin derivative photosensitiser, which 
was activated by multiphoton excitation using 760 nm laser light. In vitro PDT studies on 
MCF-7 and MDA-MB-231 human breast adenocarcinoma cells, and on HCT-116 human 
colon adenocarcinoma cells concluded that the nanoparticles exhibited no significant dark 
toxicity. However, significant phototoxicity of the conjugates upon multiphoton excitation 
reduced cell viability to ca. 44%, 33% and 27%, respectively. The authors showed that 
multiphoton irradiation of the silica nanoparticle conjugates intravenously administered 
to a HCT-116 tumour-bearing mouse model also exhibited significant in vivo PDT efficacy 
by reducing the tumour mass by ca. 70%. The silicon content in urine of mice treated with 
the silica nanoparticles was monitored using inductively coupled plasma mass 
spectrometry (ICP-MS) over the first 14 days post-PDT. It was found that the amount of 
silicon in urine reached a maximum around 6-8 days following PDT, and then decreased 
gradually till 14 days post-treatment. These findings suggest that the silica nanoparticles 
could be readily excreted from the body through the renal clearance pathway within two 
weeks of intravenous administration. 
Calcium phosphosilicate nanoparticles carrying the photosensitiser indocyanine green 
have been conjugated to anti-CD117 or anti-CD96 antibodies for targeted PDT.90 This 
study has shown that leukaemia cells overexpressing CD117 or CD96 cell-surface 
receptors can be selectively targeted for cancer cell-specific PDT.  
Multifunctional silica nanoparticles ca. 100 nm in diameter entrapping the near-infrared 
dye ATTO 647N and the photosensitiser palladium tetraphenylporphyrin (PdTPP) have 
been synthesised for dual diagnostics and PDT.91 Furthermore, the nanoparticles were 
functionalised with an arginine-glycine-aspartate (RGD) peptide to target U87-MG 
glioblastoma cells overexpressing αvβ3 integrins enabling selective binding and 
phototoxicity by the nanoparticles. 
The Prasad group also investigated the in vivo biodistribution and clearance of 20 nm 
ORMOSIL nanoparticles loaded with a near-infrared fluorescent dye or radiolabeled with 
Iodine-124.92 They found that almost all of the nanoparticles were cleared from the body 
of a mouse via the hepatobiliary system 6 days following intravenous administration. 
Examination of the liver, spleen, kidney, lungs and skin 15 days post administration 
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showed no residual nanoparticles (as determined by the lack of fluorescence of the loaded 
dye) and showed no cell or tissue damage. 
There have been a number of reports indicating that silica nanoparticles can interfere with 
cellular function and viability in vitro, and can induce systemic toxicity and organ damage 
in vivo. The effects of different sized silica particles (40 nm to 5 µm) on human and rat 
epithelial cell lines have been investigated.93 The authors found that 40-70 nm 
nanoparticles were able to enter the cell nucleus, whereas larger particles (0.2-5 µm) were 
confined to the cytoplasm. Once inside the nucleoplasm, silica nanoparticles (40-70 nm) 
induced aberrant aggregates of topoisomerase I, an enzyme crucial for processes including 
DNA replication. Subsequently, these silica nanoparticles inhibited DNA replication, 
transcription and cell proliferation, none of which were observed when the cells were 
incubated with 0.2-5 µm particles.93 An in vivo study found that intravenous 
administration of non-porous silica nanoparticles (70 nm) at a dose of 30 mg.kg-1 was 
lethal to mice, although a higher dose (100 mg.kg-1) of 0.3 µm and 1 µm silica particles had 
no effect.94 Repeated administration of a sub-lethal dose of 70 nm silica nanoparticles 
resulted in hepatic fibrosis, an indication of chronic liver injury.94 
Silica nanoparticles are highly versatile and robust nanoparticles useful for PDT studies. 
The feasibility of co-doping the nanoparticles with photosensitisers and imaging agents 
has suggested their potential as theranostic nanoplatforms. Both in vitro and in vivo 
experiments have highlighted the powerful PDT efficacy of photosensitisers entrapped 
within silica nanoparticles. Additionally, evidence of renal clearance of silica nanoparticles 
and clearance through the hepatobiliary system make them worthy of further 
investigation for clinical PDT. However, the reports suggesting the potential for silica 
nanoparticles to impair cellular function and viability, and induce systemic toxicity and 
organ damage raise concerns over in vivo use for theranostic applications, and, therefore, 
further toxicological studies should be performed. 
 
1.2.3 Polymeric nanocarriers 
Synthetic organic polymers have been routinely used for the solubilisation, stabilisation 
and encapsulation of many nanoparticles in aqueous environments. Their capacity to be 
readily loaded with photosensitisers whilst providing a platform for further 
functionalisation with biomolecules has suggested their use as nanoparticle systems for 
cancer cell-specific PDT.61 Nanoparticle size and sensitiser loading efficiency can be 
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precisely modulated by controlling polymer composition, reaction conditions and the 
chemical characteristics of the photosensitiser.61 Some sensitisers have also been 
covalently tethered to monomers prior to polymerisation and formation of nanoparticles 
to prevent leaching of physisorbed PDT drugs before reaching the target site.95 Conversely, 
weakly entrapped photosensitisers within polymeric nanoparticles have been exploited 
for the controlled release of PDT agents. For example, pH responsive polymer 
nanoparticles, such as glycol-chitosan nanoparticles, have been shown to selectively 
release photosensitisers within the acidic tumour interstitium (pH 6.84) as opposed to 
healthy tissue (pH 7.40).96,97 
Many polymers used for PDT treatment, such as polylactic-co-glycolic acid (PLGA), have 
the added advantage of being biodegradable. As a result, polymeric nanoparticle delivery 
systems can be enzymatically degraded and excreted from the body, thus minimising risks 
of long term accumulation.61 Although polymer encapsulation techniques have been 
described for a wide variety of PDT drugs, the resultant particles are typically micrometre 
sized with diameters ranging from ca. 117 nm to ca. 988 nm. Figure 1.9 demonstrates the 
PDT action of polymeric nanoparticles loaded with photosensitiser molecules, irradiated 
with a specific wavelength of visible or near-infrared light to produce cytotoxic singlet 
oxygen. 
 
Figure 1.9 A schematic representation of polymeric nanoparticles with a 
photosensitiser entrapped within the core. Irradiation of the photosensitiser 
with light generates cytotoxic singlet oxygen.  
 
Early studies of polymeric nanoparticles as PDT drug carriers showed that sulfonated zinc 
phthalocyanine and naphthalocyanine could be efficiently incorporated into 
polyisobutylcyanoacrylate and polyethyl-2-butylcyanoacrylate nanoparticles with 
diameters ranging from 10 to 380 nm.98 The size of the nanoparticles, which were formed 
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by polymerisation in the presence of the sensitisers, was strongly dependent on pH as 
smaller nanoparticles were produced at alkaline pH conditions.  
The in vitro and in vivo effects of PLGA nanoparticles have been investigated for the 
encapsulation of the lipophilic chlorin photosensitiser meso-tetraphenylporpholactol.99 
The nanoparticles had a hydrodynamic diameter of ca. 98 nm and a meso-
tetraphenylporpholactol loading efficiency of 12%. Nanoparticles (10 µM) were incubated 
with 9L glioblastoma cells for 16 h followed by irradiation at 650 nm, which caused ca. 
95% cell cytotoxicity. Intravenous administration of the nanoparticle formulation in mice 
implanted with a prostate carcinoma tumour caused significant tumour shrinkage 
following irradiation, and tumour regrowth was not observed up to 27 days post-PDT. It 
was found, however, that encapsulation reduced the efficiency of singlet oxygen 
production as a result of photosensitiser aggregation within the nanoparticle. Also, 20% of 
the photosensitiser leached out of the nanoparticles when they were kept in a 0.5% lipid 
solution for 360 min, outlining the limited stability of polymer nanoparticles for 
photosensitisers. 
Aerosol OTTM surfactant-alginate polymer hybrid nanoparticles were used to 
simultaneously encapsulate the photosensitiser methylene blue and the chemotherapeutic 
agent, doxorubicin.100 Mice bearing JC mammary adenocarcinoma tumours were used to 
compare the biodistribution and tumour delivery of the free drugs and the polymeric 
nanoparticle carriers. It was found that the nanoparticles significantly increased the 
tumour localisation of the two drugs, and enhanced their ability to reduce viability and 
induce apoptosis. Thus, the versatility of such polymeric systems outlines their potential 
to enhance the delivery of multiple drugs to tumours for synergistic combination 
therapies. Similarly, zinc phthalocyanine was co-encapsulated with docetaxal into poly ε-
caprolactone and polyethylene oxide nanoparticles.101 Nanoparticles loaded with both 
agents exhibited an enhanced cytotoxic effect on HeLa human cervical adenocarcinoma 
cells and on an in vivo orthotopic amelanotic melanoma model following irradiation, as 
compared to nanoparticles loaded with only docetaxal. 
Methylene blue was used to compare three different PDT delivery systems: 
polyacrylamide nanoparticles (20-30 nm), sol-gel silica particles (190 nm) and ORMOSIL 
particles (160 nm).102 The singlet oxygen molecular probe anthracene-9, 10-dipropionic 
acid (ADPA) was used to compare the delivery of singlet oxygen from the entrapped 
photosensitiser. It was found that the delivery of singlet oxygen was the highest using the 
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polyacrylamide nanoparticles. However, the loading of methylene blue was 3.5 times 
higher in the sol-gel silica particles than in the polyacrylamide nanoparticles. The 
Kopelman group recently reported the synthesis of two variants of polyacrylamide 
nanoparticles covalently conjugated to two methylene blue (MB) derivatives to enhance 
the loading of the photosensitiser and to prevent leaching from the nanoparticles.95 The 
nanoparticles had an average diameter of 74.4 nm and 38.4 nm, depending on the MB 
derivative. Both types of nanoparticles were either modified with PEG or conjugated to an 
F3 peptide, a molecule specific for the commonly overexpressed receptor nucleolin. The 
PDT efficacy of the nanoparticles was assessed using MDA-MB-435 human breast 
adenocarcinoma cells in vitro. A dual live/dead cell stain using Calcein-AM/propidium 
iodide (PI), respectively, revealed that both types of nanoparticles exhibited no phototoxic 
behaviour, however cytotoxicity was observed when the nanoparticles were targeted to 
the cells using the F3 peptide.  
The Hamblin group recently reported the use of hyperbranched polyether-ester 
nanoparticles composed of hybrids of chlorin e6 (Ce6) and hyperbranched ether-ester 
monomers for the enhanced PDT of Cal-27 human tongue carcinoma cells.103 The water 
soluble nanoparticles had an average diameter of ca. 50 nm. Confocal fluorescence 
imaging confirmed the intracellular localisation of the polymeric nanoparticles. The 
conjugates exhibited a 3-4-fold higher PDT efficacy of Cal-27 cell kill as compared to the 
free sensitiser. 
The Hasan group prepared PEG-PLGA block co-polymer nanoparticles entrapping the 
sensitiser benzoporphyrin derivative monoacid, which were enveloped in a liposomal 
formulation along with the anti-angiogenic agent, Avastin®.104 The ‘nanocell’ liposomal 
formulation was delivered intracellularly in AsPC-1 human pancreatic adenocarcinoma 
cells in vitro and in vivo in a pancreatic cancer tumour model. The nanocells enhanced the 
PDT therapeutic outcome through the synergistic blocking of intracellular vascular 
endothelial growth factor (VEGF) signalling by Avasitn®.  
The Boyle group studied the effects of two different polyacrylamide nanoparticles in vitro: 
nanoparticles (ca. 45 nm) entrapping polylysine modified aluminium phthalocyanine 
tetrasulfonate, and nanoparticles (ca. 95 nm) entrapping the same sensitiser with another 
surface bound porphyrin photosensitiser, 5,10,15,20-tetrakis(4-N-
methylpyridyl)porphyrin.105 The uptake of the nanoparticles in HT-29 human colon 
adenocarcinoma cells was investigated using flow cytometry and was found to be dose 
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dependent, reaching a maximum at 18 h. It was found that the polyacrylamide 
nanoparticles containing the two photosensitisers exhibited higher levels of phototoxicity. 
Cells irradiated in the presence of the nanoparticles without prior incubation were 
effectively killed even more than those incubated for 25 h before PDT. These results 
suggested that the use of two photosensitisers with different absorption profiles within 
one nanoparticle system can be more effective than using a single photosensitiser. It was 
also shown that nanoparticles in close proximity to the cells were sufficient to deliver 
cytotoxic levels of singlet oxygen. 
Experiments using non-toxic and biodegradable nanoparticles for delivering 
photosensitisers to cancer cells have proven to be effective. However, photosensitiser 
aggregation within the polymeric matrix has been reported in several instances and 
leaching of the PDT drugs from the nanoparticle may also prove to be problematic as it can 
decrease the efficiency of photosensitiser delivery to tumours.  
 
1.2.4 Multimodal magnetic nanosystems 
Magnetic nanoparticles have drawn considerable attention due to the intrinsic properties 
that enable multiple functions to be performed, including enhancement of Magnetic 
Resonance Imaging (MRI), magnetically guided treatment and magnetic hyperthermal 
therapy.106 In several studies, the intrinsic characteristics of magnetic nanoparticles have 
been combined with the potent cytotoxicity of photosensitisers to yield multifunctional 
nanoparticles for combined cancer therapy and diagnostics. Colloidal suspensions of 
magnetic nanoparticles composed of iron oxide and manganese oxide have been utilised 
as theranostic agents, which act as efficient nanocarriers of photosensitising agents for 
improved PDT, in addition to enhancing MRI-based tumour imaging and diagnosis. Figure 
1.10 is a schematic representation of a multifunctional magnetic nanoparticle modified 
with a photosensitiser.  
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Figure 1.10 A schematic of a multifunctional magnetic nanoparticle based PDT system. 
Top: Irradiation of the immobilised photosensitiser with visible or near-
infrared light producing singlet oxygen. Bottom: Magnetic properties of the 
nanoparticle core allow for imaging, magnetic guidance and hyperthermal 
treatment with an externally applied magnetic field. 
 
The synthesis of biocompatible magnetic nanoparticles functionalised with a PDT agent 
was reported by the Tedesco group who used magnetite (Fe3O4) nanoparticles coated with 
the photosensitiser zinc phthalocyanine.107 Spectroscopic characterisation confirmed that 
the phthalocyanine maintained its optical characteristics, following immobilisation onto 
the magnetic nanoparticles, and therefore retained its photosensitising capacity. In this 
instance, the system was proposed to be a potential bimodal PDT-hyperthermia agent for 
cancer treatment. Similarly, the same group reported the successful modification of 
magnetic particles with the photosensitiser pheophorbide on magnetite (Fe3O4) 
particles108 and chlorin e6 on maghemite (Fe2O3) particles,109 yielding photoactive 
magnetic nanosystems. 
The hyperthermal effects of a magnetic PDT system composed of 10 nm magnetite 
nanoparticles functionalised with either haematoporphyrin or ALA have been 
investigated.110 The authors report the successful thermalisation of the nanoparticle 
conjugates upon exposure to an alternating current magnetic field at 50 Hz. The degree of 
thermalisation of the nanoparticle conjugates was dependent on magnetic field exposure 
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time, and the nanoparticles remained stable up to 88-98 °C, depending on the sensitiser 
conjugated. 
The first report of the in vivo use of nanoparticles for PDT combined with MR imaging used 
polyacrylamide nanoparticles co-doped with the photosensitiser Photofrin® and an MRI 
contrast agent.111 The group showed that in vivo tumour growth was arrested following 
PDT using the nanoparticles which had been targeted to tumour vessels overexpressing 
αvβ3 and αvβ5 integrins using an RGD peptide bound to the surface. The entrapped MRI 
contrast agent enabled in vivo monitoring of the destruction of the tumour. 
Magnetite nanoparticles have been synthesised and modified with a porphyrin 
photosensitiser.112 Intracellular uptake of the iron oxide conjugates in HeLa cervical 
adenocarcinoma cells was observed by exploiting the fluorescence of the photosensitiser. 
Irradiation of the cells incubated with the nanoparticle conjugates with light ranging from 
540-580 nm directly induced cytotoxicity of the HeLa cells. Although no attempt at 
hyperthermal treatment was made, their potential for dual PDT-hyperthermal treatment 
was proposed. 
The Prasad group prepared magnetite nanoparticles encapsulated within a PEG-coated 
lipid micelle containing the photosensitiser Photochlor (HPPH) to treat HeLa cervical 
adenocarcinoma cells, with the potential for magnetic guidance and enhanced delivery to 
cancer cells.113 Cellular uptake of the nanoparticle conjugates was confirmed by utilising 
the fluorescence of the photosensitiser and the ability of the system to induce cell death 
was demonstrated by the MTT viability assay.113 
The in vivo PDT efficiency of MRI guided magnetite nanoparticles coated with chitosan, 
which encapsulated the porphyrin-based photosensitiser, 2,7,12,18-tetramethyl-3,8-di-(1-
propoxyethyl)-13,17-bis-(3-hydroxypropyl) porphyrin (PHPP) has been investigated.114 
PDT treatment of SW480 colorectal adenocarcinoma cells with the ca. 20 nm magnetic 
nanoparticle conjugates was demonstrated using an MTT viability assay. Importantly, the 
nanoparticles were successfully guided to a mouse tumour using an external magnetic 
field, and PDT was monitored in vivo using quantitative MRI-based imaging. An 
investigation into the biodistribution of these nanoparticles concluded that the 
nanoparticles accumulated at the tumour more than in the liver and skin.  
Similarly, iron oxide nanoparticles have been covalently modified with the photosensitiser 
chlorin e6 (Ce6).115 Using a MGC803 gastric carcinoma mouse model, the nanoparticle 
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conjugates enabled fluorescence and MRI visualisation of the tumour within 6 h of 
administration. As the nanoparticles accumulated in the tumour with the assistance of 
external magnetic guidance, the fluorescence intensity of the Ce6 bound nanoparticles 
increased, and the MRI contrast image darkened. Following PDT treatment, inhibition of 
tumour growth was the most significant for up to 28 days when the conjugates had been 
magnetically guided to the tumour.  
An alternative material that has seen significant interest in PDT-based theranostics due to 
its paramagnetic behaviour is manganese oxide. Hydrophobic monodisperse manganese 
oxide nanoparticles (ca. 14 nm in diameter) have been coated in a PEG shell with the 
photosensitiser PpIX covalently attached to the polymer.116 The study highlighted the 
potential use of this nanoparticle platform as an alternative to iron oxide for combined 
fluorescence and MRI based imaging of cancer cells by exploiting the luminescence of the 
photosensitiser and the paramagnetism of the nanoparticle core, respectively. Moreover, 
following conjugation to the nanoparticle, the photosensitiser retained its ability to 
generate singlet oxygen as confirmed by its cytotoxic effects on Caki-1 human renal 
carcinoma cells. 
Recently, the synthesis of paramagnetic core-shell nanoparticles consisting of terbium 
oxide (Tb2O3) and gadolinium oxide (Gd2O3) coated in a silica shell has been reported.117 
The shell covalently incorporated the photosensitiser 5-(4-carboxyphenyl)-10,15,20-
triphenyl-chlorin (TPC) for dual MRI imaging and PDT applications. It was found that the 
fluorescence and singlet oxygen production of the TPC within the nanoparticles was 
quenched with increasing intraparticle concentrations of the sensitiser through long-
range FRET and self-quenching processes. 
These studies outline the significant potential of such magnetic nanoparticles for the 
improvement of PDT for cancer treatment. Such magnetic nanoparticles provide an 
additional dimension to in vivo theranostics using an external magnetic field for MRI 
tumour detection, nanoparticle guidance and hyperthermal treatment using these 
versatile, multifunctional composite nanosystems. 
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1.2.5 Metal oxide semiconductors  
Some metal oxide nanoparticles are inherently photosensitising and can produce various 
forms of ROS that are usually associated with type I reactions. Examples of these are 
titanium dioxide (TiO2) and zinc oxide (ZnO) nanoparticles, which are semiconductor 
nanocrystals that catalytically generate ROS upon photoexcitation.118 Following irradiation 
with photons of energies greater than or equal to their band-gap, these metal oxide 
nanoparticles undergo a charge separation in their crystal lattice where electrons in the 
valance band move to the conduction band leaving behind a positive hole. The electron in 
the conduction band becomes trapped and recombination of this electron-hole pair 
(exciton) is delayed. This results in a long-lived charge separation, thus increasing the 
photocatalytic efficiency of ROS production at the surface of the nanoparticles. The 
positive hole can oxidise water molecules to produce •OH, and the electrons in the 
conduction band can reduce molecular oxygen to produce •O2
- and H2O2; all of these 
species can be cytotoxic oxidising species.118 Figure 1.11 demonstrates the photoinduced 
charge separation within these nanoparticles and the subsequent ROS species produced. 
 
Figure 1.11 A schematic representation of the photoinduced charge separation of 
semiconductor metal oxide nanoparticles resulting in the generation of a 
free electron (e-) and a positive hole (h+). 
 
As a result of their high rates of photocatalysis, metallic oxide nanoparticles, in particular 
TiO2 nanoparticles, have been intensely investigated for their potential in the 
photodynamic therapy of cancer. The earliest report of using TiO2 nanoparticles for UV 
induced phototoxicity for the treatment of cancer showed that 30 nm TiO2 nanoparticles 
effectively destroyed HeLa human cervical adenocarcinoma cells in vitro when exposed to 
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UV light, and also inhibited tumour growth in vivo when administered in mice.119 Tumour 
inhibition was most significant when the tumour received a second cycle of PDT treatment 
13 days following the initial cycle.  
It has been demonstrated that TiO2 nanoparticles doped with platinum exhibited greatly 
improved phototoxicity against HeLa cervical adenocarcinoma cells.120 Platinum-doped 
TiO2 nanoparticles caused a ca. 85% reduction in cancer cell viability compared to a ca. 
35% reduction in viability induced by non-doped TiO2 nanoparticles following UV 
irradiation.  
The in vivo antitumour potential of TiO2 nanoparticles was further demonstrated using 
intravenously administered nanoparticles with UV irradiation, which prolonged the life of 
U87 glioblastoma tumour bearing mice by ca. 14 days.121 However, to effectively excite the 
administered TiO2 nanoparticles, the tumour was exposed to UV light following incision 
and temporary removal of the covering skin. This highlights the limitation of using UV 
light for the photosensitisation of deeply situated tumours treated with such 
nanoparticles.  
Near-infrared light (1200 nm) has been used to indirectly activate 30 nm TiO2 
nanoparticles doped with 10 nm gold nanoparticles to overcome the limitation of short-
wavelength excitation.122 Multiphoton surface plasmon absorption of the nanogold-doped 
semiconductors resulted in a rapid injection of electrons within the TiO2 conduction band, 
allowing the potential for ROS generation in the absence of UV irradiation. TiO2 
nanoparticles doped with 5% gadolinium, 1% erbium and 1% europium were also used as 
radiosensitisers to enhance the antitumour effect of X-ray irradiation, thus enabling 
activation with deeply penetrating radiation.123 
The synthesis of 19.3 nm hybrid TiO2 nanoparticles doped with cadmium sulfide 
semiconductor nanoparticles has been reported, and the enhanced visible light activation 
of the hybrid TiO2 particles has been demonstrated.124 Excitation of the cadmium sulfide 
particle dopants with visible light results in charge separation of the semiconductor. The 
photoinduced electron is then injected into the TiO2 conduction band, thus initiating TiO2 
photochemistry. As compared to TiO2 nanoparticles, irradiation of the TiO2-CdS particles 
with a 390-425 nm LED showed a higher efficiency of radical-induced methyl orange 
degradation and an enhanced PDT efficacy on HL60 human promyelocytic leukaemia cells. 
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TiO2 nanoparticles (25 nm) have also been functionalised with antibodies specific for 
carcinoembryonic antigen to target LoVo human colon adenocarcinoma cells 
overexpressing the cell surface antigen.125 The targeted nanoparticle conjugates destroyed 
100% of the cancer cells following 90 min UV irradiation at 254 nm, which was preceded 
by electroporation to maximise the cellular uptake of the particles. Glioblastoma 
multiforme (GBM) cells overexpressing the interleukin-13α2 receptor (IL-13α2R) have 
also been targeted with 5 nm TiO2 nanoparticles functionalised with monoclonal anti-IL-
13α2R antibodies through the 3,4-dihydroxyphenylacetic acid surface linker.126 By acting 
as an electron donor to the TiO2 conduction band, 3,4-dihydroxyphenylacetic acid reduced 
the band-gap of the TiO2 nanoparticles from 3.2 eV to 1.6 eV, causing a large red shift in the 
nanoparticle absorption band. A172 GBM cells expressing high levels of IL-13α2R and U87 
GBM cells expressing low levels of IL-13α2R were incubated with the targeted 
nanoparticle conjugates and irradiated with visible light (λ>400 nm) for 5 min. 
Phototoxicity of A172 GBM cells was significantly higher than that of the U87 GBM cells, 
highlighting the efficacy of selective PDT using biofunctionalised TiO2 nanoparticles. 
There have been several reports on the use of ZnO nanoparticles for PDT. For example, the 
different photoinduced toxicities of 20, 60 and 100 nm ZnO nanoparticles coated with 
aminopolysiloxane has been explored using SMMC-7721 hepatocellular carcinoma cells.127 
Significant reduction in SMMC-7721 cell activity (ca. 80%) was observed with the 20 nm 
nanoparticles at the lowest concentration of 2.5 µg.ml-1 upon 245 nm UV irradiation for 
180 seconds. At the highest concentration of 10 µg.ml-1, all three sizes of nanoparticles 
reduced cell activity by ca. 100% although varying degrees of dark toxicity were observed. 
These findings clearly highlight the size and dose dependence of ZnO nanoparticles on 
their photodynamic activity, showing that smaller (20 nm) ZnO nanoparticles exhibit 
higher phototoxicity at lower concentrations; however they also appear to exhibit higher 
dark toxicity at larger concentrations.  
ZnO nanoparticles have also been used as photoactive delivery agents for a porphyrin 
photosensitiser bound to the ZnO surface through an L-cysteine linker.128 The ZnO 
nanoparticles have an excitation band at 300 nm and two fluorescence emission bands, 
one of which is centred at 445 nm. The emission band at 445 nm was used to excite the 
attached photosensitiser through fluorescence resonance energy transfer (FRET), which 
was found to be 83% efficient. By incubating NIH:OVCAR-3 human ovarian 
adenocarcinoma cells with the nanoparticle conjugates and irradiating them for 30 min 
with 365 nm UV light, cell viability was reduced to ca. 10% whereas in the dark, viability 
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remained at ca. 98%. Non-conjugated ZnO nanoparticles alone, however, did not induce a 
photodynamic response under the conditions of the experiment, highlighting possible 
limitations of the photosensitising capacity of ZnO.  
Overall, photocatalytic metal oxide semiconductor nanoparticles provide opportunities for 
effective PDT, especially TiO2 nanoparticles, which exhibit exceptional photocatalytic 
efficiency. However, short wavelength excitation is a significant limitation. Furthermore, 
there are many conflicting reports regarding the genotoxicity, photogenotoxicity and 
carcinogenicity of ZnO and TiO2 nanoparticles, which must be addressed before these 
nanoparticles can be used in vivo.129 
 
1.2.6 Quantum dots 
Quantum dots (QDs) are semiconductor nanocrystals that have drawn considerable 
attention for luminescence-based applications including bioimaging, bioanalytics and 
diagnostics as a result of their intrinsic photophysical characteristics. Compared to organic 
fluorophores, QDs exhibit remarkable photostability, higher fluorescence quantum yields, 
significantly longer fluorescence lifetimes and broader absorption bands.130 QDs typically 
exhibit quantum size effects with finely tuned absorption and emission profiles: the band 
gap of the QD widens with decreasing size causing a blue-shift in absorption and 
photoluminescence.130 In addition, optical properties of QDs can be controlled by 
composition and surface functionality.130 A noticeable drawback of QDs is the acute 
toxicity of cadmium (Cd), a common integral component of these semiconductor 
nanocrystals. To overcome this limitation, efforts to graft the QDs within various non-
porous polymers or shells including zinc sulfide (ZnS) have been investigated, and 
attempts to use non-toxic photoluminescent QDs, such ZnS, silicon and carbon QDs are 
ongoing.131 For example, Cd-free core-shell indium phosphide (InP)-ZnS QDs have been 
synthesised and the photosensitiser chlorin e6 (Ce6) has been encapsulated in a thin silica 
shell coating the nanoparticle.132 These authors found that the rate determining step of 
singlet oxygen production by Ce6 activated by the QD emission was the distance-
dependent energy transfer between the nanoparticle and the sensitiser. 
QDs undergo charge separation upon excitation with light of an appropriate wavelength; 
however, radiative exciton recombination readily occurs resulting in strong fluorescence 
emission and weak ROS production. It has been reported that QDs can induce significant 
cytotoxicity upon UV excitation although this is attributed to surface oxidation, crystal 
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deterioration and subsequent Cd2+ release, rather than ROS production.131 However, in 
contrast, results with cadmium telluride (CdTe) QDs have shown production of ROS in 
quantities sufficient for cancer cell kill (ca. 80% cytotoxicity); the photosensitisation 
process was proposed to be type I, as the singlet oxygen quantum yield of these quantum 
dots was found to be only 1%.133 As a result of their unique photoluminescent properties, 
QDs have been exploited for non-radiative energy transfer to photosensitisers supported 
onto their surface. Figure 1.12 shows an example of this energy transfer process that 
causes activation of a photosensitiser associated with the QDs. 
 
 
Figure 1.12 Schematic diagram of the indirect FRET-based activation of a photosensitiser 
bound to the surface of QDs following direct photoexcitation of the 
nanoparticles. Visible light emitted from the photoexcited QDs is absorbed 
by the photosensitiser which subsequently generates singlet oxygen. 
 
The Burda group were the first to successfully functionalise the surface of 5 nm cadmium-
selenide (CdSe) QDs with a phthalocyanine (Pc4) photosensitiser.134 They showed that 
non-conjugated QDs produced singlet oxygen upon excitation in toluene, but found that 
the singlet oxygen quantum yield was only ca. 0.05. By conjugating Pc4 to the QDs, a FRET 
efficiency of 77% was observed following direct excitation with 488 nm light, which 
ultimately resulted in fluorescence emission of the sensitiser at 680 nm. 
CdTe QDs have also been functionalised with the photosensitiser meso-tetra(4-
sulfonatophenyl)porphine dihydrochloride (TSPP).135 By irradiating the QD-TSPP 
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conjugates in D2O at 355 nm, a singlet oxygen quantum yield of 0.43 was determined. No 
singlet oxygen production was observed following the excitation of the non-conjugated 
QDs. However, the singlet oxygen quantum yield of these TSPP-CdTe QD conjugates has 
been found to be lower than that reported for free TSPP (0.64).136 
Another study has shown that CdTe QDs can produce singlet oxygen but with a singlet 
oxygen quantum yield of only 0.010-0.012 when irradiated at 532 nm in D2O.137 Singlet 
oxygen was quantified using the phosphorescence at 1270 nm and singlet oxygen-
mediated photobleaching of anthracene-9,10-diyl-bismethylmalonate (ADMA). However, 
the CdTe QDs conjugated to a sulfonated aluminium phthalocyanine had an elevated 
singlet oxygen quantum yield of 0.15. Once again, the free sensitiser had a higher quantum 
yield (0.36) than that of the QD-photosensitiser conjugate.  
The intrinsic photosensitising capacity of QDs was further investigated using core-shell 
CdSe-ZnS QDs and core-shell indium gallium phosphide (InGaP)-ZnS QDs.138 The authors 
observed no singlet oxygen production following excitation of these QDs, as determined by 
the lack of photooxidation of 9,10-dimethylanthracene (DMA) and the Singlet Oxygen 
Sensor Green (SOSG). Conversely, generation of nitric oxides, such as peroxynitrite, was 
detected by the photooxidation of dihydrorhodamine 123 (DHR). Peroxynitrite is the 
reaction product of nitric oxide (NO) and •O2
-. 
Non-peripherally tetra-triethyleneoxythia substituted aluminium, gallium and indium 
phthalocyanines were synthesised and their photophysical properties were investigated 
in the absence and presence of thioglycolic acid-capped CdTe QDs.139 Singlet oxygen 
quantum yields were measured in DMSO using the singlet oxygen probe 1,3-
diphenylisobenzofuran (DPBF). It was found that the singlet oxygen quantum yield of all 
the sensitisers synthesised was elevated in the presence of the QDs upon direct irradiation 
of the sensitisers. This trend was attributed to the heavy atom effect induced by the 
presence of cadmium. However, the singlet oxygen quantum yield following indirect FRET 
activation of the sensitisers in the presence of the QDs was not measured.  
Green and red-emitting core-shell CdSe/CdS QDs coated with ZnS have been synthesised 
and modified with rose bengal and chlorin e6 (Ce6), respectively.140 Singlet oxygen 
production of the conjugates was confirmed by photoluminescence centred at 1270 nm 
and also by the photobleaching of anthracene-9, 10-dipropionic acid (ADPA). It was found 
that both QD systems could act as efficient FRET donors and/or photosensitiser carriers 
for bioimaging and PDT. 
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Multiphoton excitation has also been employed for photoactivation of QD-based PDT 
systems. CdSe/ZnS core-shell QDs (ca. 5.4 nm) have been synthesised and modified with 
mercaptopropionic acid.141 These nanoparticles had an absorption band maximum at 515 
nm and an emission band centred at 535 nm. Irradiation of these QDs with 400 nm light in 
the presence of 1,3-diphenylisobenzofuran (DPBF) indicated that singlet oxygen was not 
produced by the QDs. An amine modified rose bengal derivative with an absorption band 
maximum centred at 565 nm was covalently conjugated to the QDs, which enhanced the 
aqueous solubility of the sensitiser. In vitro cell viability was assessed using the MTT assay 
upon single photon excitation of the QD-rose bengal conjugates with 365 nm light. HeLa 
human cervical adenocarcinoma cells were incubated with 0, 1, 10 and 100 µM QDs with 
no significant dark toxicity. However following irradiation at 365 nm, a ca. 33% decrease 
in cell viability was observed with 100 µM QDs. In addition, multiphoton excitation of the 
intracellular QD conjugates at 800 nm resulted in generation of singlet oxygen as 
determined by the oxidation of 2’,7’-dichlorodihydroﬂuorescein diacetate (DHFA), a 
fluorescence based singlet oxygen probe. 
Bioluminescence has recently been utilised as a source of photoexcitation of QDs, which 
enables bioimaging and phototherapy without the need for an external light source. These 
self-illuminating QD conjugates have been found to indirectly excite the photosensitiser 
Foscan® through a process referred to as bioluminescence resonance energy transfer 
(BRET).142 Commercially available carboxyl functionalised QDs with a fluorescence 
emission band at ca. 600-710 nm were used for the study. The QDs with a diameter of ca. 
19-25 nm were covalently conjugated to luciferase through EDC/NHS amide bond 
formation. Incubation of the luciferase-QD conjugates with the luciferase substrate, 
coelenterazine, resulted in a broad bioluminescence emission (390-600 nm). The 
bioluminescence subsequently excited the QDs as confirmed by the fluorescence emission 
profile of the conjugates. HeLa human cervical adenocarcinoma cells were incubated with 
the nanoparticle conjugates for 3 h, then incubated with Foscan® containing micelles for a 
further 3 h. PDT treatment was initiated by the addition of coelenterazine which triggered 
BRET activation of the QD and subsequent excitation of Foscan®. PDT efficacy was 
assessed using the MTT cell viability assay 24 h following initiation of the self-illuminating 
PDT. Cell viability was effectively reduced by ca. 40%, demonstrating the potential of a 
BRET-based QD system for PDT of cancer.  
CdTe QDs conjugated to folic acid have also been used for targeted PDT of KB human head 
and neck carcinoma cells overexpressing the folate receptor-α.143 Phototoxicity of the QDs 
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towards KB cells was found to be significantly higher than that of the HT-29 cells, which 
do not express the folate receptor-α. 
Due to the remarkably low photobleaching of QDs and their highly tuneable 
photoluminescence emission, the various potential applications of QDs for 
photodiagnostic and phototherapeutic applications are broad. Although the excitation of 
QDs is usually limited to shorter wavelengths of light, it has been shown that BRET or 
multiphoton excitation is sufficient for PDT treatment. Additionally, evidence suggests that 
QDs below 5.5 nm are readily removed from the body of rodents through renal 
clearance.144 Nevertheless, the majority of the QD-based PDT systems investigated to date 
are somewhat limited by the toxicity of the Cd based nanocrystals.  
 
1.2.7 Scintillation nanocrystals 
Light penetration through tissue has proven to be a significant barrier in activation of PDT 
systems present within solid tumours. To address this deficiency in clinical PDT, 
scintillation nanoparticles have been investigated.145,146 These self-lighting nanoparticles 
absorb ionising radiation, such as X-rays and γ-rays, that can penetrate into human tissue 
deeper than light of UV or visible wavelengths. Following absorption, the nanoparticles 
become excited and radiative recombination of the electron-hole pair results in an 
emission of visible light, i.e., scintillation.145 Some scintillation nanoparticles, also known 
as persistent luminescence nanoparticles, exhibit a sustained afterglow of visible light 
lasting for up to several hours as a result of the prolonged decay lifetime of the 
phosphors.145,147 
The scintillation nanoparticles can be utilised as FRET donors by photosensitisers 
supported on the surface, assuming that sufficient spectral overlap between the 
scintillation and sensitiser absorption exists. This scintillation phenomenon has opened up 
an array of materials that can be excited by high energy radiation for simultaneous 
photodynamic and radiation therapy for cancer, as well as in vivo imaging of solid 
tumours.146,148 Semiconducting materials, such as TiO2, ZnO, ZnS, cerium fluoride (CeF3), 
CdSe and CdTe have been proposed as potential scintillation nanoparticles for PDT.145 
Additionally, a number of doped materials have been suggested to be promising potential 
candidates for PDT using scintillation. These materials include: cerium doped lanthanum 
fluoride (LaF3:Ce3+); cerium doped lutetium fluoride (LuF3:Ce3+); manganese doped 
calcium fluoride (CaF2:Mn2+); europium doped calcium fluoride (CaF2:Eu2+); europium 
34 
 
doped barium fluoride bromide (BaFBr:Eu2+); manganese doped barium fluoride bromide 
(BaFBr:Mn2+); and manganese doped calcium phosphate CaPO4:Mn2+, all of which are 
promising potential candidates for PDT using scintillation.145 Figure 1.13 is a schematic 
representation of a model multifunctional scintillation nanoparticle modified with 
photosensitiser molecules. 
 
Figure 1.13 A schematic representation of a scintillation nanoparticle with a 
photosensitiser coating the surface. Irradiation of the nanoparticles with 
ionising radiation induces scintillation, thereby emitting visible light, which 
can activate the photosensitiser through FRET. 
 
Scintillating lanthanum fluoride nanoparticles doped with terbium ions (LaF3:Tb3+) have 
been synthesised and functionalised with the photosensitiser meso-tetra(4-
carboxyphenyl) porphine (MTCP).149 Excitation of the LaF3:Tb3+nanoparticles (ca. 15 nm) 
with 260 nm UV light resulted in multiple luminescence emission bands, centred at 489, 
542, 584 and 621 nm, which exhibited significant spectral overlap with the MTCP 
excitation spectrum. For the emission bands at 542, 584 and 621 nm a FRET efficiency of 
68%, 52% and 50%, respectively, was determined. The production of singlet oxygen 
following X-ray irradiation of the MTCP coated LaF3:Tb3+ nanoparticles was then measured 
as a function of the decrease in anthracene-9, 10-dipropionic acid (ADPA) fluorescence 
emission. It was found that both free MTCP and MTCP conjugated LaF3:Tb3+ nanoparticles 
produced singlet oxygen in a time dependent manner during X-ray irradiation, although 
the scintillation nanoparticle conjugates were significantly more efficient.  
Amine functionalised QDs have also been used as nanoscale scintillators which emit light 
at 520 nm upon X-ray excitation.150 The nanoparticles were modified with the 
SCINTILLATION 
Nanoparticle
1O2
1O2
1O2
1O2
1O2
35 
 
photosensitiser Photofrin®. By applying 6 MV of X-ray radiation, FRET at 520 nm occurred 
from the scintillation of the QD to the conjugated Photofrin® molecules. It was shown that 
X-ray irradiation of these QD conjugates generated singlet oxygen in a dose dependent 
manner from 6 Gy to 30 Gy. H460 human lung carcinoma cells were then incubated with 
48 nM of Photofrin®-conjugated QDs for 24 h, and were then exposed to a total X-ray dose 
of 6 Gy. Apoptosis was confirmed as the primary mechanism of PDT cytotoxicity by 
positive TUNEL staining.  
Preliminary studies of scintillation nanoparticles have so far been mostly promising, 
indicating that radiotherapy of tumours could be enhanced using nanoparticles that 
readily absorb ionising radiation and scintillate to activate a PDT drug. If in vivo studies 
prove successful, scintillation nanoparticles could aid radiotherapy by reducing the dosage 
of high energy rays required for tumour eradication, thereby minimising unnecessary 
secondary effects of the treatment. 
 
1.2.8 Upconverters 
An alternative route to overcome the limitation of light penetration through tissue is to 
utilise upconversion. Upconversion is a phenomenon by which light is absorbed by a 
material at one wavelength, but the photons emitted following excitation are of a shorter 
wavelength than that used for excitation.151 This photophysical process has been explored 
for possible use in PDT, where upconverting nanocrystals are excited by near-infrared 
light (Figure 1.14). These nanoparticles, which are doped with rare earth metal ions, 
typically lanthanide ions, emit light in the visible region of the spectrum. The visible light 
is then used to excite the photosensitiser supported onto the upconverter surface. This 
process activates the photosensitiser with a wavelength of light that favours tissue 
penetration.151 Upconverting nanoparticles can also exhibit multiple tuneable emission 
peaks, which can be exploited for bimodal diagnostic and photodynamic purposes. 
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Figure 1.14 An upconverting nanoparticle coated in a silica shell encapsulating 
photosensitiser molecules. Following irradiation of the nanoparticle with 
near-infrared light, the upconverter emits visible light, which can be used for 
bioimaging or diagnostics and used to activate the photosensitiser. 
 
The PDT potential of sodium yttrium fluoride (NaYF4) nanoparticles co-doped with 
ytterbium (Yb3+) and erbium ions (Er3+) has been reported.152 The NaYF4:Yb3+,Er3+ 
upconverting nanoparticles (ca. 60-120 nm) exhibit sharp emission bands centred at 537 
nm and 635 nm following excitation with 974 nm near-infrared light. The upconverters 
were embedded in a silica shell doped with the photosensitiser Merocyanine 540. 
Following modification, the upconverting nanoparticles retained their photoluminescence 
properties. The nanoparticles were found to generate singlet oxygen upon near-infrared 
irradiation in a buffered solution. To aid cancer cell-specific uptake, the upconverting 
nanoparticles were further functionalised with an anti-MUC1 antibody targeted to MUC1 
receptors overexpressed by MCF-7/AZ human breast adenocarcinoma cells. The cells 
incubated with the nanoparticle conjugates were irradiated with a 974 nm laser. 
Following 36 min of irradiation, cell morphology was altered, which was indicative of 
cytotoxicity.  
In vitro and in vivo studies have been reported highlighting the potential of using 
upconverting nanoparticles for PDT of cancer.153 These authors synthesised 
polyethyleneimine (PEI) coated NaYF4:Yb3+,Er3+ nanoparticles (ca. 50 nm). The 
nanoparticles were further modified by covalently conjugating a cancer cell targeting 
molecule, folic acid. A zinc phthalocyanine (ZnPc) photosensitiser was physisorbed onto 
the surface of the nanoparticles to enable PDT action of the conjugates. The PDT action of 
these conjugates was investigated in vitro using HT-29 human colon adenocarcinoma cells 
and the MTT assay. HT-29 cells incubated with the upconverting nanoparticle conjugates 
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for 24 h were irradiated for 30 min with a 980 nm laser. Cell viability was significantly 
reduced by ca. 80-90% following PDT, indicating that the singlet oxygen production of 
these upconverting nanoparticle-photosensitiser conjugates upon near-infrared excitation 
is sufficient for effective cancer cell kill.  
In vitro and in vivo PDT treatment has been attempted using ca. 30 nm PEG coated NaYF4 
upconverting nanoparticles doped with 20% Yb and 2% Er, modified with chlorin e6 
(Ce6).154 The Ce6 was loaded onto the nanoparticles through hydrophobic interactions 
with oleic acid present at the surface. In addition to singlet oxygen measurement and in 
vitro MTT viability assays, in vivo studies of tumour volume, mouse survival and 
pharmacokinetic behaviour of the upconverting nanoparticles were conducted. 4T1 
mouse breast cancer cells were incubated with 5 µM Ce6 equivalent of Ce6-modified 
upconverting nanoparticles for 2 h then irradiated for 10 min with a 980 nm near-infrared 
laser. Significant reduction of cell viability was observed in a dose dependent fashion 
when the cells were incubated with the Ce6-nanoparticle conjugates and irradiated. As 
expected, unmodified nanoparticles and free Ce6 did not exhibit significant phototoxicity. 
When Ce6-nanoparticle conjugates were directly injected into the tumour of a 4T1 mouse 
model and irradiated with the 980 nm laser, substantial tumour reduction was observed. 
Of the mice treated with the nanoparticle conjugates and irradiated, ca. 70% survived up 
to 60 days, whereas no mice in the control groups survived longer than 23 days. 
Core-shell NaYF4:Yb3+,Er3+-NaGdF4 upconverting nanoparticles conjugated to chlorin e6 
(Ce6) were explored as a theranostic multimodal PDT system, a luminescent bioimaging 
platform and an MRI contrast agent.155 Upon excitation at 980 nm, emission of the 
upconverters at 540 nm was used for in vivo tumour imaging and emission at 660 nm 
excited the Ce6 sensitiser. Additionally, the gadolinium-containing shell provided MRI 
contrast enhancement of tumours in vivo. Tail vein administration of the upconverting 
conjugates into mice bearing U87-MG glioblastoma tumours, followed by irradiation at 
980 nm, resulted in complete tumour growth inhibition for 14 days post-treatment. 
A recent report describes the preparation, in vitro and in vivo efficacy of NaYF4:Yb3+,Er3+ 
nanoparticles coated in a mesoporous silica shell loaded with either Merocyanine 540, 
zinc phthalocyanine, or co-loaded with both photosensitisers.156 The nanoparticles exhibit 
two main emission bands centred at 540 nm and 660 nm, at which Merocyanine 540 and 
zinc phthalocyanine maximally absorb light, respectively. Following irradiation at 980 nm, 
the nanoparticle conjugates co-loaded with both sensitisers were more effective at 
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producing singlet oxygen and reducing the viability of B16-F0 mouse melanoma cells than 
the particles loaded with an individual photosensitiser. Irradiation of a mouse tumour 
consisting of B16-F0 cells pre-incubated with co-loaded upconverters resulted in 
substantial tumour growth inhibition, as compared to irradiation alone or incubation with 
particles alone. Yttrium quantification in four organs was performed in mice that were 
intratumourally injected with the upconverters; however, the fate of systemically 
administered nanoparticles was not investigated. Co-loaded upconverters were further 
modified with PEG and folic acid, and were injected into the tail of a melanoma bearing 
mouse. Irradiation of the tumours resulted in a statistically significant enhancement in 
antitumour efficacy when treated with folic acid targeted nanoparticles. 
Selective targeted therapy using folic acid conjugated upconverting nanoparticles has also 
been demonstrated on JAR human placenta choriocarcinoma cells overexpressing the 
folate receptor.157 NaYF4:Yb3+,Er3+ upconverting nanoparticles, further modified with rose 
bengal and folic acid, exhibited a dose dependent phototoxicity of the JAR cells, whereas 
no significant toxicity was observed with NIH/3T3 mouse embryonic fibroblast cells that 
do not express the folate receptor. 
αvβ3 integrin-overexpressing U87-MG glioblastoma cells have also been effectively 
targeted with RGD peptide conjugated NaYF4:Yb,Er upconverting nanoparticles (ca. 53 
nm).158 The nanoparticles were coated with chitosan and modified with the sensitiser 
pyropheophorbide a and the RGD peptide sequence. The particles demonstrated selective 
phototoxicity of U87-MG cells, whereas no significant toxicity was observed with MCF-7 
cells that express low levels of the αvβ3 integrin. 
A thorough in vitro and in vivo study into PDT using NaYF4:Yb,Er upconverting 
nanoparticles has shown promising results.159 The particles were coated with chitosan and 
modified with a zinc phthalocyanine photosensitiser. In addition to demonstrating an 
effective dose-dependent reduction in MCF-7 human breast adenocarcinoma cell viability 
following irradiation at 980 nm, the nanoparticles significantly inhibited tumour growth 
and prolonged the survival of tumour bearing mice. Intratumoural administration of 
chitosan coated upconverting nanoparticles functionalised with the near-infrared 
fluorescent dye, indocyanine green, revealed that the particles were not carried out of the 
tumour to the heart, kidneys, spleen, liver, lungs or intestines for up to 14 days. Although 
tumour localisation of these particles is an obvious advantage, no signs of physiological 
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clearance were apparent, which could raise concerns regarding prolonged nanoparticle 
accumulation within the body.  
Upconverting nanoparticles have only relatively recently been considered for PDT, 
although substantial preliminary in vitro and in vivo studies show huge potential. 
However, long term stability and toxicity of these lanthanide-doped nanocrystals in 
various physiological environments must be systematically studied if they are to be used 
for clinical PDT. 
 
1.2.9 Future prospects for nanoparticles in photodynamic cancer therapy 
An increasing number of studies have highlighted the exciting potential of the use of 
nanoparticles for PDT. Nanoparticles exhibit multifunctionality which can dramatically 
improve current PDT modalities. The vast array of nanoparticles and their respective 
activities show promise to significantly enhance cancer therapy by increasing the delivery 
of hydrophobic photosensitisers; by radically improving photosensitiser accumulation in 
tumours through biofunctionality and targeted therapy; and by potentially maximising the 
antitumour effect of radiotherapy. However, the majority of studies with nanoparticles for 
PDT have so far not exceeded initial stages of in vitro and in vivo experimentation. 
Although many of the nanoparticles reported to date demonstrate no immediate acute 
toxicity, and there is some evidence to suggest that some nanoparticles are cleared by the 
urinary and hepatobiliary systems, significant further studies are required to establish 
their long term physiological effects before translation into clinical practice. However, it is 
clear that the future for nanoparticle technology within PDT is exceptionally promising.  
 
1.3 Targeted PDT using lectins  
1.3.1 Aberrant glycosylation pathways in cancer development and progression 
A vast number of treatments for cancer have proven to be highly effective at reducing the 
mass of tumours and prolonging the survival rates of patients. However, the majority of 
these therapeutic modalities are accompanied by severe side effects, as healthy tissue can 
also be susceptible to damage by the treatment. The lack of specificity of cancer 
treatments can result in considerable discomfort and a decline in the quality of life of 
patients. Thus, targeted therapies that selectively destroy diseased tissue, whilst leaving 
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healthy tissue unharmed are hugely appealing. Targeted treatments that discriminate 
between cancerous and healthy tissue promise to lower the overall dosage of 
administered drugs, whilst enhancing their antitumour efficacy. 
Lectins are carbohydrate binding proteins of non-immune, non-enzymatic origin. Their 
affinity for carbohydrate moieties is highly specific. The word lectin originates from the 
Latin word 'legere' meaning 'to select'.160 The discovery that lectins could selectively 
agglutinate cancer cells gave a preliminary indication of the presence of certain 
differences between surface expressed carbohydrates in healthy and cancerous cells.161,162 
Many carbohydrates and carbohydrate patterns have been associated with the cancerous 
phenotype. Some include the over or underexpression of naturally occurring glycans, 
whilst others include the novel expression of glycans usually found in foetuses, providing 
potential targets for selective cancer therapies.163  
Cell surface glycoproteins consist of three main types: N-linked glycans that are attached 
to asparagine residues, O-linked glycans that are attached to serine or threonine residues, 
and glycosaminoglycans (GAGs) that are linked to serine residues. O-linked glycans were 
initially discovered in mucin, a protein found in mucous, and were therefore termed 
mucin-type glycans.160 Many cancer-associated carbohydrates are known to be mucin-type 
glycans, but the major disadvantage of these glycans is their terminal heterogeneity. For 
this reason, many O-glycans are termed by their core sequence.160 Carbohydrate 
abbreviations are shown in Table 1.1.  
 
Table 1.1 Common carbohydrates and their abbreviations. 
Carbohydrate Abbreviation 
galactose Gal 
glucose Glc 
N-acetylgalactosamine GalNAc 
N-acetylglucosamine GlcNAc 
fucose Fuc 
mannose Man 
sialic acid/neuraminic acid Neu 
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DNA mutations can lead to the overexpression, underexpression, or deletion of many 
genes resulting in a direct observed effect on the gene products, which can subsequently 
be overexpressed, underexpressed or missing, respectively.164 Altered levels of enzymes 
responsible for post-transcriptional glycosylation can be attributed to many of the glycan 
changes associated with cancer. A common characteristic change in surface carbohydrates 
of cancer cells is increased branching of N-glycans, which can be a result of increased 
activity of the enzyme N-acetylglucosaminyltransferase V (GlcNAc-TV). This enzyme 
causes branching of β1-6GlcNAc, which are additional sites for the attachment of terminal 
sialic acid residues. Overactivity of sialyltransferases causes an overall increase in 
sialylation of N-linked glycans, a common process in core carbohydrate structures at the 
surface of cancer cells.163,165,166 Early studies have demonstrated the relationship between 
excessive sialylation and increased metastasis.165 
The overexpression of glycosyltransferases has also been linked to malignancy, as the 
downstream effect of the activity of these enzymes leads to the overexpression of terminal 
glycan epitopes. These include the Thomsen-Friedenreich (T) antigen, the Tn antigen, 
sialyl-Tn, polysialic acid (PSA), Sialyl Lewis A (sLea), Lewis Y (LeY) and Sialyl Lewis X 
(sLeX), which have been implicated in a large variety of cancers.163 Figure 1.15 shows the 
structures of common cancer-associated carbohydrate antigens. 
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Figure 1.15 Structures of common cancer-associated carbohydrate antigens. The ‘R’ 
group refers to conjugated glycan sequences. Figure adapted from Dube et 
al.163 
 
The Thomsen-Friedenreich antigen (also known as the TF antigen, T antigen, Core 1 and 
CD 176) is a mucin-type glycan found to be overexpressed in 90% of all primary human 
carcinomas including those of the lungs, pancreas, breast, bladder, colon, oesophagus, 
ovaries and prostate.163,167 The antigen is a disaccharide consisting of Galβ1-3GalNAc-O- α-
linked to a serine or threonine residue (Galβ1-3GalNAc-O-α-ser/thr) on a cell surface 
glycoprotein. The T antigen is a truncated O-glycan that is usually cryptic in healthy cells 
as it is concealed by further branched glycosylation, sialic acid residues, or sulfate 
molecules.168 It is only exposed in cancer, inflammatory diseases such as ulcerative colitis, 
and in embryonic or developmental cells, hence it is referred to as being 
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oncofoetal.163,166,168,169 The exposure of the T antigen in colonic cancers can be attributed to 
a combination of several possible defects in the glycosylation mechanisms responsible for 
further maturation of the T antigen as is usually observed in healthy cells. These include 
the decreased expression of carbohydrate sulfotransferases responsible for concealing the 
T antigen with O-sulfate esters; an increased expression of the Uridine Diphosphate-
galactose (UDP-Gal) transporter, increasing its bioavailability and therefore increasing the 
synthesis of the T antigen; and an increased pH level inside the Golgi Apparatus favouring 
T antigen synthesis.168 The fact that the T antigen is well-defined and is highly expressed 
in a wide range of cancers, makes it an attractive molecular target for cancer therapies 
such as PDT. The function of the T antigen has been previously studied and it was found 
that it mediates cancer cell adhesion to galectin-3 of the vascular endothelium, and assists 
in the metastasis of the cells.170 
The Tn antigen is also an O-linked glycan, whose overexpression is correlated with the 
cancerous phenotype. It is the biosynthetic precursor of the T antigen and structurally 
consists of a monosaccharide, GalNAc-O-, α-linked to a serine or threonine residue.166 The 
sialylated form of the Tn antigen, sialyl-Tn, is much more specific to cancer cells and arises 
as a result of the truncation of O-linked glycans.166 The expression of Tn and sialyl-Tn is 
also usually correlated with poor prognosis of the disease.171 The Tn antigen has been 
found to be expressed in 72% of colonic carcinoma cells and only in 14% of normal colonic 
cells, making it a potential target for lectin mediated therapeutic selectivity.171 
Other mucin like glycoproteins that have certain glycosylation alterations are expressed 
on cancer cell surfaces and can then be shed. These act as cancer markers that can be 
detected in the serum and aid in the diagnosis of cancer. Glycoprotein cancer markers 
include the carcinoembryonic antigen and the prostate specific antigen. 
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1.3.2 Lectins - from discovery to biomedicine 
Monosaccharides, oligosaccharides and glycoconjugates can reversibly bind to lectins with 
varying affinities. For example, the Canavalia ensoformis (Jack Bean) lectin, Concanavalin 
A, binds to methyl-α-Man with a dissociation constant (Kd) of 15.9 μM,172-174 whereas the 
Agaricus bisporus (domestic mushroom) lectin binds to the T antigen with a Kd of 3.4 
µM.175 Lectins are usually multidomain, multimeric proteins containing carbohydrate 
recognition domains where glycan moieties specifically bind. Many lectins, like enzymes, 
require one or more metal ions to associate with their carbohydrate recognition domains 
in order for their target molecules to effectively bind.176 For example, at each carbohydrate 
recognition domain in Concanavalin A, the presence of a manganese cation and a calcium 
cation is crucial for the ability of the lectin to bind to its respective carbohydrate moiety.177 
Concanavalin A will be discussed in greater detail in Chapter 3. 
Lectins play integral roles in many processes that are dependent on the selective binding 
of glycans. For example, plants use lectins to attach to nitrogen-fixing bacteria, and to 
protect themselves from plant pathogens.178 Lectins mediate cell migration and 
cytoadhesion, in addition to regulating uptake and translocation of glycoproteins.178 
Microorganisms, such as bacteria and parasites, use lectins to bind to host cells in addition 
to a number of other processes.178 
Unlike enzymes, lectins do not have intrinsic enzymatic activity associated with their 
carbohydrate recognition domains, although some lectins have catalytic activity and non-
carbohydrate recognition at different loci on the protein. Leczymes are a type of lectins 
that have dual carbohydrate recognition and mutually exclusive RNAse activity.179 An 
example of these is the sialic acid-binding lectin from Rana japonica oocytes (jSBP) which 
contains a conserved pyrimidine base-specific RNAse domain as well as a sialic acid 
binding domain.160,180  
Most lectins are multivalent, which is crucial for their ability to cross-link carbohydrates 
on different glycoconjugates.160 These glycoconjugates could be a component of the 
cellular membrane glycans, which would result in the lectin cross-linking and 
agglutinating several cells.160,181 Stillmark first discovered in 1888 that a lectin extracted 
from Ricinus communis (castor beans) agglutinates and precipitates all types of human 
erythrocytes.182 Many interactions between lectins and mammalian erythrocytes have 
been discovered since, and due to the extent of this interaction, lectins have been termed 
agglutinins, haemagglutinins, or phytohaemagglutinins (plant lectins).160 Erythrocytes are 
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a highly glycosylated cell type and express a broad diversity of saccharides with potential 
for highly specific lectin interactions.181 The specific interaction of phytohaemagglutinins 
with erythrocytes has been routinely utilised in the determination of blood types since 
their discovery. 
Many cancers have been associated with specific glycosylation patterns, alterations, and 
aberrations which have been implemented in cancer survival, metastasis, and evasion of 
immunosurveillance.163 In the past these specific glycoconjugates have been intensely 
studied and monitored in tumour progression, and many have been sequenced, purified, 
and synthesised for histochemical, diagnostic and immunotherapeutic purposes.163 
Previous studies have shown a relationship between cellular affinity to certain lectins and 
tumourigenicity, and the study of the specificity of lectins to tumours and cancer cells is 
being extensively investigated showing great potential for future targeted therapies.  
 
1.3.3 Targeting tumour cells with lectins  
Several reports have demonstrated the potential of lectins as tumour targeting proteins, 
bioactive therapeutic agents and adjuvants for existing cancer treatments. Mistletoe 
(Viscum album) extracts have seen extensive use in pre-clinical and clinical studies for the 
treatment of a large number of cancers.183 The main active component of mistletoe 
extracts is the mistletoe lectin-1 (ML-1). Mistletoe extracts under clinical investigations 
include Iscador®, Eurixor®, Helixor®, Lektinol®, Isorel®, Abnoba-viscum and recombinant 
ML-1. Phase I and II clinical trials have explored the efficacy of mistletoe extracts in the 
treatment of colorectal carcinoma, ovarian cancer, renal cell carcinoma, breast cancer, 
prostate cancer, lung cancer, stomach cancer, bladder cancer and melanoma.183 Findings 
have reported an increased quality of life, prolonged survival and lowering side effects of 
conventional treatment.183,184 The lectin consists of two chains; a cytotoxic ribosome-
inactivating enzymatic A chain and a sialic acid-binding B chain.185 The ML-1 exhibits 
unique specificity for gangliosides and glycoproteins expressing terminal Neu5Acα2-
6Gal1-4GlcNAc-, the overexpression of which has been associated with carcinomas.186-188 
The therapeutic effect of ML-1 is a result of both its direct cytotoxic effects and indirect 
immunomodulatory effects. The A chain is responsible for inducing apoptosis at low 
concentrations (fM-pM) in a death receptor-independent mechanism.189 ML-1 can also 
activate immune cells, such as natural-killer (NK) cells, and potentiate their cytotoxicity.190 
Although ML-1 has been found to agglutinate types A, B and O human erythrocytes at a 
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concentration of 1 µg.ml-1, intravenous administration at lower concentrations is routinely 
used for therapy.191 
The lectin extracted from the seeds of the Maackia amurensis tree is known to target 
terminal α2,3-sialylated O-linked glycans.192 The Maackia amurensis lectin has been used 
to effectively target melanoma cells expressing the mucin receptor podoplanin, which is 
modified with α2,3-Neu residues. Binding of the lectin to podoplanin has been shown to 
inhibit the receptor’s interaction with its natural ligand, and thus effectively hinder B16 
melanoma cell growth and metastasis.192 
The African legume lectin, Griffonia simplicifolia lectin II (GSL-II) is the only one of three 
Griffonia simplicifolia lectins that does not agglutinate human erythrocytes.193 GSL-II has a 
specificity for α- or β-linked GlcNAc residues on the non-reducing terminal of 
oligosaccharides, also known as the TK cancer-associated antigen.194 The lectin has been 
shown to bind selectively to colonic carcinoma and hyperplastic colonic tissue, but has no 
reactivity towards normal colonic tissue.194  
The Gorse seed lectin, Ulex europeaus agglutinin I (UEA-I) specifically binds to α1,2-Fuc 
residues, also known as the H antigen, in addition to the carcinoembryonic antigen.195,196 
Like GSL-II, UEA-I does not bind to normal rectal mucosa but binds with high affinity to 
hyperplastic polyps and to carcinomatous tissue.194 Furthermore, UEA-I was shown to 
bind to 12 out of 18 rectal adenomas analysed.196 However, the lectin was found to 
agglutinate type O human erythrocytes, and to a lesser extent types A and B.197 
The hexavalent Helix pomatia agglutinin (HPA) extracted from the Roman snail exhibits 
specificity towards terminal GalNAc residues and, to a lesser extent, terminal GlcNAc 
residues.198 HPA is also known to bind to the T antigen, the Tn antigen and the 
carcinoembryonic antigen.195,199,200 The lectin has been shown to specifically bind to MCF-7 
and MDA-MB-231 human breast adenocarcinoma cells, in addition to HT-29, Caco-2 and 
HTC-116 human colon adenocarcinoma cells.201-204 However, HPA was found to have no 
reactivity towards sub-normal, non-tumourigenic MCF-10A breast cells or to IEC-6 non-
transformed rat small intestine epithelial cells.204,205 The lectin specifically recognises 
human malignant melanoma cells, and lectin reactivity has been shown to be a prognostic 
indication of the metastatic potential of a tumour.206 Furthermore, HPA was only found to 
agglutinate type A human erythrocytes.198 
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Seeds from the Hairy Vetch contain the Vicia villosa lectin (VVL), which is specific for α- or 
β-linked GalNAc, although its specificity is higher for GalNAc-α- residues (Tn antigen).207 
VVL binds to 98% of Caco-2 human colorectal adenocarcinoma cells in monolayer.208 
Histological analysis revealed that VVL is reactive towards 72% of cancerous colonic 
tissue, 100% of adenomatous and hyperplastic polyps, but only 14% of normal mucosa.171 
This lectin also agglutinates all types of human erythrocytes.209  
The flowering Coral Tree contains a heterodimeric lectin, Erythrina cristagalli lectin (ECL) 
with a molecular mass of 57 kDa.210 The carbohydrate specificity of ECL is for the Galβ-
1,4GlcNAc- disaccharide. This carbohydrate structure is a precursor for many blood group 
antigens including those of type A, B, H and Lewis blood groups.210,211 Therefore ECL can 
agglutinate all types of human erythrocytes.210,211 This disaccharide is also known as the 
Type II oligosaccharide antigen, and its expression in gastrointestinal tissue is related to 
malignancy.211 A study found that Galβ-1,4GlcNAc- was overexpressed in colorectal 
carcinomas, and this finding was highly correlated with ECL reactivity.211 In a study 
including various cancerous and healthy tissue, ECL was found to bind very weakly to the 
healthy colorectal epithelium, but showed significant binding to colorectal carcinomatous 
tissue.211 ECL binding patterns to colorectal carcinomas and their respective liver 
metastases was also found to be similar.211 Additionally, the lectin was found to react to 
50% of colonic adenomatous tissue analysed. In a cellular study using Caco-2 human colon 
adenocarcinoma cells, ECL bound to all of the cells grown in monolayer.208  
Peanut agglutinin (PNA) is a T antigen-binding lectin that does not recognise the sialylated 
form of the antigen.212 PNA only agglutinates human erythrocytes upon neuraminidase 
treatment.213 The lectin has been shown to bind to MCF-7 and MDA-MB231 breast cancer 
cells with varying affinities.214 PNA also binds to the sub-normal, non-tumourigenic breast 
cell line MCF-10A, although it’s affinity is 10-fold lower towards the non-immortalised 
variant cell line MCF-10M.215 The lectin has also been found to selectively target a variety 
of colon cancer cell lines, although a major drawback of using PNA is its ability to stimulate 
the proliferation of some cells, such as HT-29, SW837, HCT-15 and LoVo colon carcinoma 
cells.216-218 
The lectin Amaranthin derived from the Amaranthus caudatus flower is another T-specific 
lectin that binds to both the sialylated and non-sialylated forms of the antigen.219 The 
lectin binds strongly to HT-29 colon adenocarcinoma cells with an equilibrium 
dissociation constant (Kd) of ca. 16 nM and reaches maximum binding within 120 min. 
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However, the lectin does exert a pro-proliferative effect on the HT-29 cells.219 Additionally, 
Amaranthin agglutinates all types of human erythrocytes.220 
The edible mushroom contains a T-specific lectin, the Agaricus bisporus lectin (ABL).216 
ABL binds to the T antigen with a dissociation constant of (Kd) of 3.4 µM.175 The lectin also 
binds to the sialylated form of the T antigen.216 Recent studies have determined the 
presence of an additional carbohydrate binding site within ABL, that has a specificity for 
GlcNAc-exposed N-linked glycans.175 ABL has been shown to reversibly inhibit the 
proliferation of HT-29 colon cancer cells, MCF-7 breast cancer cells and Caco-2 colon 
cancer cells in a dose-dependent manner.216 The lectin has also been found to agglutinate 
all types of human erythrocytes.221 
The lectin extracted from Artocarpus integrifolia (jackfruit), jacalin, is also a T antigen-
specific lectin, which will be discussed in greater detail in Chapter 4. Table 1.2 
summarises the lectins with potential for targeted cancer treatment. The biomodulatory 
effects exerted by the lectins and their haemagglutinating characteristics are outlined. 
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Table 1.2 A summary of lectins with potential clinical applications for cancer treatment. 
Lectin Species 
Carbohydrate 
Specificity 
Tumour 
Antigen 
Biomodulatory 
Effects 
Agglutinates 
Human Erythrocytes? 
Tumour 
Reactivity 
Cancer Cell 
Reactivity 
Concanavalin A 
(Con A) 
Canavalia 
ensiformis 
(Jack bean) 
α-Man222 - 
Mitogenic to  
T-lymphocytes,223 
pro-apoptotic,224 
pro-autophagic225 
Yes 
all types (weakly)226 
Breast cancer 
biopsies227 
MCF-7, BT-20, 
MDA-MB 157, 
ALAB-496,  
SK-BR-3 breast 
cancer cells228 
Mistletoe lectin 1 
(ML-1) 
Viscum 
album 
(Mistletoe) 
terminal  
Neu5Acα2-6Gal1-
4GlcNAc- 186 
- 
Toxic A chain,185 
activates natural-
killer cells190  
Yes 
all types191 
Clinically 
effective for a 
number of 
cancer183 
- 
Maackia amurensis  
lectin 
(MAL) 
Maackia 
amurensis  
(Amur 
maackia tree) 
terminal 
α2,3-Neu-O-
ser/thr192 
- 
Inhibition of cell 
growth and 
metastasis192 
Yes 
all types (weakly)229 
- 
B16 melanoma 
cells,192 BW5147 
lymphoma 
cells,229 Ehrlich 
ascites tumour 
cells229 
Griffonia 
simplicifolia 
 lectin II (GSL-II) 
Griffonia 
simplicifolia 
(African 
legume) 
α-/β-GlcNAc194 TK antigen194 - No193 
Colon carcinoma 
resections194 
- 
Ulex europeaus  
agglutinin I  
(UEA-I) 
Ulex 
europeaus 
(Gorse seed) 
α1,2-Fuc194 H antigen194 - 
Yes 
type O197 
Colon carcinoma 
resections196 
- 
Helix pomatia  
agglutinin 
(HPA) 
Helix pomatia  
(Roman 
snail) 
terminal  
GalNAc-198 
(T antigen,  
Tn 
antigen)199,200 
- 
Yes, 
type A198 
Malignant 
melanoma206 
MCF-7,  
MDA-MB-231 
breast cancer 
cells; HT-29, 
Caco-2, HTC-116 
colon cancer 
cells201-204 
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Lectin Species 
Carbohydrate 
Specificity 
Tumour 
Antigen 
Biomodulatory 
Effects 
Agglutinates 
Human Erythrocytes? 
Tumour 
Reactivity 
Cancer Cell 
Reactivity 
Vicia villosa lectin 
(VVL) 
Vicia villosa 
(Hairy Vetch) 
GalNAc-α-O-
ser/thr207 
Tn antigen207 - 
Yes 
all types209 
Colon carcinoma 
resections171 
Caco-2 colon 
cancer cells208 
Erythrina 
cristagalli lectin 
(ECL) 
Erythrina 
cristagalli 
(Flowering 
Coral tree) 
Galβ-1,4GlcNAc-210 
Type II 
antigen210 
- 
Yes 
all types210,211 
Colon carcinoma 
resections211 
Caco-2 colon 
cancer cells208 
Peanut agglutinin 
(PNA) 
Arachis 
hypogaea 
(Peanuts) 
Galβ-1,3GalNAc-α-
O-ser/thr212 
T antigen212 
Stimulates 
proliferation216-218 
No213 
In vivo colorectal 
tumour model230 
MCF-7,  
MDA-MB-231 
breast cancer 
cells; HT-29, 
SW837, HCT-15 
and LoVo colon 
cancer cells216-
218 
Amaranthin 
Amaranthus 
caudatus 
(Flower) 
Galβ-1,3GalNAc-α-
O-ser/thr,  
 
sialyl-Galβ-
1,3GalNAc-α-O-
ser/thr219 
T antigen, 
 
sialyl-T 
antigen219 
Stimulates 
proliferation219 
Yes 
all types220 
- 
HT-29 colon 
cancer cells219 
Jacalin 
Artocrapus 
integrifolia 
(Jackfruit) 
Galβ-1,3GalNAc-α-
O-ser/thr231 
T antigen231 
Inhibits 
proliferation219 
Yes 
type B˃type A232 
Cancerous and 
precancerous 
colonic 
carcinoma 
resections233 
Caco-2 and HT-
29 colon cancer 
cells208,219 
Agaricus bisporus 
lectin (ABL) 
Agaricus 
bisporus 
(Edible 
Mushroom) 
Galβ-1,3GalNAc-α-
O-ser/thr,  
 
sialyl-Galβ-
1,3GalNAc-α-O-
ser/thr216 
T antigen, 
 
sialyl-T 
antigen216 
Inhibits 
proliferation216 
Yes 
all types221 
- 
Caco-2 and 
HT-29 colon 
cancer cells; 
MCF-7 breast 
cancer cells216  
5
0
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A number of nanoparticles have been used as potential oral drug delivery agents when 
functionalised with lectins such as wheat germ agglutinin (WGA)234 and tomato lectin,235 
which target them to intestinal tissue to enhance drug uptake.236,237 WGA has also been 
used to target liposomes carrying Foscan® for antimicrobial PDT.238 Some lectin-
functionalised nanoparticles have been used to target drugs to the brain239 and lungs,240 
while other lectin-nanoparticle systems, such as gold nanoparticle conjugates241 and 
quantum dot conjugates,242 have been used for a variety of imaging techniques.242-244 
Lectins have also been used to monitor carbohydrate expression at the surface of live cells 
when conjugated to carbon nanotube electrochemical sensors.245 Fluorescently labelled 
nanospheres functionalised with PNA have also been used to detect orthotopically 
implanted colorectal tumours expressing the T antigen.230 
Owing to their exquisite specificity for a variety of cancer-associated carbohydrate 
antigens, the lectins described herein are suggested to be powerful prospective cancer 
targeting ligands. Although some lectins exhibit haemagglutinating activity above specific 
concentrations, topical application or intraperitoneal administration246,247 of these lectins 
conjugated to drugs may still prove to be of therapeutic value. The specificity of lectins 
towards cancer cells, in addition to the remarkable biological effects that lectins can exert, 
such as apoptosis induction, inhibition of proliferation and immunomodulation, make 
lectins attractive multifunctional candidates for the targeted therapy of cancer. 
 
1.4 Thesis outline 
This thesis contains a number of experiments that demonstrate the efficacy of using a 
lectin, such as jacalin, for the targeted delivery of phthalocyanine-gold nanoparticles to 
cancer cells expressing tumour-associated glycans for enhanced PDT treatment. Titanium 
dioxide nanoparticles are also explored as potential platforms for sonodynamic therapy, 
which can increase ROS production upon exposure to ultrasound.  
A detailed description of the materials, reagents, instrumentation and experimental 
procedures performed throughout the thesis is included in Chapter 2. In Chapter 3, the 
lectin Concanavalin A (Con A) and its dimeric succinylated derivative are explored as 
potential targeting ligands for PDT. Initially, the interactions between Con A and succinyl-
Con A gold nanoparticle conjugates with SK-BR-3 and MCF-7 breast cancer cells are 
investigated using optical microscopy. The adhesion of MCF-7 breast cancer cells to Con A 
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and succinyl-Con A is also assessed using a colorimetric bioassay. Con A is then used to 
attempt the targeted PDT treatment of MCF-7 cells with Con A functionalised gold 
nanoparticles carrying a zinc phthalocyanine photosensitiser. 
An alternative synthetic procedure for preparing zinc phthalocyanine gold nanoparticles 
with a higher sensitiser loading efficiency is described in Chapter 4. Jacalin is then used to 
functionalise the nanoparticles and the targeted PDT treatment of HT-29 colon cancer 
cells expressing the T antigen is attempted. Laser scanning confocal microscopy is used to 
explore the intracellular uptake of the jacalin nanoparticle conjugates. Investigations into 
the carbohydrate dependence of jacalin targeted PDT are also performed. Furthermore, 
the mechanism of jacalin targeted phototoxicity of the HT-29 cells is determined. 
A comparative study into the efficacy of jacalin and anti-HER-2 antibody targeted PDT is 
detailed in Chapter 5. The enhanced phototoxicity of the nanoparticle conjugates in SK-
BR-3 breast cancer cells and in HT-29 colon cancer cells is investigated. Using both types 
of nanoparticle conjugates, the mechanisms of the targeted phototoxicity in both cell lines 
are explored. Finally, the intracellular fate of the targeted nanoparticle conjugates is 
examined using laser scanning confocal microscopy and lysosomal colocalisation analysis. 
In Chapter 6, the potential of using titanium dioxide nanoparticles capped with 
polyacrylic acid for sonodynamic therapy of HT-29 colon cancer cells is discussed. The 
synthesis and characterisation of stable titanium dioxide nanoparticles is described. A 
number of experiments are performed to probe the sonocatalytic enhancement of ROS 
generation by the nanoparticles. In vitro sonodynamic therapy of HT-29 cells using the 
titanium dioxide nanoparticles is attempted and the outcome of the treatment is 
discussed. 
Conclusions of the findings for all the experiments within the thesis are provided in 
Chapter 7 together with detailed suggestions for future experiments.  
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Chapter 2 
Materials and Methods 
This chapter gives details of the materials, reagents, instrumentation and procedures used 
for the experiments described throughout the thesis. 
 
2.1 Concanavalin A conjugated phthalocyanine-PEG gold nanoparticles 
for targeted PDT of MCF-7 and SK-BR-3 human breast 
adenocarcinoma cells  
2.1.1 Synthesis of citrate capped gold nanoparticles 
Aqueous solutions of trisodium citrate (50 ml, 1.3 mM, 258.06 g.mol-1; Sigma-Aldrich) and 
gold (III) chloride trihydrate (HAuCl4, 100 ml, 0.2 mM, 393.83 g.mol-1; Sigma-Aldrich) were 
prepared. The solutions were heated to 60 °C, combined upon rigorous stirring and heated 
to 85 °C for 2.5 h. Once cooled to room temperature, the nanoparticle solution was filtered 
using sterile syringe driven filter units (0.22 μm polyethersulfone (PES), Millipore; 
MillexTM) to remove aggregates and stored at 4 °C. 
 
2.1.2 Conjugation of Concanavalin A and succinyl-Concanavalin A to gold 
nanoparticles through SPDP 
3-(2-pyridyldithio)propionic acid N-hydroxysuccinimide ester (SPDP, 312.36 g.mol-1; 
Thermo Scientific) was used to modify the lectins Concanavalin A (Con A, 104 kDa;1 Sigma-
Aldrich) and succinyl-Concanavalin A (S-Con A, 52 kDa; Vector Laboratories) with a 
disulfide group to allow self-assembly onto the surface of the gold nanoparticles. 
Conjugation of SPDP to the lectins was performed according to the protocol provided by 
Thermo Scientific (http://www.piercenet.com/instructions/2160279.pdf). Solutions of 
Con A and S-Con A (0.5 ml, 2 mg.ml-1) were prepared in salt-free D-Hank's buffer (0.37 mM 
Na2HPO4 (Fisher Scientific), 0.44 mM KH2PO4 (Sigma-Aldrich), 4.20 mM NaHCO3 (Fisher 
Scientific), pH 7.4).2 A solution of SPDP (20 mM) in dimethyl sulfoxide (DMSO; Fisher 
Scientific) was prepared and 12.5 μl was added to the Con A and S-Con A solutions. The 
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mixtures were incubated at room temperature for 45 min. Unbound SPDP was removed 
from the mixture containing the SPDP-activated lectin solutions by ultrafiltration in 
VivaspinTM 20 tubes (30 kDa molecular weight cut-off (MWCO), PES; Sartorius Stedim 
Biotech) using an Avanti TM J-25 centrifuge (3,659 xg, 4 °C, 5 min). Salt-free D-Hank's buffer 
was then added to replace the filtrate and the wash step was repeated a further two times. 
SPDP-activated Con A and S-Con A were added to 5 ml solutions of citrate capped gold 
nanoparticles at a molar ratio of 1:100 of gold nanoparticles to lectins.2 The SPDP-lectin 
nanoparticle mixtures were left stirring for 24 h at room temperature to allow complete 
binding of the SPDP-lectins onto the nanoparticles. To remove unbound Con A and S-Con 
A, 1 ml aliquots of Con A and S-Con A conjugated gold nanoparticles were centrifuged in 
‘NoStick’ Microcentrifuge tubes (2.0 ml, Alpha Laboratories) at 5,488 xg at 2 °C for 40 min 
in an Allegra X-22R centrifuge. The supernatant was then removed and the red soft pellet 
containing nanoparticles was resuspended in 0.3 ml D-Hank’s salt balanced buffer (137.00 
mM NaCl (Fisher Scientific), 5.40 mM KCl (Sigma-Aldrich), 0.37 mM Na2HPO4, 0.44 mM 
KH2PO4, 4.20 mM NaHCO3, pH 7.4).2 The conjugates were then stored at 4 °C. 
 
2.1.3 Approximation of lectin coverage on gold nanoparticles – electrolyte 
induced aggregation assay 
To determine the approximate number of Con A and S-Con A molecules bound to each gold 
nanoparticle, solutions of citrate capped gold nanoparticles were reacted with SPDP 
activated lectins (2 mg.ml-1) at varying molar ratios of nanoparticles to lectins for 24 h at 
room temperature according to the volumes shown in Table 2.1 and Table 2.2.  
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Table 2.1 Volumes of SPDP activated Con (SPDP-Con A) and citrate capped gold 
nanoparticles mixed to obtain molar ratios of nanoparticles to Con A of 1:0-
1:200. 
Molar ratio of 
nanoparticles:Con A 
Volume of citrate 
capped 
nanoparticles (ml) 
Volume of salt-free 
D-Hank's 
buffer (µl) 
Volume of 
SPDP-Con A 
(µl, 2 mg.ml-1) 
1:0 5.0 250.0 0.0 
1:5 5.0 244.7 5.3 
1:10 5.0 239.5 10.5 
1:15 5.0 234.2 15.8 
1:20 5.0 228.9 21.1 
1:25 5.0 223.7 26.3 
1:200 5.0 39.4 210.6 
 
 
Table 2.2 Volumes of SPDP activated S-Con A (SPDP-S-Con A) and citrate capped gold 
nanoparticles mixed to obtain molar ratios of nanoparticles to S-Con A of 
1:0-1:50. 
Molar ratio of 
nanoparticles:S-Con A 
Volume of citrate 
capped 
nanoparticles (ml) 
Volume of salt-free 
D-Hank's 
buffer (µl) 
Volume of 
SPDP-S-Con A 
(µl, 2 mg.ml-1) 
1:0 2.0 50.0 0.0 
1:20 2.0 46.4 3.6 
1:30 2.0 44.6 5.4 
1:40 2.0 42.8 7.2 
1:50 2.0 41.0 9.0 
 
 
To each solution of nanoparticle conjugates (1 ml), aqueous NaCl (0.5 ml, 1.5 M) was 
added and the UV-visible absorption spectrum was immediately measured. The surface 
plasmon absorption band of the citrate capped gold nanoparticles centred at 520 nm 
broadens and red-shifts upon particle aggregation, and the absorbance intensity of the 
sample at 685 nm increases. Therefore, the extent of nanoparticle aggregation can be 
monitored as a decrease in absorbance intensity at ca. 520 nm and an increase in 
absorbance intensity at 685 nm.3 
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2.1.4 Colorimetric labelling of breast cancer cells with lectin conjugated gold 
nanoparticles 
Con A or S-Con A conjugated gold nanoparticles (8.46 nM) used for the treatment of MCF-7 
and SK-BR-3 breast cancer cells were synthesised according to the procedure described in 
section 2.1.2. MCF-7 human breast adenocarcinoma cells (LGC Standards) were cultured 
in NUNC NunclonTM ∆ Surface culture flasks (Thermo Fisher Scientific) using Minimum 
Essential Medium (MEM) + GlutaMAXTM-I (Invitrogen) supplemented with 1x non-
essential amino acids (NEAA; Invitrogen), 1 mM sodium pyruvate (NaPyr, Sigma-Aldrich) 
and 10% Foetal Bovine Serum (FBS; Thermo Fisher Scientific). SK-BR-3 human breast 
adenocarcinoma cells (LGC Standards) were cultured in Dulbecco's Modified Eagle's 
Medium (DMEM; Invitrogen) supplemented with 1 mM L-glutamine (L-Gln, Invitrogen) 
and 10% FBS. All cells were incubated in a humidified incubator at 37 °C in a 5% CO2 
atmosphere.  
Phosphate buffered saline (PBS) solutions used for all cell-based experiments were 
prepared by dissolving 10 PBS tablets (Oxoid) in water (1 L) followed by 10 min of 
autoclaving at 110 °C. The as-prepared PBS solutions contained 8 mM Na2HPO4, 1 mM 
KH2PO4, 160 mM NaCl, and 3 mM KCl; and had a pH value of 7.3. 
When the MCF-7 and SK-BR-3 cells reached ca. 70% confluency, the cells were trypsinised 
by aspirating the growth medium, washing the cells with PBS (5 ml) followed by 0.25% 
Trypsin-EDTA (1 ml; Invitrogen), then incubating for 3 min at 37 °C in a 5% CO2 
atmosphere. Following incubation, the detached cells were suspended in 10 ml of their 
respective growth medium and counted using a Neubauer haemocytometer. The cells 
were diluted appropriately and seeded onto NUNC NunclonTM ∆ Surface 48 well 
multidishes (Thermo Fisher Scientific) in 0.5 ml aliquots (3.75x104 cells per well) 24 h 
prior to incubation with the nanoparticle conjugates. The well contents were then 
removed and the cells were washed 3 times in D-Hank’s salt balanced buffer (150 µl). 
MCF-7 cells and SK-BR-3 cells were incubated with the Con A or S-Con A conjugated gold 
nanoparticles (8.46 nM, 150 µl) for 0, 1 or 2 h. 
Prior to imaging the cells were washed 3 times with D-Hank’s salt balanced buffer (150 
µl). Finally D-Hank’s salt balanced buffer (150 µl) was added to each well and the cells 
were imaged using a ZEISS Axiovert 40CFL inverted optical microscope equipped with a 
ZEISS AxioCam MRC camera.  
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SK-BR-3 cells incubated with Con A conjugated gold nanoparticles (8.46 nM) for 1 h were 
incubated with propidium iodide (0.5 μl, 1 mg.ml-1 in PBS; Sigma-Aldrich) for 5 min in the 
dark. The cells were imaged using widefield fluorescence microscopy using a ZEISS 
Axiovert 40CFL Optical Microscope equipped with an EXFO X-Cite® SERIES 120Q 
fluorescence illumination system. Propidium iodide fluorescence was visualised using a 
ZEISS Filter Set 45, with excitation at 560 ± 20 nm and emission at 630 ± 37.5 nm. 
 
2.1.5 Concentration and time dependence of lectin conjugated gold nanoparticle 
aggregation 
Con A, Erythrina crystagalli lectin (ECL, 58 kDa; Vector Laboratories) and sheep serum 
albumin (SSA, 66 kDa; Sigma-Aldrich) were conjugated to gold nanoparticles using SPDP 
according to the procedure described in section 2.1.2. The nanoparticle conjugates were 
kept in serum-free MEM + GlutaMAXTM-I medium, supplemented with 1x NEAA and 1 mM 
NaPyr.  
MCF-7 cells were then seeded in 96 well multidishes, as described in section 2.1.4, and 
incubated at 37 °C in a 5% CO2 atmosphere with varying concentrations of the Con A, ECL 
or SSA conjugated gold nanoparticles (200 µl; 0.25, 0.50 or 1.00 nM). The cells were 
imaged following 1 h incubation with the nanoparticles using optical microscopy, as 
described in section 2.1.4. No aggregation was observed, so the nanoparticle conjugates 
were incubated for a further 23 h and imaged once again.  
 
2.1.6 Synthesis and characterisation of PEG modified gold nanoparticles 
functionalised with Con A, ECL and SSA 
α-thio-ω-carboxy polyethylene glycol (PEG, 32.7 mg ,1 mM, 3,274 Da; Iris Biotech GmbH) 
was self-assembled for 15 h onto citrate capped gold nanoparticles (10 ml, ca. 3 nM). 
Following self-assembly, unbound PEG was removed from the sample by 3 repeated 
ultrafiltrations in VivaspinTM 20 tubes (30 kDa MWCO, PES) by centrifuging at 7,741 xg at 
4 °C for 10 min. Following every centrifugation, the PEG modified gold nanoparticles were 
redispersed in an equal volume of 2-(N-morpholino)ethanesulfonic acid buffer (MES, 50 
mM, pH 5.5; Sigma-Aldrich). The PEG modified gold nanoparticles were then characterised 
using UV-visible absorption spectroscopy and transmission electron microscopy (TEM) 
imaging. 
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For TEM imaging, an aliquot of PEG modified gold nanoparticles (500 μl) was centrifuged 
in a VivaspinTM 500 (100 kDa MWCO, PES) tube at 14,300 xg at 4 °C for 30 min. The 
concentrated sample (10 µl) was then spotted onto Holey Carbon Film 300 Mesh Cu (50) 
TEM grid (Agar Scientific) on top of adsorbent filter paper. The nanoparticle sample was 
imaged using a JEOL 2000EX TEM operating at 200 kV accelerating voltage.4 The 
assistance of Dr Colin MacDonald (School of Chemistry, University of East Anglia) during 
the TEM imaging is gratefully acknowledged. 
Con A, ECL and SSA were then covalently conjugated to the PEG on the gold nanoparticles 
by amide coupling of the primary amine groups at the protein lysine residues to the 
terminal carboxyl groups of the PEG. Amide coupling was achieved by using N-(3-
Dimethylaminopropyl)-N’-ethylcarbodiimide (EDC; Sigma-Aldrich) and sulfo-N-
hydroxysuccinimide (sulfo-NHS; Fisher Scientific). EDC (1.31 µl, 2 mM, from 0.877 g.l-1 
stock) and sulfo-NHS (2.9 mg, 5 mM) were added to PEG modified gold nanoparticles in 
MES buffer (5 ml; 50 mM, pH 5.5) and were stirred for 30 min. The reaction of EDC/sulfo-
NHS with PEG carboxyl groups forms amine reactive sulfo-N-hydroxysuccinimidyl ester 
terminated PEG chains on the nanoparticles. Excess EDC and sulfo-NHS were removed by 
ultrafiltration in VivaspinTM 20 tubes (30 kDa MWCO, PES) by centrifuging at 7,741 xg at 4 
°C for 10 min. The activated sulfo-NHS ester functionalised gold nanoparticles were then 
redispersed in D-Hank’s salt balanced buffer (5 ml, pH 7.4). Aliquots of the nanoparticles 
(1.5 ml each) were mixed with Con A, ECL and SSA (1 mg.ml-1 in D-Hank’s salt balanced 
buffer) to obtain a final protein concentration which was 100x the nanoparticle 
concentration. The mixtures were stirred for 2.5 h and orbital shaken at 700 RPM for 15 h 
at room temperature. Following conjugation, the Con A, ECL and SSA functionalised, PEG 
modified gold nanoparticles were pelleted in 1.5 ml aliquots by centrifugation at 7,168 xg 
at 4 °C for 40 min. The supernatants containing unbound proteins were then replaced with 
fresh D-Hank’s salt balanced buffer (1.5 ml). The nanoparticle conjugates were 
characterised using UV-visible absorption spectrophotometry, diluted to 3 nM using D-
Hank’s salt balanced buffer and stored at 4 °C.  
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2.1.7 Physiological stability assessment of lectin conjugated, PEG modified gold 
nanoparticles  
MCF-7 cells were trypsinised as described in section 2.1.4 and seeded onto NUNC 
NunclonTM ∆ surface transparent 96 well plates (Thermo Fisher) for 24 h in 200 µl (2x104 
cells per well). The cells were incubated with the Con A, ECL or SSA conjugated, PEG 
modified gold nanoparticles (200 µl; 0.25, 0.50 or 1.00 nM in serum-free MEM + 
GlutaMAXTM-I medium supplemented with 1x NEAA and 1 mM NaPyr) and imaged at 1 h 
and 24 h following incubation, as described in section 2.1.4. 
 
2.1.8 Colorimetric formazan-based lectin cytoadhesion assay 
To determine the optimal lectin concentration for adsorption onto 96 well plates and the 
optimal cell density for the highest interaction between the cells and lectins, a cross-
calibration assay using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide 
(MTT; Sigma-Aldrich) reagent was performed. Con A (100 µl; 0, 0.1, 0.5 or 1 mg.ml-1 in D-
Hank’s salt balanced buffer) was placed in NUNC NunclonTM ∆ surface transparent 96 well 
multidishes and left to adsorb onto the wells for 1 h at room temperature. Unbound Con A 
was then removed by washing the wells once with D-Hank’s buffer (100 µl). To obtain a 
suspension of MCF-7 breast cancer cells without the use of trypsin, ca. 70% confluent cells 
were washed twice in PBS (5 ml) then once in a PBS solution containing 
ethylenediaminetetraacetic acid (EDTA, 7.5 mM; Sigma-Aldrich) and ethylene glycol 
tetraacetic acid (EGTA, 7.5 mM; Sigma-Aldrich). The cells were then kept in the PBS 
EDTA:EGTA solution (5 ml) and incubated for 15 min at 37 °C and in a 5% CO2 atmosphere 
with mild agitation every 5 min. The cell suspension was centrifuged in an Eppendorf 
5810R Centrifuge at 181 xg at room temperature for 5 min. The supernatant was 
discarded and the pelleted cells were redispersed in serum-free MEM + GlutaMAXTM-I 
medium supplemented with 1x NEAA and 1 mM NaPyr (5 ml). The MCF-7 cells were 
counted and placed in the Con A pre-treated wells at densities of 0.2x104, 0.5x104, 1.0x104 
or 2.0x104 cells per well and incubated for 1 h at 37 °C in a 5% CO2 atmosphere. The well 
contents were then removed and each well was gently washed once using serum-free 
MEM + GlutaMAXTM-I medium supplemented with 1x NEAA and 1 mM NaPyr (200 µl). The 
cells were finally kept in serum-free MEM + GlutaMAXTM-I medium (200 µl). MTT (12.5 µl, 
5 mg.ml-1 in PBS) was added to each well and incubated for 3 h at 37 °C in a 5% CO2 
atmosphere. The well contents were then removed and each well was washed twice gently 
with D-Hank’s buffer (200 µl). Finally, the formazan crystals produced by the cells were 
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dissolved in DMSO (200 µl) and the formazan absorbance at 550 nm was measured using a 
MRX-Dynatech plate reader. All assays were performed in triplicate.  
Con A, S-Con A and SSA (100 µl, 0.5 mg.ml-1) were each adsorbed onto transparent 96 well 
multidishes, as described previously for the Con A. MCF-7 cells were detached from the 
flasks, centrifuged and redispersed in serum-free MEM + GlutaMAXTM-I medium, as 
described earlier in this section. The cells were added to the pre-treated wells at a density 
of 2.0x104 cells per well (200 µl), incubated for 1 h and analysed using MTT, as described 
earlier in this section. All assays were performed in triplicate. The assay was repeated 
once more for each of the three lectins Con A , S-Con A and ECL. 
 
2.1.9 Synthesis of zinc phthalocyanine-polyethylene glycol gold nanoparticles 
The phthalocyanine photosensitiser (1,1’,4,4’,8,8’,15,15’,18,18’,22,22’-tetradecakisdecyl-
25,25’-(11,11’dithiodiundecyl) diphthalocyanine zinc; C11Pc) was kindly provided by Dr 
Isabelle Chambrier (School of Chemistry, University of East Anglia).5 Gold nanoparticles 
(ca. 4 nm in diameter) were synthesised in tetrahydrofuran (THF; Fisher Scientific) and 
stabilised with a mixed monolayer of the C11Pc (2,564 g.mol-1) photosensitiser and PEG.6,7 
The C11Pc photosensitiser (2 mg) was dissolved in THF (1 ml). The PEG (7.5 mg) was 
dissolved in THF (2 ml) and then stirred with the C11Pc solution for 5 min. HAuCl4 (1.2 
mg) was dissolved in THF (1.2 ml) and combined with the C11Pc and PEG solution and 
stirred for a further 5 min. A fresh aqueous solution of sodium borohydride (NaBH4, 1.5 
mg in 1.2 ml water, 37.83 g.mol-1; Fisher Scientific) was prepared and rapidly added to the 
solution of HAuCl4, C11Pc and PEG under vigorous stirring. The reaction was stirred for 15 
h at room temperature. The C11Pc-PEG gold nanoparticles remained stable in the THF 
while any gold nanoparticles not functionalised with the C11Pc precipitated. The solution 
containing the C11Pc-PEG gold nanoparticles was collected and the THF/water mixture 
was removed from the sample by rotary evaporation under reduced pressure at 60 °C. The 
C11Pc-PEG gold nanoparticles were dissolved in MES buffer (5.4 ml; 50 mM, 0.05% Tween 
20, pH 5.5) and centrifuged at 21,913 xg at 4 °C for 30 min to remove any unbound C11Pc 
and those C11Pc gold nanoparticles not functionalised with PEG, both of which are 
insoluble in buffer. The supernatant containing purified C11Pc-PEG gold nanoparticles 
was removed and stored at 4 °C. 
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2.1.10 Con A conjugation to C11Pc-PEG gold nanoparticles 
Con A was conjugated to the C11Pc-PEG gold nanoparticles using EDC/sulfo-NHS coupling. 
2 mM EDC (0.8 μl, 0.877 g.ml-1) and 5 mM sulfo-NHS (2.17 mg, 115.08 g.mol-1) were added 
to the C11Pc-PEG gold nanoparticles (ca. 2 μM C11Pc equivalent) in MES buffer (2 ml; 50 
mM, 0.05% Tween 20, pH 5.5) and stirred for 30 min at room temperature. Excess EDC 
and sulfo-NHS was removed by filtering the sulfo-NHS-ester functionalised C11Pc-PEG 
gold nanoparticles in 500 μl aliquots in VivaspinTM 500 (100 kDa MWCO, PES; Sartorius 
Stedim Biotech) by centrifuging at 14,300 xg at 4 °C for 30 min. The filtrate containing 
excess EDC and sulfo-NHS was discarded and the sulfo-NHS-ester functionalised C11Pc-
PEG gold nanoparticles were then redispersed in a PBS solution (500 µl; 10 mM phosphate 
buffer, 100 mM NaCl, 100 μM CaCl2.2H2O (Sigma-Aldrich), 100 μM MnCl2.4H2O (Lancaster 
Synthesis), pH 7.4).  
The 10 mM phosphate buffer solution was obtained by diluting a 100 mM stock solution of 
phosphate buffer by 10-fold. The 100 mM stock solution was prepared by combining 19 
ml of a monobasic solution of NaH2PO4 (200 mM; Fisher Scientific) with 81 ml of a dibasic 
solution of Na2HPO4 (200 mM; Fisher Scientific). 
Con A (50 µl, 1 mg.ml-1 in PBS (10 mM phosphate buffer, 100 mM NaCl, 100 μM CaCl2.2H2O, 
100 μM MnCl2.4H2O, pH 7.4)) was then added to the C11Pc-PEG gold nanoparticles (2 ml) 
to obtain a final Con A concentration of 0.24 µM, and was stirred for 15 h at room 
temperature. The unbound Con A was removed from the nanoparticle solution by six 
repeated ultrafiltrations of the samples in 500 μl aliquots in VivaspinTM 500 tubes (100 
kDa MWCO, PES) by centrifuging at 14,300 xg at 4 °C for 30 min. After each centrifugation, 
the Con A conjugated C11Pc-PEG gold nanoparticles were redispersed in PBS (500 µl; 10 
mM phosphate buffer, 100 mM NaCl, 100 μM CaCl2.2H2O, 100 μM MnCl2.4H2O, pH 7.4). 
After the fifth centrifugation the Con A conjugated C11Pc-PEG gold nanoparticles were 
redispersed in serum free, phenol red-free Leibovitz’s L15 medium (Invitrogen) 
supplemented with 1x NEAA, 1 mM NaPyr, 100 µM CaCl2.2H2O and 100 μM MnCl2.4H2O. 
The nanoparticle samples were characterised using a Hitachi U-3010 UV-visible 
absorption spectrophotometer. The concentration of the C11Pc photosensitiser assembled 
on the nanoparticle surface was determined using an extinction coefficient of 2.23x105 M-
1.cm-1 at 696 nm.8 All nanoparticle conjugates prepared were appropriately diluted as 
required for each experiment, filtered using sterile syringe driven filter units (0.22 μm 
PES) and stored at 4 °C prior to use. C11Pc-PEG gold nanoparticles without conjugation to 
Con A were synthesised and used as a control. 
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2.1.11 TEM characterisation and singlet oxygen measurement of the non-
conjugated and Con A conjugated C11Pc-PEG gold nanoparticles 
The non-conjugated and Con A conjugated C11Pc-PEG gold nanoparticles in PBS (10 mM 
phosphate buffer, 100 mM NaCl, 100 μM CaCl2.2H2O, 100 μM MnCl2.4H2O, pH 7.4) were 
characterised using TEM imaging, as described in section 2.1.6. 
Singlet oxygen production was measured using the singlet oxygen molecule probe, 
anthracene-9,10-dipropionic acid disodium salt9 (ADPA, 366.32 g.mol-1; Molecular 
Probes). Non-conjugated and Con A conjugated C11Pc-PEG gold nanoparticles in PBS (900 
µl; 10 mM phosphate buffer, 100 mM NaCl, 100 μM CaCl2.2H2O, 100 μM MnCl2.4H2O, pH 
7.4) were placed in a 1.5 ml stoppered quartz cuvette with ADPA (100 µl, 1.7 mM in 
methanol (Fisher Scientific)) and a magnetic stirrer bar. The sample was then irradiated at 
633 nm for 30 min using a 10 mW Helium-Neon (HeNe) Laser (JDS Uniphase) with 
continuous mixing and the absorbance of the ADPA was monitored at 400 nm every 5 min. 
C11Pc-free PEG gold nanoparticles were prepared as described in section 2.1.9 without 
the addition of C11Pc and used as a control.  
 
2.1.12 MTT viability assay of MCF-7 breast cancer cells following Con A targeted 
PDT treatment 
MCF-7 cells were trypsinised as described in section 2.1.4 and seeded onto two separate 
white opaque NUNC NunclonTM ∆ surface 96 well multidishes (2x104 cells per well) 24 h 
prior to incubation with the nanoparticles. The cells were washed once in PBS (100 µl), 
then kept in serum-free, phenol red-free Leibovitz’s L15 medium supplemented with 1x 
NEAA and 1 mM NaPyr (50 µl) containing 0.0, 0.1, 0.2, 0.3, 0.4 or 0.5 µM C11Pc equivalent 
of Con A conjugated or non-conjugated C11Pc-PEG gold nanoparticles. The cells were 
incubated with the nanoparticles for 3 h at 37 °C in a 5% CO2 atmosphere. The 
nanoparticles not specifically bound or internalised by the MCF-7 cells were removed by 
washing the cells 3 times in PBS (100 µl). Finally, the cells were kept in phenol red-free 
Leibovitz’s L15 medium (200 µl) supplemented with 1x NEAA, 1 mM NaPyr and 10% FBS. 
Staurosporine (20 µM; LC Labs) was used as a positive control for cytotoxicity.10 One of 
the 96 well multidishes was kept in the dark, while the other multidish was irradiated for 
5 min per well using a 10 mW 633 nm HeNe laser giving a fluency rate of 34 mW.cm-2 and 
a total light dose of 10.5 J.cm-2. The laser was positioned 15 cm above the cells being 
irradiated. Laser light intensity was measured using a Power Max 500AD Molectron Power 
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Meter. Following irradiation, the cells were incubated at 37 °C in a 5% CO2 atmosphere for 
48 h. MTT reagent (10 µl, 5 mg.ml-1 in PBS) was added to each well and the cells were 
incubated at 37 °C in a 5% CO2 atmosphere for 4 h. The well contents were then removed 
and the formazan was dissolved in DMSO (200 µl). The well contents were transferred to 
transparent 96 well multidishes and the absorbance at 550 nm was measured using a 
MRX-Dynatech plate reader. Background absorbance at 550 nm of Leibovitz’s L15 medium 
alone incubated with MTT reagent was subtracted from all measurements. Cell viability 
was calculated as a percentage of absorbance at 550 nm of untreated, non-irradiated MCF-
7 cells. All assays were performed in triplicate.  
To separate the C11Pc-PEG gold nanoparticles from the particles not functionalised with 
C11Pc, nanoparticle synthesis was repeated as described in section 2.1.9; however, a 
further nanoparticle purification stage was introduced. Following 15 h of stirring, the 
C11Pc-PEG gold nanoparticles were centrifuged at 200 xg at room temperature for 2 min 
to remove remaining nanoparticles not functionalised with C11Pc, which are unstable in 
excess THF. These C11Pc-PEG gold nanoparticles were further conjugated with Con A and 
the targeted PDT treatment of the MCF-7 cells was repeated, as described earlier in this 
section. 
The MTT viability assay following the Con A targeted PDT treatment of MCF-7 cells was 
repeated once again using a higher concentration range of C11Pc-PEG gold nanoparticle 
conjugates and increased irradiation times. To enhance the formazan production of the 
MCF-7 cells, the experiment was performed following a prolonged cell seeding time of 48 
h. The MCF-7 cells were incubated for 24 h in serum-free, phenol red-free Leibovitz’s L15 
medium supplemented with 1x NEAA and 1 mM NaPyr containing 0.00, 0.10, 0.20, 0.50, 
1.00 or 1.44 µM C11Pc equivalent of Con A conjugated or non-conjugated C11Pc-PEG gold 
nanoparticles (50 µl). This was followed by irradiation of 10 min per well using a 10 mW 
633 nm HeNe laser giving a fluency rate of 38.4 mW.cm-2 and a total light dose of 23.13 
J.cm-2. The cells were also incubated in the MEM + GlutaMAXTM-I culture medium 
supplemented with 1x NEAA, 1 mM NaPyr and 10% FBS (200 µl) following incubation of 
the nanoparticle conjugates in Leibovitz’s L15 medium to maximise the metabolic activity 
of the cells. 
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2.1.13 CellTiter-BlueTM viability assay of SK-BR-3 breast cancer cells following 
Con A targeted PDT treatment  
The targeted PDT treatment of SK-BR-3 cells using Con A conjugated C11Pc-PEG gold 
nanoparticles was attempted and cell viability was assessed using the fluorescence based 
cell viability assay, CellTiter-BlueTM (Promega).11 SK-BR-3 cells were cultured and 
trypsinised according to the procedure described in section 2.1.4. The cells were then 
seeded at a density of 2x104 cells per well in white opaque 96 well multidishes in DMEM 
medium supplemented with 1 mM L-Gln and 10% FBS, 48 h prior to nanoparticle 
incubation. The cells were washed once in PBS (100 µl), then incubated for 24 h in serum-
free, phenol red-free Leibovitz’s L15 medium supplemented with 1x NEAA and 1 mM 
NaPyr containing 0.00, 0.10, 0.20, 0.50, 1.00 or 1.44 µM (C11Pc equivalent) Con A 
conjugated or non-conjugated C11Pc-PEG gold nanoparticles (50 µl). Staurosporine (20 
µM) was used as a positive control for cytotoxicity.10 Following incubation with the 
nanoparticles, the cells were washed 3 times in PBS (100 µl). Finally the cells were kept in 
DMEM medium supplemented with 1 mM L-Gln and 10% FBS (200 µl) and irradiated for 
10 min per well, as described in section 2.1.12. Following irradiation, the cells were 
incubated at 37 °C in a 5% CO2 atmosphere for 48 h. CellTiter-BlueTM reagent (20 µl per 
well) was added to the cells and incubated for 4 h at 37 °C in a 5% CO2 atmosphere. 
Fluorescence emission at 590 nm (excitation at 560 nm) was measured using an 
EnVisionTM (Wallac) 2103 Multilabel Reader (Perkin Elmer) equipped with an EnVisionTM 
work station. Background fluorescence emission at 590 nm of DMEM medium alone 
incubated with CellTiter-BlueTM reagent was subtracted from all measurements. Cell 
viability was calculated as a percentage of fluorescence emission at 590 nm of untreated, 
non-irradiated SK-BR-3 cells. All assays were performed in triplicate.  
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2.2 Targeting the oncofoetal T antigen disaccharide with jacalin 
functionalised phthalocyanine-PEG gold nanoparticles for 
selective PDT of HT-29 colon adenocarcinoma cells 
2.2.1 Jacalin conjugation to C11Pc-PEG gold nanoparticles  
C11Pc-PEG gold nanoparticles were synthesised in THF, as described in section 2.1.9. 
Jacalin (66 kDa12; Vector Laboratories) was covalently attached to the PEG on the gold 
nanoparticles, as described for Con A in section 2.1.10, with the exception that the sulfo-
NHS-ester functionalised C11Pc-PEG gold nanoparticles were redispersed in a 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES; Sigma-Aldrich) buffered saline 
solution (2 ml; 10 mM HEPES, 150 mM NaCl, 100 μM CaCl2.2H2O, pH 7.4). Jacalin (31.74 μl, 
1 mg.ml-1 in HEPES buffered saline) was then added to the sulfo-NHS-ester functionalised 
C11Pc-PEG gold nanoparticles to obtain a final jacalin concentration of 0.24 µM and was 
stirred for 15 h at room temperature. The unbound jacalin was removed from the 
nanoparticle solution using ultrafiltration in VivaspinTM 500 tubes, as described in section 
2.1.10, and redispersed in HEPES buffered saline (500 μl; 10 mM HEPES, 150 mM NaCl, 
100 μM CaCl2.2H2O, pH 7.4). When the nanoparticles were prepared for in vitro 
experiments, the nanoparticle conjugates were redispersed in serum-free Roswell Park 
Memorial Institute (RPMI) 1640 cell culture medium (Invitrogen) supplemented with 1.5 
mM L-Gln after the fifth centrifugation. The samples were characterised using UV-visible 
absorption spectrophotometry, appropriately diluted and stored at 4 °C. The method for 
jacalin conjugation to C11Pc-PEG gold nanoparticles has now been reported.13 
 
2.2.2 Singlet oxygen production by the irradiation of non-conjugated and jacalin 
conjugated C11Pc-PEG gold nanoparticles 
To confirm that singlet oxygen produced by the irradiation of the C11Pc-PEG gold 
nanoparticles was responsible for the photobleaching of ADPA, the particles were 
irradiated in the absence and presence of oxygen. From this point onwards, 450 µl of 
nanoparticle solutions and 50 µl of ADPA (1.7 mM in methanol) were used to maximise the 
volume of air within the cuvette. A HEPES buffered saline solution of non-conjugated 
C11Pc-PEG gold nanoparticles (10 mM HEPES, 150 mM NaCl, 100 μM CaCl2.2H2O, pH 7.4) 
containing ADPA was prepared, as described in section 2.1.11. The mixture was 
deoxygenated by bubbling argon through the sample for 20 min. The sample was then 
irradiated at 633 nm using a HeNe laser for 30 min with continuous stirring. UV-visible 
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absorption spectra were recorded at 5 min intervals. The solution was then reoxygenated 
by bubbling air through the sample for a further 10 min, and then irradiated for an 
additional 30 min with UV-visible absorption spectra recorded at 5 min intervals. 
C11Pc-PEG gold nanoparticles in HEPES buffered saline (450 µl; 10 mM HEPES, 150 mM 
NaCl, 100 μM CaCl2.2H2O, pH 7.4) with and without jacalin conjugation were placed in a 
1.5 ml stoppered quartz UV-visible absorbance cuvette with 50 µl of ADPA (1.7 mM in 
methanol). The samples were irradiated at 633 nm using a HeNe laser for 30 min with 
continuous stirring and the UV-visible absorption spectra were recorded at 5 min 
intervals. 
 
2.2.3 In vitro PDT of HT-29 cells using jacalin conjugated nanoparticles 
HT-29 human colon adenocarcinoma cells (LGC Standards) were cultured in RPMI 1640 
medium supplemented with 1.5 mM L-Gln and 10% FBS. All cells were incubated in a 
humidified incubator at 37 °C in a 5% CO2 atmosphere. HT-29 cells were trypsinised 
according to the procedure described in section 2.1.4 and seeded onto clear 96 well 
multidishes (2x104 cells per well) 24 h prior to incubation with nanoparticle conjugates. 
The PDT efficacy of jacalin conjugated C11Pc-PEG gold nanoparticles on HT-29 cells was 
investigated using the MTT viability assay, as described in section 2.1.12. However, the 
HT-29 cells were incubated with 0.00, 0.10, 0.20, 0.50, 1.00 or 1.15 µM (C11Pc equivalent) 
jacalin conjugated or non-conjugated C11Pc-PEG gold nanoparticles (50 µl) for 3 h. The 
cells were then washed 3 times in PBS and irradiated for 5 min per well, as described in 
section 2.1.12. The MTT assay was performed in RPMI 1640 medium supplemented with 
10% FBS and 1.5 mM L-Gln 48 h following irradiation.  
 
2.2.4 Synthesis of high yield C11Pc-PEG gold nanoparticles in DMF 
In an attempt to increase the C11Pc loading efficiency and yield of C11Pc-PEG gold 
nanoparticles, alternative solvents were explored for the synthetic procedure to improve 
the solubility and stability of the PEG gold nanoparticles during synthesis.  
The solubility of PEG gold nanoparticles (ca. 4 nm, C11Pc-free) during synthesis was 
investigated by introducing N,N-dimethylformamide (DMF; Sigma-Aldrich) to the 
synthetic procedure. DMF (logP = -0.83) was used to incrementally replace THF (logP = 
0.53) in the procedure described in section 2.1.9, in order to vary the ratio of DMF:THF 
during the reaction. The volumes of THF and DMF used are shown in Table 2.3.  
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Table 2.3 The volumes of DMF, THF and water used for the synthesis of PEG gold 
nanoparticles (C11Pc-free) to assess the stability of the particles in DMF. 
Sample 
Volume and solvent 
used for 
PEG (3.75 mg) 
Volume and solvent 
used for 
HAuCl4 (0.6 mg) 
Volume of water 
used for 
NaBH4 (0.75 mg) 
Ratio of 
DMF:THF 
A 1.5 ml THF 0.60 ml THF 0.6 ml 0:2.1 
B 1.5 ml THF 0.15 ml DMF; 0.45 ml THF 0.6 ml 0.15:1.95 
C 1.5 ml THF 0.30 ml DMF; 0.30 ml THF 0.6 ml 0.3:1.8 
D 1.5 ml THF 0.45 ml DMF; 0.15 ml THF 0.6 ml 0.45:1.65 
E 1.5 ml THF 0.60 ml DMF 0.6 ml 0.6:1.5 
F 1.0 ml DMF; 0.5 ml THF 0.60 ml DMF 0.6 ml 1.6:0.5 
 
After mixing the reactants in their respective solvents (reactions A through F) according to 
the details in Table 2.3, the mixtures were stirred vigorously for 15 h. The nanoparticle 
solutions formed were visually assessed for the degree of stabilisation the DMF provided.  
Using the conditions for sample F, C11Pc-PEG gold nanoparticles were synthesised by 
dissolving the PEG (3.75 mg) in DMF (1 ml) and the C11Pc (0.5 mg) in THF (0.5 ml). The 
remaining experimental conditions for sample F were maintained. Synthesis of the 
nanoparticles was repeated once more using the conditions for sample F; however, 
methanol (logP = -0.69) was used instead of DMF as the main solvent for the reaction.  
Following the synthesis of C11Pc-PEG gold nanoparticle in DMF or methanol, the solvents 
were removed from each sample using rotary evaporation at 70 °C under reduced 
pressure. The particles were then redissolved in MES buffer (2.7 ml; 50 mM, pH 5.5, 0.05% 
Tween 20). The nanoparticle solutions were centrifuged at 21,913 xg at 4 °C for 30 min to 
remove any unbound C11Pc and those C11Pc gold nanoparticles not functionalised with 
PEG, both of which are insoluble in the buffer. The samples were characterised using UV-
visible absorption spectrophotometry. 
To establish whether the C11Pc present in the MES buffered nanoparticle solutions was 
associated with the gold surface, unbound C11Pc was separated from the particles 
synthesised in DMF or in methanol using thin layer chromatography (TLC). Nanoparticle 
samples synthesised in DMF or methanol (8 µl) were spotted onto TLC silica gel 60 F254 
aluminium sheets (Merck). A THF solution of C11Pc was used as a control. Toluene (Fisher 
Scientific) : methanol (95:5) was used as the mobile phase to separate the free, mobile 
C11Pc from the immobile C11Pc-PEG gold nanoparticles.  
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In order to confirm that the high yield of C11Pc present in the nanoparticle solutions 
synthesised in DMF was due to the binding of the sensitiser to the water soluble PEG gold 
nanoparticles, the synthesis was repeated using the original (0.564 mM) or half (0.282 
mM) concentrations of HAuCl4. The MES buffered solutions (50 mM, 0.05% Tween 20, pH 
5.5) of the C11Pc-PEG gold nanoparticles synthesised in DMF using 0.564 mM or 0.282 
mM HAuCl4 were characterised using UV-visible absorption spectrophotometry.  
The photoactivity of the C11Pc-PEG gold nanoparticles synthesised in DMF (1.94 µM 
C11Pc equivalent) was then investigated using the singlet oxygen probe, ADPA, as 
described in section 2.1.11.  
The effect of water within the synthetic procedure of the C11Pc-PEG gold nanoparticles 
(2.7 ml) was explored by using either an aqueous or DMF solution of NaBH4 (0.75 mg in 
0.6 ml). The two reactions were stirred for 15 h, as described earlier in this section, and 
the solvent mixtures were removed using rotary evaporation at 70 °C under reduced 
pressure. C11Pc-PEG gold nanoparticles and C11Pc were removed from the dry 
nanoparticle residues using THF (2.7 ml). The solvent was removed from the THF-soluble 
nanoparticle samples (referred to as the THF extracts) and the C11Pc-PEG gold 
nanoparticles were dissolved in MES buffer (2.7 ml; 50 mM, 0.05% Tween 20, pH 5.5). 
Unbound C11Pc and those C11Pc gold nanoparticles not functionalised with PEG were 
removed from the nanoparticle solution by centrifugation at 21,913 xg at 4 °C for 30 min. 
The nanoparticles not soluble in THF were dissolved in water (2.7 ml) and were referred 
to as the water extracts.  
The THF extracts and water extracts of the C11Pc-PEG gold nanoparticles synthesised 
using an aqueous or DMF solution of NaBH4 were characterised using UV-visible 
absorption spectrophotometry. The THF extracts contained the highest yield of C11Pc-
PEG gold nanoparticles synthesised using an aqueous or DMF solution of NaBH4 (4.35 µM 
and 5.90 µM C11Pc equivalent, respectively). TLC separation of the free C11Pc from the 
C11Pc-PEG gold nanoparticles in both THF extracts was then performed as described 
earlier in this section.  
The THF extract of the C11Pc-PEG gold nanoparticles synthesised using a DMF solution of 
NaBH4 contained the highest yield of C11Pc-PEG gold nanoparticles (5.90 µM C11Pc 
equivalent) and was therefore selected for further investigations. The singlet oxygen 
production by the irradiation of a MES buffered solution of this THF extract was measured 
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as described in section 2.1.11. The nanoparticles in this THF extract were also 
characterised using TEM imaging, as described in section 2.1.6.  
The procedure for synthesising C11Pc-PEG gold nanoparticles in DMF using a DMF 
solution of NaBH4 was used for the remainder of the thesis. 
  
2.2.5 ICP-OES elemental analysis of the C11Pc-PEG gold nanoparticles 
C11Pc-PEG gold nanoparticles were synthesised as described in section 2.2.4, dissolved 
in deionised water and centrifuged at 21,913 xg at 4 °C for 30 min to remove any unbound 
C11Pc and the C11Pc gold nanoparticles not functionalised with PEG. The gold 
nanoparticles were then destroyed in aqua regia and analysed using inductively coupled 
plasma-optical emission spectroscopy (ICP-OES) using a Varian Vista-PROTM ICP-OES 
spectrometer. The quantification of gold (Au3+) and zinc (Zn2+) ions present was used to 
obtain a ratio of gold nanoparticles to zinc phthalocyanine molecules. Claritas PPT® Grade 
Multi-Element Solution 2 and Claritas PPT® Grade Multi-Element Solution 3 (SPEX 
CertiPrep®) were used as the zinc and gold standards, respectively. The assistance of Dr 
Graham Chilvers (School of Environmental Sciences, University of East Anglia) who 
performed the ICP-OES elemental analysis is gratefully acknowledged.  
 
2.2.6 Conjugation of jacalin to C11Pc-PEG gold nanoparticles synthesised in DMF 
Jacalin was covalently attached to the PEG on the C11Pc-PEG gold nanoparticles 
synthesised in DMF using EDC/NHS chemistry, as described in section 2.2.1, although 5 
mM NHS (1.2 mg, 115.08 g.mol-1; Sigma-Aldrich) was used rather than sulfo-NHS. The 
remaining experimental procedures described in section 2.2.1 were maintained. 
 
2.2.7 Characterisation and singlet oxygen measurement of the jacalin conjugated 
C11Pc-PEG gold nanoparticles synthesised in DMF 
The jacalin conjugated C11Pc-PEG gold nanoparticles in HEPES buffered saline (500 μl; 10 
mM HEPES, 150 mM NaCl, 100 μM CaCl2.2H2O, pH 7.4) were characterised using TEM 
imaging and singlet oxygen production was assessed, as described in section 2.1.6 and 
section 2.1.11, respectively. The excitation and emission spectra of the non-conjugated 
and jacalin conjugated C11Pc-PEG gold nanoparticles were recorded using a Horiba Jobin 
Yvon FluoroLog® 3 fluorimeter.  
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2.2.8 Optical microscopy of HT-29 cells following jacalin targeted PDT 
HT-29 cells were seeded onto transparent 96 well multidishes, as described in section 
2.2.3, 24 h prior to incubation with the nanoparticles. The cells were then incubated with 
jacalin conjugated or non-conjugated C11Pc-PEG gold nanoparticles (0.00-1.15 µM C11Pc 
equivalent) synthesised in DMF and irradiated for 5 min per well according to the 
procedure outlined in section 2.2.3. 48 h following irradiation, changes in cell 
morphology following targeted PDT treatment were investigated using a ZEISS Axiovert 
40CFL Optical Microscope equipped with a ZEISS AxioCam MRC camera. 
 
2.2.9 Laser scanning confocal microscopy of HT-29 cells incubated with jacalin 
conjugated and non-conjugated C11Pc-PEG gold nanoparticles 
HT-29 cells were cultured and trypsinised according to the procedure described in 
section 2.2.3. The HT-29 cells were then seeded (2x104 cells per well) onto 18 mm round 
glass coverslips (Jencons VWR) in transparent 6 well multidishes (Thermo Fisher 
Scientific) for 48 h in RPMI 1640 medium supplemented with 10% FBS and 1.5 mM L-Gln. 
The cells were then washed once in PBS (1 ml) and incubated for 3 h at 37 °C in a 5% CO2 
atmosphere in serum-free RPMI 1640 medium supplemented with 1.5 mM L-Gln (1 ml) 
containing jacalin conjugated or non-conjugated C11Pc-PEG gold nanoparticles (1 µM or 2 
µM C11Pc equivalent). The cells were then washed 3 times in PBS (1 ml) and kept in RPMI 
1640 medium supplemented with 1.5 mM L-Gln and 10% FBS (2 ml). The cells were 
irradiated for 6 min per coverslip using a 10 mW 633 nm HeNe laser and incubated for 15 
h at 37 °C in a 5% CO2 atmosphere. The coverslips were fitted on a heated stage (37 °C) 
and 1 ml imaging medium (120 mM NaCl, 5 mM KCl, 2 mM CaCl2.2H2O, 1 mM MgCl2.4H2O, 
1 mM NaH2PO4 , 1 mM NaHCO3 , 25 mM HEPES, 11 mM D-glucose (Sigma-Aldrich), and 1 
mg.ml-1 BSA (Sigma-Aldrich)) was added to each coverslip. The cells were imaged using a 
Zeiss LSM510 META laser scanning confocal microscope with a plan-apochromat 63x/1.4 
oil immersion objective. Differential interference contrast (DIC) images were obtained 
using transmitted light from a 543 nm HeNe laser. DIC images were merged with 
fluorescence images of the jacalin conjugated or non-conjugated C11Pc-PEG gold 
nanoparticles excited using a 633 nm HeNe laser. The fluorescence emission of the C11Pc-
PEG gold nanoparticles was collected using a 650 nm long pass filter. 
Propidium iodide (5 μl, 1 mg.ml-1 in PBS) was added to each coverslip containing 1 ml 
imaging medium and was incubated in the dark for 10 min at 37 °C. Nuclei of dead cells 
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with significant membrane damage stained positive for propidium iodide, which was 
excited with a 543 nm HeNe laser. The fluorescence emission of the propidium iodide was 
collected using a 560-615 nm band pass filter. For all fluorescence microscope images, 
settings were used which caused minimal autofluorescence of cell components.  
 
2.2.10 In vitro PDT treatment of HT-29 cells using jacalin conjugated C11Pc-PEG 
gold nanoparticles synthesised in DMF – MTT viability assay  
HT-29 cells were seeded into two separate white opaque 96 well multidishes (2x104 cells 
per well) for 24 h. The cells were washed once in PBS (100 µl), then kept in serum-free 
RPMI 1640 medium (50 µl) supplemented with 1.5 mM L-Gln containing 0.00, 0.10, 0.20, 
0.50, 1.00 or 1.15 µM (C11Pc equivalent) jacalin conjugated or non-conjugated C11Pc-PEG 
gold nanoparticles. The cells were incubated with the nanoparticles for 3 h at 37 °C and in 
a 5% CO2 atmosphere. The well contents were then removed and any nanoparticles not 
specifically bound or uptaken by the HT-29 cells were removed by washing the cells 3 
times in PBS (100 µl). Finally, the cells were kept in RPMI 1640 medium (200 µl) 
supplemented with 10% FBS and 1.5 mM L-Gln. Staurosporine (20 µM) was used as a 
positive control for cytotoxicity.10 One of the 96 well multidishes was kept in the dark, 
while the other was irradiated for 6 min per well using a 10 mW 633 nm HeNe laser fitted 
with a biconvex diverging lens, giving a fluency rate of 29 mW.cm-2 and a total light dose of 
10.5 J.cm-2. Light intensity was measured using a Power Max 500AD Molectron Power 
Meter. The laser was positioned 50 cm above the cells. Following irradiation, the cells 
were incubated at 37 °C in a 5% CO2 atmosphere for 48 h.  
MTT reagent (10 µl, 5 mg.ml-1 in PBS) was added to each well and the cells were incubated 
at 37 °C in a 5% CO2 atmosphere for 4 h. The cell medium containing MTT reagent was 
then removed and the formazan was dissolved in DMSO (200 µl). The well contents were 
transferred to transparent 96 well multidishes and the absorbance of the formazan at 550 
nm was measured using a MRX-Dynatech plate reader. Background absorbance at 550 nm 
of RPMI 1640 medium alone incubated with MTT reagent was subtracted from all 
measurements. Cell viability was calculated as a percentage of absorbance at 550 nm of 
untreated, non-irradiated HT-29 cells. All assays were performed in triplicate.  
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2.2.11 Competitive inhibition of jacalin targeted phototoxicity using methyl-α-
galactopyranoside and asialofetuin  
Methyl-α-D-galactopyranoside and asialofetuin (a glycoprotein expressing T antigens on 
its surface)14 were used as competitive inhibitors of jacalin binding to HT-29 cells. The 
jacalin conjugated C11Pc-PEG gold nanoparticles in serum-free RPMI 1640 medium 
containing 1.5 mM L-Gln (500 µl, 0.5 µM C11Pc equivalent) were supplement with either 1 
µM or 2 µM asialofetuin (40 kDa; Sigma-Aldrich), or with 50 mM or 100 mM methyl-α-D-
galactopyranoside monohydrate (212.20 g.mol-1; Alfa Aesar), and stored at 4 °C for 48 h. 
An MTT viability assay was performed, as described in section 2.2.10, 48 h following 
irradiation of the HT-29 cells incubated with jacalin conjugated C11Pc-PEG gold 
nanoparticles (0.5 µM C11Pc equivalent) in the presence of asialofetuin or methyl-α-D-
galactopyranoside. Cell viability was calculated as a percentage of untreated HT-29 cells in 
RPMI 1640 medium supplemented with 1.5 mM L-Gln and 10% FBS alone, or in the 
presence of asialofetuin or methyl-α-D-galactopyranoside monohydrate. All assays were 
performed in triplicate. 
 
2.2.12 ApoTox-GloTM triplex assay following jacalin targeted PDT treatment of 
HT-29 cells 
To establish the mechanism of jacalin mediated phototoxicity of the HT-29 cells, the 
ApoTox-GloTM triplex assay (Promega) was performed on the cells incubated with jacalin 
conjugated C11Pc-PEG gold nanoparticles 48 h following irradiation. HT-29 cells were 
seeded onto two white opaque 96 well multidishes (2x104 cells per well) for 24 h. The 
cells were washed once in PBS (100 µl) and kept in serum-free RPMI 1640 medium 
supplemented with 1.5 mM L-Gln (50 µl), containing either jacalin conjugated or non-
conjugated C11Pc-PEG gold nanoparticles (1 µM C11Pc equivalent). The cells were 
incubated for 3 h with the nanoparticle conjugates and washed 3 times in PBS (100 µl). 
Finally, RPMI 1640 medium supplemented with 10% FBS and 1.5 mM L-Gln (100 µl) was 
added to the cells. Staurosporine (20 µM) was used as a positive control for cell death 
predominantly via apoptosis.10 One of the 96 well multidishes was kept in the dark, while 
the other was irradiated for 6 min per well using a 633 nm HeNe laser. The cells were then 
incubated at 37 °C in a 5% CO2 atmosphere for 48 h. 
A viability/cytotoxicity reagent was prepared using the ApoTox-GloTM triplex assay kit by 
adding 10 µl of the viability substrate, glycylphenylalanyl-aminofluorocoumarin (GF-AFC), 
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and 10 µl of the cytotoxicity substrate, bis-alanylalanyl-phenylalanyl-rhodamine 110 (bis-
AAF-R110) to 2 ml of Assay Buffer provided in the kit. The mixture was vortexed until 
both reagents were completely solubilised in the Assay Buffer. The viability/cytotoxicity 
reagent was then added to the cells (20 µl per well) and the multidishes were orbital 
shaken for 30 s at 500 RPM. The cells were then incubated at 37 °C in a 5% CO2 
atmosphere for 1 h. The products of the viability/cytotoxicity reagent were measured by 
fluorescence using an EnVisionTM (Wallac) 2103 Multilabel Reader (Perkin Elmer). The 
fluorescence emission of the product of the GF-AFC viability substrate 
(aminofluorocoumarin) was measured using a 405 nm excitation filter and a 492 nm 
emission filter. The fluorescence emission of the product of the bis-AAF-R110 cytotoxicity 
substrate (rhodamine 110) was measured using a 492 nm excitation filter and a 530 nm 
emission filter. Background fluorescence of the viability/cytotoxicity reagent with RPMI 
1640 medium alone was subtracted from all measurements. The reconstituted Caspase-
Glo® 3/7 reagent and the cells were equilibrated to room temperature. Caspase-Glo® 3/7 
reagent (100 µl) was then added to each well and the multidishes were orbital shaken for 
30 s at 500 RPM. The cells were then incubated with the Caspase-Glo® 3/7 reagent for 30 
min at room temperature. Active caspase 3/7 enzymes in apoptotic cells result in 
bioluminescence following the reaction between UltraGlo™ luciferase and aminoluciferin. 
Bioluminescence emission centred at 576 nm15 was measured using an EnVisionTM 
(Wallac) 2103 Multilabel Reader. Background bioluminescence of Caspase-Glo® 3/7 
reagent with RPMI 1640 medium alone was subtracted from all measurements. All of the 
ApoTox-GloTM triplex assays were performed in triplicate. The ApoTox-GloTM triplex assay 
was then repeated a further time 6 h following irradiation of the HT-29 cells incubated 
with jacalin conjugated or non-conjugated C11Pc-PEG gold nanoparticles. 
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2.3 A comparative study of targeted phototoxicity of HT-29 colon and 
SK-BR-3 breast adenocarcinoma cells using jacalin or anti-HER-2 
antibodies 
2.3.1 Synthesis of jacalin and anti-HER-2 antibody conjugated C11Pc-PEG gold 
nanoparticles 
Monoclonal rat IgG anti-HER-2 antibodies (77 kDa; Abcam) were conjugated to C11Pc-PEG 
gold nanoparticles synthesised in DMF using EDC/NHS chemistry, as described for jacalin 
in section 2.2.6. However, 37.04 µl anti-HER-2 antibodies (1 mg.ml-1) was added to NHS 
ester-functionalised C11Pc-PEG gold nanoparticles (2 ml, in PBS (10 mM phosphate buffer, 
150 mM NaCl, 100 μM CaCl2.2H2O, pH 7.4)) to obtain a final antibody concentration of 0.24 
µM. Following 15 h of stirring, unbound antibodies were removed from the anti-HER-2 
antibody conjugated C11Pc-PEG gold nanoparticles by six repeated ultrafiltrations in 
VivaspinTM 500 tubes (100 kDa MWCO, PES) by centrifuging at 14,300 xg at 4 °C for 30 
min. After each centrifugation, the nanoparticle conjugates were redispersed in PBS (500 
µl; 10 mM phosphate buffer, 150 mM NaCl, 100 μM CaCl2.2H2O, pH 7.4). Jacalin conjugated 
C11Pc-PEG gold nanoparticles were also synthesised as described in section 2.2.6. The 
jacalin or anti-HER-2 antibody conjugated C11Pc-PEG gold nanoparticles prepared for 
incubation with HT-29 cells were redispersed in serum-free RPMI 1640 medium 
supplemented with 1.5 mM L-Gln after the fifth centrifugation. The conjugates prepared 
for incubation with SK-BR-3 cells were redispersed in serum-free DMEM medium 
supplemented with 1 mM L-Gln after the fifth centrifugation. All nanoparticle samples 
were appropriately diluted following removal of unbound jacalin or anti-HER-2 antibodies 
and stored at 4 °C.  
 
2.3.2 Singlet oxygen measurements of the conjugated and non-conjugated 
C11Pc-PEG gold nanoparticles 
The production of singlet oxygen by the irradiation of the jacalin conjugated, anti-HER-2 
antibody conjugated or non-conjugated C11Pc-PEG gold nanoparticles was measured, as 
described in section 2.2.2. All singlet oxygen measurements were performed in PBS (10 
mM phosphate buffer, 150 mM NaCl, 100 μM CaCl2.2H2O, pH 7.4). 
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2.3.3 Comparative targeted PDT of HT-29 cells – MTT Assay 
An MTT viability assay was performed on HT-29 cells according to the procedure 
described in section 2.2.3. The cells were incubated for 3 h with 0.00-1.15 µM C11Pc 
equivalent of non-conjugated, jacalin conjugated or anti-HER-2 antibody conjugated 
C11Pc-PEG gold nanoparticles, then irradiated for 6 min per well. The MTT assay was 
performed 48 h following irradiation.  
 
2.3.4 Comparative targeted PDT of SK-BR-3 cells – CellTiter-BlueTM Assay 
A CellTiter-BlueTM viability assay was performed on SK-BR-3 cells according to the 
procedure outlined in section 2.1.13. The cells were incubated for 3 h with 0.00-1.15 µM 
C11Pc equivalent of non-conjugated, jacalin conjugated or anti-HER-2 antibody conjugated 
C11Pc-PEG gold nanoparticles, then irradiated for 6 min per well. The viability assay was 
performed 48 h following PDT treatment. 
 
2.3.5 ApoTox-GloTM triplex assay following targeted PDT treatment 
Jacalin and anti-HER-2 antibody conjugated C11Pc-PEG gold nanoparticles were prepared, 
as described in section 2.3.1. In addition, SSA conjugated C11Pc-PEG gold nanoparticles 
were prepared according to the same procedure. SSA (31.74 µl, 1 mg.ml-1) was added to 
NHS-ester functionalised C11Pc-PEG gold nanoparticles in PBS (2 ml; 10 mM phosphate 
buffer, 150 mM NaCl, 100 μM CaCl2.2H2O, pH 7.4) to obtain a final protein concentration of 
0.24 µM. The mixture was stirred for 15 h and unbound SSA was removed from the 
nanoparticle conjugates by six repeated ultrafiltrations in VivaspinTM 500 tubes, as 
described in section 2.2.1. 
SK-BR-3 and HT-29 cells were trypsinised and seeded onto white opaque 96 well 
multidishes (2x104 cells per well) 24 h prior to incubation with the nanoparticle 
conjugates. The cells were then incubated for 3 h with jacalin conjugated, anti-HER-2 
antibody conjugated or SSA conjugated C11Pc-PEG gold nanoparticles (0.1 µM or 1 µM 
C11Pc equivalent). Following incubation, the cells were irradiated for 6 min per well and 
the ApoTox-GloTM triplex assay was performed 6 h after irradiation, as described in 
section 2.2.12. Cells not incubated with nanoparticles without irradiation were used as a 
control and staurosporine (20 µM) was used as a positive control for cytotoxicity 
primarily through the apoptotic pathway.10  
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2.3.6 Lysosomal colocalisation of targeted nanoparticle conjugates 
HT-29 cells and SK-BR-3 cells were seeded onto 18 mm round glass coverslips 48 h prior 
to nanoparticle incubation, as described in section 2.2.9. The cells were then washed once 
in PBS (1 ml) and incubated for 3 h with serum-free RPMI 1640 medium (HT-29 cells) or 
serum-free DMEM medium (SK-BR-3 cells) containing jacalin or anti-HER-2 antibody 
conjugated C11Pc-PEG gold nanoparticles (1 µM C11Pc equivalent, 1 ml). Following 
incubation with the nanoparticles, the cells were washed 3 times in PBS (1 ml) and finally 
kept in their respective media containing 10% FBS (2 ml). The cells were incubated for 15 
h at 37 °C in a 5% CO2 atmosphere. Prior to imaging, the cells were incubated for 1 h with 
LysoSensorTM Green DND-189 (1 µM from 1 mM stock in DMSO; Invitrogen). The 
coverslips were mounted on a heated stage (37 °C) and 1 ml imaging medium (120 mM 
NaCl, 5 mM KCl, 2 mM CaCl2.2H2O, 1 mM MgCl2.4H2O, 1 mM NaH2PO4 , 1 mM NaHCO3 , 25 
mM HEPES, 11 mM glucose, and 1 mg.ml-1 BSA) was added to each coverslip. The cells 
were visualised with DIC imaging using transmitted light from a 458 nm Argon laser. The 
fluorescence of the C11Pc-PEG gold nanoparticles was visualised using excitation from a 
633 nm HeNe laser and the red emission was collected using a 650 nm long pass filter. The 
fluorescence of the LysoSensorTM Green DND-189 was visualised using excitation from a 
458 nm Argon laser and the green emission was collected using a 475-525 nm band pass 
filter. Colocalisation of the C11Pc-PEG gold nanoparticles with the LysoSensorTM Green 
DND-189 was assessed by the yellow coloration of the merged red and green fluorescence 
images overlaid with the DIC images. 
 
2.4 Sonodynamic therapy (SDT) of HT-29 colon adenocarcinoma cells 
using titanium dioxide nanoparticles 
2.4.1 Synthesis of tetramethylammonium hydroxide capped titanium dioxide 
nanoparticles 
Synthesis of titanium dioxide (TiO2) nanoparticles capped with tetramethylammonium 
hydroxide (TiO2NP.TMAOH) was achieved according to a previously reported protocol.16 
Tetramethylammonium hydroxide pentahydrate (TMAOH, 0.2572 mg, 181.15 g.mol-1; 
Sigma-Aldrich) was dissolved in water (150 ml) in a 250 ml 2-necked round bottom flask 
with continuous stirring. The solution of TMAOH in the round bottom flask was stirred in 
an ice bucket and cooled to 2 °C. The glassware used to prepare all of the titanium (IV) 
butoxide solutions was dried in an oven at 70 °C before use. Titanium (IV) butoxide 
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(Ti(OBu)4, 360.74 µl, 1 g.ml-1, 340.32 g.mol-1; Sigma-Aldrich) was added to n-butanol (10 
ml; Sigma-Aldrich) and thoroughly mixed. When the temperature of the TMAOH solution 
reached 2 °C, the solution was rigorously stirred and the Ti(OBu)4 solution in n-butanol 
(10 ml) was rapidly added. Immediately after addition, white precipitates of titanium 
hydroxide formed and the reaction mixture was left to stand for 10 min at 2 °C. The flask 
was then transferred to a reflux condenser and heated to 100 °C for 6 h under continuous 
argon flow. The precipitates eventually dispersed to form a fine white sol of 
TiO2NP.TMAOH particles with complete anatase crystallinity, as previously reported.16 The 
sol was then cooled to room temperature and stored in a darkened solution bottle at room 
temperature. Assuming that all the Ti(OBu)4 reacted, the final concentration of TiO2 
present in the sol was 6.61 mM.  
 
2.4.2 Thermal annealing of polyacrylic acid onto the TiO2NP.TMAOH particles 
Polyacrylic acid (PAA, 1.8 kDa; Sigma-Aldrich) was thermally annealed onto the surface of 
TiO2 nanoparticles according to a previously reported protocol.17 The as-synthesised 
TiO2NP.TMAOH particle sol (30 ml) was placed in a round bottom flask and the 
water/butanol mixture was removed by rotary evaporation under reduced pressure at 60 
°C. The dry TiO2NP.TMAOH particle residue was weighed (ca. 6.5 mg) and dissolved in a 
1% aqueous nitric acid solution (32.5 ml, pH 1; Fisher Scientific) to obtain a final 
TiO2NP.TMAOH particle sol concentration of 20% w/v (6.10 mM TiO2). The 
TiO2NP.TMAOH particle sol was sonicated (30 min, 37 kHz) to disperse the nanoparticles. 
An aliquot of the acidified aqueous TiO2NP.TMAOH particle sol (750 µl) was added to DMF 
(10 ml) in a 100 ml round bottom flask with continuous stirring. A solution of PAA (5 ml, 
30 mg.ml-1 in DMF) was prepared and added to the DMF solution containing the 
TiO2NP.TMAOH particle sol. The mixture was then heated to 150 °C with continuous 
stirring for 30 min to remove the water, which reportedly hampers the annealing 
process.17 A reflux condenser was then connected to the flask and the reaction was left 
stirring at 150 °C for a further 5.5 h. The reaction mixture containing ca. 0.305 mM TiO2 
equivalent of nanoparticles was cooled to room temperature and stored in a darkened 
solution bottle at room temperature. 
An excess of THF (10 ml) was added to an aliquot of the TiO2NP.PAA particle solution in 
DMF (5 ml). The white precipitates containing the TiO2NP.PAA particles were collected by 
centrifugation at 2,000 xg at 4 °C for 10 min. The supernatant containing unbound PAA in 
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DMF was removed and the wash step was repeated a further two times. Following the 
third centrifugation, the pellets containing the TiO2NP.PAA particles were readily 
dissolved in water (15 ml) to obtain a final nanoparticle concentration of ca. 0.102 mM 
TiO2 equivalent (ca. 1% w/v).  
Another method for removing DMF and eventually unbound PAA was attempted through 
rotary evaporation of the DMF reaction mixture containing TiO2NP.PAA particles. An 
aliquot of the crude DMF reaction mixture (5 ml) was dried using rotary evaporation 
under reduced pressure at 70 °C. The TiO2NP.PAA particle residue was redissolved in 
water (15 ml) although large aggregates were observed that remained even after 
sonication (37 kHz, 1 h).  
 
2.4.3 Imaging of TiO2NP.TMAOH and TiO2NP.PAA particles 
Samples of as-synthesised TiO2NP.TMAOH particles, TiO2NP.PAA particles in DMF, 
TiO2NP.PAA particles purified using THF precipitation and TiO2NP.PAA particles dried and 
reconstituted in water were imaged using TEM, as described in section 2.1.6.  
 
2.4.4 Photocatalytic •OH production using TiO2NP.TMAOH particles - coumarin-
3-carboxylic acid 
A 10% v/v dilution of as-synthesised TiO2NP.TMAOH particles in water (0.661 mM) was 
prepared in a solution of coumarin-3-carboxylic acid (3 ml, 0.5 mM in DMF; Sigma-
Aldrich). The mixture was placed in a 3.5 ml stoppered quartz fluorescence cuvette and 
then exposed to UV light (254 nm, 1.12 mW.cm-2) for 5 min using a 4W UVG-11 
Mineralight® UV lamp. Fluorescence emission was recorded using a Hitachi F-4500 
fluorimeter from 390 nm to 550 nm using excitation at 367 nm before, immediately after 
and 1 h after irradiation.  
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2.4.5 Photocatalytic •OH production using TiO2NP.TMAOH particles - methylene 
 blue  
An aqueous solution of methylene blue (1 ml, 10 µM, 373.19 g.mol-1; Sigma-Aldrich) was 
placed in a 1.5 ml stoppered quartz UV-visible absorbance cuvette and exposed to UV light 
(254 nm, 1.12 mW.cm-2) for 15 min. UV-visible absorption was measured every 5 min. The 
experiment was repeated in the presence of a 10% v/v dilution of as-synthesised 
TiO2NP.TMAOH particles in water (0.661 mM TiO2). 
 
2.4.6 Sonocatalytic •OH production using TiO2NP.TMAOH particles - methylene 
 blue 
An aqueous solution of methylene blue (1 ml, 10 µM) was prepared and placed in a 1.5 ml 
stoppered quartz UV-visible absorbance cuvette. JPM ultrasound transmission gel (JPM 
Products Ltd.) was applied to one side of the cuvette and the solution was exposed to 
ultrasound irradiation (1 MHz, 0.5 W.cm-2) for 15 min in the dark using a JPM KUP-200 
Ultrasound Transducer (JPM Products Ltd.). UV-visible absorption was measured every 5 
min. The experiment was repeated in the presence of a 10% v/v dilution of as-synthesised 
TiO2NP.TMAOH particles in water (0.661 mM TiO2). 
 
2.4.7 In situ sol-gel synthesis of TiO2NP.PAA particles 
TiO2 nanoparticles coated with PAA were synthesised according to an adapted version of a 
previously reported protocol.18 An aqueous solution of PAA (4.5 g, 30 mg.ml-1, 150 ml) was 
prepared in a 250 ml 2-necked round bottom flask and cooled to 2 °C in an ice bath with 
continuous stirring. A pre-prepared solution of Ti(OBu)4 (360.74 µl in 10 ml THF) was 
then rapidly added and the cloudy white mixture was left to stand for 10 min at 2 °C. The 
flask was then transferred to a reflux condenser and heated to 100 °C for 6 h under 
continuous argon flow. The white TiO2NP.PAA sol was then cooled to room temperature 
and stored in a darkened bottle at 4 °C. Assuming that all the Ti(OBu)4 reacted, the final 
concentration of TiO2 present in the sol was 6.61 mM.  
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2.4.8 Characterisation of TiO2NP.TMAOH and TiO2NP.PAA particles  
As-synthesised TiO2NP.TMAOH and TiO2NP.PAA particles were characterised using UV-
visible absorption spectrophotometry, Dynamic Light Scattering (DLS) and TEM imaging. 
DLS particle size analysis of the TiO2NP.TMAOH or TiO2NP.PAA particles (1 ml, 1% v/v 
dilution) was performed in a 1.5 ml stoppered quartz UV-visible absorbance cuvette using 
a Malvern Zetasizer Nano-ZS. TEM imaging was performed, as described in section 2.1.6. 
2.4.9 Sonocatalytic singlet oxygen production using TiO2NP.PAA particles - ADPA  
Water (941.2 µl) was placed in a 1.5 ml stoppered quartz UV-visible absorbance cuvette 
and ADPA (58.8 µl, 1.7 mM stock in methanol) was added to obtain a final ADPA 
concentration of 100 µM. JPM ultrasound transmission gel was applied to one side of the 
cuvette and the solution was exposed to ultrasound irradiation (1 MHz, 0.5 W.cm-2) for 15 
min in the dark. UV-visible absorption spectra were recorded every 5 min. The experiment 
was repeated in the presence of a 10% v/v dilution of as-synthesised TiO2NP.PAA in water 
(0.661 mM TiO2).  
Both experiments, with and without TiO2NP.PAA, were repeated in methanol. Firstly, the 
effect of 15 min ultrasound (1 MHz, 0.5 W.cm-2) on ADPA (100 µM, 1 ml in methanol) was 
assessed. In addition, a 10% v/v aqueous dilution of TiO2NP.PAA (1 ml) was dried using 
rotary evaporation at 60 °C under reduced pressure. The sample was redissolved in 
methanol (941.2 µl) and ADPA (58.8 µl, 1.7 mM stock in methanol) was added to obtain a 
100 µM solution of ADPA in methanol with a 10% v/v dilution of TiO2NP.PAA (0.661 mM 
TiO2). The effect of 15 min ultrasound (1 MHz, 0.5 W.cm-2) on this sample was also 
assessed. UV-visible absorption spectra were recorded every 5 min during ultrasound 
irradiation. 
 
2.4.10 Methanol as a scavenger for •OH but not for singlet oxygen 
Photobleaching of ADPA (100 µM in water, 1.7 mM stock in methanol) upon ultrasound 
exposure was repeated, as described in section 2.4.9, in the presence of methylene blue 
(10 µM). To investigate the effect of methanol on the ultrasound induced degradation of 
methylene blue, the experiment was also repeated in the absence of methanol. An aqueous 
solution of ADPA (100 µM, 1.7 mM stock in water) containing methylene blue (10 µM) was 
prepared and exposed to ultrasound irradiation for 15 min (1 MHz, 0.5 W.cm-2), as 
described in section 2.4.9.  
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The sonocatalytic effect of TiO2NP.PAA on the photobleaching of ADPA was compared in 
the presence or absence of methanol. The experiments on ultrasound irradiation of ADPA 
solutions in water with and without a 10% v/v dilution of TiO2NP.PAA (0.661 mM TiO2), as 
described in section 2.4.9, were repeated using stock solutions of ADPA in methanol or 
water (1.7 mM).  
 
2.4.11 In situ sol-gel synthesis of dispersed TiO2NP.PAA nanoparticles 
The procedure in section 2.4.7 describes the rapid addition of Ti(OBu)4 (360.74 µl in 10 
ml THF) to an aqueous solution of PAA (4.5 g, 30 mg.ml-1, 150 ml). In this instance a THF 
solution (10 ml) containing both Ti(OBu)4 (360.74 µl) and PAA (4.5 g) was prepared with 
the intention of adding water (150 ml) dropwise to control the hydrolysis of the Ti(OBu)4. 
However, the moderately low solubility of PAA in THF resulted in a gel-like formation. 
Another THF solution (10 ml) was prepared using a 30-fold dilution of both the Ti(OBu)4 
(12.02 µl) and the PAA (150 mg); however, the solubility of the polymer was still low. The 
ratio of water:THF for the reaction was then decreased and 60 ml of THF was used to 
prepare a solution of Ti(OBu)4 (12.02 µl) and PAA (150 mg). Stirring for 10 min was 
required to solubilise all the PAA to form a transparent colourless solution. Water (100 ml) 
was then added dropwise at a rate of 1 drop.s-1 with continuous vigorous stirring. Once 
the addition of water was complete, the transparent colourless reaction mixture was 
heated to 80 °C for 1 h to remove the THF in order to increase the water:THF ratio and 
initiate the hydrolysis of the Ti(OBu)4. As the THF evaporated, the reaction mixture 
became increasingly opaque. Boiling of the reaction mixture ceased after ca. 1 h of heating 
at 80 °C, indicating that most of the THF had evaporated. A reflux condenser was then 
connected to prevent water evaporation and the reaction was exposed to hydrothermal 
treatment at 90 °C for a further 5 h with rigorous stirring under continuous argon flow. 
The reaction mixture became transparent once again following ca. 3 h of hydrothermal 
treatment. The cooled solution of TiO2NP.PAA (x/30) nanoparticles (0.353 mM TiO2) was 
then stored in a darkened solution bottle at 4 °C. As-synthesised TiO2NP.PAA (x/30) 
nanoparticles were characterised using UV-visible absorption spectrophotometry, DLS 
(section 2.4.8) and TEM imaging (section 2.1.6). 
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2.4.12 Purification of the TiO2NP.PAA (x/30) nanoparticles 
Removal of unbound PAA was initially attempted through repeated ultrafiltrations using 
VivaspinTM 20 tubes (30 kDa MWCO, PES). Aliquots of as-synthesised TiO2NP.PAA (x/30) 
nanoparticles (15 ml) were centrifuged in VivaspinTM 20 tubes (30 kDa MWCO, PES) at 
8,000 xg at 10 °C for 30 min. Water (15 ml) was then added to the TiO2NP.PAA (x/30) 
nanoparticles and the ultrafiltration step was repeated a further 9 times. PAA content in 
the filtrate was assessed using the UV-visible absorption band centred at 217 nm. The 
TiO2NP.PAA (x/30) nanoparticle samples were characterised using UV-visible absorption 
spectrophotometry following 5 and 10 filtration steps. 
Gel filtration chromatography was also used in an attempt to remove unbound PAA. PD-10 
desalting columns (5 kDa MWCO, 50 x 14 mm Sephadex® G-25; GE Healthcare Life 
Sciences) were conditioned according to the manufacturer’s protocol. The buffer reservoir 
was removed and the column was equilibrated with 25 ml of water (2.5 ml aliquots). A 
freshly prepared sample of TiO2NP.PAA (x/30) nanoparticles (ca. 100 ml) was 
concentrated to ca. 2.5 ml using rotary evaporation at 60 °C under reduced pressure and 
loaded onto the PD-10 column. The TiO2NP.PAA (x/30) nanoparticle samples were then 
eluted with 10 x 3.5 ml aliquots of water. All elution fractions were then characterised 
using UV-visible absorption spectrophotometry. Elution fractions containing the highest 
TiO2 content (Abs 270 nm ≥ 1.5) were pooled and concentrated to ca. 2.5 ml using rotary 
evaporation at 60 °C under reduced pressure. The PD-10 column was equilibrated once 
more with water (25 ml, 2.5 ml aliquots) and the nanoparticle concentrate (ca. 2.5 ml) was 
loaded onto the column again. This process was repeated a total of 3 times. All the elution 
fractions were characterised using UV-visible absorption spectrophotometry.  
To obtain a higher resolution of separation between TiO2NP.PAA and unbound PAA, a gel 
filtration chromatography column (300 x 14 mm) was packed with Sephadex® G-25 (5 
kDa MWCO, Sigma-Aldrich) and equilibrated with 50 ml water. A peristaltic pump was 
used to increase the flow rate and separation resolution through the column. A freshly 
prepared sample of TiO2NP.PAA (x/30) nanoparticles (ca. 100 ml) was concentrated to ca. 
5 ml using rotary evaporation at 60 °C under reduced pressure and loaded onto the 
Sephadex® G-25 column. The sample was then eluted with 12 x 5 ml aliquots of water 
using a peristaltic pump and each elution fraction was characterised using UV-visible 
absorption spectrophotometry. Elution fractions containing the highest TiO2 content (Abs 
270 nm ≥ 1.5) were pooled, concentrated to ca. 5 ml using rotary evaporation at 60 °C under 
reduced pressure and loaded onto the Sephadex® G-25 column once again. All the elution 
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fractions were characterised using UV-visible absorption spectrophotometry. Elution 
fractions containing the highest TiO2 content (Abs 270 nm ≥ 1.5) were pooled, concentrated 
to ca. 2.5 ml (ca. 14.13 mM TiO2) using rotary evaporation at 60 °C under reduced 
pressure and stored at 4 °C. 
 
2.4.13 Sonocatalytic efficiency of purified TiO2NP.PAA (x/30) nanoparticles 
In order to determine whether TiO2NP.PAA (x/30) nanoparticle samples purified twice 
using the 300 x 14 mm Sephadex® G-25 column retained their ability to enhance the rate 
of ADPA photobleaching upon ultrasound irradiation, a 10% v/v aqueous dilution of the 
2.5 ml purified sample (1.41 mM TiO2) containing ADPA (100 µM) in water was prepared 
and exposed to 15 min ultrasound irradiation (1 MHz, 0.5 W.cm-2), as described in section 
2.4.9. UV-visible absorption spectra were recorded every 5 min. The photobleaching of 
ADPA was compared to that of an aqueous solution of ADPA (100 µM) without 
nanoparticles. 
Additionally, the sonochemical degradation of methylene blue (10 µM) was investigated, 
as described in section 2.4.6, following 15 min ultrasound irradiation (1 MHz, 0.5 W.cm-2) 
in the absence or presence of a 10% v/v dilution of the purified TiO2NP.PAA (x/30) 
nanoparticles (1.41 mM TiO2). 
 
2.4.14 TEM and SEM imaging, and elemental analysis of purified TiO2NP.PAA 
(x/30) nanoparticles 
TEM imaging of the TiO2NP.PAA (x/30) nanoparticle samples purified twice using the 300 
x 14 mm Sephadex® G-25 column was performed as described in section 2.4.12. Scanning 
electron microscopy (SEM) was performed using a JEOL JSM 5900 LV scanning electron 
microscope. Two aliquots of purified TiO2NP.PAA (x/30) nanoparticles (500 µl) were 
centrifuged in VivaspinTM 500 (100 kDa MWCO, PES) tubes at 14,300 xg at 4 °C for 30 min. 
One aliquot was redispersed in water (500 µl) and the remaining aliquot was redispersed 
in HEPES buffered saline (500 μl; 10 mM HEPES, 150 mM NaCl, pH 7.4). The nanoparticle 
samples (3 x 100 µl aliquots) in water or HEPES buffered saline were placed onto 
aluminium SEM imaging stubs and dried in a 60 °C oven for 15 h. Samples were coated 
with gold prior to SEM imaging using a Quorum Technologies Gold Coater CC7640. 
Topographic contrast images and chemical contrast images were obtained using 
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secondary electron imaging (SEI) and backscatter electron imaging (BSEI) techniques, 
respectively. Elemental analysis of the TiO2NP.PAA (x/30) nanoparticle sample in water 
was performed using an Oxford INCA Energy-Wave System integrated with the SEM 
microscope. The assistance of Dr Bertrand Leze (School of Environmental Sciences) who 
performed the SEM imaging is gratefully acknowledged. 
 
2.4.15 HT-29 cell tolerance to ultrasound  
HT-29 colon cancer cells were cultured in RPMI 1640 medium supplemented with 1.5 mM 
L-Gln and 10% FBS, as described in section 2.2.3. At ca. 75% confluency, the cells were 
trypsinised and seeded in transparent 6 well multidishes in 1 ml aliquots (2x105 cells per 
well) 24 h prior to ultrasound treatment. JPM ultrasound transmission gel was applied to 
the base of each well and the cells were then exposed to 0, 15, 30 or 60 s of ultrasound 
irradiation (1 MHz, 0.5 W.cm-2). Staurosporine (20 µM) was used as a positive control for 
cytotoxicity.10 The cells were then incubated for 48 h at 37 °C in a 5% CO2 atmosphere. 
MTT reagent (100 µl, 5 mg.ml-1 in PBS) was added to each well and the cells were 
incubated at 37 °C in a 5% CO2 atmosphere for 4 h. The cell medium was then removed 
and the formazan crystals produced by the viable cells were dissolved in DMSO (6 ml). 
Aliquots of the well contents (200 µl) were transferred to transparent 96 well multidishes 
and the absorbance of the formazan at 550 nm was measured using a MRX-Dynatech plate 
reader. Background absorbance at 550 nm of RPMI 1640 medium alone incubated with 
MTT reagent was subtracted from all measurements. Cell viability was calculated as a 
percentage of absorbance at 550 nm of untreated, non-irradiated HT-29 cells. All assays 
were performed in triplicate.  
 
2.4.16 Attenuation of ultrasound through 6 and 48 well multidishes 
Solutions of ADPA (100 µM, 1 ml) in RPMI 1640 medium supplemented with 1.5 mM L-Gln 
and 10% FBS were prepared and placed in one well of a 6 well multidish or a 48 well 
multidish. JPM ultrasound transmission gel was applied to the base of each well and the 
ADPA solutions were exposed to 15 min of ultrasound irradiation (1 MHz, 0.5 W.cm-2). At 
5 min intervals, the ADPA solutions were removed from the wells, transferred to a 1.5 ml 
quartz cuvette and the UV-visible absorption spectra were recorded. 
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2.4.17 MTT viability assay of HT-29 cells following SDT using TiO2NP.PAA (x/30) 
nanoparticles 
HT-29 colon cancer cells were cultured in RPMI 1640 medium supplemented with 1.5 mM 
L-Gln and 10% FBS, as described in section 2.2.3. At ca. 75% confluency the cells were 
trypsinised and seeded onto 48 well multidishes in 1 ml aliquots (2.29x104 cells per well) 
24 h prior to ultrasound treatment. The well contents were then removed, the cells were 
washed once in PBS (1 ml) and incubated for 3 h in RPMI 1640 medium supplemented 
with 1.5 mM L-Gln containing 0, 0.29, 0.74 or 1.47 mM TiO2 equivalent of TiO2NP.PAA 
(x/30) nanoparticles. The well contents were then removed and the cells were washed 3 
times in PBS (1 ml). Finally, the cells were kept in RPMI 1640 medium (1 ml) 
supplemented with 10% FBS and 1.5 mM L-Gln. JPM ultrasound transmission gel was 
applied to the base of each well and the cells were then exposed to 30 s of ultrasound 
irradiation (1 MHz, 0.5 W.cm-2). HT-29 cells incubated with the TiO2 nanoparticles but not 
exposed to ultrasound irradiation were used as a control. Staurosporine (20 µM) was used 
as a positive control for cytotoxicity.10 Following ultrasound irradiation, the cells were 
incubated at 37 °C in a 5% CO2 atmosphere. 48 h after SDT treatment, an MTT viability 
assay was performed as described in section 2.4.15, with the variation that 12.5 µl MTT 
was added to each well and the formazan crystals were finally dissolved in 2 ml DMSO.  
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Chapter 3 
Concanavalin A conjugated phthalocyanine-PEG gold 
nanoparticles for targeted PDT of MCF-7 and SK-BR-3 human 
breast adenocarcinoma cells 
This chapter describes the use of Concanavalin A (Con A) to target human breast 
adenocarcinoma cells for cancer specific photodynamic therapy with gold nanoparticles 
carrying a hydrophobic zinc phthalocyanine photosensitiser. 
 
3.1 Introduction  
3.1.1 Reactivity of Concanavalin A towards breast cancer cells  
The discovery that some lectins could selectively agglutinate cancer cells gave a 
preliminary indication that differences in surface expressed carbohydrates are present 
between healthy and cancerous cells.1,2 Concanavalin A (Con A) is a 104 kDa tetrameric α-
mannose (α-Man)-binding lectin from the jack bean (Canavalia ensiformis), which has a 
greater affinity towards polymannose (450 Man residues, Kd 0.23 ± 0.02 µM) than to the α-
Man monosaccharide (Kd 41 ± 5.4 µM).3-5 Con A has been extensively studied due to the 
high prevalence of α-linked polymannose residues in many core glycoconjugate sequences 
found in yeast cell walls and mammalian T-lymphocytes, amongst several other glycan 
complexes.4,6,7 Sumner first extracted Con A in 1918 and it was only discovered 17 years 
later that Con A had the capacity to agglutinate horse, dog, cat, rabbit, guinea pig, and rat 
erythrocytes.8,9 It must be noted that Con A can weakly agglutinate human erythrocytes. 
However, its haemagglutinating activity considerably increases upon neuraminidase, 
pronase, papain, trypsin or chymotrypsin treatment of the erythrocytes.9-11 Con A has been 
found to agglutinate some bacteria, spleen cells and lymphocytes.4,9 The α-Man-specific 
lectin is also routinely used in research as a potent T-lymphocyte mitogen.12 Con A is a 
typical homotetrameric hololectin (Figure 3.1), which contains a single calcium ion and a 
manganese ion at each of its four carbohydrate binding domains.3,13 The tetravalance of 
Con A is responsible for the lectin’s ability to crosslink glycoconjugates and cells.4,13 Above 
pH 5.6 Con A is largely in its tetrameric form, existing as a pair of dimers associated with 
hydrogen bonds; however, below pH 5.6 Con A dissociates into dimers.14,15  
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Figure 3.1 A PyMOL generated image of Con A (PDB ID 1CVN16) bound to four synthetic 
trimannoside analogues (white). A calcium ion (orange) and a manganese 
ion (cyan) are present at each carbohydrate binding domain. 
 
Numerous studies have investigated the various applications of Con A, and some have 
demonstrated the ability of the lectin to selectively bind to tumour cells.17 Furmanski et al. 
analysed a series of breast cancer biopsies and assessed the level of Con A reactivity 
towards the tumour homogenates.17 The extent of Con A reactivity was correlated with the 
probability of tumour recurrence.17 Voyles et al. conducted a cell-based study on the 
specificity of Con A towards tumour cells grown in culture.18 The study concluded that Con 
A was reactive towards MCF-7, BT-20, MDA-MB 157, ALAB-496 and SK-BR-3 breast cancer 
cells.18  
Further biological effects of Con A binding include apoptosis induction, which provides 
further potential for multimodal cancer therapy.19 Liu et al. found that Con A interacts with 
glycoproteins on A375 melanoma cells and triggers apoptosis through both mitochondrial 
dependent and caspase dependent pathways.19 Studies reviewed by Lei and Chang have 
shown that Con A can also induce autophagic cell death, activation of local T-lymphocytes, 
and induce hepatoma antigen specific T-cell memory.20 Another study reported the in vivo 
inhibition of polyoma 3T3 tumour development in hamsters following intravenous 
administration of Con A (1 mg.kg-1).21 However, intravenous administration of the lectin 
also resulted in multiple adverse effects, such as liver injury through Con A induced 
hepatocyte apoptosis.21 Such damage to hepatocytes resembles viral or autoimmune 
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hepatitis.21 Indications of Con A within medicine are largely based on diagnostics, which 
involve quantification of cancer markers in the serum, such as α-fetoprotein (AFP).22  
Nanoparticles have also been used with Con A for analytical assays that probe glycan 
expression. For example, both Con A and horseradish peroxidase (HRP) were bound onto 
gold nanoparticles and used in conjunction with nanohorn constructs to electrochemically 
monitor the dynamic carbohydrate expression of cancer cells in response to drugs.23 
Another study described the development of an electrochemical sensor using Con A 
functionalised gold nanoparticles and Con A coated gold electrodes for the qualitative and 
quantitative analysis of K562 leukaemia cell surface glycans.24 Wang et al. also used gold 
nanoparticles functionalised with a series of lectins including Con A to colorimetrically 
probe the binding of these lectins to a number of cells lines.25,26 
 
3.1.2 The dimeric succinylated derivative of Con A 
Previous studies have found that by altering the quaternary structure of Con A, the 
biological effects the lectin exhibits can vary hugely.4,27 A study by Gunther et al. 
investigated the biological activities of Con A and two dimeric derivatives of Con A: 
succinyl-Con A (S-Con A) and acetyl-Con A.4 The mitogenicity of Con A towards mouse 
spleen lymphocytes was compared to that of S-Con A. It was found that S-Con A continued 
to stimulate cell proliferation at concentrations above 5 µg.ml-1, whereas at those 
concentrations Con A became cytotoxic.4 Sheep erythrocyte agglutination by the lectin was 
also greatly hindered by succinylation, possibly due to a decrease in its carbohydrate 
valence. Importantly, the individual glycan binding capacity of each Con A carbohydrate 
binding domain was unaltered following succinylation.4 The structure of S-Con A is shown 
in Figure 3.2, highlighting the binding of the lectin to a synthetic bivalent mannoside 
derivative. The succinate molecule that serves to stabilise the dimeric lectin is also shown, 
in addition to the calcium and manganese metal ions at each carbohydrate binding 
domain.  
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Figure 3.2 A PyMOL generated image of S-Con A (PDB ID 1QGL28) bound to a synthetic 
bivalent mannoside ligand (white). The succinate molecule is shown in blue, 
the calcium ions are magenta and the manganese ions are green.  
 
S-Con A shows greater therapeutic potential than Con A for a number of reasons. S-Con A 
has a higher threshold for erythrocyte agglutination (>0.5 mg.ml-1), it does not crosslink 
membrane receptors, and is less cytotoxic than the native lectin.4 Unlike native Con A, S-
Con A was also found to be unable to induce hepatitis in vivo within a mouse model, and 
was also unable to stimulate the secretion of MMP-2, an enzyme associated with cancer 
metastasis.29,30  
Although initially S-Con A appears to be a more successful candidate for cancer cell 
targeting, it exhibits some limitations. The major potential limitation of using S-Con A for 
targeted treatment is its sustained mitogenic effect upon binding to cell surface glycans, 
with increasing concentrations of the lectin.4 However, its superior characteristics mean 
that S-Con A could be an important targeting agent for selective PDT treatment. 
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3.2 Results and Discussion  
3.2.1 Colorimetric labelling of breast cancer cells using lectin-gold nanoparticle 
conjugates 
Citrate capped gold nanoparticles (ca. 16 nm in diameter) were synthesised according to 
an adapted version of the Turkevich method,31 as described in section 2.1.1. Sodium 
citrate acts as both the reducing and capping agent, providing the gold nanoparticles with 
electrostatic stability in aqueous media. The nanoparticles exhibit an intense surface 
plasmon absorption band centred at 520 nm, as shown in the UV-visible absorption 
spectrum in Figure 3.3 (A). The concentration of the nanoparticles was determined from 
the absorption band maximum at 520 nm using an extinction coefficient (ε520nm) of 2.4x108 
M-1.cm-1.32 The surface plasmon absorption of the nanoparticles gives rise to the intense 
red colour observed in Figure 3.3 (B).  
 
Figure 3.3 A) A UV-visible absorption spectrum of citrate capped gold nanoparticles 
(3.72 nM) with a surface plasmon absorption band centred at 520 nm. B) An 
aqueous solution of the citrate capped gold nanoparticles.  
 
Plasmonic nanostructures, such as gold and silver nanoparticles display a variety of size 
and shape dependent colours, which can be used for diagnostics, bioimaging, sensing and 
bioanalytics.33,34 The unique colouration of gold nanoparticles has been previously 
exploited for the colorimetric labelling of live cells using lectin functionalised particles.25,26 
In a study by Wang et al.,25 streptavidin coated gold nanoparticles were functionalised 
with biotinylated lectins and used to assess the interaction of the conjugates with a 
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number of cancerous and healthy cell lines. This procedure was adapted in an attempt to 
colorimetrically assess the affinity of gold nanoparticles modified with Con A and S-Con A 
towards MCF-7 and SK-BR-3 human breast adenocarcinoma cells. The heterobifunctional 
linker, 3-(2-Pyridyldithio)propionic acid N-hydroxysuccinimide ester (SPDP) was used to 
modify the lectins for conjugation to the nanoparticles.35 SPDP contains a terminal amine-
reactive N-hydroxysuccinimide (NHS) ester moiety which forms an amide bond with 
lysine residues on proteins. Additionally, the linker contains a terminal dithiopyridine 
group that can autocleave and self-assemble onto gold surfaces.35 Con A and S-Con A were 
activated with SPDP and conjugated to ca. 16 nm gold nanoparticles, as described in 
section 2.1.2, and outlined in the schematic shown in Figure 3.4.  
 
 
Figure 3.4 Activation of a lectin using SPDP,35 followed by the self-assembly of the 
SPDP-activated lectin onto citrate capped gold nanoparticles.  
SPDP
+
lectin
SPDP-activated lectin
+
citrate capped
gold nanoparticles
lectin conjugated 
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Solutions of SPDP-activated Con A and S-Con A were prepared in D-Hank’s buffer without 
NaCl and KCl to avoid nanoparticle aggregation upon addition of the SPDP-activated 
lectins to the citrate capped gold particles. Following the self-assembly of the SPDP-
activated Con A or S-Con A, the gold nanoparticles were sterically stabilised in solutions 
with high ionic strengths, such as D-Hank’s salt balanced buffer. Figure 3.5 shows the UV-
visible absorption spectra of citrate capped gold nanoparticles before and after the self-
assembly of SPDP-activated Con A or S-Con A, following one centrifugation to remove the 
unbound lectins. Unmodified citrate capped gold nanoparticles exhibited a surface 
plasmon absorption band maximum at 520 nm, whereas the Con A conjugated and S-Con 
A conjugated gold nanoparticles exhibited red-shifted surface plasmon absorption band 
maxima centred at 529 nm and 522 nm, respectively. The red-shift is likely to be a result 
of a change in the refractive index at the surface of the gold nanoparticles, which is 
dependent on the molecular mass of the conjugated protein.36  
 
Figure 3.5 UV-visible absorption spectra of citrate capped gold nanoparticles (black), 
and gold nanoparticles with Con A (red) or S-Con A (blue) conjugation. The 
nanoparticle samples were in D-Hank’s salt balanced buffer. 
 
The Con A and S-Con A conjugates were prepared using a 100-fold molar excess of lectin 
to nanoparticles, as described in section 2.1.2. To obtain an approximation of the number 
of Con A or S-Con A molecules bound to the surface of each nanoparticle, an electrolyte 
induced aggregation assay was performed, as described in section 2.1.3. SPDP-activated 
Con A was self-assembled onto citrate capped gold nanoparticles at a 0, 5, 10, 15, 20, 25 or 
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200-fold molar excess to nanoparticles. The aggregation of gold nanoparticles with an 
incomplete monolayer of Con A was induced by the addition of a sodium chloride solution. 
The lowest molar excess of Con A required to prevent nanoparticle aggregation is 
representative of the number of Con A molecules present at the surface of each 
nanoparticle monolayer.37,38 The same assay was repeated for S-Con A, although 0, 20, 30, 
40 or 50-fold molar excesses of SPDP-activated S-Con A were used. Electrolyte induced 
aggregation of the particle conjugates was monitored as a decrease in absorbance 
intensity at the surface plasmon absorption band maxima (529 nm for the Con A 
conjugates and 522 nm for the S-Con A conjugates) and as an increase in absorbance 
intensity at 685 nm (Figure 3.6 (A and B, respectively)). Aggregation of the Con A 
conjugates was found to plateau at a 10-15-fold molar excess of Con A to gold 
nanoparticles (Figure 3.6 (C)), suggesting that ca. 10-15 molecules of Con A were bound 
to each particle. The aggregation of the S-Con A conjugates was found to plateau at a 20-
30-fold molar excess of S-Con A to gold nanoparticles (Figure 3.6 (D)), indicating that ca. 
20-30 molecules of S-Con A are bound to each nanoparticle. It was expected that a higher 
number of SPDP-activated S-Con A molecules (52 kDa) than Con A molecules (104 kDa) 
would self-assemble onto each nanoparticle due to the smaller size of the dimeric S-Con A.  
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Figure 3.6 UV-visible absorption spectra of A) Con A conjugated and B) S-Con A 
conjugated gold nanoparticles following the addition of NaCl (0.5 ml, 1.5 M). 
The conjugates were synthesised using SPDP-lectins at varying molar 
excesses to gold nanoparticles. C) Decreasing absorbance intensity at 529 
nm (red) and increasing absorbance at 658 nm (blue) upon aggregation of 
the Con A conjugates. D) Decreasing absorbance intensity at 522 nm (red) 
and increasing absorbance at 658 nm (blue) upon aggregation of the S-Con A 
conjugates. The dotted lines in C) and D) refer to the approximate molar 
excess of lectins at which nanoparticle aggregation is prevented. 
 
Con A or S-Con A conjugated gold nanoparticles (8.4 nM) were prepared using a 
nanoparticle to lectin ratio of 1:100 and were incubated with MCF-7 cells or SK-BR-3 cells 
for 0, 1 or 2 h, as described in section 2.1.4. Extensive aggregation of Con A gold 
nanoparticle conjugates was observed following 2 h incubation with either MCF-7 cells or 
SK-BR-3 cells (Figure 3.7 (A and B, respectively)). Although the aggregates were 
distributed over the base of the wells of the multidish, some aggregates appeared to bind 
to the MCF-7 cells and SK-BR-3 cells. However, due to the substantial instability of the Con 
A conjugates at physiological conditions, no conclusions regarding the affinity of the lectin 
nanoparticle conjugates towards the breast cancer cells could be drawn. It has been 
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reported that Con A can form temperature and pH dependent amorphous aggregates at 
physiological conditions (pH 7.4, 37 °C) in cell culture, which can be cytotoxic to LAN5 
neuroblastoma cells.39 The S-Con A nanoparticle conjugates appeared significantly more 
stable than the Con A conjugates, although no specific labelling of the MCF-7 cells or SK-
BR-3 cells was observed (Figure 3.7 (C and D, respectively)). The lack of any detectable 
binding could be attributed to the low affinity of the S-Con A nanoparticle conjugates 
towards the breast cancer cells, or due to a low sensitivity of the optical detection method 
used. 
 
Figure 3.7 Inverted optical microscope images of Con A conjugated (A and B) or S-Con A 
conjugated (C and D) gold nanoparticles (8.46 nM) incubated with MCF-7 
cells (A and C) and SK-BR-3 cells (B and D) for 2 h at 37 °C. (Scale bars are 50 
µm). 
 
The toxicity of the Con A conjugated nanoparticle aggregates was assessed using the 
fluorescent dye propidium iodide, which is a membrane-impermeable nucleotide 
interchelator that specifically binds to DNA once the cell membrane is damaged.40 SK-BR-3 
cells incubated with Con A conjugated gold nanoparticles for 1 h (Figure 3.8 (A)) were 
further incubated with propidium iodide, as described in section 2.1.4. The nuclei of the 
majority of the SK-BR-3 cells incubated with the Con A conjugated nanoparticles stained 
positive with propidium iodide (Figure 3.8 (B)) highlighting the significant cytotoxicity 
induced by the nanoparticle aggregates.  
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Figure 3.8 A) An inverted optical microscope image of SK-BR-3 cells incubated with Con 
A conjugated gold nanoparticles (8.46 nM) for 1 h. B) Fluorescence 
microscope image of the SK-BR-3 cells in (A) incubated with propidium 
iodide (0.5 µg.ml-1 in D-Hank’s buffer). Fluorescence images were acquired 
using excitation at 560 nm and emission at 630 nm. (Scale bars are 50 µm). 
 
To assess the dependence of the lectin type and the nanoparticle concentration on the 
aggregation of the Con A conjugates observed in Figure 3.7 (A and B), Con A, Erythrina 
cristagalli lectin (ECL) and sheep serum albumin (SSA) gold nanoparticle conjugates (0.25, 
0.50 or 1.00 nM) were prepared and incubated with MCF-7 cells, as described in section 
2.1.5. ECL binds to the galactose (β-1,4) N-acetylgalactosamine disaccharide(Galβ-
1,4GlcNAc-), also known as the cancer-associated Type II oligosaccharide antigen.41,42 The 
Type II antigen is known to be overexpressed in MCF-7 breast cancer cells.43 The SSA was 
used as a control. Following 1 h of incubation with the MCF-7 cells, no aggregation was 
observed with any of the nanoparticle conjugates. The conjugates were then incubated for 
a further 23 h with the cells and imaged once again. The Con A nanoparticle conjugates 
showed visible signs of aggregation at a concentration of 1.00 nM (Figure 3.9 (A)), 
although aggregation was not as extensive as when using a nanoparticle concentration of 
8.46 nM (Figure 3.7 (A and B)). Significant aggregation of the ECL conjugated 
nanoparticles was observed at a concentration of 1.00 nM (Figure 3.9 (B)) and, to a lesser 
extent, at 0.25 nM and 0.50 nM (data not shown). Finally, the SSA conjugated 
nanoparticles showed the least signs of aggregation (Figure 3.9 (C)). These results 
indicate that the degree of nanoparticle aggregation was dependent on the concentration 
of the nanoparticles, the type of protein conjugated and the length of the incubation time. 
However, all SPDP-lectin nanoparticle conjugates appeared to exhibit some degree of 
colloidal instability at physiological conditions. A previous study has shown that protein 
conformation can be significantly altered when in close proximity to the surface of gold 
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nanoparticles (ca. 90 nm in diameter) through gold-sulfur interactions at physiological 
conditions (pH 7.5).44 This destabilisation has been shown to result in the formation of 
higher order aggregates, which could explain the aggregation observed in the experiments 
reported in this section. 
 
 
Figure 3.9 Inverted optical microscope images of MCF-7 cells incubated with gold 
nanoparticles (1.00 nM) conjugated to A) Con A, B) ECL or C) SSA for 24 h in 
MEM + GlutaMAXTM-I medium. (Scale bars are 50 µm). 
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Citrate capped gold nanoparticles were modified with polyethylene glycol (PEG) prior to 
lectin conjugation, in order to enhance the stability of the particles and to distance the 
lectins from the nanoparticle surface.45 Heterobifunctional α-thio-ω-carboxy PEG was self-
assembled onto citrate capped gold nanoparticles, as described in section 2.1.6. The 
terminal thiol moiety on the PEG allows the self-assembly onto the nanoparticles, whilst 
the terminal carboxyl group allows for the conjugation of the lectins through EDC/sulfo-
NHS chemistry. Following PEG modification, the gold nanoparticles were characterised 
using TEM imaging, as described in section 2.1.6.46 The TEM image shown in Figure 3.10 
reveals that the PEG modified gold nanoparticles (ca. 16 nm) are mostly non-aggregated, 
with a predominantly spherical morphology. 
 
 
Figure 3.10 A TEM image of gold nanoparticles (ca. 16 nm) following PEG attachment.46 
(Scale bar is 50 nm). 
 
EDC/sulfo-NHS chemistry was used to convert the terminal carboxyl moieties on the PEG 
attached to the gold nanoparticles into semi-stable, amine-reactive sulfo-NHS ester 
groups, as described in section 2.1.6. Con A, ECL and SSA were conjugated to the 
nanoparticles through amide bond formation with the sulfo-NHS ester modified PEG 
molecules. The nanoparticle conjugates were then characterised using UV-visible 
absorption spectrophotometry (Figure 3.11). Following PEG attachment, the surface 
plasmon absorption band maximum red-shifted by ca. 4 nm, which is likely to be due to 
the change in the refractive index at the nanoparticle surface.36 
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Figure 3.11 UV-visible absorption spectra of the surface plasmon absorption band of the 
citrate capped gold nanoparticles before (black) and after PEG attachment 
(red), and following conjugation to Con A (green), ECL (blue) and SSA (pink).  
 
The Con A, ECL and SSA nanoparticle conjugates were incubated with MCF-7 cells at 
concentrations of 0.25, 0.50 or 1.00 nM for 24 h then imaged, as described in section 
2.1.7. Figure 3.12 shows that there was no visible aggregation of any of the nanoparticle 
conjugates at any concentration, demonstrating the stabilising effect that PEG has on the 
gold nanoparticles. However, no specific binding of the Con A or ECL conjugated PEG 
modified gold nanoparticles was observed following incubation with the MCF-7 cells. 
It was thought that the aggregation of Con A conjugated gold nanoparticles observed in 
Figure 3.7 was likely to be a result of a combination of Con A aggregation and the 
proximity of the Con A to the nanoparticle surface. The images in Figure 3.7 suggest that 
the aggregation was further potentiated by using a high nanoparticle concentration (8.46 
nM). Aggregation was significantly less when using a nanoparticle concentration of 1.00 
nM (Figure 3.9). The findings of the colorimetric labelling assay were inconclusive, 
showing limited indications of specific binding of Con A or S-Con A nanoparticle 
conjugates to the MCF-7 and SK-BR-3 cells. However, the substantial improvement in 
nanoparticle stability following PEG modification suggests an important role for the use of 
such molecules in cell-based assays. 
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Figure 3.12 Inverted optical microscope images of MCF-7 cells incubated with PEG 
modified gold nanoparticles (1 nM) conjugated to A) Con A, B) ECL or C) SSA 
for 24 h. (Scale bars are 50 µm). 
 
3.2.2 Lectin cytoadhesion assay 
To directly assess the interactions of Con A or S-Con A with MCF-7 cells, a colorimetric 
formazan-based lectin cytoadhesion assay was performed, as described in section 2.1.8. 
Mitochondrial reductase within metabolically active cells convert the 3-(4,5-Dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) reagent into purple formazan 
crystals. Formazan is insoluble in aqueous media, and requires solubilisation with a 
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solvent, such as DMSO.47 The conversion of the MTT reagent to formazan by viable cells 
that are specifically attached to the lectin-derivatised wells is shown in Figure 3.13. 
 
Figure 3.13 Reduction of the MTT reagent by mitochondrial reductase activity within 
viable cells to produce formazan.47 
 
A cross-calibration assay was initially performed to establish the optimal lectin 
concentration required for adhesion to the multidish wells and to determine the MCF-7 
cell density needed to achieve the highest binding to the lectin derivatised wells. Con A 
was adsorbed onto NUNC NunclonTM ∆ surface multidishes for the cross-calibration 
experiment, as described in section 2.1.8. The NunclonTM ∆ surface treatment increases 
the hydrophilicity of the polysterene multidishes to maximise the absorption of 
biomolecules and cells. The enzymatic treatment of cells with trypsin to detach them from 
their culture flasks can temporarily alter lectin binding patterns to the carbohydrates 
expressed at their surface.10 Therefore the MCF-7 cells were detached using the calcium 
chelators EDTA and EGTA. The optimal Con A concentration for adsorption onto the 
surface of the wells in the multidishes was found to be 0.5 mg.ml-1 (Figure 3.14). The 
optimum MCF-7 cell density was found to be 2x104 cells per well. Therefore a lectin 
concentration of 0.5 mg.ml-1 and a cell density of 2x104 cells per well were used for all the 
cytoadhesion assays. 
 
MTT reagent
(yellow, water soluble)
mitochondrial 
reductase
formazan
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Figure 3.14 Formazan absorbance at 500 nm following MTT incubation with MCF-7 cells 
that adhered to wells of a 96 well multidish pretreated with 0.0 (black), 0.1 
(red), 0.5 (green) or 1.0 mg.ml-1 (blue) Con A. MCF-7 cell densities of 0.2x104, 
0.5x104, 1.0x104 or 2.0x104 cells per well were used. (Error bars are ± 
standard error; n=3) 
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Con A and S-Con A were adsorbed onto the multidishes and SSA was used as a control 
protein with no known selective binding capacity. The relative proportions of MCF-7 cells 
specifically bound to Con A and S-Con A was determined through the MTT cell viability 
assay. Formazan production was measured using the absorbance at 550 nm. The relative 
quantification of MCF-7 cells that specifically bound to Con A, S-Con A and the SSA control 
are shown in Figure 3.15. It is clear that the binding of MCF-7 cells to Con A is ca. 2-fold 
higher than to S-Con A and ca. 4.5-fold higher than to the SSA control. This pattern can be 
attributed to the tetravalent carbohydrate binding capacity of Con A, as compared to the 
bivalence of S-Con A. The limited binding of the MCF-7 cells to the SSA control is a result of 
non-specific cell adhesion.  
 
 
Figure 3.15 Formazan production of viable MCF-7 cells interacting with Con A, S-Con A 
and the control protein SSA, adsorbed onto 96 well multidishes. Formazan 
production is expressed as the absorbance intensity at 550 nm. (Error bars 
are ± standard error; n=3). 
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The same assay was repeated with Con A and S-Con A was compared to ECL (Figure 
3.16). The binding pattern of MCF-7 cells with Con A and S-Con A is consistent with 
Figure 3.15, however the binding of MCF-7 cells to ECL is significantly higher than to Con 
A. The greater adhesion of MCF-7 cells to ECL than to Con A or S-Con A could be attributed 
to a higher binding affinity of ECL to the Galβ-1,4GlcNAc- disaccharide at the surface of the 
MCF-7 cells. However, the affinity any of ECL, Con A or S-Con A to the MCF-7 cells has not 
reported. Alternatively, the density of the Galβ-1,4GlcNAc- disaccharide at the surface of 
the MCF-7 cells could be higher than the density of cell surface α-Man residues. 
 
Figure 3.16 Formazan production of viable MCF-7 cells interacting with Con A, S-Con A 
and ECL adsorbed onto 96 well multidishes. Formazan production is 
expressed as the absorbance intensity at 550 nm. (Error bars are ± standard 
error; n=3). 
 
3.2.3 Synthesis and characterisation of Con A conjugated C11Pc-PEG gold 
nanoparticles 
Based on the findings of the lectin cytoadhesion assay, it was decided that only Con A 
would be used as a proof-of-concept to attempt targeted PDT on MCF-7 cells, as the 
binding of S-Con A to these cells appears to be significantly lower. The synthesis of 
1,1’,4,4’,8,8’,15,15’,18,18’,22,22’-tetradecakisdecyl-25,25’-(11,11’dithiodiundecyl) 
diphthalocyanine zinc (C11Pc), the photosensitiser used throughout the PDT experiments 
in this thesis, has been previously reported.48 Using an adapted version of the Brust 
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method,49 gold nanoparticles (ca. 4 nm in diameter) with a mixed monolayer of the 
disulfide C11Pc photosensitiser and thiolated carboxy PEG were synthesised, as described 
in section 2.1.9.50 The PEG molecules provided colloidal stability and aqueous solubility 
to the nanoparticle system carrying the hydrophobic C11Pc photosensitiser. Figure 3.17 
is a schematic representation of the synthesis of the C11Pc-PEG gold nanoparticles.  
 
 
Figure 3.17 Synthesis of the C11Pc-PEG gold nanoparticles following the reduction of 
gold chloride (HAuCl4) in the presence of the C11Pc photosensitiser and 
thiolated carboxy PEG using sodium borohydride. 
+ HAuCl4 +
C11Pc
PEG
sodium 
borohydride 
reduction
C11Pc-PEG 
gold nanoparticles
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The MES buffer used to dissolve the nanoparticles was at pH 5.5, as acidic buffers are 
optimal for the effective activation of the carboxyl groups on PEG using EDC/sulfo-NHS 
chemistry. Con A was covalently attached to the polyethylene glycol on the gold 
nanoparticles by amide coupling of the primary amine groups on the lectin to the terminal 
carboxyl groups of the PEG, as described in section 2.1.10. A diagrammatic 
representation of the Con A conjugated C11Pc-PEG gold nanoparticles is shown in Figure 
3.18.  
 
Figure 3.18 A representation of the Con A conjugated C11Pc-PEG gold nanoparticles. The 
C11Pc photosensitiser is shown in blue, the PEG chains are black and the Con 
A molecules are shown in red (PDB ID 1CVN16). 
 
Following the removal of unbound Con A using ultrafiltration (section 2.1.10), the 
conjugated C11Pc-PEG gold nanoparticles were redispersed in serum-free Leibovitz’s L15 
medium. The use of serum in the PDT assays was avoided to prevent potential cross-
reactivity of the Con A nanoparticle conjugates with glycoproteins expressing α-Man. The 
Con A conjugated and non-conjugated nanoparticles were characterised using UV-visible 
absorption spectrophotometry (Figure 3.19). The concentration of the C11Pc-PEG gold 
nanoparticles (C11Pc equivalent) was determined by the absorbance intensity of the 
phthalocyanine Q-band at 696 nm using an extinction coefficient (ε 696 nm) of 2.23x105 M-
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1.cm-1.51 The absence of the surface plasmon absorption band centred at ca. 520 nm 
indicates that the diameter of the gold nanoparticles is below ca. 5 nm.52 As gold 
nanoparticles decrease in size, they exhibit quantum size effects that result in the 
dampening, broadening and blue-shifting of the surface plasmon absorption band towards 
the UV region of the spectrum (ca. 300-400 nm).52  
 
Figure 3.19 UV-visible absorption spectra of the Con A conjugated (red) and non-
conjugated (black) C11Pc-PEG gold nanoparticles. The nanoparticle samples 
were in serum-free Leibovitz’s L15 medium without the phenol red 
indicator. The absorption spectrum of free C11Pc in THF is shown in blue. 
The intensity of the absorption band at 696 nm, with respect to the 
absorption band centred at 645 nm, indicates that the majority of the C11Pc 
supported onto the gold nanoparticles is present in the active monomeric 
form. 
 
The non-conjugated and Con A conjugated C11Pc-PEG gold nanoparticles were also 
characterised using TEM imaging (Figure 3.20 (A and B, respectively)). The nanoparticles 
appeared non-aggregated with a narrow size distribution. The mean diameter of the Con A 
conjugated and the non-conjugated C11Pc-PEG gold nanoparticles was found to be 4.56 ± 
0.3 nm and 4.16 ± 0.3 nm, respectively (mean ± 95% confidence interval, n=100). 
Histograms showing the size distribution of the non-conjugated and Con A conjugated 
nanoparticles are shown in Figure 3.20 (C and D, respectively). 
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Figure 3.20 TEM images of non-conjugated (A) and Con A conjugated (B) C11Pc-PEG gold 
nanoparticles in phosphate buffered saline. (Scale bars are 20 nm). C and D 
are histograms showing the size distribution of the non-conjugated (C) and 
Con A conjugated (D) nanoparticles. 
 
The photoactivity of the C11Pc-PEG gold nanoparticles was measured using the 
colorimetric singlet oxygen probe, anthracene-9,10-dipropionic acid disodium salt 
(ADPA).53 ADPA exhibits characteristic absorption bands at ca. 300-420 nm. The reaction 
of singlet oxygen with ADPA yields a photobleached endoperoxide product (Figure 
3.21).53 
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Figure 3.21 The reaction of ADPA with singlet oxygen (1O2) to form a photobleached 
endoperoxide product. Figure adapted from Lindig et al.53 
 
Both the Con A conjugated and non-conjugated C11Pc-PEG gold nanoparticle samples in 
phosphate buffered saline were irradiated at 633 nm in the presence of ADPA, as 
described in section 2.1.11. The UV-visible absorption spectra of the non-conjugated and 
Con A conjugated nanoparticle solutions during the 30 min irradiation are shown in 
Figure 3.22 (A and B, respectively). The decay in ADPA absorbance at 400 nm suggests 
that the probe is photobleached by the reaction with singlet oxygen following irradiation 
of the C11Pc-PEG gold nanoparticles at 633 nm (Figure 3.22 (C)). The irradiation of the 
PEG gold nanoparticles not functionalised with C11Pc had no effect on the ADPA 
absorbance intensity showing that the C11Pc is essential for singlet oxygen production. 
Equation 3.1 was used to calculate the maximum rate of ADPA photobleaching, which was 
normalised to the C11Pc concentration. The maximum rate of ADPA photobleaching 
following the irradiation of the non-conjugated particles was 0.712% Abs 400 nm/min/µM 
C11Pc. The maximum rate of ADPA photobleaching following the irradiation of the Con A-
conjugated particles was found to be marginally lower at 0.613% Abs 400 nm/min/µM 
C11Pc, although repeating the assay a number of times would establish if the decrease in 
singlet oxygen production was statistically significant. However, the increased cellular 
internalisation of the Con A nanoparticle conjugates could potentially overcome any 
decrease in singlet oxygen production observed.  
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 (3.1) 
 
 
 
Figure 3.22 UV-visible absorption spectra of phosphate buffered saline solutions of non-
conjugated (A) and Con A conjugated (B) C11Pc-PEG gold nanoparticles in 
the presence of ADPA (0.17 mM), irradiated at 633 nm for 30 min. C) The 
progressive photobleaching of ADPA is shown as a percentage decay in 
absorbance intensity at 400 nm following the irradiation of non-conjugated 
(black) and Con A conjugated (red) C11Pc-PEG gold nanoparticles. The 
irradiation of PEG gold nanoparticles without C11Pc (green) were used as a 
control. 
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3.2.4 Con A targeted PDT treatment of MCF-7 cells using C11Pc-PEG gold 
nanoparticles – MTT viability assay 
After establishing that Con A binds to MCF-7 cells significantly more than S-Con A, and that 
the Con A C11Pc-PEG gold nanoparticle conjugates produce singlet oxygen upon 
irradiation, the PDT efficacy of the system was investigated using MCF-7 cells, as described 
in section 2.1.12. The Con A conjugated and non-conjugated C11Pc-PEG gold 
nanoparticles were incubated with the MCF-7 cells for 3 h at a concentration range of 0.0-
0.5 µM C11Pc equivalent. The cells were irradiated for 5 min per well at 633 nm, giving a 
total light dose of 10.5 J.cm-2. Staurosporine was used as a positive control for cytotoxicity 
inducing ca.93-98% cell death primarily through the apoptotic pathway.54 Cell viability 
was assessed using the MTT assay and non-irradiated cells not incubated with the 
nanoparticle conjugates were used as a reference for 100% viable cells. The MTT assay 
was performed in phenol red-free Leibovitz’s L15 medium to avoid interference of the 
phenol red indicator with the formazan absorbance readings at 550 nm. As seen in Figure 
3.23, the cells not incubated with nanoparticles that were irradiated for 5 min per well 
exhibited only a ca. 5% reduction in viability. At nanoparticle concentrations of 0.0-0.5 µM 
C11Pc equivalent, the viability of the MCF-7 cells incubated with the non-conjugated 
(Figure 3.23 (A)) or Con A conjugated particles (Figure 3.23 (B)) was unaltered with or 
without irradiation. The lack of an observable PDT effect following the treatment of the 
MCF-7 cells suggests that there was insufficient cellular association or internalisation of 
the C11Pc-PEG gold nanoparticles, even with Con A conjugation. 
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Figure 3.23 MTT viability assay results of MCF-7 cells following PDT treatment using 
non-conjugated (A) and Con A conjugated (B) C11Pc-PEG gold nanoparticles. 
After a 3 h incubation with the nanoparticles, the cells were either irradiated 
for 5 min per well (orange) or non-irradiated (dark cyan). Viability is 
expressed as a percentage of non-irradiated cells not incubated with 
nanoparticles. ‘Irradiated’ refers to cells irradiated for 5 min per well but 
not incubated with nanoparticles. Staurosporine (+St; 20 µM) was used as a 
positive control for cytotoxicity. (Error bars are ± 95% confidence intervals; 
n=3). 
 
Following the synthesis of C11Pc-PEG gold nanoparticles in THF, as described in section 
2.1.9, gold nanoparticles not functionalised with C11Pc were unstable in excess THF and 
precipitated. It was thought that some of these C11Pc-free PEG gold nanoparticles were 
not sufficiently removed from the C11Pc-PEG gold nanoparticles, and therefore competed 
for cellular internalisation. Therefore a further purification step was introduced to the 
synthetic procedure, which involved the centrifugation of the reaction mixture prior to 
removing the THF-water from the C11Pc-PEG gold nanoparticles. The MTT assay was then 
repeated following PDT treatment of MCF-7 cells incubated with the nanoparticles 
prepared using the additional purification procedure. However, the results of the MTT 
assay revealed no significant reduction in the viability of irradiated MCF-7 cells incubated 
with either non-conjugated (Figure 3.24 (A)) or Con A conjugated (Figure 3.24 (B)) 
C11Pc-PEG gold nanoparticles. It was proposed that the lack of phototoxicity of the treated 
MCF-7 cells was still a result of insufficient intracellular accumulation of the nanoparticles, 
which could be enhanced following a prolonged incubation of the conjugates at an 
increased particle concentration. 
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Figure 3.24 MTT viability assay results of MCF-7 cells following PDT treatment using 
non-conjugated (A) and Con A conjugated (B) C11Pc-PEG gold nanoparticles. 
The nanoparticles were prepared using the additional purification step. 
After a 3 h incubation with the nanoparticles, the cells were either irradiated 
for 5 min per well (orange) or non-irradiated (dark cyan). Cells not 
incubated with nanoparticles were used as a control. ‘Irradiated’ refers to 
cells irradiated for 5 min per well but not incubated with nanoparticles. 
Staurosporine (+St; 20 µM) was used as a positive control for cytotoxicity. 
(Error bars are ± 95% confidence intervals; n=3). 
 
Non-conjugated and Con A conjugated C11Pc-PEG gold nanoparticles (0.00-1.44 µM C11Pc 
equivalent) were incubated with the MCF-7 cells for 24 h, as described in section 2.1.12, 
to maximise the internalisation of the conjugates. To increase the intracellular generation 
of singlet oxygen the MCF-7 cells were irradiated for 10 min per well, increasing the light 
dose to 23.13 J.cm-2. The MTT assay was performed in MEM medium, which is the optimal 
culture medium for MCF-7 cells. Figure 3.25 shows that the increased concentration of 
nanoparticles and prolonged incubation and irradiation times resulted in no phototoxicity. 
At the highest concentration of Con A conjugates (1.44 µM C11Pc equivalent) the viability 
of irradiated MCF-7 cells was reduced by ca. 30.24%. However, the dark toxicity of the 
particles resulted in a ca. 20.58% reduction in cell viability. The 95% confidence interval 
error bars were also high (45.13% for the irradiated control), which was likely to be due 
to the interference in formazan absorbance at 550 nm by residual phenol-red from the 
MEM medium. Residual MEM medium remaining in the wells prior to dissolution of the 
formazan crystals could also vary the pH of the final formazan solutions in DMSO. This 
variation in pH is known to induce a spectral shift in the absorbance of formazan, and 
therefore alter the true absorbance values at 550 nm.55 This variability in absorbance at 
550 nm can consequently reduce the reliability of the results.55 
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Although the targeted PDT efficacy of the nanoparticles was low in MCF-7 cells, the 
intracellular uptake of the Con A conjugated or non-conjugated C11Pc-PEG gold 
nanoparticles could be assessed using inductively coupled plasma-optical emission 
spectrometry (ICP-OES) analysis of the gold within cell homogenates. 
 
Figure 3.25 MTT viability assay of MCF-7 cells following PDT treatment using non-
conjugated (A) and Con A conjugated (B) C11Pc-PEG gold nanoparticles. 
After a 24 h incubation with the nanoparticles, the cells were either 
irradiated for 10 min per well (orange) or non-irradiated (dark cyan). Cells 
not incubated with nanoparticles were used as a control. ‘Irradiated’ refers 
to cells irradiated for 10 min per well but not incubated with the 
nanoparticles. Staurosporine (+St; 20 µM) was used as a positive control for 
cytotoxicity. (Error bars are ± 95% confidence intervals; n=3).  
 
3.2.5 Con A targeted PDT treatment of SK-BR-3 cells using C11Pc-PEG gold 
nanoparticles – CellTiter-BlueTM viability assay 
Although Con A was not able to successfully target MCF-7 cells with C11Pc-PEG gold 
nanoparticles for an enhanced PDT effect, the targeted treatment was attempted on SK-
BR-3 cells, as outlined in section 2.1.13. The fluorescence based CellTiter-BlueTM viability 
assay was used rather than the colorimetric MTT assay, as no solubilisation step for the 
assay product is required. The CellTiter-BlueTM reagent contains a non-fluorescent blue 
compound, resazurin, which is reduced by viable cells to the fluorescent product, 
resorufin, as outlined in Figure 3.26.56  
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Figure 3.26 The reduction of the non-fluorescent component of the CellTiter-BlueTM 
reagent, resazurin, to the fluorescent product, resorufin, by metabolically 
active viable cells.56 
 
Con A targeted PDT treatment of SK-BR-3 cells was performed using a nanoparticle 
concentration range of 0.00-1.44 µM C11Pc equivalent of Con A conjugated and non-
conjugated C11Pc-PEG gold nanoparticles, as described in section 2.1.13. The SK-BR-3 
cells were incubated with the nanoparticle conjugates for 24 h and irradiated for 10 min 
per well at 633 nm. The CellTiter-BlueTM assay was performed in DMEM medium 48 h 
following PDT treatment. Once again, no significant reduction in SK-BR-3 cell viability was 
observed in cells incubated with either the non-conjugated (Figure 3.27 (A)) or Con A 
conjugated (Figure 3.27 (B)) C11Pc-PEG nanoparticles, with or without irradiation.  
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Figure 3.27 CellTiter-BlueTM viability assay results of SK-BR-3 cells following PDT 
treatment using non-conjugated (A) and Con A conjugated (B) C11Pc-PEG 
gold nanoparticles. After a 24 h incubation with the nanoparticles, the cells 
were either irradiated for 10 min per well (orange) or non-irradiated (dark 
cyan). Cells not incubated with nanoparticles were used as a control. 
‘Irradiated’ refers to cells irradiated for 10 min per well, but not incubated 
with the nanoparticles. Staurosporine (+St; 20 µM) was used as a positive 
control for cytotoxicity. (Error bars are ± 95% confidence intervals; n=3).  
 
The poor PDT efficacy observed suggests that even at the highest concentration of 1.44 µM 
C11Pc equivalent, with a 24 h incubation period and a light dose of up to 23.13 J.cm-2, the 
Con A conjugates did not effectively target MCF-7 or SK-BR-3 breast cancer cells to induce 
any significant phototoxicity. 
 
3.3 Conclusions  
The aggregation of the gold nanoparticles (ca. 16 nm) functionalised with SPDP-activated 
lectins was found to be dependent on the type of lectin. The Con A conjugated 
nanoparticles (8.46 nM) aggregated substantially, whereas at the same concentration, the 
S-Con A conjugates remained largely stable at physiological conditions. Additionally, ECL 
conjugated nanoparticles (1 nM) were found to aggregate more than Con A or SSA 
nanoparticle conjugates. It was found that the aggregation was also dependent on 
concentration, as lower nanoparticle concentrations (0.25, 0.50 or 1.00 nM) of Con A, ECL 
or SSA conjugated gold nanoparticles did not aggregate following 1 h of incubation. Some 
aggregation was observed at nanoparticle concentrations of 0.25, 0.50 or 1.00 nM 
following a 24 h incubation period. Some evidence of the binding of the aggregated Con A 
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conjugates (1 nM and 8.46 nM) to MCF-7 cells and SK-BR-3 cells was observed, although 
the instability of the particles rendered these observations inconclusive. Following 
conjugation through PEG, Con A or S-Con A conjugated gold nanoparticles were unable to 
successfully label MCF-7 cells. In conclusion, it was found that PEG provides superior 
colloidal stability to gold nanoparticles (ca. 16 nm) functionalised with lectins, as 
compared to nanoparticles directly conjugated to SPDP-activated lectins. Therefore, by 
modifying the gold nanoparticles with PEG prior to lectin conjugation, the nanoparticles 
and more stable, and therefore useable for cells-based assays. 
Overall, it was found that gold nanoparticles functionalised with Con A or S-Con A were 
not effective at colorimetrically labelling MCF-7 cells or SK-BR-3 cells. An assay with 
higher sensitivity, such as TEM imaging, could provide further information regarding the 
differential binding affinities of the Con A and S-Con A nanoparticle conjugates towards 
the MCF-7 cells and SK-BR-3 cells. 
The lectin cytoadhesion assay, developed as part of this work, indicated that the binding 
affinity of Con A towards MCF-7 cells was 2-fold greater than that of S-Con A, and almost 
4.5-fold greater than that of the SSA control. The significantly greater binding of Con A to 
the MCF-7 cells, as compared to S-Con A, resulted in the decision to use Con A as a proof-
of-concept for lectin targeted PDT using C11Pc-PEG gold nanoparticles. Water soluble gold 
nanoparticles (ca. 4 nm) carrying the hydrophobic C11Pc photosensitiser and amphiphilic 
PEG derivative molecules were successfully synthesised. Singlet oxygen production of the 
aqueous nanoparticle system with and without Con A conjugation was confirmed through 
the photobleaching of the singlet oxygen molecular probe, ADPA, upon irradiation at 633 
nm.  
The targeted PDT efficacy of Con A conjugated C11Pc-PEG gold nanoparticles was 
investigated in MCF-7 and SK-BR-3 human breast adenocarcinoma cells, using non-
conjugated nanoparticles as a control. The colorimetric MTT viability assay results showed 
no significant targeted phototoxicity of MCF-7 cells using the highest concentration (1.44 
µM C11Pc equivalent) of Con A conjugated nanoparticles following a 24 h incubation 
period and 10 min irradiation. The results from the fluorometric CellTiter-BlueTM viability 
assay also showed no significant targeted phototoxicity of SK-BR-3 cells under the same 
conditions described. The poor PDT efficacy of the conjugates could be attributed to low 
binding of Con A conjugated nanoparticles to either MCF-7 or SK-BR-3 cells, resulting in 
insufficient intracellular accumulation of the photosensitiser functionalised nanoparticles. 
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Accumulation of the nanoparticles within the cells is dependent on the affinity of Con A to 
surface exposed α-Man residues, the density of the α-Man antigens at the cell surface, the 
extent of nanoparticle endocytosis and the loading efficiency of the sensitiser onto the 
particles. Further investigation into all these factors could provide a definitive reason for 
the low PDT efficacy of the Con A conjugated C11Pc-PEG gold nanoparticles. 
This chapter has highlighted the effectiveness of a colorimetric formazan-based assay for 
assessing the interaction of lectins with breast cancer cells. Additionally, the methods and 
procedures for preparing photoactive, lectin functionalised gold nanoparticles carrying a 
hydrophobic sensitiser have been established. The parameters for performing the 
colorimetric MTT viability assay and the fluorometric CellTiter-BlueTM assay to investigate 
the efficacy of PDT treatment were also established. The following chapter demonstrates 
the targeting efficiency of an alternative lectin, jacalin, for the selective PDT treatment of 
HT-29 colon cancer cells expressing the tumour-associated carbohydrate T antigen.  
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Chapter 4 
Targeting the oncofoetal T antigen disaccharide with jacalin 
functionalised phthalocyanine-PEG gold nanoparticles for 
selective PDT of HT-29 colon adenocarcinoma cells 
This chapter describes the experiments performed to effectively target the tumour-
associated T antigen at the surface of HT-29 human colon adenocarcinoma cells with 
jacalin functionalised gold nanoparticles carrying zinc phthalocyanine.  
 
4.1 Introduction  
4.1.1 The origin of the Thomsen-Friedenreich antigen  
One of the most therapeutically attractive cancer-associated carbohydrates is the 
Thomsen-Friedenreich disaccharide antigen (T antigen), also known as the TF antigen, the 
core 1 glycan, or CD176.1-3 The T antigen is a disaccharide consisting of galactose β1-3 N-
acetylgalactosamine, O-linked to a glycoprotein through serine or threonine residues 
(Galβ1-3GalNAc-α-O-ser/thr; Figure 4.1). The T antigen is often referred to as being 
oncofoetal as it is a truncated O-glycan that is usually cryptic in normal cells but its 
exposure is restricted to developing embryonic cells or cancer cells.3 The T antigen is 
expressed in more than 90% of primary human carcinomas including those from the 
lungs, pancreas, breasts, bladder, colon, oesophagus, ovaries and prostate.4,5 Tumour 
initiating cells (cancer stem cells) of the lung, breast, liver and colon were also found to 
express the T antigen at their surface.6 Consequently, the T antigen is an attractive target 
for cancer therapies.  
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Figure 4.1 Structure of the oncofoetal T antigen, Galβ1-3GalNAc-α-, O-linked to a serine 
or threonine residue on a cell surface glycoprotein. 
 
The exposure of the T antigen at the surface of cancer cells is a result of aberrant 
glycosylation mechanisms that hamper the maturation of the disaccharide. The pathways 
of O-glycan biosynthesis outlined in Figure 4.2 show that the T antigen (core 1 glycan) is 
formed from an oncofoetal cancer-associated α-linked N-acetylgalactosamine glycan, also 
known as the Tn antigen. The T antigen is formed from the Tn antigen through Core 1 β3-
galactose transferase activity by the addition of a galactose residue.7,8 Colon cancer cell 
deficiencies in β3-galactose transferase activity are suggested to be responsible for the 
exposure of the Tn and sialyl-Tn antigens, both of which are also highly correlated with 
malignancy.8 During normal O-glycan biosynthesis, the T antigen is further concealed by 
sulfate molecules, sialic acid, fucose or N-acetylglucoseamine residues, preventing further 
glycosylation. Alternatively, the T antigen can be matured into the core 2 glycan through 
core 2 β6-N-acetylglucosamine-transferase activity, leading to further branching. Colon 
cancer cells are also known to exhibit an increased expression of the core 1 glycan (T 
antigen), and a decrease in the expression of the core 3 glycan (N-acetylglucosamine β1-3 
N-acetylgalactosamine, O-linked to serine or threonine).9 Decreased synthesis of core 3 
glycans in colon cancer cells has been attributed to a marked decrease in core 3 β3-N-
acetylglucosamine transferase activity, leading to the prevalence of T antigen synthesis.7 It 
is therefore crucial that the lectin used to target cancer cells can distinguish between the T 
antigen and other structures not associated with malignancy.  
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Figure 4.2 Pathways of O-glycan biosynthesis showing the development of the T antigen 
on a glycoprotein. Figure adapted from Brockhausen (1999).7 
 
There are multiple factors thought to be responsible for incomplete O-glycan biosynthesis, 
and subsequent exposure of the T antigen. A decreased expression of carbohydrate 
sulfotransferases responsible for concealing the core 1 glycan through sulfation can lead 
to the exposure of the T antigen.3 Furthermore, increased expression of the uridine 
diphosphate-galactose (UDP-Gal) transporter increases the bioavailability of UDP-Gal, and 
therefore up-regulates the synthesis of the T antigen.3 In breast and colorectal cancer cells, 
T antigen expression was found to be highly dependent on the pH of the Golgi Apparatus. 
An increase of ca. 0.2 pH units in the Golgi Apparatus was sufficient to elevate the 
expression of the T antigen.3,10 
As the T antigen is expressed in such a large number of cancers and cancer stem cells, and 
its exposure on non-developmental cells is restricted to malignant and premalignant 
tissue, it becomes an appealing molecular target for cancer therapies such as PDT. 
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4.1.2 Jacalin as a T antigen specific lectin 
Jacalin is a 66 kDa tetrameric, galactose binding lectin (Figure 4.3) extracted from the jack 
fruit (Artocarpus integrifolia), which has a high specificity towards the T antigen.11 Jacalin 
is one of several T antigen-specific lectins that can induce various biological responses 
following adhesion to membrane-bound glycoproteins. Some lectins can modulate cell 
proliferation by binding to glycosylated cell surface receptors and activate intracellular 
signaling pathways in a similar manner to growth factors.12 For example, peanut 
agglutinin binds to the T antigen on glycosylated isoforms of the transmembrane CD44v6 
receptor, thereby activating c-Met and mitogen-activated protein kinase (MAPK) signaling, 
and thereby increasing cell proliferation.12,13 Similarly, the lectin Amaranthin causes an 
increase in cell proliferation upon binding.14 Other lectins are known to induce a 
reversible inhibition in proliferation, such as the Agaricus bisporus lectin and jacalin.14,15 
Jacalin has been found to bind specifically to the T antigen expressed at the surface of HT-
29 human colorectal adenocarcinoma cells, with a dissociation constant (Kd) of 500 ± 
50nM, reaching maximum binding in 20 minutes at 4 °C.14  
 
Figure 4.3 A Pymol generated image (PDB ID 1M2616) of jacalin complexed to two 
individual T antigens (white). The remaining two T antigens are bound at the 
posterior face of the lectin. 
 
Jacalin has been previously used to detect the T antigen expressed on precancerous and 
cancerous colonic tissue.17 Histological examination of T antigen expression using jacalin 
was compared to using the anti-T antigen antibody and the galactose oxidase-Schiff (GOS) 
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reaction. The GOS reaction colorimetrically labels tissue expressing the T antigen, 
following oxidation of the terminal galactose residue of the disacharride and treatment 
with Schiff’s reagent (basic fuchsin).18 Jacalin had the highest sensitivity of 84.3% for 
cancerous and precancerous tissue, as compared to the GOS reaction (75.7%) and 
immunostaining (50%).17 However, the anti-T antigen antibody and the GOS reaction had 
the highest selectivity for the T antigen on cancerous and precancerous tissue (100%), 
whereas jacalin had only 80% selectivity.17 It was suggested that jacalin cross-reacted 
with the sialyl-T antigen, which the lectin can also recognise.17,19 However, the binding 
affinity of jacalin to the sialylated T antigen is weaker than its affinity for the T antigen.19  
A number of photosensitising molecules have been reported to bind to jacalin with Kd 
values ranging from 0.42 mM to 7.69 µM. Binding was found to be at either the 
carbohydrate binding domain or at other regions of the lectin, depending on the sensitiser 
used.20,21 These PDT agents include phycocyanin22 (a phycobiliprotein from cyanobacteria 
and algae), meso-tetrasulfonatophenylporphyrin,20,21 and zinc meso-
tetrasulfonatophenylporphyrin.20 Jacalin was therefore proposed to act as a potential 
tumour specific PDT vehicle, directing the photosensitising molecules to cancer cells 
expressing the T antigen. However, no studies have previously demonstrated the in vitro 
or in vivo efficacy of using jacalin for targeted PDT treatment of cancer.  
A recent study by Poiroux et al.23 has highlighted the potential of using lectins for targeted 
photodynamic cancer therapy. The T antigen, as well as the Tn antigen, expressed on 
Jurkat leukaemia cells were successfully targeted with the lectin, Morniga G, covalently 
conjugated to a water soluble porphyrin photosensitiser. Targeted PDT using the Morniga 
G-porphyrin conjugate reduced Jurkat leukaemia cell viability by more than 90%, whereas 
the non-conjugated sensitiser had no PDT effect at the same concentration. 
The use of jacalin as a cancer-specific lectin to target gold nanoparticles for PDT is 
described for the first time in this chapter.24 The oncofoetal T antigen at the surface of HT-
29 human colon adenocarcinoma cells has been successfully targeted with jacalin 
functionalised C11Pc-PEG gold nanoparticles. Confocal microscopy revealed the enhanced 
intracellular uptake of the jacalin conjugates, as compared to the non-conjugated particles. 
By specifically targeting the T antigen, a dramatic reduction in cell viability was observed 
following PDT treatment. Phototoxicity of the targeted nanoparticle constructs was found 
to be predominantly through the necrotic pathway, with no signs of apoptosis. 
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4.2 Results and Discussion  
4.2.1 Synthesis of jacalin conjugated C11Pc-PEG gold nanoparticles  
C11Pc-PEG gold nanoparticles were synthesised in THF and conjugated to jacalin through 
covalent amide coupling to the PEG molecules, as described in section 2.2.1. A 
diagrammatic representation of the multifunctional jacalin conjugated C11Pc-PEG gold 
nanoparticles is shown in Figure 4.4.  
 
Figure 4.4 A schematic representing the jacalin conjugated C11Pc-PEG gold 
nanoparticles composed of a mixed monolayer of the C11Pc photosensitiser 
(blue) and PEG molecules (black) covalently conjugated to jacalin (green, 
PDB ID 1M2616).  
 
The UV-visible absorption spectra of jacalin conjugated and non-conjugated C11Pc-PEG 
gold nanoparticles in serum-free RPMI 1640 cell culture medium are shown in Figure 4.5. 
It is clear that the monomeric, photoactive C11Pc species (absorption band maximum at 
ca. 696 nm) is predominant following self-assembly to the gold nanoparticles, and after 
covalent conjugation to jacalin.  
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Figure 4.5 UV-visible absorption spectra of C11Pc-PEG gold nanoparticles in serum-free 
RPMI 1640 medium with (green) and without (blue) jacalin conjugation. 
 
4.2.2 Singlet oxygen production by the C11Pc-PEG gold nanoparticles 
To confirm that the C11Pc-PEG gold nanoparticles undergo a type II photosensitisation 
process to produce singlet oxygen, a study using deoxygenated and reoxygenated 
solutions of the nanoparticles was performed. A HEPES buffered saline solution of C11Pc-
PEG gold nanoparticles containing APDA was deoxygenated by argon saturation and 
irradiated for 30 min at 633 nm, as described in section 2.2.2. Figure 4.6 shows the UV-
visible absorption spectra of the ADPA (ca. 300-420 nm; Figure 4.6 (A)) and the C11Pc Q-
band (ca. 550-750 nm; Figure 4.6 (B)) during irradiation of the deoxygenated then 
reoxygenated solution of C11Pc-PEG gold nanoparticles. The decay in ADPA absorbance at 
400 nm by singlet oxygen, following the irradiation of the C11Pc-PEG gold nanoparticles is 
shown in Figure 4.6 (C). Singlet oxygen production by the C11Pc-PEG gold nanoparticles 
also resulted in a decay in the C11Pc absorbance intensity at 696 nm (Figure 4.6 (D)). The 
decrease in C11Pc absorption can be attributed to the photooxidation of the C11Pc 
molecules to produce 3,6-bis-decylphthalimide following irradiation at 633 nm.25 It is 
clear that during the irradiation of the deoxygenated nanoparticle solution, the rate of 
ADPA photobleaching was limited, as was the rate of C11Pc degradation. Upon 
reoxygenation of the nanoparticle solution, the rate of singlet oxygen production 
dramatically increased, as did the rate of C11Pc degradation. The oxygen dependence of 
the photobleaching of ADPA and the photodegradation of C11Pc suggest that both 
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processes are mediated by photosensitised singlet oxygen. The maximum rate of ADPA 
photobleaching upon irradiation of the nanoparticles in HEPES buffered saline was 4.83% 
Abs 400 nm/min/µM C11Pc.  
The singlet oxygen production of a HEPES buffered saline solution of jacalin conjugated 
C11Pc-PEG gold nanoparticles was also measured using ADPA. A maximum rate of ADPA 
photobleaching following irradiation of the jacalin nanoparticle conjugates was calculated 
to be 2.86% Abs 400 nm/min/µM C11Pc.  
 
 
Figure 4.6 UV-visible absorption spectra of a HEPES buffered solution of C11Pc-PEG 
gold nanoparticles containing the singlet oxygen molecular probe, ADPA 
(0.17 mM). The absorbance profiles of ADPA (A) and the C11Pc Q-band (B) 
are shown during the irradiation of the deoxygenated and reoxygenated 
solution at 633 nm. Progressive decay in absorbance of ADPA at 400 nm (C) 
and C11Pc at 696 nm (D) are a result of singlet oxygen production following 
irradiation.  
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4.2.3 PDT of HT-29 cells using the jacalin conjugated C11Pc-PEG gold 
nanoparticles synthesised in THF 
After confirming that both jacalin conjugated and non-conjugated C11Pc-PEG gold 
nanoparticles could produce significant quantities of singlet oxygen, the in vitro PDT 
efficacy of jacalin conjugated nanoparticles was investigated in HT-29 human colon 
adenocarcinoma cells. HT-29 cells have been shown to express ca. 4.4x107 T antigens per 
cell.14 Jacalin conjugated or non-conjugated C11Pc-PEG gold nanoparticles were prepared 
as described in section 2.2.1. A range of concentrations between 0.00-1.15 µM C11Pc 
equivalent were incubated with the HT-29 cells for 3 h. Transparent 96 well multidishes 
were used to enable in situ optical imaging following PDT treatment. Following incubation 
with the nanoparticles, the cells were irradiated for 5 min per well at 633 nm. Inspection 
of the HT-29 cells using optical microscopy following PDT treatment using either non-
conjugated or jacalin conjugated particles revealed no morphological changes associated 
with cell death. The viability of the cells was assessed using the MTT assay 48 h after 
irradiation, as described in section 2.2.3. The viability of the HT-29 cells following PDT 
treatment is expressed as a percentage of control cells not incubated with nanoparticles 
without irradiation (Figure 4.7). The non-ionic surfactant, Triton X-100, was used as a 
positive control for cytotoxicity. Figure 4.7 (A) shows the HT-29 cell viability following 
incubation with 0.00-1.15 µM C11Pc equivalent of non-conjugated C11Pc-PEG gold 
nanoparticles. No significant changes in cell viability were observed in cells kept in the 
dark or those irradiated at 633 nm at any concentration of nanoparticles used. Similarly, 
Figure 4.7 (B) shows that no significant difference in viability is observed between cells 
kept in the dark or those irradiated following incubation with jacalin-conjugated C11Pc-
PEG gold nanoparticles. However, the jacalin conjugated C11Pc-PEG gold nanoparticles 
induced a substantial dose-dependent reduction in viability to a similar extent in cells with 
or without irradiation (ca. 60.70-62.51% reduction at 1.15 µM C11Pc equivalent, Figure 
4.7 (B)). Although the MTT results show a noticeable reduction in cell viability following 
incubation with the jacalin conjugated particles, the morphology of the HT-29 cells 
appeared largely unaltered, as compared to the untreated control cells. This reduction in 
viability of HT-29 cells incubated with the jacalin nanoparticle conjugates could be 
attributed to a non-cytotoxic inhibition of HT-29 cell proliferation upon jacalin binding. 
Previous findings have shown that jacalin (20 µg.ml-1) can reversibly inhibit HT-29 cell 
proliferation by up to 46 ± 4% by down-regulating the extracellular signal-regulated 
kinase (ERK) signalling pathway through the activation of the tumour suppressor 
membrane protein, pp32.14,26 
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The results outlined in this section suggest that jacalin conjugated C11Pc-PEG gold 
nanoparticles bind to the HT-29 cells, as confirmed by the drastic anti-proliferative effects 
the conjugates exert. However, although sufficient concentrations of C11Pc were used in 
this experiment, it is likely that a low C11Pc loading efficiency onto the nanoparticles is 
responsible for the lack of an observable PDT effect. A low C11Pc loading efficiency can 
lead to insufficient intracellular accumulation of the sensitiser and a poor efficacy of 
phototoxicity, given that nanoparticle uptake may still be significant. Inductively coupled 
plasma-mass spectrometry (ICP-MS) analysis has previously shown that the C11Pc-PEG 
gold nanoparticles synthesised in THF have ca. 10 molecules of C11Pc per gold 
nanoparticle.27 By increasing the C11Pc loading efficiency, an enhanced intracellular 
accumulation of the sensitiser may be achieved at the same concentration of C11Pc 
equivalent. The higher C11Pc loading efficiency could ultimately reduce the concentration 
of gold nanoparticles required to achieve effective cell kill when using the same 
concentration range of C11Pc equivalent (0.10-1.15 µM).  
 
 
Figure 4.7 MTT viability assay following PDT treatment of HT-29 cells using non-
conjugated (A) and jacalin conjugated (B) C11Pc-PEG gold nanoparticles. HT-
29 cells were seeded 24 h prior to incubation with the nanoparticles. After a 
3 h incubation with the nanoparticles, the cells were either irradiated for 5 
min per well (orange) or non-irradiated (dark cyan). Cells not incubated 
with nanoparticles were used as a control . ‘Irradiated’ refers to cells 
irradiated for 5 min per well but not incubated with nanoparticles. Triton X-
100 (+TrtX; 1%) was used as a positive control for cytotoxicity. (Error bars 
are ± 95% confidence intervals, n=3). 
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4.2.4 Synthesis and characterisation of high yield C11Pc-PEG gold nanoparticles 
in DMF 
As discussed in section 4.2.3, the C11Pc-PEG gold nanoparticles synthesised in THF are 
likely to be carrying C11Pc at quantities insufficient for cell kill. The typical yield of C11Pc-
PEG gold nanoparticles synthesised in THF was ca. 2 µM C11Pc equivalent. Following the 
reduction of gold (III) chloride by sodium borohydride, the instability of PEG gold 
nanoparticles (C11Pc-free) in excess THF during synthesis causes the particles to rapidly 
precipitate. This could possibly lead to a lower efficiency of C11Pc self-assembly, lower 
yields of C11Pc-PEG gold nanoparticles and a higher PEG:C11Pc ratio at the surface of the 
gold nanoparticles. To investigate whether enhancing the stability of the PEG 
nanoparticles during synthesis could increase the C11Pc loading and the yield of C11Pc-
PEG gold nanoparticles, the use of an alternative solvent was explored. N,N-
dimethylformamide (DMF) was used to incrementally replace THF in the synthesis of the 
nanoparticle conjugates. PEG gold nanoparticles without C11Pc were synthesised with 
varying ratios of DMF:THF, as described in section 2.2.4. Following 15 h of stirring, 
samples A to F (Figure 4.8) were visually inspected for nanoparticle precipitation. It is 
apparent that by increasing the ratio of DMF:THF, the PEG gold nanoparticles were 
increasingly more stable in the reaction solvent mixture.  
 
 
Figure 4.8 Samples of PEG gold nanoparticles (C11Pc-free) synthesised using varying 
proportions of DMF to THF. As the ratio of DMF to THF increases, the stability 
of the brown PEG gold nanoparticles in the reaction mixture is enhanced.  
 
Increasing ratio of DMF : THF
0:2.1 0.15:1.95     0.3:1.8    0.45:1.65      0.6:1.5    1.6:0.5
A           B C          D           E           F
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As the nanoparticles in sample F (Figure 4.8) appeared to be the most stable, the 
synthetic reaction conditions were used to synthesise C11Pc-PEG gold nanoparticles using 
DMF as the main solvent, as described in section 2.2.4. THF was only used to dissolve the 
C11Pc. Following 15 h of stirring, the C11Pc-PEG gold nanoparticle reaction mixture 
appeared more stable and the MES buffered solution of nanoparticles was ca. 6 µM C11Pc 
equivalent. The use of DMF as the main solvent was compared to using methanol, as PEG 
gold nanoparticles were also found to be highly stable in methanol. The MES buffered 
solutions of nanoparticles synthesised in DMF or methanol are shown in Figure 4.9 (A). 
To confirm that the C11Pc present in the solution of nanoparticles was directly bound to 
the gold surface rather than non-covalently associated with the PEG, TLC separation of the 
nanoparticles synthesised in DMF or methanol was investigated (Figure 4.9 (B) and (C), 
respectively). Following TLC separation of the nanoparticle sample synthesised in DMF, a 
blue residue of C11Pc-PEG gold nanoparticles remained at the stationary phase and some 
free C11Pc travelled with the mobile phase. When methanol was used as the main solvent, 
only brown PEG particles remained at the stationary phase and the majority of the C11Pc 
travelled with the mobile phase. It is therefore likely that the C11Pc was associated with 
the PEG at the surface of the nanoparticles synthesised in methanol, and was not directly 
bound to the gold particles. Therefore, it was concluded that C11Pc was only bound to the 
surface of gold nanoparticles synthesised using DMF as the main solvent. For this reason, 
DMF was used as the solvent of choice for nanoparticle synthesis for the remainder of the 
results reported in this chapter.  
 
 
Figure 4.9 A) C11Pc-PEG gold nanoparticles dissolved in MES buffer synthesised in DMF 
or methanol (MeOH). TLC separation of free C11Pc from the MES buffered 
solutions of gold nanoparticles (8 µl) synthesised in DMF (B) and in 
methanol (C). Free C11Pc in THF was used as a control. Toluene/methanol 
(98:2) was used as the mobile phase for the separation of unbound C11Pc 
from the nanoparticles. 
BA C
free 
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To confirm that the higher yield of C11Pc-PEG gold nanoparticles synthesised in DMF was 
due to the stabilisation of C11Pc by the nanoparticles, the synthesis was performed using 
0.564 mM or 0.282 mM of gold (III) chloride. The image shown in Figure 4.10 (A) 
demonstrates that the solution of nanoparticles synthesised in DMF using 0.564 mM gold 
(III) chloride appeared to contain a significantly higher amount of C11Pc than those 
synthesised using 0.282 mM gold (III) chloride. The UV-visible absorption spectra in 
Figure 4.10 (B) shows that the yield of C11Pc-PEG gold nanoparticles was found to be 
dependent on the concentration of the gold (III) chloride used for the synthesis. The yield 
of the C11Pc-PEG gold nanoparticles synthesised using 0.282 mM gold (III) chloride (3.54 
µM C11Pc equivalent) was significantly lower than the yield of nanoparticles synthesised 
using 0.564 mM gold (III) chloride (9.26 µM C11Pc equivalent). This difference further 
confirms that the gold nanoparticles were responsible for stabilising the C11Pc in aqueous 
media.  
 
Figure 4.10 A) Samples of C11Pc-PEG gold nanoparticles in MES buffer synthesised in 
DMF using 0.564 mM or 0.282 mM gold (III) chloride. B) UV-visible 
absorption spectra of MES buffered solutions of the C11Pc-PEG gold 
nanoparticles synthesised using 0.564 mM (black) or 0.282 mM (blue) gold 
(III) chloride.  
 
The singlet oxygen production by C11Pc-PEG gold nanoparticles synthesised in DMF was 
then investigated using ADPA as the singlet oxygen molecular probe, as described in 
section 2.2.4. The UV-visible absorption spectra of C11Pc-PEG gold nanoparticles in the 
presence of ADPA (0.17 mM) during 30 min of irradiation at 633 nm is shown in Figure 
4.11 (A). The characteristic ADPA absorption bands at ca. 300-420 nm (Figure 4.11 (B)) 
decrease in intensity upon singlet oxygen generation following irradiation of the C11Pc-
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PEG gold nanoparticles. Irradiation of the C11Pc-PEG gold nanoparticles also resulted in a 
decay in the C11Pc Q-band at ca. 550-750 nm upon irradiation at 633 nm (Figure 4.11 
(C)). The C11Pc Q-band decay is associated with photooxidation of the sensitiser following 
singlet oxygen generation, as discussed in section 4.2.2. The maximum rate of ADPA 
decay following irradiation at 633 nm of the nanoparticles in MES buffer was ca. 0.91% 
Abs 400 nm/min/µM C11Pc (Figure 4.11 (D)). This rate was found to be significantly lower 
than that obtained following the irradiation of a MES buffered solution of C11Pc-PEG gold 
nanoparticles synthesised in THF (ca. 3.73% Abs 400 nm/min/µM C11Pc). The C11Pc-PEG 
gold nanoparticles synthesised in DMF were not sufficiently purified after synthesis. It is 
possible that the reason for this decrease in the maximum rate of ADPA decay, and rate of 
singlet oxygen production, is as a result of the presence of PEG gold nanoparticles, without 
C11Pc functionalisation. The presence of such particles could increase the light scattering 
and hinder C11Pc activation. Therefore, the removal of the PEG gold nanoparticles not 
functionalised with the phthalocyanine could be crucial in maximising the singlet oxygen 
production by the C11Pc-PEG gold nanoparticle conjugates. 
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Figure 4.11 A) UV-visible absorption spectra of a MES buffered solution of C11Pc-PEG 
gold nanoparticles (1.94 µM C11Pc equivalent) synthesised in DMF in the 
presence of ADPA (0.17 mM), irradiated at 633 nm for 30 min. B) 
Photobleaching of the ADPA absorption bands by singlet oxygen upon 
irradiation of the C11Pc-PEG gold nanoparticles. C) Decrease in the 
absorbance intensity of the phthalocyanine Q-band following singlet oxygen 
production upon irradiation. D) Progressive photobleaching of ADPA 
expressed as a percentage decay in absorbance intensity at 400 nm. 
 
Nanoparticles were synthesised again in DMF, as described in section 2.2.4, with an 
additional purification step that uses a THF extraction procedure to separate the 
nanoparticles functionalised with C11Pc from the dried nanoparticle mixture. The portion 
of the nanoparticles soluble in THF was dried and dissolved in MES buffer (THF extract) 
while the portion of the nanoparticles insoluble in THF was dissolved in water (water 
extract). The UV-visible absorption spectra of the two extracts are shown in Figure 4.12. 
The THF extract has a higher yield of C11Pc-PEG gold nanoparticles (4.35 µM C11Pc 
equivalent) than the water extract (3.92 µM C11Pc equivalent). The UV-visible absorption 
spectra in Figure 4.12 show a greater absorption intensity between 300-400 nm, which 
suggests a higher content of gold nanoparticles in the water extract than in the THF 
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extract. Overall, it is apparent that the nanoparticles synthesised in DMF contain varying 
amounts of C11Pc at their surface. The particles with a higher degree of C11Pc 
functionalisation are more readily soluble in THF. 
 
Figure 4.12 UV-visible absorption spectra of C11Pc-PEG gold nanoparticles synthesised 
in DMF using an aqueous solution of sodium borohydride. A fraction of the 
C11Pc-PEG gold nanoparticles was soluble in both THF and water (THF 
extract, green, 4.35 µM C11Pc equivalent). The other fraction of 
nanoparticles was only soluble in water (water extract, black, 3.92 µM C11Pc 
equivalent).  
 
To investigate the effect of the absence of water on the C11Pc distribution on the 
nanoparticles, the synthesis of the C11Pc-PEG gold nanoparticles was repeated a further 
time using DMF. However, on this occasion DMF was also used as a solvent for the sodium 
borohydride, rather than water. The additional purification step using THF was also 
incorporated into this synthetic strategy. The UV-visible absorption spectra of the THF and 
water extracts of the C11Pc-PEG gold nanoparticles (Figure 4.13) show that the THF 
extract had a ca. 4.2-fold higher yield of C11Pc-PEG gold nanoparticles than the water 
extract. Additionally, the THF extract contained a ca. 1.55 µM C11Pc equivalent higher 
concentration of nanoparticles (Figure 4.13) than the THF extract of the particles shown 
in Figure 4.12. The higher C11Pc-PEG gold nanoparticle yield indicates that the absence of 
water during the synthesis leads to a more distinct separation between particles with a 
high C11Pc loading efficiency and particles with a low C11Pc loading efficiency.  
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Figure 4.13 UV-visible absorption spectra of the C11Pc-PEG gold nanoparticles 
synthesised in DMF using a DMF solution of sodium borohydride. A fraction 
of C11Pc-PEG gold nanoparticles was soluble in both THF and water (THF 
extract, blue, 5.9 µM C11Pc equivalent). The second fraction was only soluble 
in water (water extract, brown, 1.39 µM C11Pc equivalent). 
 
THF extracts of C11Pc-PEG gold nanoparticles synthesised in DMF, using either an 
aqueous solution or a DMF solution of sodium borohydride (Figure 4.14 (A)), were 
spotted onto TLC plates. In both instances the free C11Pc was separated from the 
nanoparticle conjugates, as described in section 2.2.4. It is clear from Figure 4.14 (B) 
that both THF extracts predominantly consisted of C11Pc-PEG gold nanoparticles and the 
amount of unbound C11Pc is negligible. 
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Figure 4.14 A) THF extracts of C11Pc-PEG gold nanoparticles in MES buffer synthesised 
in DMF with either a DMF solution (DT) or an aqueous solution (WT) of 
sodium borohydride. B) TLC separation of free C11Pc from the THF extracts 
of C11Pc-PEG gold nanoparticles in MES buffer (8 µl). Both samples were 
synthesised in DMF using a DMF solution (DT) or an aqueous solution (WT) 
of sodium borohydride. Free C11Pc in THF was used as a control. The mobile 
phase used for the separation was toluene/methanol (98:2). 
 
As the yield of the C11Pc-PEG gold nanoparticles was higher when a DMF solution of 
sodium borohydride was used, this procedure was used for further investigations into 
singlet oxygen production. To facilitate the removal of the PEG gold nanoparticles not 
functionalised with C11Pc, a further purification step was introduced. Following the 
synthetic reaction of the nanoparticles, excess THF was added and the precipitated PEG 
gold nanoparticles not functionalised with C11Pc were removed by centrifugation. The 
remainder of the procedure was then performed as usual. 
C11Pc-PEG gold nanoparticles were synthesised in DMF using a DMF solution of sodium 
borohydride, with the additional THF extraction purification steps. ADPA (0.17 mM) was 
used to measure the singlet oxygen production by the MES buffered solution of C11Pc-PEG 
gold nanoparticles following irradiation at 633 nm for 30 min. Figure 4.15 shows that the 
maximum rate of ADPA decay was 2.70% Abs400 nm/min/µM C11Pc. This rate is greater 
than that of the C11Pc-PEG gold nanoparticles synthesised using an aqueous solution of 
sodium borohydride (0.91% Abs400 nm/min/µM C11Pc, Figure 4.11 (D)). The increase in 
the maximum rate of ADPA decay confirms that the removal of C11Pc-free PEG gold 
nanoparticles enhanced the singlet oxygen production by the irradiation of the C11Pc-PEG 
gold nanoparticles. C11Pc-PEG gold nanoparticles in MES buffer were imaged using the 
TEM. Figure 4.16 shows that the nanoparticles are non-aggregated with a diameter of ca. 
2-4 nm.  
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Figure 4.15 The percentage decay in ADPA absorbance intensity at 400 nm upon singlet 
oxygen generation following irradiation of C11Pc-PEG gold nanoparticles in 
MES buffer.  
 
 
 
Figure 4.16 A TEM image of C11Pc-PEG gold nanoparticles in MES buffer showing non-
aggregated nanoparticles ca. 2-4 nm in diameter. (Scale bar is 20 nm). 
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Table 4.1 summarises the finalised method for synthesising the C11Pc-PEG gold 
nanoparticles, which was used for the remainder of the experiments described in this 
thesis.  
Table 4.1 The optimised experimental procedure for the synthesis of C11Pc-PEG gold 
nanoparticles. 
Step Procedure Details 
1 2 mg C11Pc in 1 ml THF stirred continuously 
2 7.5 mg PEG in 2 ml DMF stirred with C11Pc for 5 min 
3 1.2 mg gold (III) chloride in 1.2 ml DMF stirred with C11Pc and PEG for 5 min 
4 1.5 mg sodium borohydride in 1.2 ml DMF added to the mixture and stirred for 15 h 
5 5.4 ml THF added stirred for 2 min 
6 PEG gold nanoparticles (C11Pc free) removed centrifuged at 200 xg for 2 min 
7 solvent mixture removed rotary evaporation at 70 °C 
8 5.4 ml THF added C11Pc-PEG gold nanoparticles extracted 
9 THF removed rotary evaporation at 70 °C 
10 5.4 ml MES buffer added C11Pc-PEG gold nanoparticles dissolved 
11 free C11Pc removed centrifuged at 21,913 xg for 30 min 
 
 
Elemental analysis of the C11Pc-PEG gold nanoparticles using inductively coupled plasma-
optical emission spectrometry (ICP-OES), as described in section 2.2.5, revealed that the 
as-synthesised nanoparticles had a gold concentration of 29.10 ± 0.05 µg.ml-1 and a zinc 
concentration of 4.90 ± 0.005 µg.ml-1. This gives a gold to zinc ratio of 1:0.168. Based on 
the approximation that ca. 4.2 nm diameter gold nanoparticles consist of a total of 923 
atoms formed of 6 layers,28 each 0.7 nm apart,29 then ca. 155 C11Pc molecules were 
assembled onto each gold nanoparticle. Assuming that each thiol occupies ca. 21.4 Å2 on a 
gold surface, the theoretical maximum number of thiol groups bound to a gold 
nanoparticle with a diameter of 4.2 nm is ca. 259 thiols per nanoparticle.30 Consequently, a 
calculated value of 155 C11Pc molecules per nanoparticle does appear to be realistic. This 
calculated value is ca. 15.5-fold higher than that previously reported for C11Pc-PEG gold 
nanoparticles synthesised in THF.27 Therefore, the alternative synthetic procedure 
described in this section increases both the C11Pc-PEG gold nanoparticle yield and the 
C11Pc loading efficiency. 
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Based on the approximation that an average of ca. 155 molecules of C11Pc are bound to 
each nanoparticle, a 6 µM solution of C11Pc-PEG gold nanoparticles contains ca. 38.7 nM 
gold nanoparticles. By reacting a ca. 38.7 nM solution of EDC/NHS-activated C11Pc-PEG 
gold nanoparticles with 0.24 µM jacalin, the lectin is at a 6.2-fold molar excess of gold 
nanoparticles. 
 
4.2.5 Jacalin conjugation and characterisation of C11Pc-PEG gold nanoparticle 
conjugates 
Jacalin was covalently conjugated to the C11Pc-PEG gold nanoparticles using EDC/NHS 
coupling, as described in section 2.2.6. The UV-visible absorption spectra of the jacalin 
conjugated and non-conjugated nanoparticles (Figure 4.17) reveal that the conjugation 
procedure and the removal of unbound jacalin did not alter the predominantly monomeric 
C11Pc at the surface of the nanoparticles. The jacalin conjugated C11Pc-PEG gold 
nanoparticles were also characterised using TEM imaging (Figure 4.18). The 
nanoparticles appear to be non-aggregated and monodisperse, with an average diameter 
of 4.30 ± 0.18 nm (mean ± 95% confidence interval, n=100). 
 
 
Figure 4.17 UV-visible absorption spectra of C11Pc-PEG gold nanoparticles with (green) 
and without (blue) jacalin conjugation in serum-free RPMI 1640 medium. 
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Figure 4.18 A TEM image of the jacalin conjugated C11Pc-PEG gold nanoparticles in 
HEPES buffered saline. (Scale bar is 20 nm) 
 
The singlet oxygen production by the jacalin conjugated C11Pc-PEG gold nanoparticles in 
HEPES buffered saline was measured using ADPA, as described in section 2.2.7. The UV-
visible absorption spectra of the nanoparticle conjugates in the presence of ADPA (0.17 
mM) during 30 min of irradiation at 633 nm are shown in Figure 4.19 (A). Singlet oxygen 
production was confirmed by the photobleaching of ADPA in addition to the 
photooxidation of the C11Pc. The maximum rate of ADPA decay of the jacalin conjugated 
C11Pc-PEG gold nanoparticles (Figure 4.19 (B)) was found to be 2.82% Abs400 nm/min/µM 
C11Pc, as compared to 3.35% Abs400 nm/min/µM C11Pc for the non-conjugated 
nanoparticles (data not shown). Although jacalin conjugation decreased the maximum rate 
of ADPA decay, this potential limitation may be overcome if the cellular internalisation of 
the nanoparticles is significantly enhanced through targeting with jacalin. 
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Figure 4.19 A) UV-visible absorption spectra of a HEPES buffered solution of jacalin 
conjugated C11Pc-PEG gold nanoparticles (2.15 µM C11Pc equivalent) in the 
presence of ADPA (0.17 mM), irradiated at 633 nm for 30 min. B) 
Progressive photobleaching of ADPA following irradiation, expressed as a 
decay in percentage absorbance at 400 nm.  
  
4.2.6 Imaging of HT-29 cells subject to jacalin targeted PDT 
HT-29 cells were seeded onto transparent multidishes and incubated with jacalin 
conjugated and non-conjugated C11Pc-PEG gold nanoparticles (0.00-1.15 µM C11Pc 
equivalent), as described in section 2.2.8. The higher yield of C11Pc-PEG gold 
nanoparticles synthesised in DMF could suggest a higher degree of C11Pc loading onto the 
nanoparticle surface. A higher loading efficiency of C11Pc is likely to enhance the 
intracellular accumulation of the sensitiser, leading to a greater PDT efficacy than that 
observed with the nanoparticles described in section 4.2.3. Following irradiation of the 
cells incubated with non-conjugated C11Pc-PEG gold nanoparticles, no visible changes in 
cell morphology were observed, even at the highest concentration of 1.15 µM C11Pc 
equivalent (Figure 4.20 (A and B)). The jacalin conjugated nanoparticles appeared to 
induce minimal cell damage at the highest concentration of 1.15 µM C11Pc equivalent 
without irradiation (Figure 4.20 (C)). However, following irradiation, the jacalin 
conjugated C11Pc-PEG gold nanoparticles induced drastic HT-29 cell morphological 
changes (Figure 4.20 (D)), which was strongly indicative of PDT induced cytotoxicity.  
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Figure 4.20 Inverted optical microscope images of HT-29 cells incubated with 1.15 µM 
C11Pc equivalent of non-conjugated (A and B) and jacalin conjugated (C and 
D) C11Pc-PEG gold nanoparticles. The HT-29 cells were irradiated at 633 nm 
(B and D) for 5 min. (Scale bars are 100 µm). 
 
To confirm that the jacalin conjugated C11Pc-PEG gold nanoparticles were internalised by 
the HT-29 cells, the fluorescence of the C11Pc sensitiser was exploited in order to 
determine the localisation of the nanoparticle conjugates. The fluorescence excitation and 
emission spectra of the non-conjugated and jacalin conjugated C11Pc-PEG gold 
nanoparticles are shown in Figure 4.21 (A and B, respectively). The C11Pc-PEG gold 
nanoparticles were excited at 633 nm, to mimic the excitation of the 633 nm HeNe laser of 
the laser scanning confocal microscope. Excitation at this wavelength resulted in a 
fluorescence emission band centred at 780 nm. 
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Figure 4.21 Fluorescence excitation (blue)/emission (red) spectra of non-conjugated (A) 
and jacalin conjugated (B) C11Pc-PEG gold nanoparticles (1 µM C11Pc 
equivalent). Samples were in serum-free RPMI 1640 medium, excited at 633 
nm with the emission centred at 780 nm.  
 
HT-29 cells were seeded onto glass coverslips, as described in section 2.2.9, and 
incubated with jacalin conjugated or non-conjugated C11Pc-PEG gold nanoparticles (1 µM 
or 2 µM C11Pc equivalent). Following irradiation, the cells were imaged using differential 
interference contrast (DIC) imaging overlaid with fluorescence images using excitation at 
633 nm. Figure 4.22 and Figure 4.23 show the combined DIC and fluorescence images of 
the HT-29 cells incubated with 1 µM and 2 µM C11Pc equivalent of C11Pc-PEG gold 
nanoparticles, respectively. At both concentrations, it is apparent that the intracellular 
internalisation of the jacalin conjugated C11Pc-PEG gold nanoparticles (Figure 4.22 and 
Figure 4.23 (A)) was significantly more efficient than that of the non-conjugated C11Pc-
PEG gold nanoparticles (Figure 4.22 and Figure 4.23 (B)). Following irradiation of the 
cells incubated with either concentration of jacalin conjugated nanoparticles, drastic 
changes in cellular morphology were observed (Figure 4.22 and Figure 4.23 (C)). The 
absence of apoptotic bodies strongly suggested that PDT cytotoxicity was not occurring 
through apoptosis. Cell membrane perforation and degradation is a key indicator of cell 
death via the necrotic pathway. Perforation of the cell membrane was assessed using the 
fluorescent marker propidium iodide. Propidium iodide is a membrane-impermeable 
nucleotide interchelator that specifically binds to DNA once the cell membrane is 
damaged.31 The HT-29 cells incubated with the jacalin conjugated C11Pc-gold 
nanoparticles stained positive with propidium iodide following PDT treatment at both 
concentrations of nanoparticles (Figure 4.22 and Figure 4.23 (D)). 
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Figure 4.22 Combined DIC and confocal fluorescence microscopy images of HT-29 cells 
incubated with jacalin conjugated (A) and non-conjugated (B) C11Pc-PEG 
gold nanoparticles (1 µM C11Pc equivalent). C) HT-29 cells incubated with 
jacalin conjugated C11Pc-PEG gold nanoparticles following irradiation at 
633 nm for 6 min. D) HT-29 cells following jacalin targeted PDT, incubated 
with propidium iodide. (Scale bars are 10 µm). 
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Figure 4.23 Combined DIC and confocal fluorescence microscopy images of HT-29 cells 
incubated with jacalin conjugated (A) and non-conjugated (B) C11Pc-PEG 
gold nanoparticles (2 µM C11Pc equivalent). C) HT-29 cells incubated with 
jacalin conjugated C11Pc-PEG gold nanoparticles following irradiation at 
633 nm for 6 min. D) HT-29 cells following jacalin targeted PDT, incubated 
with propidium iodide. (Scale bars are 10 µm). 
 
  
163 
 
The confocal microscopy images in Figure 4.22 and Figure 4.23 demonstrate the 
significant improvement in intracellular accumulation of C11Pc-PEG gold nanoparticles, 
when conjugated to jacalin. PDT treatment of the HT-29 cells incubated with either 1 µM 
or 2 µM C11Pc equivalent of jacalin nanoparticle conjugates resulted in radical 
morphological changes associated with necrosis. Positive propidium iodide staining of the 
nuclei within the HT-29 cells following jacalin targeted PDT treatment further suggested 
that necrosis was induced. The findings detailed in this section reveal that the 
internalisation of the jacalin nanoparticle conjugates within HT-29 cells is responsible for 
the dramatic changes in morphology observed following irradiation at 633 nm. The effects 
on HT-29 cell viability following PDT treatment using the jacalin conjugated or non-
conjugated C11PC-PEG gold nanoparticles are discussed in the next section. 
 
4.2.7 Viability assessment of jacalin targeted PDT of HT-29 cells 
The optical imaging and the laser scanning confocal microscopy demonstrated that the 
HT-29 cells could be targeted and subsequently killed with PDT using the jacalin 
conjugated C11Pc-PEG gold nanoparticles. To assess the degree of targeted phototoxicity 
of HT-29 cells by the jacalin nanoparticle conjugates, an MTT cell viability assay was 
performed using 0.00-1.15 µM C11Pc equivalent of jacalin conjugated and non-conjugated 
C11Pc-PEG gold nanoparticles, as described in section 2.2.10. Statistical significance was 
calculated using a one-tailed student’s t-test. Without jacalin conjugation, no significant 
reduction in cell viability was observed at all concentrations used (Figure 4.24 (A)). 
However, with jacalin conjugation, a significant photodynamic reduction in viability was 
observed at 0.5 µM C11Pc equivalent of jacalin conjugated nanoparticles (Figure 4.24 (B), 
P<0.05). In the dark, viability of HT-29 cells incubated with 0.5 µM C11Pc equivalent of 
jacalin conjugated nanoparticles was ca. 100.2%, whereas cell viability following 
irradiation was at ca.79.3%. At 1 µM and 1.15 µM C11Pc equivalent of jacalin conjugated 
nanoparticles, cell viability reached a minimum of ca. 43%.  
In section 4.2.3 the MTT viability assay results following PDT treating using nanoparticles 
synthesised in THF show that incubation with jacalin conjugated particles reduced the 
proliferative activity of both the irradiated and non-irradiated HT-29 cells. In this section, 
incubation with jacalin conjugated nanoparticles at the same equivalent concentration of 
C11Pc did not induce the same reduction in HT-29 cell proliferation. This difference in 
anti-proliferative activity suggests that although the C11Pc concentration is consistent in 
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both experiments, the total concentration of jacalin nanoparticle conjugates incubated 
with the cells following the DMF synthetic method is significantly lower than that 
following synthesis using the THF method. Consequently, the jacalin targeted PDT effect 
on the HT-29 cells is dramatically improved. 
The findings of the MTT assay indicate that jacalin effectively targeted the T antigen on 
HT-29 cells to induce an enhanced efficiency of photodynamic cell kill. However, it was 
suggested that the 633 nm HeNe laser beam diameter of 5 mm was insufficient for the 
direct irradiation of all the cells present in the wells of the multidishes. Therefore, by 
increasing the laser beam diameter, irradiation of a greater proportion of the monolayer of 
HT-29 cells in the wells may be achieved. 
 
Figure 4.24 MTT viability assay following PDT treatment of HT-29 cells using non-
conjugated (A) and jacalin conjugated (B) C11Pc-PEG gold nanoparticles. 
After a 3 h incubation with the nanoparticles, the cells were either irradiated 
for 5 min per well (orange) or non-irradiated (dark cyan). Cells not 
incubated with nanoparticles were used as a control. ‘Irradiated’ refers to 
cells not incubated with nanoparticles but irradiated for 5 min per well. 
Staurosporine (+St; 20 µM) was used as a positive control for cytotoxicity. 
(Error bars are ± 95% confidence intervals, n=3. * indicates statistical 
significance at P<0.05 and ** at P<0.005 using a one-tailed t-test). 
 
To increase the beam diameter of the HeNe laser from 5 mm to 8 mm, the laser was fitted 
with a biconvexed divergent lens and positioned ca. 50 cm above the cells. Expanding the 
beam diameter reduced the laser fluency rate from 34 mW.cm-2 to 29 mW.cm-2. Therefore 
the irradiation time was increased to 6 min to maintain a consistent total light dose of 10.5 
J.cm-2. The jacalin targeted PDT treatment of the HT-29 cells was repeated using the laser 
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with the increased beam diameter. A minimal reduction in cell viability was observed with 
the non-conjugated C11Pc-PEG gold nanoparticles following 6 min irradiation at all 
concentrations used (Figure 4.25 (A)). However, with jacalin conjugation, a substantial 
dose-dependent reduction in viability was observed following irradiation (Figure 4.25 
(B)) reaching a minimum of ca. 4-5% viability. The phototoxicity of the HT-29 cells 
following PDT treatment is shown in Figure 4.25 (C). Irradiation of the cells incubated 
with non-conjugated C11Pc-PEG gold nanoparticles resulted in minimal phototoxicity at 
all nanoparticle concentrations used. However, irradiation of the cells incubated with the 
jacalin conjugated C11Pc-PEG gold nanoparticles induced considerable phototoxicity (ca. 
95-96%) at 1.00-1.15 µM C11Pc equivalent, with a sigmoidal dose-dependent relationship.  
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Figure 4.251 MTT viability assay following PDT treatment of HT-29 cells using non-
conjugated (A) or jacalin conjugated (B) C11Pc-PEG gold nanoparticles. After 
a 3 h incubation with the nanoparticles, the cells were irradiated for 6 min 
per well (orange) using a 633 nm HeNe laser fitted with a biconvexed 
divergent lens, or non-irradiated (dark cyan). Non-irradiated cells, not 
incubated with nanoparticles were used as a control. ‘Irradiated’ refers to 
cells irradiated at 633 nm, but not incubated with nanoparticles. 
Staurosporine (+St; 20 µM) was used as a positive control for cytotoxicity. C) 
Photodynamic toxicity of jacalin conjugated (X) and non-conjugated (X) 
nanoparticles following PDT treatment of HT-29 cells. (Error bars are 95% 
confidence intervals, n=3. ** indicates statistical significance at P<0.005, x at 
P<0.001 and *** at P<0.0005 using a one-tailed t-test). 
 
To confirm that the enhanced phototoxicity of the HT-29 cells was due to specific 
interactions between the jacalin functionalised C11Pc-PEG gold nanoparticles and the T 
antigen exposed at the cell surface, a competitive inhibition study was performed using 
methyl-α-D-galactopyranoside and asialofetuin. Simple sugars such as galactose (Gal) and 
N-acetylgalactosamine (GalNAc) have previously been used to inhibit the interaction 
0.1 µM 0.2 µM 0.5 µM 1 µM 1.15µM +St Control Irradiated
0
20
40
60
80
100
[C11Pc Nanoparticles] 
%
 V
ia
b
ili
ty
0.1 µM 0.2 µM 0.5 µM 1 µM 1.15µM +St Control Irradiated
0
20
40
60
80
100 ******
********
[C11Pc Nanoparticles]
%
 V
ia
b
ili
ty
0.2 0.4 0.6 0.8 1.0 1.2
0
20
40
60
80
100
x
***
***
 
Concentration of C11Pc Nanoparticles/M
%
 P
h
o
to
d
y
n
a
m
ic
 T
o
x
ic
it
y
***
A B
C
  
167 
 
between jacalin and HT-29 cells at a concentration of 50 mM.14 Studies of the 
carbohydrate specificity of jacalin showed that the lectin has a ca. 40-fold higher affinity to 
galactose when in the α-conformation, such as in methyl-α-D-galactopyranoside.32 
Asialofetuin, a glycoprotein expressing the T antigen, is known to bind to jacalin with a Kd 
of 0.4 nM.33 Asialofetuin has been used to inhibit the binding of jacalin to HT-29 cells at a 
concentration of 40 μg.ml-1 (0.8 μM).14 Consequently, methyl-α-D-galactopyranoside 
monohydrate and asialofetuin were both used to competitively inhibit the jacalin targeted 
phototoxicity of HT-29 cells, as described in section 2.2.11. It is clear from Figure 4.26 
that the presence of methyl-α-D-galactopyranoside or asialofetuin inhibited the 
photodynamic toxicity of the HT-29 cells by the jacalin conjugated C11Pc-PEG gold 
nanoparticles. A statistically significant inhibition of phototoxicity was observed at both 
concentrations of each inhibitor (P<0.05). The results of the competitive inhibition assay 
suggest that the enhanced photodynamic efficacy observed with the jacalin conjugated 
C11Pc-PEG gold nanoparticles was dependent on the targeted binding of jacalin to the T 
antigen on the HT-29 cell surface. Therefore, jacalin at the nanoparticle surface acts as a T 
antigen-specific endocytic ligand that transports the C11Pc-PEG gold nanoparticles into 
the HT-29 cells prior to photosensitisation.  
 
Figure 4.26 Inhibition of the photodynamic toxicity of HT-29 cells by jacalin conjugated 
nanoparticles (0.5 µM C11Pc equivalent) using asialofetuin (1 µM or 2 µM) 
or methyl-α-D-galactopyranoside (50 mM or 100 mM, Me-α-Gal). (Error bars 
are 95% confidence intervals, n=3. * indicates statistical significance at 
P<0.05 and ** at P<0.005 using a one-tailed t-test). 
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4.2.8 Determining the mechanism of jacalin targeted PDT cytotoxicity 
Confocal imaging of HT-29 cells following jacalin targeted PDT treatment revealed that the 
cell nuclei stained positive with propidium iodide, suggesting that the primary mechanism 
of cell death was through necrosis. To establish the precise mechanism of jacalin mediated 
phototoxicity of the HT-29 cells, the ApoTox-GloTM triplex assay was performed on the 
cells incubated with jacalin conjugated C11Pc-PEG gold nanoparticles 48 h following 
irradiation. 
A viability/cytotoxicity reagent was prepared, as described in section 2.2.12, consisting of 
the viability substrate, glycylphenylalanyl-aminofluorocoumarin (GF-AFC), and the 
cytotoxicity substrate, bis-alanylalanyl-phenylalanyl-rhodamine 110 (bis-AAF-R110). The 
membrane permeable viability substrate, GF-AFC, is enzymatically cleaved by live cell 
proteases to release the fluorescent product aminofluorocoumarin (excitation at 405 nm, 
emission at 492 nm). The membrane impermeable cytotoxicity substrate bis-AAF-R110 is 
enzymatically cleaved by active dead cell proteases to release the fluorescent product 
rhodamine 110 (excitation at 492 nm, emission at 530 nm). The Caspase-Glo® 3/7 
apoptosis reagent was also prepared, which contains a luminogenic substrate that is 
cleaved by active caspase 3/7 enzymes in apoptotic cells to release aminoluciferin. The 
reaction between UltraGlo™ luciferase and aminoluciferin results in bioluminescence 
centred at 576 nm.34 
As can be seen from Figure 4.27 (A), the viability of the HT-29 cells following jacalin 
targeted PDT treatment was reduced to ca. 5%, whereas no phototoxicity was observed 
with the cells incubated with non-conjugated C11Pc-PEG gold nanoparticles. These results 
are consistent with the MTT viability assay results shown in Figure 4.25. However, the 
results of the cytotoxicity component of the triplex assay shown in Figure 4.27 (B) are 
inconsistent with the results of the viability component of the assay in Figure 4.27 (A). It 
was expected that cytotoxicity would be observed following staurosporine treatment, 
although the levels of cytotoxicity found were comparable to those of the control. No 
cytotoxicity of the HT-29 cells was observed when the cells were incubated with non-
conjugated nanoparticles with or without irradiation. Unexpectedly, some cytotoxicity was 
observed with jacalin conjugated nanoparticles without irradiation, although following 
irradiation, the cytotoxicity levels were below those of the control. The apoptosis 
component of the assay also gave unexpected results, as shown in Figure 4.27 (C), with no 
apoptotic response detected above that of the cells under the control conditions. 
Treatment with staurosporine, which was used as a positive control for cytotoxicity 
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predominantly through apoptosis, caused no apparent increase in apoptosis. These results 
concluded that although the viability component of the assay was reliable, the cytotoxicity 
and apoptosis components of the assay were not effective 48 h following PDT treatment. It 
was thought that cytotoxicity or apoptosis of the HT-29 cells induced by PDT treatment or 
through staurosporine treatment was too extensive at 48 h following treatment. 
Therefore, at 48 h following PDT treatment, negligible activity of dead cell proteases or 
caspases were detected. It was therefore decided that the assay would be repeated 6 h 
following irradiation, at which time apoptosis induced DNA fragmentation in HT-29 cells 
following staurosporine treatment is observable.35  
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Figure 4.27 Assessment of HT-29 cell viability (A), cytotoxicity (B) and apoptosis (C) 
using the ApoTox-GloTM triplex assay performed 48 h after PDT treatment. 
The HT-29 cells were incubated for 3 h with C11Pc-PEG gold nanoparticles (1 
µM C11Pc equivalent), with (conjugated) or without (non-conjugated) jacalin 
conjugation. Following incubation, the cells were either irradiated at 633 nm 
for 6 min per well (orange) or kept in the dark (dark cyan). Cells not 
incubated with nanoparticles were used as a control. Staurosporine (+St; 20 
µM) was used as a positive control for cytotoxicity, predominantly through 
apoptosis. (Error bars are ± 95% confidence intervals, n=3). 
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The ApoTox-GloTM triplex assay was repeated, as described in section 2.2.12, on HT-29 
cells incubated with either jacalin conjugated or non-conjugated C11Pc-PEG gold 
nanoparticles, 6 h after PDT treatment. Following irradiation, the viability of HT-29 cells 
incubated with jacalin conjugated nanoparticles (1 µM C11Pc equivalent) was drastically 
reduced to ca. 2.7% (P<0.0005), as shown in Figure 4.28 (A). The viability of HT-29 cells 
incubated with non-conjugated C11Pc-PEG gold nanoparticles was reduced to ca. 57.2% 
(P<0.0005) following irradiation. HT-29 cell viability following irradiation of the cells 
incubated with non-conjugated nanoparticles (Figure 4.28 (A)) is significantly lower than 
that observed when the assay was performed 48 h following irradiation (ca. 107%; Figure 
4.27 (A)). This difference suggests that the reduction in viability observed in Figure 4.28 
(A) is likely to be a temporary, non-cytotoxic inhibition in cell proliferation. Furthermore, 
no cytotoxicity or apoptosis is observed in HT-29 cells incubated with non-conjugated 
C11Pc-PEG gold nanoparticles following irradiation (Figure 4.28 (B and C)). A reduction 
in viability (Figure 4.28 (A)) that is not accompanied by any detectable cytotoxicity 
(Figure 4.28 (B)) or apoptosis (Figure 4.28 (C)) indicates that irradiation of HT-29 cells 
incubated with non-conjugated nanoparticles halts cell proliferation. Further 
investigations into cell growth and cell cycle arrest at varying time points following PDT 
treatment could give an insight into the extent of the cell damage induced by non-
conjugated nanoparticles.36 HT-29 cells incubated with jacalin conjugated C11Pc-PEG gold 
nanoparticles showed a ca. 5.2-fold increase in cytotoxicity following irradiation, as 
compared to the untreated control (P<0.0005, Figure 4.28 (B)). Additionally, no increase 
in apoptosis of the HT-29 cells incubated with jacalin conjugated C11Pc-PEG gold 
nanoparticles was observed following irradiation (Figure 4.28 (C)), thus confirming that 
jacalin targeted PDT of HT-29 cells induces cytotoxicity through necrosis at the defined 
conditions of the experiment. The mechanisms of PDT induced cytotoxicity are dependent 
on a large number of factors, which include the type and concentration of the 
photosensitiser used, the intracellular localisation of the PDT agent, the light dosage and 
the cell type investigated.37 Following irradiation, a decrease in HT-29 cell viability and an 
increase in cytotoxicity were observed in cells incubated with 1 µM C11Pc equivalent of 
jacalin conjugated particles. Additionally, no indications of apoptosis were apparent. The 
findings of the ApoToxGloTM triplex assay are consistent with the laser scanning confocal 
microscope images in Figure 4.22 and Figure 4.23. Positive staining with propidium 
iodide, the lack of visible apoptotic bodies and the absence of an apoptotic response all 
strongly suggest that jacalin targeted PDT induces substantial necrosis in HT-29 cells 
expressing the T antigen.  
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Figure 4.28 Assessment of HT-29 cell viability (A), cytotoxicity (B) and apoptosis (C) 
using the ApoTox-GloTM triplex assay performed 6 h after PDT treatment. 
The HT-29 cells were incubated for 3 h with the C11Pc-PEG gold 
nanoparticles (1 µM C11Pc equivalent), with (conjugated) or without (non-
conjugated) jacalin conjugation. Following incubation, the cells were either 
irradiated at 633 nm for 6 min per well (orange) or non-irradiated (dark 
cyan). Cells not incubated with nanoparticles were used as a control. 
Staurosporine (+St; 20 µM) was used as a positive control for cytotoxicity, 
predominantly through apoptosis. (Error bars are ± 95% confidence 
intervals, n=3). *** indicates statistical significance at P<0.0005) 
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4.3 Conclusions 
The effective targeted PDT treatment of HT-29 human colon adenocarcinoma cells with 
jacalin conjugated C11Pc-PEG gold nanoparticles has been described in this chapter. 
Initially, the C11Pc-PEG gold nanoparticles synthesised in THF, with jacalin conjugation 
were ineffective against the HT-29 cells following irradiation at 633 nm. A dose-dependent 
reduction in viability was observed in both irradiated and non-irradiated HT-29 cells 
incubated with jacalin conjugated nanoparticles. The reduction in viability could be 
attributed to the non-cytotoxic inhibition in HT-29 cell proliferation following jacalin 
incubation.14 The lack of PDT efficacy was possibly a result of a low number of C11Pc 
molecules per gold nanoparticle. The low C11Pc loading efficiency onto the nanoparticles 
could lead to insufficient intracellular accumulation of the sensitiser. It was previously 
reported that the C11Pc-PEG gold nanoparticles synthesised in THF have ca. 10 molecules 
of C11Pc per nanoparticle, as determined by ICP-MS analysis.27 Therefore, an alternative 
synthetic procedure was explored to enhance the C11Pc loading efficiency onto the gold 
nanoparticles. 
A novel protocol for synthesising C11Pc-PEG gold nanoparticles in DMF was introduced, 
which resulted in nanoparticles with a ca. 3-fold higher yield of C11Pc equivalent and ca. 
155 molecules of C11Pc associated with each gold nanoparticle, as determined by ICP-OES 
analysis. The nanoparticle conjugates were ca. 4 nm in diameter and effectively generated 
singlet oxygen upon irradiation at 633 nm following conjugation to jacalin. Preliminary 
optical microscopy studies revealed the PDT efficacy of these jacalin nanoparticle 
conjugates on HT-29 cells. Cell morphology and integrity were severely compromised 
following targeted PDT treatment, whereas in the dark the cells remained largely 
unaffected. Non-conjugated C11Pc-PEG gold nanoparticles, at the same concentrations as 
the jacalin conjugates, induced no visible cell damage in the dark or following irradiation. 
Laser scanning confocal microscopy, in combination with differential interference contrast 
imaging, showed that jacalin conjugation vastly improves the intracellular accumulation of 
the C11Pc-PEG gold nanoparticles. Fluorescence confocal microscopy of the jacalin 
conjugated C11Pc-PEG gold nanoparticles following excitation with a 633 nm HeNe laser, 
revealed the intracellular localisation of the nanoparticles, which could be further 
confirmed using Z-stacked three-dimensional images. The intracellular distribution of the 
jacalin-nanoparticle conjugates indicates that their internalisation was likely to be through 
an endocytic pathway, as opposed to diffusion through the membrane to the cytoplasm. 
Following irradiation, the HT-29 cells incubated with jacalin conjugated particles 
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appeared spherical in morphology with a poorly defined cell periphery, typical of dead 
cells. The lack of apoptotic bodies indicate that cell death was predominantly through the 
necrotic pathway.38 In addition, positive staining of the nuclei of those cells with 
propidium iodide suggested that cell membrane integrity was impaired.31,38  
The MTT viability assay was used to investigate the extent and dose-dependence of jacalin 
targeted phototoxicity by the C11Pc-PEG gold nanoparticle conjugates. It was found that 
the jacalin conjugated C11Pc-PEG gold nanoparticles induced a significant reduction in 
viability (ca. 60% at 1.15 µM C11Pc equivalent), which was greatly enhanced following a 
ca. 3 mm increase in the beam diameter of the 633 nm HeNe laser used for irradiation. 
Statistical analysis using a one-tailed student’s t-test revealed that a statistically significant 
reduction in viability was observed following the irradiation of the HT-29 cells incubated 
with all concentrations of the jacalin conjugates. It was found that a sigmoidal dose-
dependence in cytotoxicity was observed with the jacalin conjugated C11Pc-PEG gold 
nanoparticles, reaching a maximum of ca. 96% at 1.15 µM C11Pc equivalent concentration. 
Conversely, the non-conjugated C11Pc-PEG gold nanoparticles exhibited minimal 
phototoxicity, suggesting that jacalin significantly promotes the specific endocytosis of the 
nanoparticle conjugates. The MTT assay was also utilised to perform a competitive 
inhibition study to determine the significance of the carbohydrate binding capacity of 
jacalin conjugated particles on their PDT efficacy. Methyl-α-D-galactopyranoside and 
asialofetuin have been previously used to inhibit the selective binding of jacalin to 
carbohydrates.14,32 It was found that both methyl-α-D-galactopyranoside and asialofetuin 
significantly inhibited the phototoxicity of jacalin conjugated C11Pc-PEG gold 
nanoparticles (0.5 µM C11Pc equivalent). Inhibition of phototoxicity of the jacalin 
conjugated nanoparticles confirmed that the enhanced PDT effect observed with the HT-
29 cells was a result of jacalin binding to the T antigen at the surface of the cells. 
Therefore, jacalin conjugation significantly increases the specific internalisation of the 
C11Pc-PEG gold nanoparticle conjugates within the HT-29 cells, as compared to the non-
conjugated nanoparticles. 
Preliminary indications that necrosis was the mechanism of jacalin mediated PDT 
cytotoxicity were suggested by the morphology of the treated cells and by the positive 
staining of the cell nuclei with propidium iodide. The ApoTox-GloTM triplex assay, which 
assesses cell viability, cytotoxicity and apoptosis, further indicated that necrosis was 
predominant following jacalin targeted PDT. Following incubation with jacalin conjugated 
C11Pc-PEG gold nanoparticles and irradiation at 633 nm, the HT-29 cells exhibited a 
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significant decrease in viability and a marked increase in cytotoxicity. Furthermore, no 
indications of apoptosis were observed. 
In conclusion, it was found that by conjugating the lectin jacalin to C11Pc-PEG gold 
nanoparticles, the oncofoetal T antigen disaccharide was successfully targeted at the 
surface of HT-29 cells. Following recognition and binding to the T antigen at the HT-29 cell 
surface, the jacalin conjugated C11Pc-PEG gold nanoparticles were delivered 
intracellularly, as confirmed by laser scanning confocal microscopy. Irradiation of the 
intracellular nanoparticle conjugates at 633 nm induced cell death of a remarkable 
proportion of HT-29 cancer cells (ca. 95-98%) via necrosis. Conversely, no significant dark 
toxicity was observed in the non-irradiated HT-29 cells incubated with the jacalin 
conjugated nanoparticles. HT-29 cells incubated with non-conjugated nanoparticles 
exhibited no significant reduction in viability, even following irradiation, although some 
reduction in viability was observed at 1 µM C11Pc equivalent, only at 6 h following 
irradiation. Since the T antigen is expressed by more than 90% of primary human 
carcinomas4 and by a number of cancer stem cells,6 it is an appealing target for a range of 
cancer therapies. The ability to target the T antigen with jacalin conjugated C11Pc-PEG 
gold nanoparticles and then to efficiently destroy the cells with PDT is a significant first, 
and potentially an important development in cancer therapy. In the following chapter, the 
efficacy of using lectins as cancer targeting ligands will be compared to the use of 
monoclonal antibodies for selective PDT. 
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Chapter 5 
A comparative study of targeted phototoxicity of HT-29 colon 
and SK-BR-3 breast adenocarcinoma cells using jacalin or 
anti-HER-2 antibodies 
In this chapter, the PDT targeting efficiency of jacalin is compared to that of anti-HER-2 
antibodies. Both proteins were covalently conjugated to zinc phthalocyanine-PEG gold 
nanoparticles and the photodynamic efficacy of the conjugates was investigated using HT-
29 human colon adenocarcinoma cells and SK-BR-3 human breast adenocarcinoma cells. 
The experiments performed to compare the targeted PDT efficacy of the lectin and the 
antibody are described. Further investigations into the mechanisms of targeted cell death 
and the intracellular localisation of the nanoparticle conjugates are detailed in this 
chapter. 
 
5.1 Introduction  
5.1.1 Cancer targeting ligands 
Active targeting of cancer tissue relies on the identification of specific cancer-associated 
molecular targets and their respective exogenous targeting ligands. Cancer-associated 
molecular targets include overexpressed cell surface receptors or newly expressed 
receptors that are not usually expressed in healthy cells (neoexpression). An example of 
an overexpressed cell surface molecular target is the folate receptor, which is 
overexpressed in more than 90% of human ovarian cancer cells.1 The folate receptor can 
be targeted with anticancer agents conjugated to folic acid that enables the preferential 
accumulation of the anticancer agents within the tumour cells. An example of receptor 
neoexpression during the transformation of healthy cells to malignant cells is the 
appearance of N-cadherin, which is observed in 44% of colonic carcinoma tissue.2 
Neoexpression of N-cadherin is suggested to play a role in cancer cell invasion and 
metastasis.2 Receptors expressed at the surface of angiogenic vessels can also be targeted 
to impede the blood supply to tumours. Receptors expressed in tumour vessels include 
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vascular endothelial growth factor receptor (VEGFR) and vascular cell adhesion molecule-
1 (VCAM-1).3 
Natural ligands of tumour-associated receptors can be exploited to specifically deliver an 
anticancer agent to cancer cells expressing the target receptor. For example transferrin 
bioconjugates have been widely used for monitoring disease progression and targeted 
therapy of cancer cells overexpressing the transferrin receptor.4  
Studies screening peptide sequences for specific affinities towards cancer-associated 
targets have established a number of oligopeptides with potential for cancer targeting.5-8 
For example, peptides containing the arginine-glycine-aspartate (RGD) sequence are 
commonly used to target αvβ3 integrins and αvβ5 integrins that are overexpressed by a 
number of cancer cells and activated angiogenic vascular endothelial cells.6-9 Additionally, 
peptides containing the asparagine-glycine-arginine (NGR) sequences target the CD13 
receptor, which is overexpressed by several tumour and endothelial cells.5,8 
Aptamers are low molecular weight oligonucleotide sequences (DNA or RNA) that exhibit 
high specificity towards target molecules.10 The generation of aptamers typically involves 
the screening and selection of oligonucleotides from a pool of sequences based on their 
affinity towards molecular targets. Aptamers can be specific for individual cancer-
associated proteins, such as MUC-1,11 or even for whole live cancer cells.12 Binding 
affinities of aptamers to their targets can have equilibrium dissociation constants (Kd) 
from the nanomolar to the picomolar range, making them highly attractive targeting 
ligands.12 Additionally, aptamers are non-immunogenic allowing for repeated intravenous 
administration without a decline in efficacy.10 
Carbohydrates have also been used to directly target endogenous lectins that are 
overexpressed by cancer cells or tumour vessels. For example, mannose receptors have 
been found to be overexpressed by MCF-7, MDA-MB-231 and HCT-116 cells.13 Silica 
nanoparticles functionalised with mannose have been used to target mannose receptors 
expressed by HCT-116 tumours.14 Tumour targeting using mannose has been shown to 
enhance the delivery of a photosensitiser to the tumour and to improve the in vivo efficacy 
of PDT.14 Human serum albumin conjugated to mannose-6-phosphate has also been shown 
to effectively deliver a chemotherapeutic agent, doxorubicin, to cancer cells expressing the 
mannose-6-phosphate receptor, both in vitro and in vivo.13 As discussed in Chapter 1 and 
Chapter 4, exogenous lectins have also been used for the reverse targeting of cell surface 
carbohydrates.  
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Tumour cells can also be targeted by exploiting abnormal protease expression that is up-
regulated during malignancy. Such proteases include matrix metalloproteases -2 and -9 
(MMP-2 and MMP-9), which are overexpressed by human cancer cells such as HCT-116 
colon cancer cells, PC3 prostate cancer cells, and Hep2 epidermoid cancer cells.15 A 
tumour-specific pro-drug is usually formulated by conjugating a therapeutic agent to a 
neutralising agent through a peptide. The peptide linker used for conjugation is a 
substrate for a cancer-associated protease. Cleavage of the pro-drug by the extracellular 
proteases up-regulated in tumours results in the selective extracellular activation of the 
drug and subsequent accumulation of the drug within the cancer cells.15 
Antibodies are of the most commonly used targeting agents due to the high affinity for the 
respective antigen (Kd values typically in the nanomolar range) and due to the feasibility of 
generating antibodies for virtually any given antigen.16 Examples of the use of antibodies 
for targeted cancer therapies are described in greater detail in section 5.1.2.  
 
5.1.2 Antibodies 
Antibodies are immunological proteins that exhibit unique individual specificity for a 
broad range of antigens.17 Antibodies, also known as immunoglobulins (Ig), are 
synthesised by B lymphocytes within the mammalian immune system to target foreign 
invading bodies.17-19 Initially, antibodies are restricted to the membrane of B cells, each of 
which express antibodies of an individual antigen specificity. Following the interaction of 
the surface-bound antibodies with their specific immunogenic target, the B cells become 
activated and the synthesis of soluble extracellular antibodies is initiated.17-19 This 
immunisation phenomenon is exploited for the generation of antibodies for diagnostic and 
therapeutic applications. Polyclonal antibodies consist of a mixture of antibodies, each 
with affinities for different epitopes on the same antigen. These are typically extracted 
from the immunised host species using affinity chromatography with an antigen 
derivatised separation column.17 Monoclonal antibodies are generated by the fusion of a 
single activated B lymphocyte with an immortalised cell line to form a hybridoma. The 
hybridoma produces antibodies with a single antigen epitope specificity.17,18  
The typical structure of a monomeric antibody is depicted in Figure 5.1.17 Antibody 
monomers consist of two heavy chains and two light chains. The N-terminus at each of the 
four chains form the two antigen binding fragments (Fab). The C-terminus at each of the 
two heavy chains form the constant fragment (Fc), which is responsible for the initiation 
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of the immune response.17 There are several primary classes of antibodies that are 
distinguished by their heavy chains, which serve different functions at their physiological 
site of action. These antibody classes are denoted IgA, IgD, IgE, IgG and IgM. IgA antibodies 
exist either monomers or dimers, IgD, IgE and IgG antibodies are typically monomers, and 
IgM antibodies are usually pentameric.17-19 Furthermore, each heavy chain is glycosylated 
at the Fc region with exposed aldehyde groups, which play a role in antigen clearance.19,20 
The aldehyde group is commonly used for antibody modification. The aldehyde is typically 
oxidised using periodate and bound to an amine group or hydrazine derivative on the 
conjugate molecule.21  
 
 
Figure 5.1 A schematic representation of a monomeric antibody with bivalent antigen 
specificity. The two antigen binding fragments (Fab) at the N-terminus 
exhibit antigen recognition. The constant fragment (Fc) at the C-terminus 
contains exposed aldehyde groups (CHO) at the antibody glycosylation sites.  
 
Antibodies or antibody fragments are of the most commonly used cancer targeting 
ligands.16 Antibody conjugates, also known as immunoconjugates, have seen wide-spread 
use for in vitro, in vivo and clinical applications.16 Immunogenicity and subsequent 
physiological clearance of antibody immunoconjugates by the human immune system are 
of the major limitations of using antibodies and other globular proteins for targeted 
therapy.16 Imunogenicity can be overcome by the generation of chimeric antibodies (ca. 
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66% human DNA) or humanised antibodies (ca. 90% human DNA), which are fusions of 
human Fc fragments with cancer-specific animal monoclonal Fab fragments.16,22 The use of 
antibodies for targeted cancer treatment also includes the functional blocking of signalling 
pathways involved in cancer survival and progression.23 For example, the clinically 
approved humanised IgG1 monoclonal antibody, Avastin®, is used to block VEGF 
signalling, and thus inhibits angiogenesis and other downstream signalling effects 
associated with the disease.23,24 
Within PDT, a large number of studies have reported the direct conjugation of a 
photosensitiser with a cancer-targeting antibody to yield photoimmunoconjugates for 
selective photodynamic treatment.25 Two isothiocyanate derivatives of water soluble 
porphyrin photosensitisers have been synthesised and conjugated to monoclonal 
antibodies that target cell internalising receptors (FSP 77 and 17.1A antibodies) and a 
non-internalising receptor (35A7 antibody).26 The photoimmunoconjugates retained the 
binding specificities of the unmodified antibodies and enhanced the tumour localisation of 
the sensitisers in mouse tumour models bearing a subcutaneously implanted LS174T 
colon carcinoma (35A7 photoimmunoconjugates) and an SKOV ovarian carcinoma (FSP 77 
photoimmunoconjugates). Furthermore, the FSP 77 cell internalising 
photoimmunoconjugates induced a greater level of phototoxicity in SKOv3-CEA-1B9 cells 
than the non-internalising 35A7 conjugates.26 
NIH:OVCAR-5 human ovarian carcinoma cells overexpressing the epidermal growth factor 
receptor (EGFR) have been targeted with an anti-EGFR monoclonal antibody conjugated to 
the photosensitiser benzoporphyrin derivative monoacid ring A.27 Treatment of the 
ovarian cancer cells and EGFR-positive Chinese hamster ovary cells with the 
photoimmunoconjugate directly blocked EGFR receptor signalling and enhanced the 
cellular uptake and phototoxicity of the PDT agent.27  
Anti-HER-2 antibodies have been used for targeting human breast cancer cells 
overexpressing the HER-2 receptor with zinc phthalocyanine functionalised gold 
nanoparticles.28 Following irradiation, the antibody conjugated nanoparticles were able to 
selectively reduce the viability of HER-2 overexpressing cells. Cells not expressing the 
HER-2 receptor and subnormal, non-transformed MCF-10A breast epithelial cells were 
unaffected by the treatment.28  
HepG2 hepatocellular carcinoma cells were successfully targeted with anti-CD44 antibody 
functionalised liposomal formulations encapsulating the anticancer drug doxorubicin.29 
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Antibody targeted treatment with the liposomal doxorubicin formulation increased the 
percentage of apoptotic cells, as compared to treatment with the free drug. Furthermore, 
the targeted liposomal preparation was found to dramatically enhance the accumulation 
of doxorubicin within a hepatocellular carcinoma murine tumour model in vivo.29  
Antibodies have also been conjugated to toxins (immunotoxins) that selectively induce 
cytotoxicity in cancer cells.16 The process of photochemical internalisation (PCI) has been 
used in conjunction with immunotoxin administration to facilitate cytoplasmic release of 
the targeted conjugate and potentiate its toxicity.30 PCI treatment using immunotoxins 
was performed on the HER-2 receptor-positive cell line, Zr-75-1, which is resistant to 
functional blocking treatment with anti-HER-2 antibodies. Tetraphenylchlorin disulfonate 
was used as the photosensitiser for endosomal compartment rupture following incubation 
with the anti-HER-2 anitbody-saponin toxin conjugate.30 It was found that the 
immunotoxin was significantly more effective at reducing cell viability following PCI than 
the toxin alone, highlighting the enhanced cellular homing of the targeted immunotoxin.30  
A number of other studies have highlighted the enhanced therapeutic effect of antibody 
targeted treatments for cancer by improving tumour accumulation and by minimising 
peripheral damage to healthy tissue.23 Functional blocking of signalling pathways is one of 
the main mechanisms of antibody treatments currently used, and combinatory 
mechanisms of targeting using antibody-drug conjugates are proving to be of increasing 
significance.23,31,32 
 
5.1.3 The EGFR family of receptors 
Epidermal growth factor receptors (EGFRs), also known as human epidermal growth 
factor receptors (HERs) or erythroblastoma gene B (ErbB) receptors, are a tyrosine kinase 
family of transmembrane receptors that modulate cellular growth and proliferation.33 
Upon ligand binding, EGFRs activate a complex network of intracellular signalling 
pathways.33 The receptor family consists of four homologues of the receptor: EGFR (ErbB-
1), HER-2 (ErbB-2/neu), HER-3 (ErbB-3) and HER-4 (ErbB-4).33 There are 13 natural 
ligands identified to date, which specifically bind to and activate the EGFR receptor 
family.34 The natural ligands of EGFR include EGF, amphiregulin (AR), betacellulin (BTC), 
transforming growth factor-α (TGF-α), epiregulin (EPR), heparin-binding ERGF-like 
growth factor (HB-EGF) and epigen. The ligands that recognise HER-3 include neuregulins 
1 and 2 (NRG-1 and NRG-2, respectively) and Herregulins 1 and 2 (HRG-1 and HRG-2, 
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respectively), although the receptor lacks intrinsic tyrosine kinase activity and is 
dependent on dimerisation with another EGFR receptor. The natural ligands of HER-4 
include HRG-1, -2, -3 and -4, BTC, EPR, NRG-1, -2, -3 and -4, and HB-EGF.34  
The HER-2 receptor is an orphan receptor as it has no ligand binding capacity.34 Therefore, 
activation of the receptor is dependent on heterodimerisation with another EGFR.34 The 
functional blocking monoclonal antibody trastuzumab (Herceptin®) binds to the HER-2 
receptor and prevents its dimerization and activation.35 It has been found that although no 
ligand binds to HER-2, the transmembrane mucin, MUC4, stabilises the receptor, interacts 
with it and activates its signalling pathways within pancreatic and ovarian cancer cells.36,37 
Homodimerisation or heterodimerisation of the four EGFR receptors results in a total of 
ten possible dimer combinations that are responsible for the complex EGFR signalling 
network.35 Homodimerisation of the enzymatically inactive HER-3 receptors leads to no 
signal transductions, and homodimerisation of the remaining EGFR receptors leads to 
weak signalling.35  
The EGFR signalling network regulates apoptosis, migration, proliferation, growth, 
adhesion and proliferation, and thus plays a crucial role in maintaining healthy cellular 
function.33 Intracellular signalling pathways controlled by the EGFR signalling network 
include the Ras-mitogen-activated protein kinase (Ras-MAPK) pathway and the AKT 
pathway.16,33 These pathways are responsible for the transcription of proto-oncogenes 
such as myc, fos and jun, amongst other genes.17,35 Within cancer, deregulation of the EGFR 
signalling network by the overexpression or underexpression of EGFR receptors (or their 
respective ligands) results in a variety of abnormal cellular processes.34,35 Deregulation of 
the EGFR network is associated with tumourigenesis and the occurrence of cancers of the 
breast, colon, head and neck, pancreas and ovaries, amongst others.34,35 
HER-2 is of particular importance in cancer due to its specific downstream intracellular 
effects upon overexpression.35 The overexpression of the HER-2 receptor is usually a 
result of the amplification of its proto-oncogene, ERBB2.38 Elevated levels of cell surface 
HER-2 receptor expression promote the heterodimerisation of the receptor with either of 
the remaining three EGFRs.35 The receptor is activated following heterodimerisation and 
the binding of EGF or NRG factors.35 HER-2 activation is typically accompanied by low-
specificity ligand interactions, prolonged ligand association and prolonged signalling 
responses.35 The HER-2 receptor is overexpressed in 10-34% of human breast cancers, 
and the overexpression is correlated with disease prognosis and clinical outcome.39 The 
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effects of the overexpression of the HER-2 receptor directly increase cancer cell 
proliferation and migration, and also result in apoptosis resistance and resistance to 
therapy.35,37 As the overexpression of the HER-2 receptor is related to cancer progression, 
and the activation of the receptor can be effectively blocked with monoclonal antibodies, 
the receptor has proven to be a viable target for selective cancer therapies using 
antibodies.  
In this chapter, the targeting of the HER-2 receptor was achieved using a rat monoclonal 
IgG2a antibody that is specific for the extracellular domain of the receptor. The antibody 
was covalently conjugated to the PEG molecules on C11Pc-PEG gold nanoparticles. The 
nanoparticle conjugates were used to comparatively study the targeted PDT efficacy with 
that of jacalin conjugated nanoparticles described in Chapter 4. The HER-2 receptor is 
overexpressed in SK-BR-3 human breast adenocarcinoma cells and in HT-29 human 
colorectal adenocarcinoma cells.40-43 SK-BR-3 cells are known to express ca. 1-2x106 HER-
2 receptors per cell,44 and IgG anti-HER-2 monoclonal antibodies are known to bind to 
these cells with a Kd of 14-36 nM.45 Moreover, HT-29 cells express ca. 4.4 ± 0.3x107 T 
antigens per cell, which jacalin binds to with a Kd of 500 ± 50 nM.46 The significance of cell 
surface receptor density and targeting ligand binding affinity on the efficacy of targeted 
PDT using C11Pc-PEG gold nanoparticles are discussed in this chapter. The phototoxicity 
of these two targeting systems has been investigated using both SK-BR-3 and HT-29 cells 
and the intracellular localisation was determined using confocal fluorescence microscopy.  
 
5.2 Results and Discussion  
5.2.1 Jacalin and anti-HER-2 antibody C11Pc-PEG gold nanoparticle conjugates 
C11Pc-PEG gold nanoparticles were synthesised as described in section 2.2.4. Jacalin and 
anti-HER-2 rat monoclonal IgG2a antibodies were conjugated to the gold nanoparticles 
using EDC/NHS coupling, as described in section 2.3.1. The jacalin or anti-HER-2 
antibodies were reacted with the EDC/NHS activated nanoparticles at a molar ratio of 
6.2:1. Figure 5.2 shows schematic representations of jacalin conjugated (A) and anti-HER-
2 antibody conjugated (B) C11Pc-PEG gold nanoparticles. The degree of jacalin or 
antibody grafting onto the nanoparticle conjugates could be approximated by dynamic 
light scattering (DLS) particle size analysis before and after conjugation. Additionally, ζ 
potential measurements of the C11Pc-PEG gold nanoparticles before and after jacalin or 
antibody conjugation could give further insight into the extent of biofunctionalisation. 
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Figure 5.2 A schematic representation of C11Pc-PEG gold nanoparticles functionalised 
with A) jacalin or B) anti-HER-2 antibodies. Images of jacalin (PDB ID 
1M2647) and the IgG2a antibody (PDB ID 1IGT48) were generated using 
PyMOL. 
 
Following the conjugation of jacalin or anti-HER-2 antibodies to the gold nanoparticles, the 
nanoparticle conjugates were characterised using UV-visible absorption 
spectrophotometry. As can be seen from the absorption spectra in Figure 5.3, both types 
of nanoparticle conjugates retain the optical characteristics of predominantly monomeric 
C11Pc.  
 
A B
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Figure 5.3 UV-visible absorption spectra of jacalin (green) or anti-HER-2 antibody 
(blue) conjugated C11P-PEG gold nanoparticles in serum-free RPMI 1640 
medium. 
 
To effectively compare the targeting efficiency of jacalin conjugates with anti-HER-2 
antibody conjugates, the singlet oxygen production following the irradiation of the 
conjugated C11Pc-PEG gold nanoparticles was compared, as described in section 2.3.2. 
Non-conjugated C11Pc-PEG gold nanoparticles were used as a control. Singlet oxygen 
production was measured in phosphate buffered saline using ADPA as the colorimetric 
singlet oxygen probe. The quantification of singlet oxygen was calculated using a 1:1 
stoichiometry of singlet oxygen to ADPA. The number of moles of singlet oxygen produced 
were normalised to the concentration of C11Pc equivalent present within the samples of 
nanoparticle conjugates. It is clear from the graph shown in Figure 5.4 that there is no 
significant difference in singlet oxygen production by the irradiation of the C11Pc-PEG 
gold nanoparticles conjugated to either jacalin (Figure 5.4, green) or the anti-HER-2 
antibody (Figure 5.4, blue). Following conjugation to either targeting ligands, the singlet 
oxygen production of the nanoparticle conjugates is slightly reduced, as compared to the 
higher photoactivity of the non-conjugated C11Pc-PEG gold nanoparticles (Figure 5.4, 
black). However, if targeting significantly enhances the cellular internalisation of the 
nanoparticle conjugates as compared to the non-conjugated nanoparticles, the slight 
reduction in photoactivity following conjugation may be overcome.  
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Figure 5.4 Singlet oxygen production (nmoles/µM C11Pc) by the irradiation at 633 nm 
of non-conjugated (black), jacalin conjugated (green) and anti-HER-2 
antibody (blue) conjugated C11P-PEG gold nanoparticles. Nanoparticle 
samples were in phosphate buffered saline (10 mM, 150 mM NaCl, pH 7.4).  
 
5.2.2 Targeted PDT of HT-29 cells – MTT viability assay 
HT-29 cells were incubated with non-conjugated, jacalin conjugated or anti-HER-2 
antibody conjugated C11Pc-PEG gold nanoparticles and irradiated at 633 nm (0.00-1.15 
µM C11Pc equivalent), as described in section 2.3.3. 48 h following PDT treatment, an 
MTT viability assay was performed on the HT-29 cells. Figure 5.5 shows the viability of 
the cells following jacalin targeted (A) or anti-HER-2 antibody targeted (B) PDT. Statistical 
significance was calculated using a one-tailed student’s t-test. Following irradiation, 
viability of the HT-29 cells incubated with the jacalin conjugated or anti-HER-2 antibody 
conjugated nanoparticles was significantly reduced to ca. 10.1% and ca. 19.2%, 
respectively (using 1.15 µM C11Pc equivalent of nanoparticles). However, without 
irradiation at the same nanoparticle concentration, viability remained at ca. 62.0% and ca. 
77.3%, respectively. No significant difference in the dose-dependent phototoxicity of the 
HT-29 cells was observed following targeted PDT treatment using jacalin conjugated 
(Figure 5.5 (C), green) or anti-HER-2 antibody conjugated (Figure 5.5 (C), blue) 
nanoparticles at concentrations of 0.0-0.5 µM C11Pc equivalent. However, at 1.15 µM 
C11Pc equivalent, phototoxicity induced by the jacalin conjugated nanoparticles was ca. 
9.3% higher than that induced by the anti-HER-2 antibody conjugated particles (P<0.05). 
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The greater reduction in HT-29 cell viability following jacalin targeted PDT could also be 
attributed to a greater level of dark toxicity (ca. 38% reduction in viability), as compared 
to incubation with the antibody conjugates (ca. 23% reduction in viability) when using a 
nanoparticle concentration of 1.15 µM C11Pc equivalent. 
Irradiation of HT-29 cells incubated with 0.00-1.15 µM C11Pc equivalent of non-
conjugated nanoparticles did not result in any significant phototoxicity (Figure 5.5 (C), 
black). At nanoparticle concentrations of 0.20-1.15 µM C11Pc equivalent, targeted PDT 
treatment using either jacalin or anti-HER-2 antibody conjugates significantly enhanced 
the phototoxicity of the HT-29 cells, as compared to non-targeted treatment (P<0.05).  
  
  
190 
 
 
Figure 5.5 MTT viability assay results of HT-29 cells following PDT treatment with the 
jacalin conjugated (A) or anti-HER-2 antibody conjugated (B) C11Pc-PEG 
gold nanoparticles. Cells were irradiated at 633 nm for 6 min per well 
(orange) or non-irradiated (dark cyan). C) Phototoxicity of HT-29 cells 
incubated with the jacalin conjugated (green), anti-HER-2 antibody 
conjugated (blue) or non-conjugated (black) nanoparticles. Staurosporine 
(+St, 20 µM) was used as a positive control for cytotoxicity. (Error bars are ± 
95% confidence intervals, n=3. * indicates statistical significance in viability 
reduction following irradiation at P<0.005, ** at P<0.0025 and *** at 
P<0.0005 using a one-tailed t-test). 
 
5.2.3 Targeted PDT of SK-BR-3 cells – CellTiter-BlueTM viability assay 
Targeted PDT using jacalin or anti-HER-2 antibody nanoparticle conjugates was then 
investigated on SK-BR-3 cells, as described in section 2.3.4. An MTT assay was attempted 
on SK-BR-3 cells following targeted PDT treatment; however, residual DMEM medium in 
the wells during the formazan solubilisation step caused significant variation in the 
formazan colour (data not shown).49 Therefore, the CellTiter-BlueTM fluorometric cell 
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viability assay was performed on SK-BR-3 cells following targeted PDT treatment as no 
solubilisation step is involved with this assay. 
As shown in Figure 5.6, the viability of the SK-BR-3 cells appeared to be significantly 
lower than that of the HT-29 cells following targeted PDT treatment with the same range 
of nanoparticle concentrations. The lower viability of the SK-BR-3 cells could be attributed 
to variation resulting from the use of different viability assays for each cell line. 
Alternatively, the SK-BR-3 cells could be more susceptible to phototoxicity or have less 
repair mechanisms than the HT-29 cells to recover from oxidative damage.50 
At 0.5 µM C11Pc equivalent of jacalin conjugated nanoparticles, PDT treatment 
dramatically reduced SK-BR-3 cell viability to ca. 2.6%, whereas without irradiation 
viability remained at ca. 86.4% (Figure 5.6 (A)). Similarly, at the same concentration of 
nanoparticles, anti-HER-2 antibody targeted PDT reduced cell viability to ca. 5.4%, whilst 
the viability of non-irradiated cells was at ca. 111.4% (Figure 5.6 (B)). The limited dark 
toxicity of the anti-HER-2 antibody conjugates offers an obvious advantage over the jacalin 
conjugates. At nanoparticle concentrations of 1 µM and 1.15 µM C11Pc equivalent, both 
jacalin and anti-HER-2 antibody targeted PDT induced ˃99% cell kill, whereas viability in 
the dark remained at ca. 58.9-70.2% (Figure 5.6 (A)) and ca. 85.5-98.5% (Figure 5.6 (B)), 
respectively. As observed with the HT-29 cells, the phototoxicity of the SK-BR-3 cells 
induced by non-conjugated C11Pc-PEG gold nanoparticles was negligible at the 
concentrations used for this experiment (Figure 5.6 (C)). A dose-dependent phototoxicity 
of the SK-BR-3 cells incubated with the jacalin or anti-HER-2 antibody conjugated particles 
was also observed. Jacalin conjugation appeared to provide a statistically significant 
improved PDT effect at 0.10 µM C11Pc equivalent, as compared to anti-HER-2 antibody 
conjugation (P<0.05). The marginally greater PDT efficacy observed with the jacalin 
conjugated particles, as compared to the anti-HER-2 antibody conjugated nanoparticles, 
could be attributed to higher binding kinetics of jacalin. However, the viability of the SK-
BR-3 cells incubated with the jacalin conjugates (0.10 µM C11Pc equivalent) was ca. 4% 
lower than when incubated with the anti-HER-2 antibody conjugates at the same 
concentration. Further investigations into the variations in dark toxicity, binding affinity, 
kinetics and uptake of the two nanoparticle conjugates would provide a more conclusive 
explanation. The cellular uptake rates of jacalin conjugated and antibody conjugated 
nanoparticle can be determined using fluorescence-activated cell sorting (FACS) analysis 
in addition to quantitative gold and zinc ICP-OES elemental analysis at varying time points 
during nanoparticle incubation.  
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Figure 5.6 CellTiter-BlueTM viability assay results of SK-BR-3 cells following PDT 
treatment with the jacalin conjugated (A) or anti-HER-2 antibody conjugated 
(B) C11Pc-PEG gold nanoparticles. Cells were irradiated at 633 nm for 6 min 
per well (orange) or non-irradiated (dark cyan). C) Phototoxicity of HT-29 
cells incubated with the jacalin conjugated (green), anti-HER-2 antibody 
conjugated (blue) and non-conjugated (black) nanoparticles. Staurosporine 
(+St, 20 µM) was used as a positive control for cytotoxicity. (Error bars are ± 
95% confidence intervals, n=3. # indicates statistical significance in viability 
reduction following irradiation at P<0.001, * at P<0.005 and *** at P<0.0005 
using a one-tailed t-test). 
 
5.2.4 Comparative study of targeted PDT – ApoTox-GloTM triplex assay 
In order to investigate whether different pathways of cell death were induced following 
targeted PDT using either jacalin or anti-HER-2 antibody targeted PDT, the ApoTox-GloTM 
triplex assay was performed, as described in section 2.3.5. Additionally, the effect of 
nanoparticle concentration on the cell death mechanism was explored by using either 0.1 
µM or 1 µM C11Pc equivalent of nanoparticle conjugates. The significance of non-specific 
protein-cell interactions on enhancing the PDT efficacy of conjugated C11Pc-PEG gold 
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nanoparticles was also examined by using sheep serum albumin (SSA) conjugated 
nanoparticles as a control.  
As can be seen from Figure 5.7 (A), viability levels of irradiated HT-29 cells incubated 
with 0.1 µM C11Pc equivalent of jacalin, anti-HER-2 antibody or SSA conjugated 
nanoparticles are similar (ca. 80-85%). However, at 1 µM C11Pc equivalent, nanoparticles 
conjugated to jacalin reduced HT-29 cell viability to ca. 31.3%, which were significantly 
more effective than SSA conjugated nanoparticles (ca. 51.5% viability, P<0.001). Anti-HER-
2 antibody conjugated nanoparticles were also significantly more efficient than SSA 
conjugated nanoparticles at reducing HT-29 cell viability (ca. 42.7% viability, P<0.05).  
The viability of irradiated SK-BR-3 cells incubated with 1 µM C11Pc equivalent of 
nanoparticles conjugated to jacalin, anti-HER 2 antibodies or SSA was reduced to ca. 1.6%, 
3.3% and 4.9%, respectively (Figure 5.7 (B)). At this concentration, phototoxicity was 
extensive with all types of nanoparticles, suggesting that selective cellular uptake is not 
observed at higher concentration of particle conjugates. Additionally, the jacalin 
conjugated nanoparticles (1 µM C11Pc equivalent) were more efficient than the anti-HER-
2 antibody conjugated particles at reducing SK-BR-3 cell viability (P<0.001). However, 
non-irradiated SK-BR-3 cells incubated with the jacalin conjugates exhibit a ca. 22.7% 
lower viability than those incubated with the antibody conjugates (data not shown). 
Therefore, a greater level of dark toxicity could contribute to the apparent improvement in 
jacalin targeted PDT using a particle concentration of 1 µM C11Pc equivalent. At 0.1 µM 
C11Pc equivalent of nanoparticle conjugates, the difference between targeted PDT and 
non-targeted SSA-mediated PDT becomes more apparent. Both jacalin and anti-HER-2 
antibody conjugated nanoparticles were significantly more effective at reducing cell 
viability than the SSA conjugated particles (P<0.0005). The viability of irradiated SK-BR-3 
cells incubated with the jacalin conjugated, anti-HER-2 antibody conjugated or SSA 
conjugated particles was reduced to ca. 22.0%, 34.8% and 77.9%, respectively. At a 
nanoparticle concentration of 0.1 µM C11Pc equivalent, jacalin targeting appeared to be 
more effective at reducing irradiated SK-BR-3 cell viability than anti-HER-2 antibody 
targeting (P<0.005). However, the viability of the non-irradiated cells incubated with the 
jacalin conjugates was ca. 5% lower than the viability of the cells incubated with the 
antibody conjugates (data not shown).te 
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Figure 5.7 Viability results of the ApoTox-GloTM triplex assay showing the viability of 
HT-29 cells (A) and SK-BR-3 cells (B) incubated with 0.1 µM or 1 µM C11Pc 
equivalent of C11Pc-PEG gold nanoparticles following irradiation at 633 nm. 
The nanoparticles were conjugated to jacalin (-jacalin), anti-HER-2 
antibodies (-anti-HER-2 Ab) or sheep serum albumin (-SSA). Viability is 
expressed as a percentage of fluorescence emission of the untreated control 
cells at 492 nm. Staurosporine (+St, 20 µM) was used as a positive control for 
cytotoxicity. (Error bars are ± 95% confidence intervals, n=3). 
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Irradiated HT-29 cells incubated with 1 µM C11Pc equivalent of jacalin conjugated or anti-
HER-2 antibody conjugated nanoparticles exhibited a ca. 2.8-fold and 1.7-fold increase in 
cytotoxicity, respectively, as compared to the untreated control cells (Figure 5.8 (A)). 
Incubation with either 0.1 µM or 1 µM C11Pc equivalent of SSA conjugated nanoparticles 
induced no cytotoxicity of the HT-29 cell following irradiation. Therefore, specific ligand- 
receptor interactions are likely to be responsible for the enhanced PDT effect observed in 
the HT-29 cells incubated with the jacalin conjugated or anti-HER-2 antibody conjugated 
nanoparticles. Moreover, the selective uptake of the jacalin conjugated or anti-HER-2 
antibody conjugated nanoparticles by the HT-29 cells is more apparent at higher 
concentrations. 
As can be seen in (Figure 5.8 (B)), the cytotoxicity of SK-BR-3 cells was more extensive 
than that of HT-29 cells following PDT treatment, which agrees with the viability results 
(Figure 5.7 (B)). At 0.1 µM C11Pc equivalent, jacalin or anti-HER-2 antibody conjugated 
nanoparticles induced similar levels of cytotoxicity in SK-BR-3 cells (ca. 5.6-fold increase 
in cytotoxicity), as compared to the SSA conjugated particles (ca. 1.6-fold increase in 
cytotoxicity, P<0.0005). At a higher nanoparticle concentration of 1 µM C11Pc equivalent, 
jacalin conjugated and anti-HER-2 antibody conjugated particles induced a ca. 7.5-fold and 
a ca. 5.7-fold increase in cytotoxicity in irradiated SK-BR-3 cells. At a nanoparticle 
concentration of 1 µM C11Pc equivalent, greater cytotoxicity of irradiated SK-BR-3 cells 
was observed following incubation with the SSA conjugated particles (7.8-fold increase in 
cytotoxicity). These findings further suggest that above a certain critical nanoparticle 
concentration, cellular internalisation of the conjugates into the SK-BR-3 cells becomes 
non-specific. Therefore at lower nanoparticle concentrations, the selective enhancement 
in phototoxicity using targeted nanoparticle conjugates is observed. Dead cell protease 
activity is largely dependent on the time delay between PDT treatment and assay 
execution. Performing the triplex assay at varying time points following initiation of PDT 
within the SK-BR-3 cells would give further insight into the time dependence and extent of 
targeted and non-targeted PDT cell damage.  
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Figure 5.8 ApoTox-GloTM triplex assay results showing the cytotoxicity of irradiated HT-
29 cells (A) and SK-BR-3 cells (B) incubated with 0.1 µM or 1 µM C11Pc 
equivalent of C11Pc-PEG gold nanoparticles. The nanoparticles were 
conjugated to jacalin (-jacalin), anti-HER-2 antibodies (-anti-HER-2 Ab) or 
sheep serum albumin (-SSA). Cytotoxicity is expressed as a normalised 
fluorescence emission at 530 nm. Staurosporine (+St, 20 µM) was used as a 
positive control for cytotoxicity predominantly through apoptosis. (Error 
bars are ± 95% confidence intervals, n=3).  
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The apoptotic response of irradiated HT-29 cells (Figure 5.9 (A)) and SK-BR-3 cells 
(Figure 5.9 (B)) following nanoparticle incubation (0.1 µM or 1 µM C11Pc equivalent) 
indicates that targeted PDT treatment using jacalin conjugated or anti-HER-2 antibody 
conjugated nanoparticles did not induce apoptosis. Furthermore, SSA conjugated 
nanoparticles did not induce apoptosis at both concentrations in either cell line. Apoptosis 
was only observed in the positive control cells incubated with staurosporine (20 µM).  
 
Figure 5.9 ApoTox-GloTM triplex assay results showing the apoptotic response of 
irradiated HT-29 cells (A) and SK-BR-3 (B) cells incubated with 0.1 µM or 1 
µM C11Pc equivalent of C11Pc-PEG gold nanoparticles. The nanoparticles 
were conjugated to jacalin (-jacalin), anti-HER-2 antibodies (-anti-HER-2 Ab) 
or sheep serum albumin (-SSA). Apoptosis is expressed as a normalised 
bioluminescence emission at 576 nm.51 Staurosporine (+St, 20 µM) was used 
as a positive control for cytotoxicity predominantly through apoptosis.52 
(Error bars are ± 95% confidence intervals, n=3). 
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5.2.5 Lysosomal colocalisation of targeted nanoparticle conjugates 
After establishing the PDT efficacy of jacalin conjugated and anti-HER-2 antibody 
conjugated C11Pc-PEG gold nanoparticles on both HT-29 cells and SK-BR-3 cells, the 
intracellular fate of both nanoparticle conjugates was investigated using laser scanning 
confocal microscopy. HT-29 cells and SK-BR-3 cells were incubated with C11Pc-PEG gold 
nanoparticles (1 µM C11Pc equivalent) with jacalin or anti-HER-2 antibody conjugation. 
The cells were also incubated with LysoSensorTM Green DND-189, a marker of acidic 
organelles, as described in section 2.3.6. It has been shown that nanoparticles can be 
uptaken into cells through a receptor mediated endocytic pathway, which results in 
intracellular nanoparticle accumulation within the endosomal compartments.53,54 
Maturation of endosomes leads to their eventual acidification through combination with 
lysosomes down the endocytic degradation pathway.55 Internalised nanoparticles present 
in endosomes may also be redirected to the extracellular domain prior to endosomal 
maturation and acidification.53 Colocalisation of nanoparticle conjugates with acidic 
organelle markers would suggest that the conjugates are uptaken through an endocytic 
pathway.55 Acidic organelles within the HT-29 cells and SK-BR-3 cells were visualised 
using the green fluorescent marker LysoSensorTM Green DND-189 (1 µM) using excitation 
at 458 nm. Conjugated C11Pc-PEG gold nanoparticles (1 µM C11Pc equivalent) were 
visualised by exploiting the fluorescence of C11Pc upon excitation at 633 nm. 
Colocalisation of the nanoparticle conjugates with LysoSensorTM Green DND-189 was 
assessed using the colocalisation analysis function within the BioImageXD software. 
Regions of colocalised red and green fluorescence from the conjugated C11Pc-PEG gold 
nanoparticles and the acidic organelles, respectively, were isolated and false coloured 
yellow. An upper colocalisation threshold of 4095 and a lower colocalisation threshold of 
705 was used throughout the analyses of all the images. Quantitative colocalisation 
analysis of three random images of SK-BR-3 cells or HT-29 cells incubated with the jacalin 
or anti-HER-2 antibody conjugated nanoparticles was performed using the BioImageXD 
software. Colocalisation was quantified as a percentage of voxels (volumetric pixels) in the 
red channel (C11Pc-PEG gold nanoparticles) that were colocalised with the voxels in the 
green channel (LysoSensorTM Green DND-189) (Table 5.1). It appears that there is a 
significantly greater error in the mean % voxel colocalisation values of the jacalin 
conjugated nanoparticles than the anti-HER-2 antibody conjugated particles in both cell 
lines analysed. This suggests that there are likely to be differences between the cellular 
uptake processes of both nanoparticle conjugates, as their respective cell surface targets 
differ in nature. 
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Table 5.1 Mean percentage voxel colocalisation of jacalin conjugated or anti-HER-2 
antibody conjugated C11Pc-PEG gold nanoparticles (red channel) with 
LysoSensorTM Green DND-189 (green channel). 
Adenocarcinoma 
Cell Line 
Ligand Conjugated to 
the Nanoparticles 
Mean % Voxel Colocalisation with the 
LysoSensorTM ± 95% Confidence Interval 
HT-29 jacalin 27.60 ± 20.09 
HT-29 anti-HER-2 antibody 30.51 ± 7.48 
SK-BR-3 jacalin 43.19 ± 27.68 
SK-BR-3 anti-HER-2 antibody 22.42 ± 2.24 
 
Figure 5.10 shows the laser scanning confocal microscope images of HT-29 cells 
incubated with the jacalin conjugated C11Pc-PEG gold nanoparticles (A) and LysoSensorTM 
Green DND-189 (B). The brightness of the green channel was reduced by 9% and the 
contrast of the red channel was increased by 10% for clarity. However, colocalisation 
isolation and quantitative image analysis was performed on unaltered images, as-
obtained. Regions of colocalisation of the nanoparticles with the LysoSensorTM are shown 
in yellow (Figure 5.10 (C)). A merge of the differential interference contrast (DIC) image 
with the fluorescence images of the conjugated C11Pc-PEG gold nanoparticles and the 
LysoSensorTM is shown in (Figure 5.10 (D)).  
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Figure 5.10 Confocal microscope images of HT-29 cells incubated with the jacalin 
conjugated C11Pc-PEG gold nanoparticles (1 µM C11Pc equivalent). A) 
Excitation at 633 nm resulted in a red fluorescence emission of the 
conjugated C11Pc-PEG gold nanoparticles. B) Acidic organelles were 
visualised by the green fluorescence emission of LysoSensorTM Green DND-
189 upon excitation at 458 nm. C) Colocalisation of the conjugated C11Pc-
PEG gold nanoparticles and the LysoSensorTM is shown in yellow. D) The DIC 
image and the fluorescence images of C11Pc and the LysoSensorTM were 
merged. (Scale bars are 10 µm). 
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Figure 5.11 shows the confocal microscope images of HT-29 cells incubated with the anti-
HER-2 antibody conjugated C11Pc-PEG gold nanoparticles (1 µM C11Pc equivalent). The 
brightness of the green channel was reduced by 9% and the contrast of the red channel 
was increased by 10% for clarity. Colocalisation isolation and quantitative image analysis 
was performed on unaltered images.  
 
Figure 5.11 Confocal microscope images of HT-29 cells incubated with the anti-HER-2 
antibody conjugated C11Pc-PEG gold nanoparticles (1 µM C11Pc equivalent). 
A) Excitation of the conjugated C11Pc-PEG gold nanoparticles at 633 nm 
results in red fluorescence emission. B) Acidic organelles are visualised by 
the green fluorescence emission of LysoSensorTM Green DND-189 upon 
excitation at 458 nm. C) Colocalisation of the conjugated C11Pc-PEG gold 
nanoparticles and the LysoSensorTM is shown in yellow. D) The DIC image 
and the fluorescence images of C11Pc and the LysoSensorTM were merged. 
(Scale bars are 10 µm).  
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Figure 5.12 is a collection of the confocal microscope images of SK-BR-3 cells incubated 
with the jacalin conjugated C11Pc-PEG gold nanoparticles (1 µM C11Pc equivalent). The 
brightness of the green channel was reduced by 9% for clarity; however, colocalisation 
isolation and analysis was performed on unaltered images.  
 
Figure 5.12 Confocal microscope images of SK-BR-3 cells incubated with the jacalin 
conjugated C11Pc-PEG gold nanoparticles (1 µM C11Pc equivalent). A) 
Excitation of the conjugated C11Pc-PEG gold nanoparticles at 633 nm results 
in red fluorescence emission. B) Acidic organelles are visualised by the green 
fluorescence emission of LysoSensorTM Green DND-189 upon excitation at 
458 nm. C) Colocalisation of the conjugated C11Pc-PEG gold nanoparticles 
and the LysoSensorTM is shown in yellow. D) The DIC image and the 
fluorescence images of C11Pc and the LysoSensorTM were merged. (Scale 
bars are 10 µm). 
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The confocal microscope images of SK-BR-3 cells incubated with C11Pc-PEG gold 
nanoparticles conjugated to anti-HER-2 antibodies (1 µM C11Pc equivalent) are shown in 
Figure 5.13. The brightness and contrast of all the images are as-obtained. 
 
 
Figure 5.13 Confocal microscope images of SK-BR-3 cells incubated with anti-HER-2 
antibody conjugated C11Pc-PEG gold nanoparticles (1 µM C11Pc equivalent). 
A) Excitation of the conjugated C11Pc-PEG gold nanoparticles at 633 nm 
results in red fluorescence emission. B) Acidic organelles are visualised by 
the green fluorescence emission of LysoSensorTM Green DND-189 upon 
excitation at 458 nm. C) Colocalisation of the conjugated C11Pc-PEG gold 
nanoparticles and the LysoSensorTM is shown in yellow. D) The DIC image 
and the fluorescence images of C11Pc and the LysoSensorTM were merged. 
(Scale bars are 10 µm). 
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The findings of the laser scanning confocal microscopy imaging experiments strongly 
suggest that both jacalin and anti-HER-2 antibody conjugated C11Pc-PEG gold 
nanoparticles partially accumulate within the acidic organelles within the HT-29 cells and 
the SK-BR-3 cells. Regions of red fluorescence that are not colocalised with the 
LysoSensorTM are possibly nanoparticle conjugates within endosomal compartments that 
have not yet matured into late endosomes or have been redirected back to the surface.53 
Thus, conjugated C11Pc-PEG gold nanoparticles targeted to HT-29 colon cancer and SK-
BR-3 breast cancer cells using jacalin or anti-HER-2 antibodies are likely to enter the cells 
through a receptor mediated endocytic pathway and remain within the endosomal 
compartments.  
 
5.3 Conclusions 
In this chapter, the efficacy of using the lectin jacalin as a cancer-specific targeting protein 
was compared to anti-HER-2 antibodies. Both targeting ligands were covalently 
conjugated to C11Pc-PEG gold nanoparticles and were found to produce similar quantities 
of singlet oxygen upon irradiation at 633 nm. By using the MTT viability assay, it was 
shown that nanoparticles conjugated to either jacalin or anti-HER-2 antibodies 
significantly reduced HT-29 cell viability, as compared to the non-conjugated particles. At 
a nanoparticle concentration of 1.15 µM C11Pc equivalent, HT-29 cell viability was 
reduced to ca. 10% and 19% following jacalin or anti-HER-2 antibody targeted PDT 
treatment, respectively. However, at the same concentration, viability of HT-29 cells 
incubated with non-conjugated particles remained at ca. 94%. The SK-BR-3 cells appeared 
to be more susceptible to PDT damage than the HT-29 cells. At a nanoparticle 
concentration of 1.15 µM C11Pc equivalent, SK-BR-3 cell viability was reduced to ca. 3% 
and 5% following targeted PDT treatment with nanoparticles conjugated to jacalin or anti-
HER-2 antibodies, respectively. However, at the same concentration, non-conjugated 
nanoparticles reduced SK-BR-3 cell viability by only ca. 5% following irradiation.  
The ApoTox-GloTM triplex assay was performed on both HT-29 cells and SK-BR-3 cells to 
investigate whether using the different targeting ligands would result in variations in the 
cell death mechanisms. The effect of nanoparticle concentration on the cell death pathway 
was also investigated by comparing particles at 0.1 µM and 1 µM C11Pc equivalent. 
Nanoparticles conjugated to SSA were used as a control to explore any non-specific 
enhancement in PDT cytotoxicity. It was found that at 0.1 µM C11Pc equivalent, no 
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significant difference in HT-29 cell viability reduction was observed between SSA 
conjugated and jacalin or anti-HER-2 antibody conjugated nanoparticles. At 1 µM C11Pc 
equivalent, jacalin and anti-HER-2 antibody conjugated nanoparticles reduced HT-29 cell 
viability significantly more than SSA conjugated particles (P<0.05). Cytotoxicity of 
irradiated HT-29 cells was only detected when the cells were incubated with the jacalin or 
anti-HER-2 antibody conjugated nanoparticles at 1 µM C11Pc equivalent. SSA conjugated 
particles failed to induce HT-29 cell cytotoxicity at either concentration. Therefore the 
enhanced PDT effect on the HT-29 cells observed with the jacalin or anti-HER-2 antibody 
conjugated nanoparticles is largely due to specific ligand-receptor interactions. Apoptosis, 
however, was not observed in HT-29 cells following PDT treatment with any of the C11Pc-
PEG gold nanoparticle conjugates at any concentration.  
At 0.1 µM C11Pc equivalent, the jacalin conjugated and anti-HER-2 antibody conjugated 
nanoparticles reduced SK-BR-3 cell viability significantly more than the SSA conjugated 
particles (P<0.0005). At 1 µM C11Pc equivalent a dramatic reduction in SK-BR-3 cell 
viability was observed with all three types of nanoparticles (ca. 95.0-98.5%). However, 
both jacalin and anti-HER-2 antibody conjugated nanoparticles were more effective than 
SSA conjugated particles (P<0.05). Cytotoxicity of SK-BR-3 cells was observed with both 
concentrations of the jacalin conjugated or anti-HER-2 antibody conjugated C11Pc-PEG 
gold nanoparticles (ca. 5.6-7.5 fold increase in cytotoxicity). However, the SSA conjugated 
nanoparticles only induced a significant level of SK-BR-3 cell cytotoxicity (ca. 7.8-fold 
increase in cytotoxicity) when using a nanoparticle concentration of 1 µM C11Pc 
equivalent. At a lower nanoparticle concentration of 0.1 µM C11Pc equivalent only a ca. 
1.6-fold increase in cytotoxicity was observed. The concentration dependence in SSA-
mediated cytotoxicity suggests that above a certain nanoparticle concentration, active 
targeting is overcome by non-specific particle uptake in the SK-BR-3 cells. A concentration 
course viability assay following targeted and non-targeted PDT treatment would define 
the nanoparticle concentration range at which active cancer cell targeting is optimal. 
 As with the HT-29 cells, no apoptosis was observed in the SK-BR-3 cells following PDT 
treatment with any of the nanoparticle conjugates at both concentrations used. Once 
again, the jacalin conjugated particles were more effective than the anti-HER-2 antibody 
conjugated nanoparticles at reducing SK-BR-3 viability at both concentrations of 0.1 µM 
and 1 µM C11Pc equivalent (P<0.005). However, the cytotoxicity of SK-BR-3 cells 
incubated with anti-HER-2 antibody conjugated and SSA conjugated particles was higher 
than those incubated with the jacalin conjugated particles at 1 µM C11Pc equivalent 
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(P<0.005). This difference suggests a role in the time dependence of dead cell protease 
activity, which may not entirely correlate with the viability analysis. 
The intracellular localisation of the jacalin conjugated or anti-HER-2 antibody conjugated 
C11Pc-PEG gold nanoparticles was investigated in HT-29 cells and SK-BR-3 cells using 
laser scanning confocal microscopy. Accumulation of the targeted nanoparticle conjugates 
within acidic organelles was assessed by the colocalisation of the red C11Pc fluorescence 
from the conjugated nanoparticles with the green LysoSensorTM Green DND-189 
fluorescence. The degree of colocalisation was analysed using the BioImageXD software. It 
was found that both the jacalin conjugated and anti-HER-2 antibody conjugated 
nanoparticles partially colocalised with the LysoSensorTM Green DND-189 and remained in 
the acidic organelles within both the HT-29 cells and the SK-BR-3 cells. Colocalisation 
suggests that both types of nanoparticle conjugates were internalised through receptor 
mediated endocytosis. Unlike the anti-HER-2 antibody conjugated particles, the high 
variability of the colocalisation analyses of the jacalin conjugated particles with the 
LysoSensorTM Green DND-189 in both cells lines could indicate a difference in the 
mechanism of endocytosis. Further investigations into the internalisation and recycling of 
the HER-2 receptor and the T antigen-bearing glycoproteins could provide valuable 
insight into the differences in cellular uptake of the targeted nanoparticle conjugates. 
Additionally, the intracellular integrity of the conjugated C11Pc-PEG gold nanoparticles 
could be studied by using dark-field microscopy to determine the localisation of the gold 
nanoparticles with respect to the C11Pc fluorescence. 
In conclusion, this chapter outlines a number of investigations comparing the efficacy of 
the lectin, jacalin, with the anti-HER-2 antibody as cancer-specific targeting ligands. Both 
targeting ligands conjugated to C11Pc-PEG gold nanoparticles significantly reduced the 
viability of HT-29 colon adenocarcinoma cells and SK-BR-3 breast adenocarcinoma cells 
following irradiation at 633 nm. Cytotoxicity was observed following targeted PDT using 
either the lectin or the antibody, whereas no evidence of apoptosis was observed. 
Evidence suggests that at certain nanoparticle concentrations, jacalin conjugation was 
more effective than anti-HER-2 antibody conjugation at targeted PDT cell kill; however, 
this could be attributed to the higher levels of dark toxicity induced by the jacalin 
conjugates. Based on the dissociation constants of jacalin binding to HT-29 cells (500 ± 50 
nM)46 and anti-HER-2 antibodies binding to SK-BR-3 cells (14-36 nM),45 it was expected 
that antibody targeting would be more efficient than lectin targeting. However, SK-BR-3 
cells express ca. 1-2x106 HER-2 receptors per cell,44 whereas HT-29 cells express ca. 
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4.4x107 T antigens per cell.46 These findings suggest an important role for cell surface 
receptor density on the outcome of targeted PDT treatments for cancer. Investigations into 
the binding kinetics of the nanoparticle conjugates to the cells could help explain the 
differences between using the lectin or the antibody. The studies described in this chapter 
outline how lectins, such as jacalin, may have great potential for targeted cancer therapy 
by exploiting the high levels of cancer-associated carbohydrate antigen expression, e.g. 
4.4x107 T antigens per cell.  
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Chapter 6 
Sonodynamic therapy of HT-29 colon adenocarcinoma cells 
using titanium dioxide nanoparticles 
This chapter describes the synthesis and characterisation of stable polyacrylic acid coated 
titanium dioxide nanoparticles. The potential of sonocatalytic enhancement in the 
production of reactive oxygen species is investigated and in vitro sonodynamic therapy of 
HT-29 cells is explored. 
 
6.1 Introduction  
6.1.1 Sonochemistry 
Acoustic waves are longitudinal propagations of mechanical vibrations travelling through 
a medium, the frequencies of which are expressed as Hertz (Hz, cycles per second).1 
Ultrasound waves consist of cycles of low pressure (rarefaction) and high pressure 
(compression), which oscillate at frequencies greater than 16 kHz.1 High frequency 
ultrasound (1-20 MHz) is widely used for medical imaging and diagnostics. The frequency 
of ultrasound waves is inversely proportional to the tissue penetration depth; with 
increasing frequency, transmission through tissue is attenuated.2 For example, ultrasound 
penetration through soft tissue is ca. 150 mm when using an ultrasound frequency of 3.5 
MHz; however, penetration is reduced to ca. 20 mm when using 10 MHz ultrasound.3 
Additionally, the spatial resolution of ultrasound images is improved with increasing 
frequency.3 High intensity focused ultrasound has been exploited for selective surgical 
tissue necrosis, and has been utilised for the selective ablation of a variety of tumours 
using ultrasound frequencies of 0.8-4 MHz and intensities of 1,000-20,000 W.cm-2.4  
The physical effects of ultrasound on water can lead to the sonochemical generation of 
several cytotoxic reactive oxygen species (ROS), including radicals and singlet oxygen.1,5 
Sonochemical reactions are initiated by the violent collapse of cavitation bubbles formed 
by the exertion of an ultrasonic field in a liquid medium. Acoustic cavitation of water 
begins with the nucleation of a gas or vapour filled microbubble upon oscillating cycles of 
compression and rarefaction within the applied ultrasonic field.6 Two distinct yet 
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interconnected mechanisms of cavitation exist: stable and transient cavitation.6,7 During 
stable acoustic cavitation, the diameter of the bubble stably oscillates with the incident 
acoustic frequency. However, during transient acoustic cavitation, the bubble forms and 
rapidly grows with the oscillating cycles of compression and rarefaction. Once the 
microbubble reaches an unstable size, it violently collapses. At this stage, the liquid-gas 
interface velocity of the collapsing bubble nears that of the speed of sound, which results 
in hotspots with extreme localised temperatures and pressures, i.e. 2,000 °C and 10,000 
atm, respectively.6 The processes during transient acoustic cavitation are explained in 
Figure 6.1. 
 
 
Figure 6.1 The processes involved in transient acoustic cavitation during ultrasound 
irradiation. Upon oscillating waves of acoustic compression and rarefaction, 
gas or vapour filled microbubbles are formed, expand, and then collapse to 
generate hotspots with areas of high temperatures and pressures. Figure 
adapted from Suslick.8 
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Visible light is also emitted during cavitation; this phenomenon is known as 
sonoluminescence.7,9,10 The first sonochemical reaction to occur during ultrasonic 
irradiation of water is the sonolysis of H2O into H• and •OH radicals.6 Light spanning the 
UV-visible and near-infrared regions of the spectrum is emitted during cavitation as a 
result of radiative recombination of radicals, in addition to the radiative relaxation of 
excited species formed during cavitation.7 The optical properties of sonoluminescence in 
water are influenced by the frequency of the ultrasound and the nature of the gases 
dissolved in the water.7 For example, sonoluminescence emission maxima centred at 310 
nm, 360 nm and 430 nm are observed upon the exposure of air saturated water to 
ultrasound (450 kHz).7 The sonolysis of water propagates a variety of radical chain 
reactions producing strongly oxidising species such as hydroxyl radicals (•OH) and 
hydrogen peroxide (H2O2), amongst others.6 The possible reactions that occur during 
cavitation bubble collapse are described in equations 6.1-6.12.1,6,11 Additionally, the 
presence of oxygen within a cavitation bubble has been reported to result in the formation 
of singlet oxygen in addition to peroxy radicals.5 Sonolysis of water results in the 
production of hydrogen radicals and hydroxyl radicals (6.1). These radicals can recombine 
to form water once again (6.2).6 
 
H2O   →  H• + •OH   (6.1)   
H• + •OH → H2O    (6.2) 
 
Alternatively, the combination of two hydroxyl radicals can result in the formation of 
hydrogen peroxide (6.3), hydrogen and oxygen (6.4), or water and oxygen (6.5). Hydroxyl 
radical attack of water can also lead to the production of hydrogen peroxide and oxygen 
radicals (6.6).6 
 
•OH + •OH → H2O2   (6.3) 
•OH + •OH → H2 + O2   (6.4) 
2•OH + 2•OH → 2H2O + O2  (6.5) 
•OH + H2O → H2O2 + O•  (6.6) 
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The combination of two hydrogen radicals can result in the formation of hydrogen gas 
(6.7). Hydrogen radicals can also react with hydrogen peroxide to produce hydroxyl 
radicals and water (6.8). The reaction of hydrogen radicals with oxygen leads to the 
generation of hydroperoxyl radicals (6.9). Hydroperoxyl radicals may further react with 
hydrogen radicals to produce hydrogen peroxide (6.10).6 
 
H• + H•   → H2   (6.7) 
H• + H2O2  → •OH + H2O  (6.8) 
H• + O2   → HO2•   (6.9) 
HO2• + H• → H2O2   (6.10) 
 
The combination of two hydroperoxyl radicals may lead to the generation of hydrogen 
peroxide and oxygen (6.11). Additionally, hydroperoxyl radicals may react with oxygen 
radicals to produce hydrogen peroxide (6.12). 6 
 
HO2• + HO2• → H2O2 + O2  (6.11) 
H2O• + O• → H2O2   (6.12) 
 
The large variety of radical intermediates and ROS species produced during the exposure 
of water to ultrasound has led to a significant number of studies exploring the therapeutic 
potential of ultrasound.12 
 
6.1.2 Sonosensitisers and ultrasound enhanced chemotherapeutics  
Sonosensitisers are agents that become sensitising following exposure to ultrasound 
frequencies, leading to the generation of ROS. It has been shown that a large number of 
photosensitisers act as sonosensitisers that produce singlet oxygen amongst other ROS 
species following exposure to ultrasound.12 Sonoluminescence is thought to be primarily 
responsible for the photoexcitation of the sensitisers through typical type I and type II 
reactions. The ultrasonic irradiation of other non-photosensitising compounds and 
chemotherapeutics, such as Adriamycin® and 5-fluorouracil, has also been found to exhibit 
a synergistic antitumour effect.12 The mechanisms underlying ultrasound enhanced 
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chemotherapy differ from those of sonoluminescent activation of photo/sonosensitisers.12 
Ultrasound is suggested to play a role in the sonoporation of cells, promoting the transport 
of drugs through the cell membrane.12 Additionally, chemotherapeutics are thought to 
assist the shear forces during ultrasound exposure that can physically destabilise cell 
membranes. Sonochemically generated alkoxyl and peroxyl radicals produced from 
chemotherapeutic sonosensitisers are also responsible for cell membrane lipid 
peroxidation through radical chain reactions.12 
 
6.1.3 In vitro and in vivo sonodynamic therapy  
Reports of using photosensitisers for sonodynamic therapy (SDT) demonstrate the clinical 
prospects for using a combination of chemical agents and ultrasound to reduce cancer cell 
viability and inhibit tumour growth. SDT treatment of an implanted S180 sarcoma tumour 
using protoporphyrin IX and haematoporphyrin showed a ca. 43% and 35% inhibition of 
tumour growth, respectively, when administration of the photo/sonosensitisers was 
combined with ultrasound exposure (2.2 MHz, 5 W.cm-2).13 The use of haematoporphyrin 
as a sonosensitiser was also investigated on hepatoma 22 cells.14 Sonodynamic toxicity of 
hepatoma 22 cells was observed in both an ultrasound exposure time-dependent manner 
and a sensitiser concentration-dependent manner. Reduction in cell viability was most 
effective when the cells were incubated with haematoporphyrin (200 µg.ml-1) and exposed 
to 60 s of ultrasound irradiation (1.43 MHz, 2 W.cm-2).14 In vivo, haematoporphyrin 
administration followed by ultrasound irradiation exhibited a synergistic antitumour 
effect on implanted hepatoma 22 cells, which was reported to significantly inhibit tumour 
growth.14 
C6 glioma cells were also responsive to SDT treatment using a monoethyl ether derivative 
of haematoporphyrin.15 SDT treatment by the combination of ultrasound (1 MHz, 1 W.cm-
2) and the haematoporphyrin derivative induced a significant increase in intracellular 
production of ROS and an increase in the rate of C6 cell apoptosis. A marked decrease in 
the mitochondrial membrane potential in the C6 cells was also observed.  
A comparative investigation into the anticancer effects of photodynamic and sonodynamic 
therapies has been reported using chloroaluminium phthalocyanine disulfonate incubated 
with B16FO murine melanoma cells and NIH3T3 murine ﬁbroblast cells.16 A drastic 
reduction in the viability of both cell lines was observed following PDT treatment (660 nm, 
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15 J.cm-2) and following SDT treatment (1 MHz, 2 W.cm-2) at all concentrations of the 
sensitiser used (0.5-100 µM). 
The sonodynamic efficacy of chlorin e6 has been investigated in a SPCA-1 human lung 
adenocarcinoma mouse tumour xenograft model.17 Sensitiser administration alone or 
ultrasound irradiation of the tumour without the sensitiser did not lead to an observable 
effect on tumour size. However, sonodynamic treatment using sensitiser administration 
followed by ultrasound irradiation induced a dose-dependent and ultrasound intensity-
dependent inhibition of tumour growth. Maximal antitumour effects were observed at 40 
mg.kg-1 of chlorin e6 in combination with ultrasound (1 MHz 1.6 W.cm-2). 
Recently, a systematic study on the in vitro and in vivo efficacy of indocyanine green as 
both a photosensitiser and a sonosensitiser has been reported.18 RIF-1 murine 
fibrosarcoma cells incubated with indocyanine green were exposed to ultrasound 
irradiation alone (1 MHz, 2 W.cm-2), which reduced cell viability by ca. 65%. Cells 
incubated with the sensitiser irradiated with near infrared light (880 nm, 37.8 J.cm-2) 
followed by exposure to ultrasound (1 MHz, 2 W.cm-2) exhibited a ca. 90% reduction in 
viability. Following intratumoural administration of indocyanine green, a ca. 42% 
inhibition of tumour growth was observed after PDT alone, a ca. 67% inhibition was 
observed after SDT alone, and a ca. 98% tumour growth inhibition was exerted after a 
combination of PDT and SDT. These results, amongst others, outline the potential of using 
deeply penetrating ultrasound to activate sensitisers for effective cancer treatment. The 
reports also suggest an important role for ultrasound in assisting conventional PDT 
modalities.  
 
6.1.4 Titanium dioxide as a sonosensitiser  
Nanostructured titanium dioxide (TiO2) is a widely used material with various 
applications in photocatalysis, photovoltaics, electrochemistry, hydrogen storage and gas 
sensing.19 TiO2 nanoparticles are semiconductors, which photocatalytically generate ROS 
at their surface following irradiation. Upon photoirradiation, the presence of a positive 
hole and an electron at the surface of the TiO2 results in the generation of cytotoxic ROS 
species. Figure 6.2 (A) demonstrates the photogeneration of hydrogen peroxide (H2O2) 
and superoxide anions (•O2-) from water at the site of the surface electron(e-). At the site of 
the positive hole (h+), hydroxyl radicals (•OH) are also generated from molecular oxygen. 
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The direct energy transfer from photoexcited TiO2 can also result in singlet oxygen 
production through a type II photosensitisation reaction.20 
TiO2 nanoparticles have also proven to be useful for a number of anticancer indications 
using SDT. The sonodynamic enhancement of ROS production by TiO2 nanoparticles 
occurs through multiple mechanisms that can overlap. Given that the sonoluminescent 
emission during acoustic cavitation is of an appropriate wavelength and a sufficient 
intensity to excite the TiO2, ROS production can be amplified in the presence of the 
nanoparticles (Figure 6.2 (B, top)).20 Furthermore, crevices and defects at the surface of 
the TiO2 nanoparticles can act as gas pockets at the solid-liquid interface that can stabilise 
micronuclei during acoustic cavitation.1,21,22 Stabilisation of the micronuclei during 
cavitation through this ‘Crevice Model’ can act to lower the threshold for cavitation.1,6,21,23 
A lower threshold for cavitation leads to an enhancement in the sonochemical generation 
of ROS (Figure 6.2 (B, bottom)).  
 
Figure 6.2 A) A schematic representation of a photoexcited TiO2 nanoparticle 
generating ROS species at surface trapped h+ and e-. Singlet oxygen is also 
produced through energy transfer from the photoexcited nanoparticle. B, 
top) Sonoluminescent activation of a TiO2 nanoparticle producing ROS 
species upon exposure to ultrasound. B, bottom) Enhanced cavitation of 
water at the surface crevices and defects of the TiO2 nanoparticle, leading to 
the sonochemical ROS production. 
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Within SDT, recent reports highlight the potential use of TiO2 nanoparticles for the 
effective SDT treatment of cancer. Commercial TiO2 nanoparticles with a diameter of ca. 
102 nm have been coated with polyacrylic acid and further modified with the pre-S1/S2 
protein, extracted from the hepatitis B virus.24 The nanoparticle-protein conjugates, with 
selectivity towards hepatocytes were used to target HepG2 human hepatocellular 
carcinoma cells. The intracellular localisation of the nanoparticles was confirmed by 
immunostaining of the targeting ligand. Exposure of the cells to ultrasound (1 MHz, 0.4 
W.cm-2) caused an increase in membrane damage, which was significantly enhanced by 
the presence of non-conjugated TiO2 nanoparticles. Membrane damage was markedly 
higher following SDT treatment using the pre-S1/S2 protein nanoparticle conjugates.  
SDT treatment using TiO2 nanoparticles (ca. 6 nm) was also effective against C32 
melanoma cells in vitro and against subcutaneously implanted C32 solid melanoma 
tumours in mice.25 C32 cells were incubated with 0.025% or 0.050% nanoparticle 
preparations and exposed to ultrasound irradiation (1 MHz, 1 W.cm-2). Cell viability was 
reduced to ca. 81.3% and ca. 53.6%, respectively, following exposure to ultrasound. 
Administration of the TiO2 nanoparticles alone or exposure to ultrasound alone had no 
significant antitumour effect. However, SDT treatment induced by the combination of both 
nanoparticle administration and ultrasound irradiation had a noticeable inhibitory effect 
on tumour growth.  
PEG modified TiO2 nanoparticles (ca. 50 nm) also exhibited a sonodynamic effect on U251 
human glioblastoma cells.26 Incubation of the glioblastoma cells with TiO2 nanoparticles 
(100 µg.ml-1) followed by ultrasound irradiation (1 MHz, 1 W.cm-2) for 50 s reduced cell 
viability to ca. 10%. Conversely, in order to reduce U251 cell viability to ca. 10% with PDT 
using the TiO2 nanoparticles, UV irradiation at 360 nm (5 mW.cm-2) for 1 h was required. 
The presence of the radical scavenger, glutathione, inhibited PDT induced cytotoxicity 
significantly more than sonodynamic toxicity. This difference in inhibition of cytotoxicity 
was suggested to be due to a synergistic role of TiO2 nanoparticles in enhancing 
mechanical cavitation stress to cells in addition to ROS generation.  
These reports, amongst others, demonstrate the efficacy of TiO2 nanoparticles as 
sonosensitisers for the SDT treatment of cancer. The synthesis of biocompatible TiO2 
nanoparticles for the SDT treatment of HT-29 human colon adenocarcinoma cells is 
described in this chapter. The nanoparticles were capped with polyacrylic acid to provide 
the particles with multiple carboxyl functionalities to enable the bioconjugation of 
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targeting ligands. Investigations into the nature of the sonochemically generated ROS 
species are outlined, in addition to preliminary in vitro SDT studies.  
 
6.2 Results and Discussion  
6.2.1 Synthesis and characterisation of cation stabilised TiO2 nanoparticles 
The synthesis of TiO2 nanoparticles capped with tetramethylammonium hydroxide 
(TMAOH) was performed as described in section 2.4.1. Figure 6.3 shows the structure of 
TMAOH stabilised TiO2 nanoparticles (TiO2NP.TMAOH). 
 
 
Figure 6.3 Schematic representation of TiO2 nanoparticles stabilised by the 
tetramethylammonium cation. 
 
The synthesis of the nanoparticles proceeds via a two-step reaction, as previously 
reported.27 The initial step involves the hydrolysis of titanium (IV) butoxide to form 
titanium hydroxide clusters (6.13). The second step is the polycondensation of titanium 
hydroxide upon hydrothermal treatment to form the TiO2 nanoparticles, which is 
catalysed by the TMAOH (6.14). TMAOH also serves to stabilise the condensed 
nanoparticles by capping their exposed surface –OH groups with a tetramethylammonium 
ion (TMA+) (6.15).27 The notations ‘x’, ‘y’ and ‘z’ refer to the proportions of the titanium, 
oxygen, and hydrogen atoms, respectively, within a TiO2 nanoparticle. 
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Ti(OBu)4 + 4 H2O → Ti(OH)4 + 4 BuOH     (6.13) 
TiOH + TMAOH → TiO- + TMA+ + H2O     (6.14) 
TixOyHz + TMAOH → (TixOyHz-1)TMA+ + H2O    (6.15) 
 
The TEM images of as-synthesised TiO2NP.TMAOH particles are shown in Figure 6.4. The 
particles appear to be clusters (ca. 100-150 nm) of smaller nanoparticles. It is likely that 
the aggregation of the particles was due to a lack of stability provided by the TMAOH. 
Acidification of the nanoparticle solution could protonate the capping molecules, thus 
enabling electrostatic stabilisation of the nanoparticles. 
 
 
Figure 6.4 TEM Images of as-synthesised TiO2NP.TMAOH particles in water. (Scale bars 
are 100 nm). 
 
To enhance the biocompatibility of the TiO2 nanoparticles and to allow for further 
conjugation to targeting biomolecules, modification with polyacrylic acid (PAA) containing 
multiple carboxyl groups was attempted. The initial protocol for modification with PAA 
was adapted from Kanehira et al.28 The procedure involved the thermal annealing of the 
polymer onto the TiO2NP.TMAOH nanoparticles in acidified N,N-dimethylformamide 
(DMF). Following removal of the water/butanol mixture present following the synthesis 
reaction, the nanoparticles were redispersed in 1% nitric acid and imaged using TEM, as 
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described in section 2.4.3. The TEM image of the nanoparticles after ultrasonic dispersion 
in nitric acid (Figure 6.5) revealed that the nanoparticles (ca. 5-10 nm in diameter) were 
largely non-aggregated. The prevalence of the non-aggregated, dispersed particles allowed 
for further modification of the individual nanoparticles with PAA.  
 
 
Figure 6.5 TEM image of TiO2NP.TMAOH nanoparticles in 1% nitric acid following 
ultrasonic dispersion. (Scale bar is 50 nm). 
 
The UV-visible absorption spectra of the as-synthesised TiO2NP.TMAOH particles before 
and after sonication (Figure 6.6 (A)) show that the as-synthesised nanoparticle 
aggregates have a significantly lower extinction in the UV region, as compared to the 
dispersed particles. The absorption band maximum of the aggregated particles is centred 
at 320 nm, whereas the dispersed particles exhibit a blue shift in the absorption band 
maximum, which is centred at 270 nm. This spectroscopic shift is typical for TiO2 
nanoparticles, which exhibit a blue shift in the absorption band maximum with a 
decreasing particle diameter.29 The TiO2NP.TMAOH particles sonicated in a nitric acid 
solution exhibit two distinct absorption bands centred at 270 nm and 320 nm, (Figure 6.6 
(B)) which correspond to a mixed species of dispersed and aggregated particles, 
respectively. 
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Figure 6.6 A) UV-visible absorption spectra of 10% v/v dilutions of as-synthesised 
TiO2NP.TMAOH particles in water before (black) and after (red) 15 min of 
ultrasonic dispersion. B) UV-visible absorption spectrum of a 20% w/v 
solution of TiO2NP.TMAOH particles in 1% nitric acid, dispersed by 30 min of 
sonication.  
 
Following ultrasonic dispersion of the TiO2NP.TMAOH particles in nitric acid, PAA was 
thermally annealed onto the nanoparticles in DMF, as described in section 2.4.2. Removal 
of DMF and unbound PAA from the TiO2 nanoparticles capped with PAA (TiO2NP.PAA, 
Figure 6.7) was reported to be achieved through precipitation of the particles with 
isopropanol.28 However, to avoid Fisher esterification between exposed carboxyl groups 
on the TiO2NP.PAA particles and isopropanol, precipitation with an excess of THF was 
attempted. Furthermore, removal of the DMF following the thermal annealing reaction 
was also attempted using rotary evaporation, as described in section 2.4.2.  
 
 
Figure 6.7 Schematic representation of PAA capped TiO2 nanoparticles (TiO2NP.PAA). 
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Figure 6.8 shows the TEM images of the TiO2NP.PAA nanoparticle samples in DMF 
following the thermal annealing of PAA (Figure 6.8 (A)). The TEM images of the 
TiO2NP.PAA particles precipitated with THF (Figure 6.8 (B)) or rotary evaporated 
(Figure 6.8 (C)) are also shown. Following the thermal annealing reaction of PAA onto the 
TiO2 particles in DMF the nanoparticles appeared stable and non-aggregated, with a 
diameter of ca. 4 nm (Figure 6.8 (A)). Although the nanoparticles were successfully 
precipitated upon addition of excess THF, the recovery of the nanoparticles was poor as no 
particles were observed during TEM imaging (Figure 6.8 (B)). Rotary evaporation was 
successful at removing the DMF following the thermal annealing reaction; however, the 
nanoparticles appeared to aggregate on drying, and dissolution in water was unsuccessful 
(Figure 6.8 (C)). The macroscopic TiO2NP.PAA aggregates present following rotary 
evaporation failed to redisperse in water even after 1 h of sonication.  
 
Figure 6.8 A) TEM image of TiO2NP.PAA following thermal annealing of PAA in DMF 
(scale bar is 20 nm). The nanoparticles were precipitated using excess THF 
and redissolved in water (B) or rotary evaporated and redissolved in water 
(C).(Scale bars in B and C are 100 nm). 
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6.2.2 Photocatalytic and sonocatalytic •OH generation by TiO2NP.TMAOH 
particles 
Preliminary attempts to remove the DMF and unbound PAA were largely unsuccessful, 
therefore it was decided that the photocatalytic activity of the TiO2NP.TMAOH particles 
would be investigated prior to further attempts to synthesise TiO2NP.PAA nanoparticles. It 
has been reported that coumarin-3-carboxylic acid (3-CCA) incorporated into polymeric 
nanoparticles can act as a fluorescent probe for sensing •OH species.30 3-CCA was initially 
used to monitor •OH production following UV irradiation (245 nm) of DMF in the absence 
or presence of TiO2NP.TMAOH particles, as described in section 2.4.4. When excited at 
367 nm, no fluorescence emission at 450 nm was observed in the 3-CCA solutions with or 
without nanoparticles. The lack of fluorescence was unexpected as 7-hydroxy-coumarin-3-
carboxylic acid, the product of the reaction between 3-CCA and •OH, exhibits a 
fluorescence emission band centred at 450 nm.30 Therefore methylene blue was explored 
as an alternative probe for •OH production. Methylene blue has been reported to be 
mineralised by •OH into CO2, water, sulphates and nitrates;31 and has therefore been used 
as a colorimetric probe for the detection of •OH species.32 The photocatalytic degradation 
of methylene blue by the UV irradiation (245 nm) of the TiO2NP.TMAOH particles was 
therefore investigated in water, as described in section 2.4.5. Figure 6.9 (A) shows that 
the UV irradiation (245 nm, 15 min) of aqueous methylene blue (10 µM) resulted in 
minimal degradation of the dye. However, in the presence of TiO2NP.TMAOH particles 
(Figure 6.9 (B)) the degradation of methylene blue is significantly enhanced, 
demonstrating the photocatalytic activity of the nanoparticles. Due to the light scattering 
by the TiO2NP.TMAOH particles, degradation of methylene blue was shown as the decay in 
the absorbance intensity at 664 nm (Figure 6.9 (C)). 
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Figure 6.9 UV-visible absorption spectra of the photocatalytic degradation of A) 
aqueous methylene blue (10 µM) and B) methylene blue (10 µM) in the 
presence of a 10% v/v dilution of TiO2NP.TMAOH particles upon 15 min UV 
irradiation (245 nm). C) Degradation of methylene blue shown as a decay in 
absorbance intensity at 664 nm following UV irradiation (254 nm) in the 
absence (black) or presence (red) of a 10% v/v dilution of TiO2NP.TMAOH 
particles. 
 
Exposure of TiO2 pellets to ultrasound irradiation has previously been reported to 
sonocatalytically enhance the degradation of aqueous methylene blue.33 Cavitation bubble 
collapse during ultrasound irradiation is thought to be responsible for the degradation of 
methylene blue following sonochemical •OH production.33 This was further supported by 
the observation that mannitol and dimethylsulfoxide (•OH scavengers) inhibited the 
sonocatalytic degradation of methylene blue.33  
An aqueous solution of methylene blue (10 µM) was exposed to ultrasound irradiation (1 
MHz, 0.5 W.cm-2) for 15 min, as described in section 2.4.6. The exposure of the methylene 
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blue to ultrasound resulted in the substantial degradation of the dye (Figure 6.10 (A)). 
However, the presence of the TiO2NP.TMAOH particles prevented any sonochemical 
degradation of methylene blue, thus indicating that the nanoparticles are ineffective for 
the sonocatalytic enhancement of •OH production (Figure 6.10 (B)). Absorption in the UV 
region of the spectra shown in Figure 6.10 (B) significantly increases upon ultrasound 
irradiation, as the TiO2NP.TMAOH particles are dispersed. Figure 6.10 (C) shows the 
decay in absorbance intensity at 664 nm following the sonochemical degradation of 
methylene blue in the absence or presence of the TiO2NP.TMAOH particles. 
 
 
Figure 6.10 UV-visible absorption spectra of the sonocatalytic degradation of A) aqueous 
methylene blue (10 µM) and B) methylene blue (10 µM) in the presence of a 
10% v/v dilution of TiO2NP.TMAOH particles following ultrasound 
irradiation (1 MHz, 0.5 W.cm-2). C) Degradation of methylene blue is shown 
as a decay in absorbance intensity at 664 nm upon ultrasound irradiation in 
the absence (black) and presence (red) of a 10% v/v dilution of 
TiO2NP.TMAOH particles. 
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6.2.3 In situ synthesis of PAA capped TiO2 particles 
Although methylene blue was found to be an effective colorimetric probe for sonochemical 
•OH generation, the TiO2NP.TMAOH particles appeared to have an inhibitory effect on the 
production of the radical. Chen et al.34 have previously reported the synthesis of TiO2 
nanoparticles in the presence of PAA. The PAA acts as both a chelator and a stabilising 
agent for the nanoparticles formed. This protocol was therefore adapted and used to 
synthesise TiO2NP.PAA nanoparticles in situ, as described in section 2.4.7, without the 
need for TMAOH. The butanol used in the reported protocol34 was replaced with THF to 
avoid Fisher esterification between the alcohol and the carboxyl groups of PAA.  
To compare the colloidal stability of the TiO2NP.PAA particles and the TiO2NP.TMAOH 
particles, both solutions were sonicated for 1 h then left to stand for 15 h. Figure 6.11 
shows that the TiO2NP.PAA particles synthesised in situ exhibited higher colloidal stability 
than the TiO2NP.TMAOH particles. The latter particles sedimented when left to stand for 
15 h. Therefore, the PAA plays an important role in nanoparticle stabilisation in addition 
to biocompatibility. 
 
Figure 6.11 Aqueous solutions of as-synthesised TiO2NP.TMAOH particles (left) and 
TiO2NP.PAA particles synthesised in situ (right). Following synthesis, the 
particles were dispersed by 1 h sonication then left to stand for 15 h.  
 
Dynamic light scattering (DLS) size analysis by intensity shows the relative intensities of 
the light scattering of particles, which is proportional to the sixth power of their diameter. 
The histograms in Figure 6.12 (A and B) show the size distribution by intensity of the 
TiO2NP.TMAOH particles and the TiO2NP.PAA particles, respectively. The size distribution 
of the aggregates is emphasised as a result of the increased intensity of light scattered by 
the aggregates, as compared to the smaller particle species. DLS analysis by number 
applies a spherical correlation function for the particles and corrects for the increased 
light scattering of larger particles. Therefore, the size approximation of non-spherical 
.TMAOH .PAA
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particles may not be accurate, although the number of the predominant particle species is 
more representative of the sample. DLS analysis by number revealed that both the 
TiO2NP.TMAOH particles and the TiO2NP.PAA particles have similar hydrodynamic 
diameters. The TiO2NP.TMAOH particles were mostly ca. 197.3 nm in diameter (Figure 
6.12 (C)). The TiO2NP.PAA particles were mostly ca. 189.9 nm in diameter, although the 
sample also contained a negligible amount of larger aggregates ca. 1.69 µm in diameter 
(Figure 6.12 (D)).  
 
 
Figure 6.12 A and B) DLS particle size analysis by intensity of a 1% v/v dilution of 
TiO2NP.T0MAOH particles TiO2NP.PAA particles, respectively, in water. C and 
D) DLS particle size analysis by number of the TiO2NP.T0MAOH particles 
TiO2NP.PAA particles, respectively. 
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Although both types of nanoparticles are present in clusters of ca. 190-200 nm in 
diameter, it is apparent that PAA provides the particles with a superior level of colloidal 
stability than TMAOH. The TEM images of the TiO2NP.TMAOH and TiO2NP.PAA particles 
(Figure 6.13 (A and B, respectively)) revealed that both types of particles exist as 
aggregates that are too large to be effectively used for the SDT treatment of cancer cells.  
 
 
Figure 6.13 TEM images of A) TiO2NP.TMAOH particles and B) TiO2NP.PAA particles in 
water. (Scale bars are 200 nm). 
 
6.2.4 Sonocatalytic singlet oxygen and •OH generation by TiO2NP.PAA particles 
To explore the potential of singlet oxygen production upon the ultrasound irradiation of 
water, an aqueous solution of the singlet oxygen probed ADPA (100 µM) was exposed to 
15 min of ultrasound irradiation (1 MHz, 0.5W.cm-2), as described in section 2.4.9. As can 
be seen from Figure 6.14 (A), the absorbance intensity of ADPA decreases upon the 
ultrasound irradiation of water indicating that singlet oxygen was being produced. The 
stock solution of ADPA used (1.7 mM) was prepared in methanol. Methanol is a known 
scavenger for •OH, therefore the observed decay in ADPA absorbance is likely to be due to 
singlet oxygen production rather than degradation by radicals such as •OH.35 In the 
presence of the TiO2NP.PAA particles the photobleaching of ADPA was enhanced (Figure 
6.14 (B)). The enhanced photobleaching of ADPA in the presence of the particles suggests 
that the TiO2NP.PAA sample acts as a sonocatalyst for singlet oxygen production (Figure 
6.14 (C)). The photobleaching of ADPA is shown as the decay in absorbance intensity at 
400 nm, as the TiO2NP.PAA sample also contributes to the overall absorption at 400 nm.  
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Figure 6.14 Photobleaching of ADPA (100 µM from 1.7 mM stock in methanol) upon 
ultrasound irradiation (1 MHz, 0.5 W.cm-2) of A) water or B) a 10% v/v 
dilution of TiO2NP.PAA particles in water. C) Photobleaching of ADPA is 
shown as a decay in the absorbance intensity at 400 nm in the absence 
(black) or presence (red) of TiO2NP.PAA particles in water following 
ultrasound irradiation. 
 
To confirm that the photobleaching of ADPA was as a result of cavitation bubble collapse 
in water, and the consequent generation of singlet oxygen, the experiment was repeated in 
methanol (in the absence of water), as described in section 2.4.9. As can be seen from 
Figure 6.15, no decay of ADPA absorption occurs in the absence or presence of the 
TiO2NP.PAA particle solutions in methanol (A or B, respectively). This confirms that the 
sonochemical photobleaching of ADPA is a process that is dependent on the ultrasonic 
irradiation of water that can be further enhanced by the presence of the TiO2NP.PAA 
particles. Figure 6.15 (C) shows the minimal changes in the ADPA absorbance intensity at 
400 nm following ultrasound irradiation in the absence and presence of the TiO2NP.PAA 
particles. It is likely that the enhancement in ADPA photobleaching, and therefore singlet 
oxygen production, is the result of a combination of sonoluminescent activation of the 
TiO2NP.PAA particles leading to the photogeneration of ROS, in addition to the increased 
rate of cavitation at the surface of the particles. 
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Figure 6.15 Changes in the UV-visible absorption bands of ADPA (100 µM) upon 
ultrasound irradiation (1 MHz, 0.5 W.cm-2) of A) methanol or B) a 10% v/v 
dilution of TiO2NP.PAA particles in methanol. C) Changes in ADPA 
absorbance intensity at 400 nm with (red) and without the TiO2NP.PAA 
particles (black) in methanol upon ultrasound irradiation.  
 
To confirm that methanol was acting as a selective scavenger for •OH, and therefore singlet 
oxygen was responsible for the decay in the absorption of ADPA, two aqueous solutions 
were prepared each containing both ADPA (100 µM) and methylene blue (10 µM). One of 
the combined ADPA-methylene blue samples was prepared using a methanol stock 
solution of ADPA (1.7 mM) and the second sample was prepared using an aqueous stock 
solution of ADPA (1.7 mM). Both solutions were exposed to 15 min of ultrasound 
irradiation (1 MHz, 0.5 W.cm-2), as described in section 2.4.10. When using a methanol 
stock solution of ADPA (Figure 6.16 (A)) the absorption of ADPA decreases upon 
ultrasound exposure, although there is no decay in the absorbance intensity of methylene 
blue. When using an aqueous stock solution of ADPA (Figure 6.16 (B)) the absorption of 
both ADPA and methylene blue decreases upon exposure to ultrasound irradiation. This 
confirms that methanol prevents radical attack of either methylene blue or ADPA, and that 
the ADPA photobleaching observed is a result of singlet oxygen production.  
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Figure 6.16 Ultrasound irradiation (1 MHz, 0.5 W.cm-2) of combined solutions containing 
both ADPA (100 µM) and methylene blue (10 µM) prepared using either A) a 
methanol stock solution of ADPA or B) an aqueous stock solution of ADPA. 
 
The enhancement in the sonochemical photobleaching of ADPA by the presence of the 
TiO2NP.PAA particles was also investigated using either a methanol or aqueous stock 
solution of ADPA, as described in section 2.4.10. In the absence of methanol, a greater 
decay in ADPA absorption was observed than when using a methanol stock solution of 
ADPA (Figure 6.17). This difference could be attributed to the small quantity of methanol 
present (5.88% v/v) when using a methanol stock solution of ADPA to prepare the 
samples. The presence of methanol could decrease the surface tension of the water, 
thereby increasing the threshold for acoustic cavitation.36 In both instances, the 
TiO2NP.PAA particles enhanced the photobleaching of ADPA upon ultrasound irradiation 
showing that the particles contributed to the sonochemical generation of singlet oxygen. 
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Figure 6.171 Decay in absorbance intensity at 400 nm following ultrasound irradiation (1 
MHz, 0.5 W.cm-2) of an aqueous solution of ADPA (100 µM) prepared using a 
methanol (dash) or aqueous (line) ADPA stock solution, in the absence 
(black) or presence (red) of a 10% v/v dilution of TiO2NP.PAA particles. 
 
6.2.5 In situ synthesis of monodisperse PAA capped TiO2 nanoparticles 
Although it was shown that TiO2NP.PAA particles can enhance the sonochemical 
generation of singlet oxygen, the nanoparticles synthesised in situ described in section 
6.2.3 were aggregated and had a hydrodynamic diameter of ca. 190 nm. The synthesis 
procedures of TMAOH capped and PAA capped TiO2 nanoparticles described in sections 
2.4.1 and 2.4.7, respectively, involve the rapid addition of titanium (IV) butoxide to 
aqueous solutions of the capping agents. It was thought that the controlled hydrolysis of 
the titanium (IV) butoxide by the dropwise addition of water would yield non-aggregated, 
monodisperse nanoparticles. A THF solution of titanium (IV) butoxide and PAA was 
prepared, as described in section 2.4.11. The same molar ratios of titanium (IV) butoxide 
to PAA used for the in situ synthesis of TiO2NP.PAA particles in section 6.2.3 were 
maintained. However the reaction was performed using a 30-fold dilution of all the 
reactants to enable complete solubilisation of PAA. Water was then added dropwise to 
gradually initiate the hydrolysis of the titanium (IV) butoxide in the presence of PAA to 
form dispersed TiO2 nanoparticles capped with PAA (TiO2NP.PAA (x/30)). The resultant 
nanoparticle preparation appeared transparent with no visible sedimentation of 
nanoparticle aggregates (Figure 6.18 (A)). The TEM image of the TiO2NP.PAA (x/30) 
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nanoparticles (Figure 6.18 (B)) shows that the samples were mostly non-aggregated with 
a mean diameter of 65.67 ± 8.73 nm (mean ± 95% confidence interval; n = 20). However, 
the resolution of the TEM image was low at the magnification used, possibly due to the 
presence of unbound PAA. DLS analysis by intensity (Figure 6.18 (C)) reveals the 
presence of aggregates at 207.9 nm and 477.5 nm. DLS analysis by number (Figure 6.18 
(D)) shows that the hydrodynamic diameter of 98% of the nanoparticles was 62.75 nm 
with a polydispersity index of 0.462, which agrees with the size determined by TEM 
imaging. However, 1.6% and 0.4% of the sample were found to be aggregates with 
approximate hydrodynamic diameters of 194.9 nm and 466.2 nm, respectively. These 
aggregates could eventually be removed by centrifugation or filtration using a 220 nm 
syringe driven filter unit. 
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Figure 6.18 A) Photograph, B) TEM image (Scale bar is 500 nm), C) DLS size analysis by 
intensity and D) DLS size analysis by number of the as-synthesised 
TiO2NP.PAA (x/30) nanoparticles in water.  
 
Hydrodynamic 
Diameter (nm)
Number 
(%) Width (nm) 
Peak 1 466.2 0.4 90.29
Peak 2 194.9 1.6 48.23
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Removal of unbound PAA (1.8 kDa) was initially attempted by repeated ultrafiltrations 
using VivaspinTM 20 tubes with a molecular weight cut-off of 30 kDa, as described in 
section 2.4.12. The UV-visible absorption spectra shown in Figure 6.19 (A) show the 
absorption profiles of the filtrates of the VivaspinTM 20 tubes during 5 ultrafiltration 
cycles. Some free PAA was still observed in the fifth filtrate as determined by the 
absorbance at ca. 217 nm, therefore the nanoparticles were subject to a further 5 cycles of 
ultrafiltration. However, following the sixth filtration, aggregates of the TiO2NP.PAA (x/30) 
nanoparticles were observed. Additionally, the nanoparticles themselves were found in 
the sixth filtrate, as confirmed by the absorption band centred at ca. 270 nm (Figure 6.19 
(B)). The particles were not sufficiently stable for the complete removal of unbound PAA 
using ultrafiltration, therefore an alternative purification procedure was explored. 
 
 
Figure 6.19 UV-visible absorption spectra of a solution of TiO2NP.PAA (x/30) 
nanoparticles during A) 5 ultrafiltrations using a VivaspinTM 20 (30 kDa 
MWCO, PES), followed by B) a further 5 ultrafiltrations of TiO2NP.PAA (x/30). 
The arrow shown in B highlights the absorption profile of TiO2NP.PAA (x/30) 
nanoparticles following 10 cycles of ultrafiltration. 
 
Removal of free PAA was then attempted by gel filtration chromatography using PD-10 
desalting columns, which have a molecular weight cut off of 5 kDa. As synthesised 
TiO2NP.PAA (x/30) nanoparticles were concentrated to ca. 2.5 ml from ca 100 ml, as 
described in section 2.4.12, and loaded onto the PD-10 desalting columns. By monitoring 
the UV-visible absorption spectra of each eluent, it was apparent that fractions 2, 3 and 4 
contained the highest nanoparticle content (Abs270 nm ≥ 1.5). Following three cycles of gel 
filtration chromatography using the PD-10 desalting columns it was apparent that the 
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separation resolution of the PD-10 columns was too low for the efficient separation of 
unbound PAA from the TiO2NP.PAA (x/30) nanoparticles. Both PAA (217 nm, Figure 6.20 
(A)) and the TiO2NP.PAA (x/30) nanoparticles (270nm, Figure 6.20 (B)) were found to be 
in the same elution fractions in all three cycles of gel filtration. 
 
Figure 6.20 The PAA content (A, 217 nm) and the TiO2NP.PAA (x/30) nanoparticle 
content (B, 270 nm) in the elution fractions of the first (black), second (red) 
and third (blue) cycles of gel filtration using a PD-10 desalting column.  
 
In order to increase the resolution of separation, Sephadex® G-25 (5 kDa MWCO) was 
packed into a 300 x 14 mm column and the crude concentrated nanoparticle mixture was 
loaded onto the Sephadex® G-25 column, as described in section 2.4.12. It was thought 
that the greater separation distance of the 300 x 14 mm Sephadex® G-25 column would 
enhance the separation efficiency, as compared to the 15 x 14 mm PD-10 desalting 
column. The graph shown in Figure 6.21 (A) reveals that PAA is retained by the 
Sephadex® G-25 column for longer than the PD-10 column. Figure 6.21 (B) shows that the 
nanoparticle content in the elution fractions decreased as the particles were eluted from 
the column, whilst the PAA content remained high until the end of the first cycle of gel 
filtration. Elution fractions 4-8 with the highest nanoparticle content (Abs270 nm ≥ 1.5) were 
pooled, concentrated, and loaded onto the Sephadex® G-25 column once more. Figure 
6.21 (C) shows that by elution fraction 12 of the second cycle of gel filtration, the 
absorbance intensity of the PAA (217 nm) and the nanoparticles (270 nm) was similar. 
The little difference observed between the content of PAA and the nanoparticles suggests 
that two cycles of gel filtration may be sufficient for the removal of the majority of the 
unbound PAA from the TiO2NP.PAA (x/30) nanoparticles. 
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Figure 6.21 A) Improved retention of PAA on the Sephadex® G-25 column as compared to 
the PD-10 column, as determined by the absorbance at 217 nm. The 
nanoparticle content (270 nm) and the PAA content (217 nm) in the 12 
elution fractions of first (B) and second (C) cycles of gel filtration are shown. 
The blue arrows in A) and B) highlight the retention of the PAA on the gel 
filtration columns. 
 
To investigate the sonocatalytic enhancement of singlet oxygen generation by the purified 
TiO2NP.PAA (x/30) nanoparticles, an aqueous solution of ADPA (100 µM) was exposed to 
ultrasound irradiation (1 MHz, 0.5 W.cm-2) in the presence of a 10% v/v dilution of the 
purified nanoparticles (section 2.4.13). Figure 6.22 (A) demonstrates the effective 
photobleaching of an aqueous solution of ADPA following ultrasound irradiation. In the 
presence of the purified TiO2NP.PAA (x/30) nanoparticles, the rate of ADPA 
photobleaching is considerably enhanced (Figure 6.22 (B)). The decay in ADPA 
absorbance at 400 nm is shown in Figure 6.22 (C) following the sonochemical 
photobleaching of the probe in the absence and presence of the nanoparticles.  
 
1 2 3 4 5 6 7 8 9 10 11 12
0
1
2
3
4
5
A
b
s
o
rb
a
n
c
e
Elution Fraction
 PAA - Abs 217 nm
 TiO2 - Abs 270 nm
1 2 3 4 5 6 7 8 9 10 11 12
0
1
2
3
4
5
A
b
s
o
rb
a
n
c
e
Elution Fraction
 PAA - Abs217 nm
 TiO2 - Abs270 nm
1 2 3 4 5 6 7 8 9 10 11 12
0
2
4
6
8
10
A
b
s
 2
1
7
 n
m
Elution Fraction
 PD-10 Column - Elution Set 1
 Sephadex
®
 G-25 Column - Elution Set 1
B
A
C
  
239 
 
 
Figure 6.22 Photobleaching of ADPA (100 µM from 1.7 mM aqueous stock) upon 
ultrasound irradiation (1 MHz, 0.5 W.cm-2) of A) water or B) a 10% v/v 
dilution of TiO2NP.PAA (x/30) nanoparticles in water purified using a 
Sephadex® G-25 column. C) Photobleaching of ADPA shown as a decay in 
absorbance intensity at 400 nm in the absence (black) or presence (red) of 
TiO2NP.PAA (x/30) nanoparticles in water upon ultrasound irradiation. 
 
To explore the effect of the presence of the purified TiO2NP.PAA (x/30) nanoparticles on 
the sonochemical degradation of methylene blue, an aqueous solution of the dye was 
exposed to ultrasound irradiation in the absence or presence of a 10% v/v dilution of the 
purified nanoparticles, as described in section 2.4.13. The spectrum of the methylene 
blue solution containing the nanoparticles shows that the dye is sonochemically degraded 
during the 15 min of ultrasound irradiation (Figure 6.23 (A)). However, the presence of 
the particles has an inhibitory effect on the degradation of methylene blue (Figure 6.23 
(B)). This could be attributed to the quenching of •OH by the PAA coating on the particle 
surface.  
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Figure 6.23 A) UV-visible absorption spectrum of an aqueous solution of methylene blue 
(10 µM) in the presence of a 10% v/v dilution of the purified TiO2NP.PAA 
(x/30) nanoparticles exposed to 15 min ultrasound irradiation (1 MHz, 0.5 
W.cm-2). B) Decay in the methylene blue absorbance intensity at 664 nm 
following the ultrasound irradiation of water in the absence (black) or 
presence (red) of the nanoparticles.  
 
Scanning electron microscopy (SEM) was used to investigate the morphology of the 
purified TiO2NP.PAA (x/30) nanoparticles, as described in section 2.4.14. The images in 
Figure 6.24 (A and B) are secondary electron images, also known as topical contrast 
images, that analyse the outer surface of the sample. It is clear that following purification, 
there is still a considerable matrix of PAA embedded with the TiO2NP.PAA (x/30) 
nanoparticles. Thus the surface morphology of the nanoparticles cannot be seen. Complete 
removal of unbound PAA can be attempted using density gradient centrifugation which 
separates the nanoparticles from the free capping polymer. 
The image shown in Figure 6.24 (C) is a secondary electron image of the purified 
nanoparticles in HEPES buffered saline. Numerous surface spots were visible, which 
preliminarily appeared to be the nanoparticles. Backscatter electron imaging (chemical 
contrast imaging) was performed on the nanoparticle sample in HEPES buffered saline 
(Figure 6.24 (D)). Electron dense materials, such as TiO2, appear brighter when using 
backscatter electron imaging. The surface spots observed in Figure 6.24 (C) did not 
correlate with the regions of high electron density in the backscatter electron image 
(Figure 6.24 (D)), suggesting that the surface spots were an artefact of the dried buffer. 
However, the bright regions in Figure 6.24 (D) suggest that the TiO2NP.PAA (x/30) 
nanoparticles are embedded within the matrix of dried buffer.  
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Figure 6.24 SEM images of the purified TiO2NP.PAA (x/30) nanoparticles. A and B) are 
secondary electron images (topical contrast images) of the purified 
TiO2NP.PAA (x/30) nanoparticles in water. C) Secondary electron images 
(topical contrast images) of the purified TiO2NP.PAA (x/30) nanoparticles in 
HEPES buffered saline (10 mM, 150 mM NaCl, pH 7.4). D) Backscatter 
electron images (chemical contrast images) of the nanoparticle sample 
shown in (C). 
 
To confirm the presence of TiO2 within the purified nanoparticle sample, elemental 
analysis of the purified TiO2NP.PAA (x/30) nanoparticle sample in water was performed 
using the Energy Dispersive X-ray Analysis (EDXA) function of the SEM (Figure 6.25). The 
analysis confirmed the strong presence of Ti and C originating from the TiO2 nanoparticles 
and the organic PAA capping polymer, respectively. The presence of Au in the EDXA 
analysis is attributed to the gold coating used in the preparation of the samples prior to 
SEM imaging.  
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Figure 6.25 Elemental analysis of a purified sample of TiO2NP.PAA (x/30) nanoparticles 
performed using the EDXA function of the SEM microscope. 
 
The resolution of the TEM images of the unpurified TiO2NP.PAA (x/30) nanoparticles was 
low (Figure 6.18), as the presence of the excess PAA was likely to impair the focus of the 
nanoparticles within the TEM imaging grid. TEM imaging was therefore performed on the 
purified TiO2NP.PAA (x/30) nanoparticles, as described in section 2.4.14. The TEM image 
in Figure 6.26 revealed that the nanoparticles remain largely non-aggregated following 
purification and had a mean diameter of 57.43 ± 11.29 nm (diameter ± 95% confidence 
interval; n = 20). The nanoparticles were not colloidal, but appeared irregular in 
morphology with a mixture of cubed, cuboidal and prismal structures. The resolution of 
the TEM images was vastly improved following purification and removal of the unbound 
PAA. Nanoparticle deterioration is also shown in Figure 6.26, which was observed 
following prolonged exposure to the electron beam.  
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Figure 6.26 TEM image of a purified sample of TiO2NP.PAA (x/30) in HEPES buffered 
saline (10 mM, 150 mM NaCl, pH 7.4). (Scale bar is 100 nm). 
 
 6.2.6 In vitro SDT of HT-29 cells using TiO2 nanoparticles 
Prior to exploring the in vitro sonodynamic efficacy of the TiO2 nanoparticles, the 
tolerance of HT-29 cells to an ultrasonic field was evaluated by exposing the cells to 0, 15, 
30 or 60 s of ultrasound irradiation (1 MHz, 0.5 W.cm-2). HT-29 cell viability was assessed 
using the MTT assay following ultrasound irradiation, as described in section 2.4.15 
(Figure 6.27). Exposure of the HT-29 cells to 15 s or 30 s of ultrasound irradiation 
reduced cell viability by ca. 8.1%. However, when exposed to 60 s of ultrasound 
irradiation, a ca. 18.4% reduction in viability was observed. It was therefore decided that 
30 s of ultrasound exposure would be sufficient, as a previous study observed a significant 
sonodynamic reduction in C32 melanoma cell viability when incubated with TiO2 
nanoparticles and exposed to 1 MHz ultrasound at 0.5 W.cm-2 for 10 s.25 
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Figure 6.27 MTT viability assay following the ultrasound irradiation (1 MHz, 0.5 W.cm-2) 
of HT-29 cells in 6 well multidishes for a duration of 15, 30 and 60 s. The 
cells were kept in RPMI 1640 medium supplemented with 1.5 mM L-
glutamine (L-Gln) and 10% foetal bovine serum (FBS). +St refers to 
incubation with 2 µM Staurosporine, which was used as a positive control for 
cytotoxicity. (Error bars are ± 95% confidence intervals). 
 
The attenuation of ultrasound frequency by different sizes of multidishes was examined 
using solutions of ADPA in RPMI 1640 medium, supplemented with 1.5 mM L-Gln and 
10% FBS, as described in section 2.4.16. Figure 6.28 shows that ADPA photobleaching 
following 15 min ultrasound irradiation was significantly enhanced when a 48 well 
multidish was used rather than a 6 well multidish. Therefore, the 48 well multidishes were 
used for the subsequent in vitro SDT treatment of the HT-29 cells. This difference in ADPA 
photobleaching could be due to the difference in depth of the medium within the wells 
exposed to the ultrasound, which is significantly greater when using the 48 well 
multidishes. A greater depth of the irradiated RPMI medium resulted in the exposure of a 
greater proportion of the medium to the ultrasonic field, which lead to an observable 
increase in microbubble formation and consequent ADPA photobleaching. 
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Figure 6.28 Comparison of the attenuation of ultrasound frequency through A) 6 well 
and B) 48 well multidishes following 15 min ultrasound irradiation (1 MHz, 
0.5 W.cm-2) of ADPA (100 µM) in RPMI 1640 medium supplemented with 1.5 
mM L-Gln and 10% FBS. C) The photobleaching of ADPA in 6 well (blue) or 48 
well (red) multidishes is shown as a decay in absorbance intensity at 400 
nm. 
 
HT-29 cells seeded onto 48 well multidishes were incubated with 0.29, 0.74 and 1.47 mM 
TiO2 equivalent of purified TiO2NP.PAA (x/30) nanoparticles and exposed to 30 s of 
ultrasound irradiation (1 MHz, 0.5 W.cm-2), as described in section 2.4.17. The 
approximate concentrations of TiO2 equivalent were calculated based on the assumption 
that all the titanium (IV) butoxide reacted during the synthesis. This assumption was 
made based on the fact that the water (5.56 moles) was present in a substantial molar 
excess of the titanium (IV) butoxide (3.53x10-5 moles) during the hydrolysis stage. 
Typically, the concentration of TiO2 nanoparticles could be determined using the 
extinction coefficient of the particles. However, the extinction coefficient of TiO2 
nanoparticles is dependent on the particle diameter and the dispersity of the particles is 
critical. As the TiO2NP.PAA (x/30) nanoparticle samples prepared in this chapter contain a 
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small proportion of aggregates, the determination of nanoparticle concentration using UV-
visible absorption spectrophotometry would be unreliable. To accurately evaluate the 
concentration of TiO2 present within the nanoparticle preparations elemental analysis of 
the titanium in the nanoparticle solutions can be quantified using ICP-OES analysis. 
The results of the MTT viability assay in Figure 6.29 show that in the absence of 
nanoparticles, cell viability is reduced to ca. 74% following ultrasound irradiation. The 
decrease in cell viability can be attributed to a combination of sonodynamic ROS 
generation and shear mechanical stresses. A dose-dependent cytotoxicity of the HT-29 
cells was observed with increasing concentrations of the TiO2NP.PAA (x/30) 
nanoparticles, both with and without ultrasound irradiation. When incubated with 0.29, 
0.74 and 1.47 mM TiO2 equivalent of nanoparticles without ultrasound irradiation, 
viability is reduced to ca. 91%, 73% and 58%, respectively. Following ultrasound 
exposure, cell viability of HT-29 cells incubated with 0.29, 0.74 and 1.47 mM TiO2 
equivalent of nanoparticles was at ca. 94%, 76% and 63%, respectively. Therefore, it was 
suggested that the reduction in viability was the direct result of nanoparticle toxicity. 
These findings suggest that the incubation of the TiO2NP.PAA (x/30) nanoparticles with 
the HT-29 cancer cells followed by the removal of unbound or non-internalised particles is 
ineffective at inducing sonodynamic cytotoxicity. The degree of association or 
internalisation of the nanoparticles by the HT-29 cells is unknown; therefore conclusions 
regarding the efficiency of intracellular SDT cannot be made. Findings of a previously 
reported study suggest that the extracellular localisation of a porphyrin 
photo/sonosensitiser (ATX-70) is critical for sonodynamic cell death.37 This dependence 
on extracellular sonosensitisation is likely to be due to the lack of evidence for 
intracellular acoustic cavitation required for intracellular sonodynamic activation of 
sonosensitisers.12 Therefore, it is possible that an enhancement in the ultrasound induced 
cytotoxicity could be observed if the cells were exposed to ultrasound irradiation without 
the removal of the TiO2 nanoparticles present extracellularly.37 
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Figure 6.29 MTT viability assay of HT-29 cells following SDT treatment using 0.29, 0.74 
and 1.47 mM TiO2 equivalent of TiO2NP.PAA (x/30) nanoparticles. The cells 
were either irradiated with 30 s of ultrasound (1 MHz, 0.5 W.cm-2; white) or 
non-irradiated (black). +St refers to incubation with 2 µM Staurosporine, 
which was used as a positive control for cytotoxicity. Cells not incubated 
with nanoparticles irradiated with 30 s of ultrasound (1 MHz, 0.5 W.cm-2) 
were used as a control. (Error bars are ± 95% confidence intervals). 
 
6.3 Conclusions 
In this chapter, the successful synthesis of colloidally stable TiO2 nanoparticles capped 
with PAA was described. Initially the TiO2 nanoparticles capped with TMAOH were 
synthesised and the thermal surface annealing of PAA in DMF was performed. Removal of 
the DMF and the unbound PAA was attempted, but recovery of dispersed nanoparticles 
was unsuccessful. Using an adapted version of a previously reported protocol,34 PAA 
capped TiO2 nanoparticles were synthesised in situ through the controlled hydrolysis of 
titanium (IV) butoxide in the presence of the capping polymer. The resultant nanoparticles 
appeared largely monodisperse and had a mean diameter of ca. 57 nm, as determined by 
TEM imaging and DLS size analysis. Elemental analysis using the EDXA function of the SEM 
microscope also confirmed the presence of titanium within the purified nanoparticle 
preparations.  
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The effect of ultrasound irradiation (1 MHz) on water was investigated using the singlet 
oxygen molecular probe ADPA and the dye methylene blue. Methylene blue has been 
previously shown to degrade in aqueous solutions exposed to ultrasound irradiation 
through sonochemically generated •OH species.33 It was shown that the sonochemical 
degradation of methylene blue is completely inhibited by the presence of 5.88% v/v 
methanol, a known scavenger for •OH. The presence of the TiO2 nanoparticles strongly 
inhibited the degradation of methylene blue, possibly due to •OH quenching by the PAA 
coating. The predominant ROS species produced by the photoexcitation of TiO2 
nanoparticles are H2O2, •O2
- and •OH.19 To maximise the therapeutic outcome of 
sonodynamic TiO2 activation, the use of an alternative capping agent that doesn’t quench 
•OH species, yet retains the capacity for biofunctionalisation, could be explored.  
ADPA was used to detect sonochemically generated singlet oxygen, which has been 
observed in air saturated solutions exposed to ultrasound.5 The degradation of ADPA by 
sonochemically generated •OH was not likely as the sonochemical decay of the ADPA 
absorbance intensity occurred even in the presence of the •OH scavenger, methanol. The 
presence of the TiO2 nanoparticles enhanced the photobleaching of ADPA during 
ultrasound irradiation, both in the absence and presence of 5.88% v/v methanol. The 
findings described herein suggest that the TiO2 nanoparticles stabilised with PAA can 
effectively enhance the generation of singlet oxygen upon ultrasound irradiation, as 
confirmed by the photobleaching of the singlet oxygen molecular probe ADPA. Conversely, 
the presence of the nanoparticles prevents ultrasound induced •OH degradation of 
methylene blue, possibly through quenching of the radical by the PAA coating. Methylene 
blue has been reported to electrostatically adsorb onto PAA coated nanoparticles, 
suggesting that the capping polymer plays a protective role against radical degradation of 
the dye.38 
HT-29 colon adenocarcinoma cells exhibited a ca. 26% reduction in viability following 30 s 
of ultrasound irradiation (1 MHz, 0.5W.cm-2). The ultrasound irradiation of the cells 
incubated with ca. 0.29, 0.74 and 1.47 mM TiO2 equivalent of TiO2NP.PAA (x/30) 
nanoparticles showed no significant enhancement in sonodynamic cytotoxicity, as 
compared to the cells not exposed to ultrasound irradiation. Incubation of the HT-29 cells 
with the nanoparticles, without exposure to ultrasound, resulted in a noticeable dose-
dependent decrease in cell viability (ca. 9-42% reduction). Although no in vitro 
sonodynamic effect on the HT-29 cells was observed with the TiO2 nanoparticles, further 
investigations into the association or internalisation of the nanoparticles within the 3 h 
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incubation period should be performed. Furthermore, the cells were washed to remove 
unbound nanoparticles prior to ultrasound irradiation and therefore no extracellular 
particles were present during the exposure of the cells to ultrasound. Reports on SDT 
suggest that acoustic cavitation occurs extracellularly, and that the extracellular presence 
of the sonosensitiser is critical for effective sonodynamic toxicity.12,37 
In conclusion, the synthesis and characterisation of monodisperse TiO2 nanoparticles 
coated with a biocompatible polymer, PAA, is described. Multiple carboxylic acid groups 
provide the nanoparticles with electrostatic stability, in addition to the potential of further 
biofunctionalisation. Ultrasound exposure of aqueous solutions of the nanoparticles 
appears to enhance the sonochemical generation of singlet oxygen, whilst inhibiting 
sonochemically produced •OH species. The in vitro SDT treatment of HT-29 cells incubated 
with the TiO2 nanoparticles showed no sonodynamic effect at the conditions of the 
experiment described. Further investigations of extracellular SDT could provide results 
that are consistent with those reported. Sonodynamic therapy using TiO2 nanoparticles 
and ultrasound waves with optimal tissue penetration could prove to be invaluable for the 
treatment of solid tumours where visible or near-infrared light cannot typically reach 
during PDT treatment. Furthermore, bioconjugated TiO2 nanoparticles could provide 
enhanced tumour selectivity for the sonodynamic destruction of cancerous tissue. 
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Chapter 7 
Conclusions and Future Work 
This thesis describes the use of biofunctionalised nanoparticles for the targeted 
photodynamic therapy of cancer. The conclusions of the investigations into the efficacy of 
lectins as cancer-specific targeting agents for PDT using phthalocyanine-PEG gold 
nanoparticles are summarised in this chapter. Additionally, the findings of the 
comparative study using lectins and antibodies as targeting ligands are outlined. 
Furthermore, the potential use of titanium dioxide nanoparticles for sonodynamic cancer 
therapy is discussed. Suggestions for future work are highlighted. 
 
7.1 Con A targeted PDT – proof-of-concept 
In Chapter 3 citrate capped gold nanoparticles, ca. 16 nm in diameter, were functionalised 
with the lectin Concanavalin A (Con A) and its dimeric derivative succinyl-Concanavalin A 
(S-Con A) for the colorimetric labelling of breast cancer cells. Conjugation of the lectins to 
the nanoparticles was initially achieved using the heterobifunctional linker 3-(2-
pyridyldithio)propionic acid N-hydroxysuccinimide ester (SPDP). The stability of the 
nanoparticle conjugates during a 1 h incubation period with the MCF-7 and SK-BR-3 
human breast adenocarcinoma cells at 37 °C was found to be dependent on the type of 
lectin. Using a nanoparticle concentration of 8.46 nM, the Con A functionalised 
nanoparticles were shown to be significantly less stable than the S-Con A functionalised 
particles, which showed no signs of aggregation. Additionally, the concentration of the 
nanoparticle conjugates used also had a direct impact on the stability of the particles. At 
lower nanoparticle concentrations of 0.25, 0.50 or 1.00 nM, 1 h incubation of the Con A 
functionalised nanoparticles with the MCF-7 cells at 37 °C did not result in particle 
aggregation. Overall, the nanoparticles conjugated to Con A or S-Con A through the SPDP 
linker were unable to successfully label the MCF-7 or SK-BR-3 cells. 
To prevent nanoparticle aggregation, citrate capped gold nanoparticles were modified 
using a heterobifunctional polyethylene glycol linker (PEG). Conjugation of the lectins to 
the PEG modified gold nanoparticles was then achieved using covalent amide coupling. 
During a 24 h incubation period with the MCF-7 cells at 37 °C the Con A functionalised PEG 
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modified nanoparticles (0.25, 0.50 or 1.00 nM) were remarkably stable. The exceptional 
colloidal stability of the lectin-PEG gold nanoparticle conjugates demonstrated the 
importance of the PEG modification of gold nanoparticles for use in cell-based assays at 
physiological conditions. However, the Con A functionalised PEG gold nanoparticles were 
not able to colorimetrically label the MCF-7 breast cancer cells, possibly due to the lack of 
sensitivity of the inverted optical microscopy technique. 
By using a formazan-based colorimetric cytoadhesion assay, the binding efficiency of MCF-
7 cells to Con A adsorbed onto the wells of a 96 well multidish was found to be 
approximately 2-fold higher than to the S-Con A derivatised wells. MCF-7 cell binding to 
the sheep serum albumin (SSA) control wells was significantly lower than that to the Con 
A or S-Con A derivatised wells, thus suggesting that cell binding to the lectins was due to 
specific cell glycan recognition. Since the MCF-7 cells bound to the Con A with a 
significantly higher binding efficiency, Con A was selected as a cancer targeting ligand to 
deliver gold nanoparticles carrying the zinc phthalocyanine photosensitiser, C11Pc, for the 
targeted PDT treatment of breast cancer cells. 
Gold nanoparticles, ca. 4 nm in diameter, were functionalised with the hydrophobic C11Pc 
photosensitiser and amphiphilic PEG derivative molecules as previously reported.1 The 
method was further adapted to covalently conjugate Con A to the C11Pc-PEG gold 
nanoparticles. By using the singlet oxygen molecular probe, anthracene-9,10-dipropionic 
acid disodium salt (ADPA), the nanoparticles were shown to effectively produce singlet 
oxygen both with and without Con A conjugation upon irradiation at 633 nm. MCF-7 and 
SK-BR-3 human breast cancer cells were used to investigate the targeted PDT efficacy of 
Con A conjugated C11Pc-PEG gold nanoparticles. Following a 24 h incubation period of the 
MCF-7 cells with the nanoparticle conjugates (0.00-1.44 µM C11Pc equivalent) and 10 min 
irradiation at 633 nm, the colorimetric MTT viability assay revealed that Con A 
conjugation provided no enhancement in the phototoxicity of the MCF-7 cells, as 
compared to the non-conjugated nanoparticles. The fluorometric CellTiter-BlueTM viability 
assay was utilised to assess the viability of SK-BR-3 cells following Con A targeted PDT 
treatment, as the solublisation step required during the MTT assay resulted in a noticeable 
variation in the results. However, no significant enhancement in phototoxicity of the SK-
BR-3 cells was observed, as compared to the non-conjugated particles. Con A was found to 
be unsuitable as a targeting ligand to selectively deliver C11Pc-PEG gold nanoparticles to 
the MCF-7 or SK-BR-3 breast cancer cells. However, an effective methodology was 
established through which potentially any lectin could be covalently conjugated to 
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nanoparticles carrying C11Pc and PEG molecules to generate singlet oxygen, and hence 
potentially induce cytotoxicity, upon irradiation at 633 nm. The revised nanoparticle 
synthetic method described in Chapter 4 yielded C11Pc-PEG gold nanoparticles with a 
higher C11Pc loading efficiency. It is possible that Con A conjugation to the C11Pc-PEG 
gold nanoparticles with a higher C11Pc loading efficiency may enable positive cell kill 
results. 
 
7.2 Targeting the T antigen for selective PDT treatment 
In Chapter 4 the lectin jacalin was covalent conjugated to C11Pc-PEG gold nanoparticles 
using EDC/NHS chemistry. Jacalin was used to target the cancer-associated Thomsen-
Friedenreich (T) antigen at the surface of HT-29 human colon adenocarcinoma cells. 
Incubation with the jacalin conjugated C11Pc-PEG gold nanoparticles caused no significant 
difference in the viability of the irradiated or non-irradiated HT-29 cells. However, a dose-
dependent inhibition in proliferation was observed. This observation was in agreement 
with findings that reported similar effects on HT-29 cell proliferation following incubation 
with jacalin.2 The lack of morphological changes in the HT-29 cells following jacalin 
targeted PDT suggested that the reduction in viability was as a direct result of the anti-
proliferative effects of jacalin binding, as oppose to cytotoxicity.  
C11Pc-PEG gold nanoparticles synthesised in tetrahydrofuran were previously reported to 
carry ca. 10 molecules of C11Pc per gold nanoparticle, as determined by inductively 
coupled-plasma mass spectrometry analysis.1 An alternative synthetic protocol using N,N-
dimethylformamide (DMF) was therefore established, which produced nanoparticles with 
a higher photosensitiser loading efficiency of ca. 155 molecules of C11Pc per gold 
nanoparticle and a ca. 3-fold higher yield of C11Pc-PEG gold nanoparticles. The C11Pc-PEG 
gold nanoparticles synthesised using the DMF synthetic protocol were conjugated to 
jacalin and were shown to effectively produce singlet oxygen following irradiation at 633 
nm. HT-29 cells incubated with these nanoparticle conjugates and irradiated at 633 nm 
exhibited drastic morphological changes upon examination with an inverted optical 
microscope, whereas cells incubated with the non-conjugated particles remained largely 
unaltered.  
Laser scanning confocal microscopy, in combination with differential interference contrast 
(DIC) imaging, showed that jacalin conjugation significantly improved the intracellular 
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accumulation of the C11Pc-PEG gold nanoparticles, as compared to the non-conjugated 
particles. The fluorescence of the C11Pc-PEG gold nanoparticle conjugates following 
excitation with a 633 nm HeNe laser, revealed the localised intracellular accumulation of 
the nanoparticles, suggesting that their internalisation was through a receptor mediated 
endocytic pathway. Following irradiation for 6 min, the cells incubated with jacalin 
conjugated particles exhibited drastic morphological changes that were typically 
associated with cytotoxicity. Positive staining of the nuclei of those cells with propidium 
iodide confirmed that the cells had lost their membrane integrity, and jacalin targeted PDT 
was likely to have induced cytotoxicity through necrosis.  
The MTT viability assay performed on the HT-29 cells following PDT treatment found that 
the jacalin conjugated C11Pc-PEG gold nanoparticles induced a significant reduction in 
viability (ca. 40% viability at 1.15 µM C11Pc equivalent concentration). The viability of the 
HT-29 cells following targeted PDT treatment was further reduced to ca. 4% following a 3 
mm increase in the beam diameter of the 633 nm HeNe laser. A statistically significant 
sigmoidal dose-dependent relationship in phototoxicity was observed with the jacalin 
conjugated C11Pc-PEG gold nanoparticles, whereas the non-conjugated particles resulted 
in minimal phototoxicity. Thus, jacalin was shown to significantly enhance the endocytosis 
of the nanoparticle conjugates. Competitive inhibition of jacalin binding to the T antigen 
on the HT-29 cells was achieved using methyl-α-galactopyranoside and asialofetuin, 
confirming that the enhanced phototoxicity of the conjugates was dependent on the 
carbohydrate binding capacity of the lectin.2,3 The ApoTox-GloTM triplex assay was 
performed 6 h following PDT treatment to establish the primary mechanism of 
cytotoxicity following irradiation of the HT-29 cells incubated with the jacalin conjugated 
nanoparticles. It was found that the HT-29 cells exhibited a significant decrease in 
viability, an increase in cytotoxicity, and no indications of apoptosis following jacalin 
targeted PDT treatment. The findings suggest that necrosis was the predominant 
mechanism of cell death following jacalin targeted PDT treatment at the conditions of the 
experiment. The results described in Chapter 4 show for the first time that lectins can be 
used to selectively deliver nanoparticles to cancer cells for targeted PDT. The methodology 
established in this thesis could be utilised to potentially conjugate any lectin to the C11Pc-
PEG gold nanoparticles and assess the PDT efficacy of the nanoparticle conjugates. 
However, as demonstrated in Chapter 3, a variety of factors must be considered when 
selecting a lectin, as carbohydrate binding affinities, receptor densities and cell 
penetrating characteristics are all likely to contribute to the outcome of the targeted PDT 
treatment.  
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7.3 Comparative study of lectin versus antibody targeting 
Chapter 5 outlined investigations comparing the efficiency of using the lectin, jacalin, and 
monoclonal anti-HER-2 antibodies as targeting ligands to deliver C11Pc-PEG gold 
nanoparticles. Jacalin was conjugated to the C11Pc-PEG gold nanoparticles to target the T 
antigen (ca. 4.4x107 antigens per HT-29 colon cancer cell).2 The anti-HER-2 antibody was 
also conjugated to C11Pc-PEG gold nanoparticles to target the HER-2 receptor (ca. 1-2x106 
receptors per SK-BR-3 breast cancer cell).4 
Importantly, it was found that there was no significant difference in singlet oxygen 
production following the irradiation of either type of nanoparticle conjugate. As 
determined by the MTT assay, the viability of the HT-29 cells following PDT treatment 
with nanoparticles conjugated to either jacalin or anti-HER-2 antibodies was significantly 
reduced, as compared to the non-conjugated particles. HT-29 cell viability was reduced to 
ca. 10% and 19% following jacalin or anti-HER-2 antibody targeted PDT treatment, 
respectively, at the highest nanoparticle concentration of 1.15 µM C11Pc equivalent. 
However, at the same concentration, the non-conjugated particles reduced viability by 
only ca. 6%. Jacalin conjugated C11Pc-PEG gold nanoparticles were shown to be more 
effective than anti-HER-2 antibody conjugated nanoparticles at reducing HT-29 cell 
viability at 1.15 µM C11Pc equivalent (p<0.05). However, the enhanced reduction in HT-29 
cell viability following jacalin targeted PDT was accompanied by a ca. 15% greater level of 
dark toxicity, as compared to the antibody conjugates at the same nanoparticle 
concentration of 1.15 µM C11Pc equivalent. Although jacalin appears to be effective at 
targeting the HT-29 cells, the use of antibody conjugated nanoparticles is favourable due 
to the lower levels of dark toxicity that are induced. 
Using the CellTiter-BlueTM assay, the viability of the SK-BR-3 cells was reduced to ca. 3% 
and 5% following targeted PDT treatment with the nanoparticles conjugated to jacalin or 
anti-HER-2 antibodies, respectively (1.15 µM C11Pc equivalent). Once again, the same 
concentration of non-conjugated particles induced a minimal reduction in viability (ca. 
5%) following irradiation. 
The difference in PDT efficacy between the HT-29 cells and the SK-BR-3 cells could be due 
to a higher susceptibility of the SK-BR-3 cells to photodynamic damage, but could also be 
attributed to a number of other factors. For example, the assays used to measure cell 
viability following PDT treatment are different; therefore the differences in viability 
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between the two cell lines could be a result of variations when using either the MTT assay 
or the CellTiter-BlueTM assay.  
To establish whether there was a difference between the jacalin or anti-HER-2 targeted 
PDT cell death pathways, the ApoTox-GloTM triplex assay was performed on both the HT-
29 cells and the SK-BR-3 cells. Nanoparticles conjugated to sheep serum albumin (SSA) 
were used as a control to explore the significance of non-specific protein-cell interactions 
in enhancing the PDT effect of the C11Pc-PEG gold nanoparticles. Furthermore, the use of 
either 0.1 µM or 1 µM C11Pc equivalent of conjugated nanoparticles was compared to 
investigate the impact of nanoparticle concentration on the cell death pathways. It was 
found that at a concentration of 0.1 µM C11Pc equivalent, no significant difference in the 
reduction of HT-29 cell viability was observed between the jacalin or anti-HER-2 antibody 
conjugated nanoparticles, and the SSA conjugated particles. However, at a concentration of 
1 µM C11Pc equivalent, the jacalin and anti-HER-2 antibody conjugated nanoparticles 
reduced the viability of irradiated HT-29 cells significantly more than the SSA conjugated 
particles (P<0.05). The cytotoxicity of irradiated HT-29 cells was only detected when the 
cells were incubated with jacalin or anti-HER-2 antibody conjugated nanoparticles at 1 µM 
C11Pc equivalent. The SSA conjugated particles failed to increase HT-29 cell cytotoxicity at 
either concentration, suggesting that the HT-29 cell cytotoxicity was a result of active 
targeting by the lectin or antibody conjugated nanoparticles. Apoptosis was not observed 
with the HT-29 cells following PDT treatment using any type of the C11Pc-PEG gold 
nanoparticle conjugates.  
At a nanoparticle concentration of 0.1 µM C11Pc equivalent, the jacalin and anti-HER-2 
antibody conjugated nanoparticles reduced SK-BR-3 cell viability significantly more than 
the SSA conjugated particles (P<0.0005). At a nanoparticle concentration of 1 µM C11Pc 
equivalent, a dramatic reduction in SK-BR-3 cell viability was observed with all three types 
of nanoparticles (ca. 95-99%), suggesting that above certain nanoparticle concentrations 
SK-BR-3 cells non-specifically internalise the SSA conjugated C11Pc-PEG gold 
nanoparticles. The cytotoxicity of SK-BR-3 cells was observed at both concentrations of 
jacalin or anti-HER-2 antibody conjugated C11Pc-PEG gold nanoparticles (ca. 5.6-7.5-fold 
increase in cytotoxicity). SSA conjugated nanoparticles also elicited a ca. 7.8-fold increase 
in SK-BR-3 cell cytotoxicity at 1 µM C11Pc equivalent. However, at 0.1 µM C11Pc 
equivalent of SSA nanoparticle conjugates only a ca. 1.6-fold increase in cytotoxicity was 
observed, further demonstrating the effectiveness of specific targeting ligand-cell 
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interactions. No apoptosis was observed with the SK-BR-3 cells following PDT treatment 
with any of the nanoparticle conjugates at either concentration used.  
Laser scanning confocal microscopy was used to assess the intracellular localisation of the 
jacalin and anti-HER-2 antibody conjugated C11Pc-PEG gold nanoparticles in the HT-29 
cells and the SK-BR-3 cells. LysoSensorTM Green DND-189 was used as a fluorescent 
marker for acidic organelles. Colocalisation of the red C11Pc fluorescence from the 
conjugated nanoparticles with the green LysoSensorTM Green DND-189 fluorescence 
suggested that the nanoparticle conjugates accumulated within the acidic organelles. The 
degree of colocalisation was analysed using the BioImageXD software. It was found that 
both jacalin and anti-HER-2 antibody conjugated nanoparticles partially colocalised with 
the LysoSensorTM Green DND-189 and remained in the acidic organelles within the HT-29 
cells (ca. 27% and 31% colocalisation, respectively) and within the SK-BR-3 cells (ca. 43% 
and 22% colocalisation, respectively). These findings suggested that both types of 
nanoparticle conjugates were internalised through receptor mediated endocytosis.  
Despite the differences in the binding affinities of jacalin (Kd of ca. 500 nM)2 and anti-HER-
2 antibodies (Kd of ca. 14-36 nM)5 to their respective antigens, it is apparent that cell 
surface receptor density could play a large role in the outcome of targeted PDT treatment. 
Antibodies are already in use for cancer therapy and the findings described in Chapter 5 
suggest the huge potential that lectins, such as jacalin, could have for the targeted PDT 
treatment of tumours using biofunctionalised nanoparticles.  
 
7.4 Sonodynamic therapy 
Chapter 7 describes the synthesis of titanium dioxide (TiO2) nanoparticles coated with 
polyacrylic acid (PAA) for applications in the sonodynamic therapy of cancer. TiO2 
nanoparticles with diameters ranging from 5-10 nm capped with the organic base, 
tetramethylammonium hydroxide (TMAOH), were successfully synthesised. Thermal 
annealing of the biocompatible polymer PAA onto the nanoparticle surface was then 
performed. However, recovery of the modified nanoparticles was unsuccessful. The 
controlled in situ hydrolysis of titanium (IV) butoxide in the presence of PAA, followed by 
hydrothermal treatment yielded dispersed, water soluble TiO2 nanoparticles with a mean 
diameter of ca. 57-66 nm, as determined by TEM imaging and dynamic light scattering. 
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The presence of titanium within the purified nanoparticle preparations was also 
confirmed by elemental analysis using Energy Dispersive X-ray Analysis. 
The PAA capped TiO2 nanoparticles were explored as potential sonocatalysts using 
ultrasound irradiation with a frequency of 1 MHz and an intensity of 0.5 W.cm-2. 
Sonochemical generation of singlet oxygen was monitored by the photobleaching of ADPA 
and the sonochemical production of •OH was monitored by the degradation of methylene 
blue.6 Methanol is a known scavenger of •OH, and it was found that the sonochemical 
degradation of aqueous methylene blue was completely inhibited by the presence of 
5.88% v/v methanol.7 The presence of TiO2 nanoparticles in an aqueous solution of 
methylene blue was found to prevent the sonochemical degradation of the dye, possibly 
through PAA protection from •OH attack. However, the presence of the TiO2 nanoparticles 
enhanced the photobleaching of ADPA upon exposure to ultrasound irradiation. This 
enhancement in ADPA photobleaching was also observed in the presence of 5.88% v/v 
methanol, thus suggesting that •OH attack of ADPA was not responsible for its 
photobleaching, but was rather a result of sonocatalytic singlet oxygen production.8,9  
The exposure of the HT-29 colon cancer cells to 30 s of ultrasound irradiation (1 MHz and 
0.5 W.cm-2) following a 3 h incubation with 0.29, 0.74 or 1.47 mM TiO2 equivalent of PAA 
capped TiO2 nanoparticles resulted in no significant enhancement in sonodynamic toxicity. 
Incubation of the HT-29 cells with nanoparticles without exposure to ultrasound resulted 
in a dose-dependent reduction in viability, which was not enhanced by ultrasound 
irradiation. The findings of the in vitro sonodynamic therapy study show that the 
incubation of the cells with the nanoparticles is insufficient for effective sonodynamic 
toxicity and that the extracellular presence of the particles may be required. 
The studies described in this thesis exemplify how nanoparticles can act as 
multifunctional systems enhancing PDT therapies for cancer, by providing aqueous 
solubility of hydrophobic photosensitisers and by providing a platform for conjugation to 
cancer-specific targeting ligands. Specifically, this thesis highlights the first use of tumour-
specific lectins to functionalise nanoparticles for the targeted PDT of cancer cells.10 The 
targeted PDT efficacy of the T antigen-specific lectin jacalin was found to be similar to the 
targeting efficiency of the anti-HER-2 antibody. With consideration of the dissociation 
constants (Kd) that define the binding efficiencies of jacalin versus the anti-HER-2 antibody 
to their respective target antigen (ca. 500 nM vs. ca. 14-36 nM, respectively), this is 
somewhat a surprising result.2,5 However, the similarity in targeting efficiency could 
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indicate the importance of receptor density on targeted treatments. Overall, nanoparticles 
have proven to be powerful mediators in photodynamic therapy that promise to maximise 
the clinical outcome of the treatment. Through the multifunctionality provided by 
nanoparticles, targeted cancer treatment using lectin conjugates hold great potential for 
selective cancer therapy. 
  
  
261 
 
7.5 Future Work 
The in vivo biodistribution, tumour selectivity and targeting efficacy of the jacalin 
conjugated C11Pc-PEG nanoparticles could be investigated in tumour mouse models to 
further assess the clinical potential of lectin targeted PDT treatment. The targeting 
efficiency of alternative T antigen binding lectins, such as the Agaricus bisporus lectin and 
Helix pomatia agglutinin, could also be explored to selectively deliver the nanoparticles to 
cancer cells overexpressing the T antigen.11-13 Additionally, lectins that target alternative 
cancer-associated carbohydrate antigens, such as the Tn antigen-specific Vicia villosa 
lectin, could be conjugated to the C11Pc-PEG gold nanoparticles for targeted PDT 
treatment of different cell lines.14 However, the use of lectins that increase cell 
proliferation, such as the peanut agglutinin, must be avoided as these lectins are likely to 
have a negative impact on the therapeutic outcome of the treatment by promoting cancer 
cell growth.15 The biomodulatory effects that some lectins exert on cancer cells upon 
binding could also be exploited for multimodal cancer therapy in a similar manner to 
treatment using functional blocking antibodies, such as anti-vascular endothelial growth 
factor (VEGF) antibodies.16 Lectins, such as the Maackia amurensis lectin which is specific 
for α2,3-sialylated O-linked glycans, could be conjugated to photosensitising nanoparticle 
constructs to selectively deliver sensitisers to cancer cells whilst inhibiting cell growth and 
metastasis.17 Alternatively, two or more lectins could be conjugated onto one nanoparticle 
carrying a PDT agent: a lectin to target the cancer-associated glycan, and a second lectin 
with potent anti-metastatic and anti-proliferative characteristics. 
Further investigations into ‘necroptosis’ (programmed necrosis), cell cycle arrest and 
autophagic induction could be performed in order to elucidate the exact cellular processes 
that occur following jacalin targeted PDT treatment. Additionally, it would be informative 
to establish the nanoparticle concentration range at which jacalin targeted PDT occurs as a 
result of specific T antigen recognition. 
The sonodynamic cytotoxic effect of TiO2 nanoparticles could be further investigated by 
exposing the cancer cells to ultrasound irradiation during the extracellular presence of the 
particles. Furthermore, the bioconjugation of cancer-targeting ligands to the TiO2 
nanoparticles could be explored to establish whether an increase in the specific particle 
adhesion with the cancer cell membranes would promote their sonodynamic toxicity.  
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